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OVERALL ABSTRACT 
 
 
The overall objective of this thesis is to provide additional data to assist clinicians and 
experimental neurologists alike in the quest for better understanding, more accurately 
diagnosing and more successfully treating patients suffering from Parkinson’s disease (PD). 
The general theme of the thesis is the interaction between certain environmental stimuli, 
including the exposure to adverse events during early central nervous system (CNS) 
development and the manifestation of elements of neurodegeneration, whether by means of 
neurochemical changes or expressed as a dysfunctional voluntary motor system.  
 The first chapter provides a general introduction to the research theme of the thesis. This 
includes, in particular, a discussion on current understanding concerning the etiology and 
clinical profile of PD, the relative contribution made by genetic factors compared to 
environmental ones, and current treatment strategies for treating the disease. Mention is also 
made of the failure of these therapeutic applications for reversing or protecting against the 
disease, due to the side-effects associated with them. The material covered in chapter 1 
provides the basis for the more complete discussion concerning these various aspects, 
contained in the chapters to follow.  
The overall aim was also to characterise the effects of commonly used toxin-induced animal 
models of PD, and the extent of vulnerability that the CNS displays towards them. The 
destruction of dopaminergic neurons following the administration of 6-OHDA at targeted points 
along the nigrostriatal tract is used extensively to model PD pathology in rats and is an 
established animal model of the disease. However, mature or even aged animals are mainly 
used in these studies, while the effects that the toxin might have on the developing CNS remain 
unclear. The study reported in chapter 4 aimed to elucidate some of 6-OHDA’s actions on the 
young adolescent (35 days-old) CNS by comparing the motor and biochemical effects of a 
unilateral infusion of the toxin into two anatomically distinct basal ganglia loci: The medial 
forebrain bundle (MFB) and the striatum. Animals were randomly assigned to receive either a 
direct delivery of 6-OHDA (12µg/4µl) into the MFB or an indirect injection, into the striatum. 
Although both lesion types were used, the MFB model is considered a more accurate portrayal 
of end-stage PD, while the striatum-model better reflects the long-term progressive pathology of 
the disease. The different lesions’ effects on motor function were determined by observing 
animal’s asymmetrical forelimb use to correct for weigh shifting during the vertical exploration of 
a cylindrical enclosure. Following the final behavioral assessment, the concentration of 
dopamine (DA) and DA metabolites remaining in the post-mortem brains were determined using 
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HPLC electrochemistry (HPLC-EC) and the levels compared between the two groups. The 
HPLC-EC results revealed a compensatory effect for DA production and DA turnover on the 
lesioned hemisphere side of the toxin-infused animal group. Thus, following 6-OHDA treatment, 
there appears to be extensive adaptive mechanisms in place within the remaining dopaminergic 
terminals that may be sufficient for maintaining relatively high extracellular and synaptic 
concentrations of DA. However, since substantial changes in motor-function were observed, it is 
suggested that the capacity of the remaining dopaminergic neurons to respond to increased 
functional demands may be limited. In addition, the behavioral results indicate that the distinct 
indices relating to different functional deficits depend on the lesioning of anatomically distinct 
structures along the nigrostrial tract.  
It has long been known that far fewer women are diagnosed with PD than men are. This 
seeming protection offered to females against degenerative disease of the CNS may relate to 
estrogen, although the hormone’s mechanism of action on the dopaminergic system is poorly 
defined. With an estimated 10-15 million women using oral contraceptives (OCs) in the United 
States alone, the aim of chapter 2 was to examine the evidence for a possible relationship 
between PD and the female reproductive hormone estrogen. A review of the current literature 
available on the topic was performed by consulting Medline, and by performing a search of the 
case-reports contained within the World Health Organization’s (WHO) International Drug 
Monitoring database, for possible PD-related symptoms that may arise from estrogen 
replacement therapy (ERT). The results, whilst conflicting, seem to suggest that estrogen 
protects women from obtaining the disease, or at least some features of it. Intensive research 
efforts are called for, with sufficient power to establish the relationship between ERT and the 
onset and development of parkinsonism. Chapter 3 reports on the results obtained from an 
experiment that subjected young Sprague-Dawley rats, 35 days of age, to a lower and a higher 
dose of 6-OHDA delivered to the MFB. Control rats received equivalent saline infusions. At 14 
days post-surgery, the rats were evaluated for forelimb akinesia. For the higher dose of 6-
OHDA the female rats were less impaired than males in making adjustment steps in response 
to a weight shift and in the vibrissae-evoked forelimb placing test. In addition, Tyrosine 
hydroxylase (TH) immunoreactivity was significantly higher for the female rats. Early gender 
differences in cell survival factors and/or other promoters of neuroplasticity may have 
contributed to the beneficial outcome seen in the females. For example, nerve growth factor 
(NGF) was found to be higher in the female rats following administration of the DA neurotoxin. It 
is unclear whether gonadal steroids are involved, and, if so, whether female hormones are 
protective or whether male hormones are prodegenerative. Determining the mechanisms for the 
improved outcome seen in the young female rats may lead to potential treatment strategies 
against PD.   
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Many studies have shown that early life stress may lead to impaired brain development, and 
may be a risk factor for developing psychiatric diseases, including clinical depression. However, 
few studies have investigated the impact that early stress may have on the onset and 
development of neurodegenerative disorders such as PD. The study reported on in chapter 5 
conjointly subjected rat pups to a maternal separation (MS) paradigm that is a well 
characterised model of adverse early life events, and a unilateral, intrastriatal injection of 6-
OHDA. The combined effects of these models on motor deficits and brain protein levels were 
investigated. Specifically, the animals were assessed for behavioral changes at 28 days post-
lesion with a battery of tests that are sensitive to the degree of DA loss sustained. The results 
show that animals that had been subjected to MS display poorer performance in the vibrissae 
and single-limb akinesia test compared to non-MS control animals (that had also been 
subjected to the toxin exposure). In addition, there was a significant increase in the loss of TH 
staining in MS rats compared to non-MS ones. The results from this study therefore suggest 
that exposure to adverse experiences during the early stages of life may contribute towards 
making dopaminergic neurons more susceptible to subsequent insults to the CNS occurring 
during mature stages of life. Therefore, taken together, early exposure to stress may predispose 
an individual towards the onset and development of neurodegenerative disease, which 
especially becomes a threat during the later stages of adult life.  
Moreover, within the framework of these characteristics, the capacity of a widely-used 
pharmacological agent (statins) was tested for possible future therapeutic application in PD 
(chapter 7). Although the precise cause of sporadic PD remains an enigma, evidence suggests 
that it may associate with defective activity of complex I of the mitochondrial electron transport 
chain. Mitochondrial DNA transmit and express this defect in host cells, resulting in increased 
oxygen free radical production, depressed antioxidant enzyme activities, and greater 
susceptibility to apoptotic cell death. Simvastatin is a member of the 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors (statins) group of drugs that are widely used for 
lowering cholesterol levels in patients who display elevated concentrations of low-density 
lipoprotein cholesterol. The study aimed to investigate the effects that statin-treatment have on 
motor-function and at the mitochondrial-protein level, using rotenone, a mitochondrial complex I 
inhibitor, as a rat-model of PD. Adult male Sprague-Dawley rats were treated either with 
simvastatin (6mg/day for 14 days) or with a placebo. Two different tests to assess motor 
function were used: The apomorphine-rotation test, and the vibrissae-elicited forelimb 
placement test. Following the drug administration protocol, the nigrostriatal tract was unilaterally 
lesioned with either rotenone (3 µg/4 µl) or, for the controls, were sham-operated by infusing the 
vehicle (DMSO:PEG) only. Five days later the rats were killed and a highly purified 
concentration of isolated mitochondria was prepared from the substantia nigra (SN) sections. 2-
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Dimensional electrophoresis (2-DE) with subsequent identification of the spots using 
electronspray ionization quadruple time-of-flight mass spectrometrical (ESI-Q-TOF MS) was 
performed and the results BLAST-searched using bio-informatics tools for naming the identified 
peptides. The motor test results indicate that while unilateral rotenone causes behavioral 
asymmetries, treatment with simvastatin improved motor function relative to the rotenone-
induced ones. Mass Spectroscopy identified 23 mitochondrial proteins that differ significantly in 
protein expression (p < 0.05) following simvastatin treatment. The altered proteins were broadly 
classified according to their cellular function into 6 categories, with the majority involved in 
energy metabolism. This study effectively illustrated how neuroproteomics, with its sophisticated 
techniques and non-biased ability to quantify proteins, provides a methodology with which to 
study the changes in neurons associated with neurodegeneration. As an emerging tool for 
establishing disease-associated protein profiles, it also generates a greater understanding as to 
how these proteins interact and undergo post-translational modifications. Furthermore, due to 
the advances made in bioInformatics, insight is created concerning their functional 
characteristics. Chapter 4 summarises the most prominent proteomics techniques and discuss 
major advances made in the fast-growing field of neuroproteomics in PD. Ultimately, it is hoped 
that the application of this technology will lead towards a presymptomatic diagnosis of PD, and 
the identification of risk factors and new therapeutic targets at which pharmacological 
intervention can be aimed.  
The final chapter (chapter 8) provides a retrospective look at the academic work that had 
been performed for the purpose of this thesis, recaps on the main findings, and also highlights 
certain aspects of the project and provides relevant suggestions for future research. Lastly, the 
appendix provides a detailed overview of the methods followed for the experiments described in 
this thesis. It provides not only a comprehensive description of the techniques that had been 
followed, but provides information concerning the care taken with the animals (i.e. post-surgery) 
in order to control for the potential influence of experimental variables on the results.  
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ALGEHELE OPSOMMING 
 
Die algemene doel van die tesis is om addisionele data te verskaf ten einde klinisie en 
eksperimentele neuroloë van hulp te verskaf ten einde Parkinson se siekte (PS) beter te 
verstaan, meer akkuraat te diagnoseer en meer suksesvol te behandel. Die algemene tema van 
die tesis is die interaksie tussen bepaalde omgewings stimuli, insluitende blootstelling aan 
adverse faktore tydens die sentrale senuwee stelsel (SSS) se ontwikkeling en die manifestasie 
van elemente van neurodegenerasie, hetsy d.m.v. neurochemiese veranderings of uitgedruk as 
‘n disfunksionele willekeurige motor stelsel.  
 Hoofstuk 1 verstaf ‘n algemene inleiding tot die navorsings-tema van die tesis. Dit sluit in 
spesifieke bespreking van die huidige verstandhouding rakende die etiologie en kliniese profiel 
van PS, die relatiewe bydra gemaak deur genetiese faktore vergeleke met omgewings faktore, 
asook die huidige behandelings-strategiëe waarmee die siekte behandel word. Melding word 
ook gemaak van die gebrek aan sukses met die bepaalde terapeutiese applikasies ten einde 
teen die siekte te beskerm of sy progressie te vertraag. Die material gedek in hoofstuk 1 verskaf 
die basis vir die meer omslagtige bespreking rakende die verskillende aspekte, wat volg in die 
daaropvolgende hoofstukke.  
 Die algemene doel was ook om die effekte van algemeen gebruikte toksien-geinduseerde 
diere modelle van PS asook die mate van weerloosheid wat die SSS daarteenoor toon te 
karakteriseer. Die vernietiging van dopaminergiese neurone deur die administrasie van 6-
OHDA by geteikende punte in die nigrostriatale neuronale baan, word ekstensief gebruik ten 
einde PS te modeler in rotte en verteenwordig ‘n gevestigde diere model van die siekte. 
Volwasse of verouderde diere word egter meestal gebruik in die studies, terwyl die effekte wat 
die toksien het op die ontwikkelende SSS steeds onduidelik is. Die studie gerapporteer in 
hoofstuk 4 se doel was om sommige van die effekte van ‘n unilaterale infusie van 6-OHDA op 
jong adolessente diere (35 dae oud) in 2 anatomiese aparte basale ganglia loki: Die mediale 
voorbrein bondel en die striatum, te omskryf i.t.v. die motoriese en biochemiese effekte. Diere is 
verdeel in 2 groepe, wat of ‘n dosis 6-OHDA (12µg/4µ) direk togedien is in die mediale 
voorbrein bondel, of indirek, deur intespuit in die striatum. Alhowel albei letsel modelle gebruik 
word, word die mediale voorbrein bondel model beskou as ‘n meer akkurate voorstelling van 
eind-fase PS, terwyl die striatum-model die lang-termyn progressiewe patologie van die siekte 
beter reflekteer. Die verskillende effekte van die letsels op motor gedrag is bepaal deur die 
diere se asimmetriese voor-ledemaat gebruik tydens die vertikale eksplorasie van ‘n silinder te 
analiseer. Na die finale gedrags ontleding, is die konsentrasie dopamien, en dopamien-
metaboliete bepaal in die post-mortem breine d.m.v. HPLC-elektrochemie (HPLC-EC) en die 
vlakke is vergelyk tussen die 2 groepe. Die HPLC-EC resultate het ‘n kompenserende effek vir 
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dopamien-produksie en -metabolisme getoon aan die geletselde kant van die toksien 
geadministreerde diere. Dus, na die 6-OHDA behandeling, blyk dit of daar ekstensiewe 
aanpassings meganismes te werke is binne die oorblywende dopaminergiese terminale wat 
moontlik voldoende is ten einde relatiewe hoë ekstrasellulere en sinaptiese konsentrasies van 
dopamien te handhaaf. Dit blyk egter, aangesien groot verskille in motoriese funksie 
geobserveer is, dat die oorblywende neurone se vermoë om te reageer op stygende 
funksionele eise beperk is. Hiermee saam dui die gedrags resultate aan dat aparte meetings-
indekse, blykbaar verwant aan die verskillende funksionele tekorte, afhanklik is van watter 
anatomies-aparte struktuur, inherent tot die nigrostriatale neuronale baan, geletsel is.  
 Dit is reeds lank bekend dat heelwat minder vrouens gediagnoseer word met PS as mans. 
Hierdie blykbare beskerming teen degeneratiewe siektes van die SSS mag verband hou met 
estrogeen, alhowel die hormoon se meganisme van effek op die dopaminergiese stelsel 
onvolledig gedefinieerd is. Met ‘n geskatte 10-15 miljoen vrouens wat van orale kontrasepsie 
middels gebruik maak in die VSA alleen, was die doel van hoofstuk 2 van die tesis om 
ondersoek intestel na die bewyse vir ‘n moontlike verband tussen PS en die vroulike gonodale 
hormoon estrogeen. ‘n Soektog na die huidig-beskikbare literatuur rakende die onderwerp is 
uitgevoer. Die Medline databasis is gekonsulteer en ‘n soektog is ook uitgevoer op die gevalle-
studies ingesluit in die Wêreld Gesondheids Organisasie se Internasionale Medisyne-Middel 
Moniterings Databasis, vir moontlike PS-verwante simptome wat mag voorkom a.g.v. estrogeen 
vervangings terapie (EVT). Die resultate, alhoewel konflikterend, dui daarop dat estrogeen 
vrouens beskerm teen die siekte, of minstens sekere aspekte daarvan. Intensiewe navorsings 
pogings is nodig met genoeg statistiese krag om die verband te ontleed tussen EVT en die 
ontstaan en ontwikkeling van PS. Hoofstuk 3 rapporteer die resultate van ‘n eksperiment wat 
jong Sprague-Dawley rotte, 35 dae oud, onderwerp het aan ‘n laer vs. ‘n hoër dosis 6-OHDA 
gelewer aan die mediale voorbrein bondel. Kontrole rotte het ‘n gelywaardige hoeveelheid van 
die toksiese middel se vervoerstof (“saline”) ontvang. Teen 14 dae na die sjirurgie is die rotte 
geëvalueer vir voor-ledemaat akinesie. Vir die hoër dosis 6-OHDA was die vroulike rotte minder 
geinhibeer as die manlike diere om aanpassings-stappe te maak in respons tot ‘n 
gewigsverskuiwing asook in die “vibrissae-evoked forelimb placing test”. Tirosien hidroksielase 
(TH) immunoreaktiwiteit was statisties hoër as vir die vroulike rotte. Geslags verskille in sel 
oorlewing en ander promoters van neuroplastisiteit, met moontlike oorsprong uit die neonatale 
of selfs pre-neonatale tydperk mag bygedra het tot die voordelige effek toegestaan aan die 
vroulike rotte. Byvoorbeeld, ‘n opgradering van neuronale groei factor (NGF) was gevind in die 
vroulike rotte na administrasie van die dopaminergiese neurotoksien. Dit is onduidelik of 
gonodale steroïd hormone betrokke is by die effek, en indien wel, of vroulike hormone 
beskerming verskaf en of manlike hormone pro-degeneratief is. Deur die meganismes betrokke 
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in die finale uitkoms van die jong vroulike rotte te bepaal, mag lei tot potensiele behandelings 
strategiëe vir PS.  
 Verskeie studies het getoon dat vroëe lewens stres lei tot ‘n nadelige effek op brein 
ontwikkeling en mag ‘n risiko faktor wees in die ontwikkeling van verskeie psigatriese siektes, 
ondermeer kliniese depressie. ‘n Beperkte aantal studies het egter die impak van vroëe lewens-
stress op die ontstaan en ontwikkeling van neurodegeneratiewe siektes soos PS bestudeer. Die 
studie gerapporteer in hoofstuk 5 het gesamentlik rot neonate onderwerp aan ‘n maternale 
separasie (MS) paradigma, wat ‘n goed gekaraktiseerde model is van adverse vroëe lewens 
gebeure, asook ‘n unilaterale, intra-striatale inspuiting van 6-OHDA. Die effekte van die 
gekombineerde modelle op motoriese gedrag en brein protein vlakke is ondersoek. Die diere is 
spesifiek geëvalueer vir gedrags veanderinge teen 28 dae na afloop van die sjirurgie met ‘n 
battery toetse wat sensitief is vir die mate van dopamien verlore. Die resultate het gewys dat die 
rotte onderwerp aan MS swakker presteer het in die toetse in vergelyking met die kontrole rotte 
wat nie blootgestel is aan MS nie, maar wel die 6-OHDA intra-serebrale inspuiting ontvang het. 
Daarmee saam was daar ‘n statisties beduidende toename in die verlies van TH in die MS rotte. 
Die resultate van die studie dui dus daarop dat blootstelling aan adverse lewensgebeure tydens 
die vroëe lewens-jare mag bydra daartoe om dopamienergiese neurone meer weerloos te maak 
teenoor daaropvolgende effekte wat spruit uit blootstelling aan adverse ervarings tydens die 
volwasse lewensjare. Saamgevat dui die resultate van die studie dus daarop dat blootstelling 
aan stress mag die individu predispositioneer tot die onstaan en ontwikkeling van 
neurodegeneratiewe siektes, wat toeneem in risiko tydens die latere lewensfases.  
 Daarmee saam, binne die raamwerk van die karakter-eienskappe kenmerkend van die 
diere-modelle van PS, is daar ondersoek ingestel na die vermoë van ‘n farmakologiese middel 
(statiene) wat wye gebruik vind as ‘n potensieel toekomstige terapeutiese middel in PS 
(hoofstuk 7). Alhowel die definitiewe rol van PS enigmaties bly, dui verskeie studies daarop dat 
dit moontlik assosieer met ‘n defektiewe aktiwiteit van kompleks I van die mitokondriale elektron 
vervoer ketting. Die defek word deur mitokondriale DNS uitgedruk in selle, wat lei tot ‘n 
toename in suurstof vry radikale produksie, onderdrukte anti-oksidant ensiem aktiwiteite, asook 
groter weerloosheid teenoor apoptotiese sel-dood. Simvastatin is ‘n lid van die 3-hydroxy-3-
methylglutaryl koënsiem A (HMG-CoA) reduktase inhibeerders (statiene) groep middels wat 
gebruik word om cholesterol vlakke te verlaag in pasiënte wat lei aan patologiese hoë vlakke 
van lae-digtheid lipoprotein cholesterol. Die studie het ten doel gehad om die effekte wat 
statiene het op motoriese gedrag en op die mitokondriale protein-vlak te ondersoek, deur 
rotenoon, ‘n mitochondriale kompleks I inhibeerder te gebruik as a rot model van PS. Volwasse 
manlike Sprague-Dawley rotte is behandel hetsy met simvastatin (6mg/dag vir 14 dae) of met ‘n 
placebo. Twee verskillende toetse ten einde motor funksies te evalueer is gebruik: Die 
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apomorfien-rotasie toets en die “vibrissae-elicited forelimb placing test”. Na die statien 
administrasie van 14 dae is die nigrostriatale neuronale baan unilateraal met hetsy rotenoon (3 
µg/4 µl) of, vir die kontrole diere, slegs met die vervoerstof van die toksien (DMSO:PEG) 
geletsel. Vyf dae later is die rotte gedekapiteer en ‘n hoë konsentrasie van geisoleerde 
mitokondria is voorberei vanaf die substantia nigra seksies. 2-Dimensionele elektroforesis met 
“eletronspray ionisation” kwadrupool tyd-van-vlug massa spektrometriese (ESI-Q-TOF-MS) 
identifikasie van die “spots” was uitegevoer en die resultate is geBLAST soek m.b.v. bio-
informatieka sagteware, ten einde die geidentifiseerde peptiede te benoem. Die motoriese 
toets-resultate dui daarop dat alhoewel die unilaterale infusie van rotenoon gedrags-asimmetrie 
veroorsaak, behandeling met simvastatin dié gedrag verbeter in vergelyking met die placebo en 
rotenoon behandelde diere. Massa spektroskopie het altesaam 23 proteine geïdentifiseer wat 
statisties belangrik verskil i.t.v. protein ekspressie (p < 0.05), as ‘n resultaat van simvastatin 
behandeling. Die proteine wat verandering getoon het is breedweg geklassifiseer in 6 
katergorïee volgens hul sellulêre funksie, met die meerderheid wat betrokkenheid toon by 
energie metabolisme. Hierdie studie het effektief aangetoon hoe “neuroproteomics”, met sy 
gesofistikeerde tegnieke en onsydige vermoë om proteine te kwantifiseer, ‘n metodologie 
verskaf waarmee die veranderinge in neurone wat assosieer met neurodegenerasie, bestudeer 
kan word. As ‘n ontwikkelende tegniek vir die bevestiging van siekte-geassosieerde protein 
profiele, genereer dit ook groter insig rakende hoe die proteine inter-reageer en post-translasie 
veranderings ondergaan. Hiermee saam het die verbeteringe gebring in die area van bio-
informatika insig geskep rakende proteine se funksionele eienskappe. Hoofstuk 4 som die mees 
prominente proteomiese tegnieke op en bespreek die mees belangrike verbeteringe in die snel-
groeiende veld van “neuroproteomics” in PS. Die uiteindelike hoop is dat die tegnologie 
aangewend kan word ten einde ‘n presimptomatiese diagnose van PS met meer sekerheid te 
kan maak, asook die identifikasie van risiko faktore en nuwe terapeutiese teikens waarop 
farmakologiese intervensie gerig kan word.  
 Die finale hoofstuk (hoofstuk 8) verskaf ‘n retrospektiewe blik op die akademiese werk 
uitegevoer vir die tesis, som die hoof- bevindinge op, terwyl dit ook sekere aspekte van die 
projek benadruk en relevante voorstelle maak vir toekomstige navorsing. Laastens verskaf die 
appendiks ‘n gedetailleerde oorsig van die metodes gevolg vir die eksperimente wat beskryf 
word in die tesis. Hoofstuk 8 verskaf nie net ‘n komprehensiewe beskrywing van die tegnieke 
gevolg nie, maar verskaf ook informasie rakende die sorg verskaf aan die diere (bv. na afloop 
van die sjirurgie) ten einde beheer uitteoefen oor die potensiële invloed van enige 
eksperimentele veranderlike op die resultate. 
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CHAPTER 1  
 
PARKINSON’S DISEASE – AN OVERVIEW 
 
1. Eponym Parkinson’s disease:  A brief introduction to the disease   
Parkinson’s disease (PD) is a commonly occurring neurodegenerative disease that was first 
described as Paralysis agitans by the English physician Dr. James Parkinson (for his 
photograph, see Fig. 1, the image on the left) in his essay, entitled An essay on the shaking 
palsy, published in 1817. This provided the classical characteristics namely bradykinesia, 
tremor and rigidity that PD is clinically recognized by. Postural instability was added later by the 
French physician Jean-Martin Charcot (for a photograph of him, see Fig. 1, the image on the 
right). Together they set the core symptoms that describe the disease. However, since its 
original description, the clinical conception of the disease has undergone a dramatic 
transformation in that it is now increasingly recognized as being a more complex syndrome than 
originally thought, involving both motor and non-motor systems.  
 
 
Fig.  1.     Photographs of Dr. James Parkinson (1755-1825) on the left and of Prof. Jean-Martin 
Charcot (1825-1893) on the right. 
 
2.  Socio-economic implications of Parkinson’s disease 
Due to the ever-increasing proportion of the populations of developed countries that comprise of 
elderly individuals and the recognized relation between ageing and the development of 
parkinsonism, PD and other related neurodegenerative diseases, place a growing economic 
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burden on the health care systems of many countries. It has been estimated that caring for PD 
patients may cost the U.K. Health and Social services £380m per annum, with half the sum that 
is spent on placing patients in nursing homes and other institutions of care (The Parkinson's 
Disease Society, 1994). In the same document, it is estimated that the annual cost of the 
disease per individual to be in the range of ₤42,000. However, this does not take into account 
the indirect socio-economic costs associated with the disease, such as loss of productivity. A 
further difficulty in accurately estimating the costs involved is that the cost per patient is not 
linearly distributed throughout the course of the disease. During the early phases of the 
disease, when the patient is still independent and needs a relatively simple drug regimen, less 
money is spent compared to the later stages of the illness, when more complex and expensive 
drug regimens are required (Dodel et al., 1994).  
 
3.  The epidemiology of Parkinson’s disease:  How common is the disease?  
3.1.  Age of onset 
Epidemiological studies suggest PD to be the second most common neurodegenerative 
disorder after Alzheimer’s disease (AD) (Hague et al., 2005), affecting ~2% of the population 
over the age of 60 years. PD cases are far more unusual in people under the age of 40, and 
usually these so-called juvenile onset types associate with a clear genetic origin, while non-
genetic disease types are principally considered a disease of the elderly. The average age of 
onset for the sporadic, non-genetic form of PD is approximately 55-60 years, with the rate of PD 
rising sharply after the fifth decade. This observation was epidemiologically confirmed by Hoehn 
and Yahr (1967) who revealed that 2/3 of the patients included in their study were between the 
ages of 50 and 69 when first diagnosed with PD. Only a few other incidence studies on PD 
have been published, and the Hoehn and Yahr estimations for distribution of age at onset seem 
to be relevant even today. However, it remains controversial whether there is a progressive rise 
in PD cases during the later stages of life or if an incidence decline can be seen beyond the 6th 
decade of life (Mayeux et al., 1995; Morens et al., 1996; Hofman et al., 1989). 
 
3.2.  Disease duration in years 
In one long-term investigation regarding the distribution of disease duration (Sutcliffe & Meara, 
1995), the number of years that patients had been affected by PD ranged from 0 to 42, with a 
median of 6 years. Only 8% of the patients included in this study had been affected by PD for 
longer than 20 years.  
The Hoehn & Yahr scale (Hoehn & Yahr, 1967) was introduced as a stage-based rating 
scale of disease severity. The scale comprises of 5 stages, ranging from unilateral disease 
(stage I) to the patient being confined to bed or a wheelchair (stage V). The authors suggested 
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that the median duration of illness since onset of the disease was 3 years for stage I and 14 
years for stage V. The scale was modified with the introduction of Levodopa into clinical 
practice that remains the “gold standard” for pharmacologically treating the disease. It was 
suggested that the duration of each stage should be prolonged by 3-5 years, when patients 
receive L-DOPA therapy (Hoehn, 1987). 
 
3.3. The correlation between disease prevalence and geographical distribution  
Most European and U.S. studies report a prevalence rate of 0.1-0.2%, although a slightly higher 
figure (0.3%) has also been reported (Aquilonius & Hartvig, 1986). The highest prevalence 
reported for the disease is for Europe and North America, while this is lower in Asian countries 
(0.05%). The widespread prevalence rate for China has been estimated to be at 
1,700/1,000,000 cases for all people aged ≥65 years (Zhang et al., 2005a). Africa seemingly 
has the lowest prevalence, although it may be argued that the disease often goes undiagnosed 
in some underdeveloped countries where patients lack access to sophisticated health services 
(Li et al., 1985; Schoenberg et al., 1988; Okada et al., 1990).  
It has been argued that prevalence rates may be affected by socio-economic differences that 
stem from using “survival” as the sole outcome measure, and problems relating to the 
implementation and execution of population surveys (Bermejo et al., 2001). Therefore, the 
incidence rates reported for the USA (Rajput, 1984) of 20.5 per 100,000 people, may be a more 
reliable indicator of the extent of the disease.  
 
3.4.  Racial and ethnic differences in Parkinson’s disease prevalence  
It should be noted that although data trends (as discussed in the section above) suggest the 
incidence of PD to vary by race/ethnicity (Van Den Eeden et al., 2003), published reports often 
contradict each other. For example, some authors suggest that disease prevalence is lower 
amongst Blacks compared to non-Hispanic Whites (Marttila & Rinne, 1981; Richards & 
Chaudhuri, 1996; Kurtzke & Goldberg, 1988; Lilienfeld et al., 1990; Schoenberg et al., 1985; 
Van Den Eeden et al., 2003), while another study found a higher incidence for PD amongst a 
Black population (Mayeux et al., 1995). Other figures report increasing rates in Blacks (10.2), 
among Asians (11.3), and non-Hispanic Caucasians (13.6), with the highest occurrence found 
in Whites of Hispanic descent (16.6) (Van Den Eeden et al., 2003). It remains unclear whether 
methodological differences, such as variation in population characteristics and exposures, case-
finding methods and limitations in denominator accuracy may explain this disparity or whether 
PD is indeed more common among Blacks, but simply underreported. In this regard, the lack of 
replication for studies suggesting a higher prevalence rate amongst Blacks may be due to 
inherent methodological errors of the studies. For example, it has been postulated that the 
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difference between Whites and Blacks for PD prevalence may rather be explained by the 
discrepancy between the population groups in terms of access to medical care (Schoenberg et 
al., 1985; Mayeux et al., 1995).  
 
3.5.  Gender variance in Parkinson’s disease incidence 
Gender differences in the basic disease characteristics, the pattern of motor deterioration and 
nigrostriatal degeneration have been reported in a number of studies. Epidemiological studies 
report that the prevalence of PD in men range from 1.5 to twice that found in women (Van Den 
Eeden et al., 2003; de Lau et al., 2004; Wooten et al., 2004; Schrag et al., 2000; Claveria et al., 
2002; Benito-Leon et al., 2003). In addition, a higher incidence rate for the disease had been 
reported in men (19.0 per 100,000) than in women (9.9 per 100,000) (Van Den Eeden et al., 
2003). The age of disease onset for women is also slightly later in women than in men (Twelves 
et al., 2003). 
 It has been postulated that the reported gender-based variance could be related to the 
difference in circulating reproductive hormones, most notably estrogens, with several findings 
seeming to support a protective role played by estrogen towards developing PD. Possible 
gender variance in PD remains a rigorously debated topic, This issue is more comprehensively 
discussed in chapter 2 of the Thesis.  
 
4.   Current understanding of Parkinson’s disease aetiology  
In the vast majority of PD cases that take on a sporadic appearance, the true aetiology behind 
the onset and progression of the disease remains completely unknown, and its elucidation 
remains one of the major challenges of neuroscience. However, in order to comprehend the full 
extent of the pathology of the disease, one should first consider the mechanics of the intact 
nervous system, particularly the mechanisms responsible for controlling motor function, after 
which an assessment can be made of how patho-mechanisms could impact on normal function.  
 
4.1.   Motor-related features of Parkinson’s disease 
4.1.1.   The organisation of the intact motor system   
Motor behaviour is the product of a complex orchestration of functions induced by the 
extrapyramidal system. This system consists of a number of interrelated structures that form 
multiple parallel loops that function to control normal voluntary motor activity (Nyholm, 2003). It 
is also involved in regulating complex non-motor behaviour (Alexander & Crutcher, 1990). 
Specific structures include the cortex; striatum (consisting of large subnuclei, including the 
putamen, which, in turn consists of the external and internal pallidum segments and the ventral 
pallidum); subthalamic nucleus (STN; consisting of the nucleus caudatus and nucleus 
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accumbens); globus pallidum and thalamus (commonly referred to as the cortico-striato-pallido-
thalamocortical circuit); and the nigral substance (pars reticulata and pars compacta, with the 
latter containing dopaminergic (DA-ergic) neurons). These subnuclei are intrinsically located in 
the forebrain and midbrain and relate at a structural and functional level.  
The cerebellum also forms a prominent component of this motor-function system, while the 
basal ganglia plays a key facilitative role to accurately select, prepare and execute normal, 
everyday movements (Albin et al., 1989; DeLong, 1990; Obeso et al., 2000).  
 DA-ergic projections originating in the Substantia Nigra pars compacta (SNpc) terminate on 
dendrites of the medium-sized spiny neurons in the striatum. These terminating neurons are 
located in two nucleic zones of the striatum, the caudate nucleus and the putamen (Kotter, 
1994). In addition, at cytoarchitectorally, morphologically and neurochemically distinct cell 
groups, interneurons locate to the striatum (DiFiglia et al., 1976; Gerfen, 2004). These two 
classes of cells differ hugely in terms of relative abundance, with medium-sized spiny neurons 
representing approximately 95-97% of the total population, while the interneurons contribute 
merely 3-5% to total neuronal content (Gerfen, 2004).  
 The various input and output structures of the striatum have vast interconnections (Gerfen, 
2004), connecting the direct and indirect pathways of the basal ganglia (Bolam et al., 2000) with 
multiple feedback and feed-forward loops that add to the stability of the basal ganglia network 
(Olanow et al., 2006). The striatum acts as an ‘input structure’ to govern basal ganglia function 
(Parent et al., 1995; Parent & Hazrati, 1995; Gerfen & Wilson, 1996; Wise et al., 1996) by 
receiving and converging external glutamatergic inputs stemming from the cerebral cortex, 
thalamus, and limbic structures. Moreover, frontal-cortical-intralaminar-thalamic as well as 
brainstem nuclei also target the STN, to provide additional input stimuli processed by the basal 
ganglia (Gerfen, 2004). In addition, the DA-ergic and serotoneric systems (that originates from 
the raphe nuclei) also modulate the nature of this input.  
 Together, the globus pallidus pars interna (GPi) and the SNpr provide the main ‘output’ 
nuclei of the basal ganglia, by projecting inhibitory γ-aminobutyric acid (GABA)-ergic 
somatotopical connections to the various thalamic nuclei, colliculi superior and brainstem 
reticular formations. In addition, the basal ganglia receives ‘external’ information from every 
region of the cerebral cortex, midline, intralaminar thalamic nuclei and limbic structures, 
including the amygdala and hippocampus. Additionally, serotonergic inputs from the raphe 
nuclei and cholinergic fibers from the peduncopontine nucleus project to parts of the basal 
ganglia. The basal ganglia-thalamocortical system plays a prominent role in the development 
and fine-tuning of various processes, most notably those associated with learning, that are 
essential for producing certain motor as well as non-motor behaviour. For establishing these 
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processes, behavioral reinforcement is essential, for which the DA-ergic system plays a critical 
role.  
As stated, the cerebellar circuit plays a prominent complimentary role, especially in 
establishing the exact timing with which motor-behaviour is executed. Once the learning phase 
of a movement has surpassed, behavioral programs are automated by the basal ganglia, while 
the cerebellum continues to fine-tune output in relation to sensory feedback. The final 
behavioral program with which a specific action is executed by is the product of deliberate 
choices between movements with different probabilistic outcomes by the basal ganglia and 
cerebellum. 
 DA fulfils an integral role in stabilizing the basal ganglia network by modulating glutamate-
induced excitability of striatal neurons. The DA receptors are divided into 2 classes: those that 
are D1-like and the D2-like. While the D3 and D4 receptor subtypes relate to the D2 family, the D5 
subtype is similar to D1-like (Sibley et al., 1993). Striatal D1 receptors mainly synapse post-
synaptically with neurons located in the stratum (the direct pathway), where they couple to a 
specific G-protein that activates adenylate cyclase, the enzyme that converts ATP to cyclic AMP 
(Okada et al., 1994). D2-like receptors are found in high concentrations within the caudate and 
putamen (Kandel et al., 2000) that forms part of the indirect projection pathway (Gerfen et al., 
1990) to primarily inhibit adenylate cyclase. DA exerts both exertive and inhibiting effects on the 
D1 and D2-like DA receptors of the striatum (Lee et al., 2005; West & Grace, 2002). DA’s 
excitatory effect takes place via its transmission through the direct D1-mediated pathway, 
exerting an inhibitory effect that is mediated by the indirect D2-mediated pathway (Clark & 
White, 1987) on cortical motor areas.  
 The consistent striatal DA-ergic stimulation which characterize the nigrostriatal DA-ergic 
neurons serve to regulate glutamatergic input from the cortex to the direct and indirect pathway 
that extend from here (Levy et al., 1997). GABA-ergic efferents project both directly as well as 
indirectly to the internal segment of the GPi and the SNpr to form the two major output nuclei of 
the basal ganglia (Chase et al., 1998). Whereas basal ganglia output directs to several thalamic 
and brainstem nuclei with a direct, monosynaptic pathway leading from the striatum to the GPi, 
the indirect pathway includes synapses formed in the external segment of the globus pallidus 
(GPe) and the SN (Nyholm, 2003).  
 
4.1.2.  Motor-related clinical features of Parkinson’s disease 
Throughout the 19th century, clinical signs indicating an adverse effect exerted on the voluntary 
motor system was established as the symptoms that entail the PD syndrome. However, the 
cardinal pathological feature responsible for this functional impairment, namely a functional 
disturbance of the DA-ergic neuronal system due to the chronic, progressive degeneration of 
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mesencephalic DA-ergic neurons resident to the SNpc (Nakano & Hirano, 1984; Perry et al., 
1985; Rinne et al., 1989) was only established much later.  
The syndrome comprises of a reduced speed with which patients execute movements 
(bradykinesia), scarcity of spontaneous movements (hypokinesia), tremor, rigidity and postural 
instability (LeWitt & Oertel, 1995). Hypokinesia has often mistakenly been regarded as 
“weakness”, exemplified by the term ‘Paralysis Agitans’, an alternative term for describing PD 
symptoms.  
A brief definition and description will now be given of some of the common features that 
make up the clinical phenotype of PD. 
Dyskinesias can be consistent, or present episodically as abnormal movements. They 
essentially comprise of movements that had been slowed down considerably compared to the 
speed with which they were performed in the absence of disease (bradykinesia). Additional 
features include an inhibition of spontaneous movements (akinesia), or the excessive display of 
spontaneous movements (hyperkinesias).  
Tremor is described clinically as rhythmic, involuntary, oscillatory movements, characterized 
by fixed amplitude and extended duration. Although tremor is the best-recognized symptom of 
PD, only 60-70% PD patients ever suffer from it. Its manifestation may be due to a disinhibition 
of the thalamus that stems from an underlying striatal-DA deficiency. Evidence for this derives 
from the finding that stereotactic lesions made at this level provide symptomatic relief (Wilms et 
al., 1999).  
Rigidity is an additional clinical hallmark in parkinsonism. It is believed that enhanced long-
latency stretch reflex underlies this clinical phenomenon, resulting in increased resistance. The 
cogwheel phenomenon is seen during clinical investigation of PD sufferers when patients 
complain of experiencing a sense of stiffness during movements carried out on the patient by 
the physician that entails passive flexion/extension (Jankovic, 1992). This symptom may co-
manifest with a loss of dexterity, micrographia, hypophonia, and a shuffling small-stepped gait. 
Often at times, this may co-manifest with bradykinesia.  
 Postural imbalance is the least specific, though often the most disabling parkinsonian 
symptom, producing the stooped posture, pro- and retropulsion by which the disease is so often 
recognized by (Jankovic, 1992). It is likely that parkinsonian gait and postural instability result 
from a combination of bradykinesia, rigidity and loss of proprioceptive reflexes.  
 Additional symptoms of the disease include ocular (specifically, impaired saccadic and 
smooth pursuit eye movements) and speech abnormalities. These symptoms may express in 
consequence to a dysfunction of the striatal DA-system, particularly of the parallel ocular and 
phonological circuits based within the extrapyramidal system (Marsden & Obeso, 1994).  
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 In addition, the clinical phenotype that associates with early-onset recessive 
parkinsonism (that often have an underlying genetic mutation), often includes dystonia at onset 
and hyperreflexia, with the disease progressing relatively slower than with the sporadic type 
(Gasser, 2005). However, it should be noted that only a weak correlation between clinical 
manifestation and type of genetic mutation has been described. However, the available case 
series indicate that patients with point mutations tend to be more mildly affected than patients 
with deletions (Lohmann et al., 2003). 
 
4.1.3. Patho-mechanisms involved in the manifestation of motor-related features of 
Parkinson’s disease 
Although both DA-ergic and non-DA-ergic nuclei belonging to the nigrostriatal pathway are 
adversely affected in PD (Dauer & Przedborski, 2003), the destruction of DA-ergic neuronal 
afferents in the SN, resulting in reduced DA levels in the corpus striatum (Ascherio et al., 2003) 
is widely accepted as being PD’s cardinal pathological hallmark. In addition, the fact that 
various regions of the cerebral cortex are innervated by DA-ergic neurons entails that the 
functions associated with these areas may also be altered by the disease (Thierry et al., 1973; 
Thierry et al., 1974; Divac et al., 1978). DA fibre terminals are predominantly confined to the 
deeper layers of the frontal, cingular, and entorhinal cortical areas. In contrast, the 
noradrenergic (NA) axonal terminals widely disperse throughout this anatomical region (Hökfelt 
et al., 1974; Berger et al., 1976).  
 Various compensatory mechanisms are triggered in response to reduced DA production. 
These become prominent during the initial stages of the disease. Under these conditions, 
robust DA reuptake mechanisms are in place for sufficiently maintaining striatal and synaptic 
DA concentrations, thereby exposing synaptic and extrasynaptic striatal DA receptors to DA 
concentrations that undergo relatively few fluctuations. In addition, increased activity by the 
surviving DA neurons, downregulation of DA transporters (DAT), increased sensitivity of 
postsynaptic DA receptors, and modified firing rates of the basal ganglia neurons may occur. 
However, in the long-term these compensations fail, eventually leading to a loss of cortico-
striatal functions that would normally be modulated by DA (Calabresi, 1993). In addition, the 
ability of striatal neurons to undergo long-term potentiation and long-term depression become 
impaired (Calabresi, 1993; Centonze et al., 1999), while the firing frequencies and firing 
patterns of neuronal populations in the GPe, GPi and STN are distorted (Albin et al., 1989; 
DeLong, 1990; Obeso et al., 2000; Raz et al., 2000). Furthermore, DA depletion results in the 
desynchronized firing of pallidal neurons in response to peripheral stimuli, leading to an 
impaired ability to accurately select an intended movement (Filion et al., 1988; Nini et al., 1995).  
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 A significant reduction in the number of postsynaptic DA receptors can also induce PD, 
leading to a functionally misbalancing striatal output structures, thereby producing the same 
overt signs and symptoms as other forms of spontaneous-onset PD.  
 
4.5. Non-motor features of Parkinson’s disease 
New insights gained into the pathological processes underlying the disease, have led to the 
realisation that PD is a syndrome that stems from the degeneration of a multitude of 
physiological systems. Extensive neuronal connections exist between the motor- and the limbic 
system for relaying and processing emotive and cognitive-associated information that the motor 
system reacts on. The mechanisms of the intact interrelation between the cortical, limbic and 
motor system will now be discussed, followed by the clinical features associated with its 
diseased-state, and then a discussion on the patho-mechanisms that might be responsible for 
these clinical manifestations.  
 
4.5.1. The organisation of the intact cortical and limbic systems and their relation to 
the motor system 
The human cerebral cortex consists of an extensive neocortical territory and a smaller 
allocortical region. The neocortex is partitioned into primary fields to allow for motor functions 
and for processing sensory information reaching the brain from the sensory organs. Each 
neocortical primary sensory field receives somatosensory, visual and auditory information, and 
is surrounded by unimodal secondary areas, each connected to additional, unimodal as well as 
heteromodal association areas (Braak et al., 1998; Zilles, 1990). Sensory (auditory and visual) 
and somatosensory exteroceptive input reach their matrix of related association areas within the 
neocortex via the primary fields and secondary areas. Once it has reached its destination, data 
are conveyed by means of long cortico-cortical pathways towards the extensive region that 
makes up the prefrontal cortex. Short pathways lead away from this region towards subordinate 
fields through premotor areas, into the primary motor field. Incorporated into these pathways 
are the striatal and cerebellar loops that guide the information back to the primary motor field. In 
this way, large portions of the basal ganglia, the lower brain stem, and the cerebellum all 
participate to regulate cortical output.  
The prefrontal cortex is constantly inundated by a large supply of vast amounts of largely 
irrelevant exteroceptive stimuli arriving from the sensory association areas. Neocortical data 
flow into the limbic loop via two entry ports. If the receiver regards the data as being useful, this 
is filtered out of the main stream arriving via many intermediate neocortical relay stations, 
eventually converging on the temporal pro-neocortex and periallocortical transentorhinal region, 
located in the entorhinal region and amygdala, situated at the first entry point to the limbic 
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system. The second port of entry for neocortical data entering the limbic loop comprises of the 
lateral nucleus of the amygdala. Under non-pathological conditions, both the central amygdala 
nucleus and the bed nucleus of the stria terminalis exert an influence over the autonomic and 
neurosecretory nuclei of the hypothalamus. In addition, the central nucleus of the amygdala 
also directs the processing of viscero-sensory data and controls all viscero-motor areas of the 
brainstem and spinal cord.  
The efferent trunk of the limbic loop consist of projections running from the entorhinal region, 
amygdala and hippocampal formation, exerting an important influence on the prefrontal cortex. 
Finally, the central nucleus of the amygdala exerts critical influences on all non-thalamic nuclei 
with diffusely connecting projections extending to the cerebral cortex and many other structures 
of the central nervous system (CNS). These projecting nuclei that include the cholinergic 
magnocellular nuclei of the basal forebrain, the GABAergic tuberomamillary nucleus of the 
hypothalamus, the serotonergic raphe nuclei, the DA-ergic nuclei of the ventral tegmentum and 
the noradrenergic locus coeruleus, undergo severe pathological changes during the 
progression of PD.  
The allocortex essentially comprises of the hippocampal formation and the presubicular and 
entorhinal regions, while the subcortical amygdala is a closely related structure. The entorhinal 
territory and the lateral nucleus of the amygdala act as a gateway to either allow or forbid 
information transfer. Fig. 3 below shows the relation between these regions.  
 The centres of the limbic loop subsequently dispatch their efferents in the direction of the 
neocortex, specifically towards the prefrontal areas (Holstege, 1996; Mesulam, 1998; 
Nieuwenhuys, 1996). From the above description, it is therefore clear that these efferents exert 
considerable influence on the neocortex, forming a constituent component of the motor system. 
As can be viewed from Fig. 4, all these centres are intricately connected. The limbic loop 
performs a crucial role in maintaining emotional equilibrium, the individual’s ability to learn, and 
memory function. Simultaneous, it affects motor function, such as the influence the limbic 
system has on the prefrontal cortex. This may serve to explain why motor activity can perhaps 
be regarded as reflecting the individual’s emotional state.  
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Fig.  2.     
The 
relatio
n 
betwee
n the 
limbic 
system 
and the 
neocor
tex. 
The 
figure 
shows 
the 
frontal, parietal, occipital and temporal neocortices, with each comprising of a primary field (indicated by 
the large dots), a belt of secondary fields (indicated by the small dots), and related higher-order 
processing areas (the white areas). Figure taken (with permission) from Braak et al. (2003). 
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Fig.  3.     A schematic representation of the limbic and motor system that facilitates the 
perception of intimate connections and the tight relations between these two systems. Figure 
taken (with permission) from Braak et al. (2003). 
 
4.2.2.  Non-motor clinical features of Parkinson’s disease 
Although PD can manifest purely motorically, motor symptoms often co-expresses with 
complex, non-motor behavioral abnormalities. These may include cognitive, emotional, 
neuropsychiatric, motivational and autonomic dysfunction. In addition, a disturbed nocturnal 
sleep pattern with excessive daytime sleepiness is frequently co-diagnosed along with PD, the 
occurrence of which seemingly increases with advancing disease (Askenasy, 1993; Tandberg 
et al., 1999). These non-motor abnormalities may occur intrinsically to the disease or 
extrinsically due to dopaminomimetic and/or neurosurgical therapeutic interventions (van de 
Berg et al., 2007). Whereas some of these complications are possibly induced by 
dopaminomimetic therapy, others might be linked to disease progression instead (Nyholm, 
2003). 
 Therefore, the primary motor dysfunctions that characterize PD are frequently 
accompanied by cognitive impairments, such as memory deficits, decreased conceptual ability, 
behavioral deregulation and defective visuo-spatial functions (Mizoguchi et al., 2004; Sullivan & 
Gratton, 1998). It is now a well established that patients with PD also have markedly impaired 
olfactory function (Doty et al., 1988; Hawkes, 2003), with this clinical feature corresponding well 
to neuropathological findings, such as the presence of Lewy bodies (LBs) found in the anterior 
olfactory nucleus (Hawkes, 2003).  
Impulse control disorders (ICDs) can seemingly also occur in a subset of patients with PD. 
This spectrum of disorders, which is characterized by excessive or poorly controlled 
preoccupations, urges, or behaviours that includes punding, pathologic gambling and 
hypersexuality, as well as compulsive shopping and binge eating. However, in a small 
percentage of patients, these behavioral abnormalities associate with the overuse of DA 
replacement therapy (DRT) and are referred to as a homeostatic hedonistic dysregulation, or as 
DA dysregulation syndrome (DDS) (Giovannoni et al., 2000). 
 It is frequently reported that patients who suffer from abnormalities that affect the motor-
system, also suffer from a range of psychiatric disorders (i.e. psychosis, affective disorders or 
somatization disorders). It is generally accepted that the expression of motor symptoms is 
influenced by the patient’s state of mood. Emotionally straining situations, and those evoking 
anxiety or general stress tend to predispose the manifestation of dyskinesias, while their 
prevalence seems to decrease, or even completely fail to manifest during relaxed periods. 
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Clinical evidence suggests that stress can increase the severity of PD symptoms (Smith et al., 
2002). For example, reactions such as anxiety and anger, as responses to stressful situations 
may effectively worsen patient’s tremor (Schwab & Zieper, 1965).  
Due to a severe DA deficiency existing in the caudate and accumbens nuclei, psychomotor 
retardation and apathy are frequently seen in PD patients. The affective and emotional 
deregulation resulting in depression-like symptoms in the patient, leading to further social 
isolation and social stress. It has been suggested that difficulties in coping with the physical 
restraints imposed by the disease and accepting the invalidating condition that is PD, as well as 
concomitant fatigue and physical pain may play a defining role in this symptom manifesting 
(Langer, 1994).  
 In addition, other psychological elements, such as feelings of guilt, loss of self-respect, fear 
of the inability to continue to partake in occupational and recreational activities, as well as 
fearing the loss of independence, may also contribute to the severity with which the disease 
manifests in patients (Dakof & Mendelsohn, 1989). It has been suggested that these psycho-
social factors may be important in the development of PD-related depression, stress and social 
isolation (Seiler et al., 1992). 
 
4.3. Cellular and molecular features of Parkinson’s disease 
The molecular pathways leading to PD’s pathological picture remain complex. A number of 
patho-mechanisms other than a depletion of DA have been proposed to play a part in the 
etiogenesis of the disease, including the role played by oxidative stress, glutamate-induced 
excitotoxicity, depleted levels of endogenous antioxidants, reduced expression of trophic 
factors, inflammatory processes and a dysfunctional protein degradation (for a comprehensive 
recent review, see Schapira, 2006). Since the themes of protein aggregation, mitochondrial 
dysfunction and proteasomal stress continue to be observed in many models of PD as well as 
in clinical studies, it is conceivable that these factors may play central parts at some stage of 
PD pathogenesis, and novel therapeutic strategies are aimed at.  
 
4.3.1.  Misfolded protein aggregation as a contributing cause of Parkinson’s disease 
Presently it is unclear whether accumulation of misfolded proteins leading to PD’s characteristic 
cytoplasmic inclusions, serve a toxic or a neuroprotective purpose (Thomas & Beal, 2007). 
While Sir James Parkinson originally described the clinical characteristics of PD in a monograph 
published in 1913, Friederich Lewy was the first to observe neuronal cell loss in the nucleus 
basalis of Meynert of patients with PD (Greenberg et al., 1985). In addition, he is given credit for 
being the first to describe the presence of LBs. These round, eosinophilic inclusions display a 
pale halo, and are found abundantly in the neuronal cytoplasm of the SN of PD brains. Their 
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microscopic observation have also been made in surviving DA-ergic neurons of other brain 
areas not classically associated with the disease, such as the cortex and the magnocellular 
basal forebrain nuclei (Braak et al., 1995). It should however be noted that LBs also appear in 
the brain of certain neurologically intact individuals as well as several other completely 
unrelated neuropathological conditions, such as sub-acute sclerosing panencephalitis and 
Hallervorden-Spatz disease (Calne, 2004), thereby diminishing the previously held edifice 
concerning the pathological significance of LBs. The biochemical constituents of LBs remained 
unknown until the publication of two studies that brought the alpha-synuclein (SNCA) protein to 
centre stage. Polymeropoulos et al. (1997) reported finding a missense mutation in the gene 
encoding for SNCA on chromosome 4 in a family that displayed juvenile PD. In addition, using 
post-mortem PD brains, antibodies against SNCA strongly stained for LBs and LNs (Spillantini 
et al., 1997).  
Morphological differences between LBs and LNs have been detected based on the brain 
region where they were detected. For example, LBs observed in the brainstem region comprise 
of an eosinophilic hyaline core and a pale-staining peripheral halo. In addition, LBs and 
neuronal loss is frequently accompanied by macrophages filled with pigment and gliosis when 
present in the pigmented parabrachialand paranigral nuclei of the ventral tegmentum, locus 
ceruleus, raphe nuclei of the ventral tegmentum, locus ceruleus, raphe nuclei, dorsal motor 
nucleus of the vagal nerve, and the endoplasmic reticular (ER) formation (Braak et al., 2003).  
It was revealed through microscopic investigations that LBs are present in monoamine 
producing cells. Thereby LB-presence has effectively become the sine qua non for confirming a 
non-differential diagnosis of PD (Calne, 2005), since these abnormal protein aggregations have 
been detected in both sporadic and familial forms of the disease (Mezey et al., 1998; Spillantini 
et al., 1998). Furthermore, knowledge on the existence of a relationship between LB formation 
and PD pathology also led to discovering that the first pathological changes that precede full 
disease-pathology, commence in the olfactory bulb, particularly in the anterior olfactory nuclues 
(Del Tredici et al., 2002).  
However, in recent times the belief that LBs form the hallmark of the disease has been 
resisted with the discovery by Rajput et al. (1991) that in certain patients who display all the 
clinical features of PD, neurofibrillary tangles, instead of LBs are present in the SN. However, 
the reason for the absence of LBs in this subgroup of patients remain elusive.  
The disease may be in consequence to changes occurring in the neuronal cytoskeleton that 
develop in only a few susceptible types of nerve cells. The afflicted neurons eventually develop 
alterations that can be observed as intracytoplasmic inclusions evolving to become LBs in the 
perikarya and LNs in the neuronal processes (for a review, see Braak et al., 2000). These are 
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presumably located in portions of axon. Currently it is a matter of debate whether LNs are 
produced in the dendrites as well.  
The major structural components of LBs and LNs are abnormally phosphorylated 
neurofilaments of the cytoskeleton as well as fibrillar SNCA (Spillantini et al., 1998). SNCA is a 
chaperon protein that attaches to lipid membranes under normal conditions, preferentially 
localizing in axons and presynaptic terminals of the neurons that are found widely dispersed 
throughout the brain. It is primarily involved in the maintenance, storage and regulation of DA 
vesicles at the synaptic terminals (Clayton & George, 1998). During the pathological processes 
that underlie PD and for reasons that are currently unknown, this presynaptic protein changes 
its conformation, aggregates and accumulates in the axons and soma of vulnerable neurons. 
However, whether it is the inclusion body itself, or its principal protein component (SNCA) that is 
responsible for the effects exerted on the DA-ergic neurons remains an open question. Kramer 
et al. (2007) demonstrated a less prominent role for LBs in neural toxicity, by using a protein 
aggregate filtration assay to show that abundant presynaptic terminal associated SNCA 
aggregates promote synaptic pathology and neurodegeneration.  
 
4.3.2. Mitochondrial dysfunction as a contributing cause of Parkinson’s disease 
Mitochondrial pathology has been suggested to play an underlying role in PD pathogenesis 
(Silvestri et al., 2005; Sim et al., 2006). The active compound of MPTP, the neurotoxin MPP+ 
shows the capacity to inhibit mitochondrial complex I (Lee & Martens, 1986). This finding 
supports the suggestion that an energy failure resulting from the inhibition of the mitochondrial 
respiratory chain is a likely mechanism to result in neuronal death in cases of MPTP-induced 
Parkinsonism. In addition, a decrease in complex I activity has been reported in biopsies done 
on skeletal muscle (Schapira et al., 1990; Mizuno et al., 1989). A reduction of 45% in respiratory 
chain complex I activity compared to control subjects were also detected in the platelets of PD 
patients (Parker et al., 1989), to indicate that the complex I defect can be present in the 
peripheral tissue of PD patients as well. In contrast, Mann et al. (1992) reported normal platelet 
and skeletal muscle complex I activities in PD. In addition, respiratory chain complexes I and IV 
of the lymphocytes of PD patients were found to be impaired compared with age-matched 
control subjects (Santosh & Pasupathy, 2006). However, in a study performed by Yoshino et al. 
(1992) contrasting results were obtained revealing normal complex I and IV function and a 
merely slight decrease in the activity of complex II, when lymphocytes of PD patients were 
analysed. 
An elevation of iron has also been observed in the SN with staging of PD, especially in the 
SN zona compacta (SNzn). The iron has been found present in glia, active microglia, 
macrophages, oligodendrocytes that lie outside of the degenerated DA neurons and as a mild 
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halo around LBs and within melanized dopamine neurons of SNzc. The iron in SNpc may 
induce oxidative stress and thus associate with the reported decreases of glutathione 
peroxidase activity, reduced glutathione (GSH), mitochondrial complex I activity, calcium 
binding protein and increased basal lipid peroxidation. To support these claims, Schapira et al. 
(1990) and Mizuno et al. (1989) found a marked reduction in complex I activity during 
postmortem analyses done on the SN of brain samples obtained from PD patients. 
What remains uncertain are the mechanisms responsible for these functional defects of 
mitochondria, and whether these are the primary or secondary cause of the disease. It has 
been postulated that the respiratory chain defects might be secondary to the effects of 
environmental toxins that inhibit the respiratory chain and result in increased free radical 
production (Langston, 1985; Nicklas et al., 1985; Nagatsu & Yoshida, 1988). Such an inhibition 
could ultimately result in nonselective damage incurred to components of the respiratory chain 
(Dexter et al., 1989; Leehey & Boyson, 1991).  
Damage sustained at the protein coding level is also a distinct possibility (Ikebe et al., 
1990). The vast majority of mitochondrial proteins are encoded for within the nuclear DNA. 
These include numerous components of the electron transport chain, proteins involved in 
mitochondrial DNA replication, transcription and translation, as well as all matrix, inner and 
outer membrane proteins. These proteins are transported to their specific mitochondrial 
compartments by means of signal peptides. Therefore, disruption of the electron transport chain 
could potentially occur in either mitochondrial or nuclear DNA.  
It is clear that further work is required at the molecular level to determine the precise clinical 
relevance of these molecular disorders. This topic will be returned to in chapter 5 of this Thesis, 
where it forms a major theme of this particular chapter.  
 
4.3.3. The involvement of the ubiquitin proteasome system (UPS) in Parkinson’s 
disease 
Parkin is one of three (the others being DJ-1 and PINK1) mutated genes associated with 
familial parkinsonism. It is typically found present in autosomal recessive inherited forms of the 
disease and is implicated in mitochondria and oxidative stress-related survival pathways 
(Abeliovich and Beal, 2006). It is by now well established that parkin functions as an ubiquitin 
ligase in the cellular ubiquitination/protein degradation pathway (Shimura et al., 2000), by 
encoding for (at the carboxy terminus) an E3 ubiquitin ligase with the characteristic two Really 
Interesting New Gene (RING) finger domains separated by an IBR (In Between Ring) domain. 
This domain is common to other E3 ligases as well. Parkins’s domain structure suggests it acts 
as a gatekeeper, to covalently add ubiquitin chains to tag proteins prior to their destruction by 
proteasomes. It has been demonstrated that the parkin gene not only mediates the well-studied 
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addition of ubiquitin via lysin48 (K48), which accounts for directing ubiquitinylated proteins for 
proteasomal degradation, but also via lysin63 (K63). This may play a role in intracellular 
signaling processes as well as in LB formation (Lim et al., 2005), since dardarin, ubiquitin and 
other proteins involved in ubiquitin metabolism form the major constituents of LBs (van de Berg 
et al., 2007). However, it remains uncertain whether and how the loss of ubiquitin function leads 
to neurodegeneration. The uncertainty is largely due to inconclusive evidence for a single 
putative toxic protein responsible in this chain of events, although it has been hypothesized to 
accumulate due to the lack of parkin in PD patients or parkin knock-out mice (Gasser, 2005).  
  
4.3.4. Microglial activation as a possible contributing cause of Parkinson’s disease 
Certain infections, including encephalitis lethargica, Creutzfeldt-Jakob disease (CJD), Acquired 
Immune Deficiency Syndrome (AIDS) and syphilis, present with the same cognitive, behavioral 
and motor deficits as seen in PD cases. Moreover, these infectious diseases all show infected 
microglia, a neuropathological feature shared by PD. Under ordinary circumstances, microglia 
are regarded as the resident immune cells of the CNS (del Rio-Hortega, 1932). Microglia and 
related perivascular macrophages provide a first line of defense to protect the CNS 
microenvironment against injury or disease. Their functions range from performing an 
immunological survey of the brain parenchyma to a neuroprotective role. They do so by 
monitoring extracellular chemical changes, debris accumulation, pathogen invasion and altered 
neuronal signalling. In addition, they may play a role during apoptosis and secrete a number of 
soluble factors, amongst them glial-derived neurotrophic factor that possibly play a role in 
ensuring neuronal survival (Streit, 2006).  
Several lines of clinical and experimental evidence support the hypothesis that glial 
activation and inflammatory processes play a role in the pathogenesis of PD (Purisai et al., 
2007). NADPH oxidase is a complex enzyme that is composed of three cytosolic as well as two 
membrane-bound subunits (Babior, 2004). Microglial activation results in these cytosolic 
components migrating towards the membrane. Upon reaching their destined location, they bind 
to the other subunits to assemble active oxidase, which is capable of catalyzing the one-
electron reduction of oxygen to superoxide (Purisai et al., 2007). Experimental neurotoxins such 
as 6-OHDA and MPTP possibly exacerbate the neurodegenerative process by activating 
microglia. Moreover, epidemiological studies report a lower risk for developing PD in patients 
who regularly use non-steroidal anti-inflammatory drugs (Chen et al., 2005). In addition, 
increased numbers have been found in the SN and striatum of patients with idiopathic PD 
(McGeer & McGeer, 2004; Ouchi et al., 2005), while subsequent to injecting themselves with 
MPTP, post mortem studies done on the SN of patients who had developed a parkinsonian 
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syndrome, revealed clusters of reactive microglia based around nerve cells (Langston et al., 
1999).  
The aging brain is characterized by a demonstrable degree of atrophy, presumably due to 
the loss of neurons and myelinated axons (Conde & Streit, 2006). In contrast, glial cells appear 
to increase in the aging brain, exhibiting greater immunoreactivity with both astrocytic and 
microglial markers. During normal aging, microglia undergo structural deterioration, such as 
abnormalities in microglial cytoplasmic structure, including deramification, spheroid formation, 
gnarling and fragmentation of processes (Streit et al., 2004). Although this may easily be 
interpreted as normal aging-related neuroinflammation, no definite correlation between 
ostensible microglial activation and neurodegeneration has thus far been demonstrated, with no 
correlation found between the location of activated microglia and the location of damaged or 
lost neurons (Finch et al., 2002). 
The literature on acute microglial activation with aging does not reveal entirely consistent 
findings, in large part due to the diversity of injury models, species, anatomic regions, microglial 
markers and methods of analysis that were used. It is therefore reasonable to assume that 
there are no obvious aging-related impaired ability of the microglia to respond to CNS injury. 
However, this statement only applies to experimental animals, primarily rodents, where it is 
possible to perform time-based studies of acute microglial activation. In human beings, the 
scenario is likely to be different and far more complicated in consequence to the extended 
lifespan of the species.  
Experimental work performed on rodents suggests that microglia are subject to replicative 
senescence, such as loss of mitotic ability following repeated rounds of replication. The concept 
of microglial senescence offers a novel perspective on aging-related neurodegenerative 
disease, of which PD is a notable example, by regarding neurodegeneration as secondary to 
microglial degeneration, adversely affecting the viability and self-renewal capacity of microglia. 
Such attrition of the brain's immune system could contribute to the development of 
neurodegenerative disease by diminishing glial neuroprotection. 
Rodrigues et al. (2004) demonstrated that an interaction between astroglial and microglial 
cells might be involved in incurring damage and in repair-based cascade of events taking place 
within the ventral tegmental area (VTA) in a unilaterally lesioned 6-OHDA rat model of PD. The 
Tyrosine hydroxylase (TH) positive DA cells, the glial fibrillary acidic protein (GFAP) immuno-
labeled astrocytes and the OX42 immunoreactive microglia were visualized by means of 
immunohistochemistry and quantified with stereologic methods. Their results include a 46% 
decrease in the number and density of TH immunoreactive cells in the VTA of 6-OHDA injected 
rats. GFAP immunohistochemistry also revealed an increased number and density of astroglial 
cells, with a 6-OHDA dosage-related increase of 154% and 166% compared to the unlesioned 
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control side. Increased number (76% to control) and density (77% to control) of OX42 microglial 
labeled profiles and microglial processes (51% to control) were also found in the ipsilateral VTA 
of the OHDA injected animals that had received a medium dosage. This suggests that the 
retrograde degeneration of the mesostriatal dopamine pathways induced by a striatal injection 
of 6-OHDA, leads to astroglial and microglial reactions in the VTA. 
Microglia have also been implicated in the production of reactive oxygen species (ROS) and 
the selective degeneration of nigrostriatal DA-ergic neurons as a consequence of exposure to 
all the known neurotoxicants used during both in vitro and in vivo experimental paradigms of 
PD. This includes systemic exposure to the lipophilic pesticide rotenone (Gao et al., 2003; 
Sherer et al., 2003; Ling et al., 2004) and MPTP (Gao et al., 2003; Sherer et al., 2003). 
Although a single intraperitoneal injection of 10 mg/kg of the herbicide paraquat did not cause a 
loss of DA-ergic neurons in the mouse SNpc (McCormack et al., 2005), it appears to induce 
microglial activation (Purisai et al., 2007). A significant number of cells displaying morphological 
and immunocytochemical characteristics of activated microglia were already present at 1 day 
after paraquat administration. Although, the exact relationship between this phenomenon and 
neurodegeneration is still to be elucidated, intraneuronal deposition of SNCA and the selective 
degeneration of DA-ergic neurons in the SN, comprising the pathological hallmarks of the 
disease, are only seen following subsequent exposures to paraquat (Manning-Boð et al., 2002; 
McCormack et al., 2002; Thiruchelvam et al., 2003; Peng et al., 2004). This suggests that the 
initial exposure to the toxin only predispose DA-ergic cells to degeneration, with the effect 
coming to a full once the cells have been subjected to a subsequent challenge (McCormack et 
al., 2005). Such a “priming” effect may be highly relevant to PD since it could underlie the 
mechanism of disease risk factors and help to identify conditions that enhance the vulnerability 
of DA-ergic cells to degenerative processes. 
 
4.3.5.  Genetic mutations as a cause of Parkinson’s disease 
The aetiology of PD remains incompletely understood. Although an interaction between genetic 
and environmental factors is believed to underlie sporadic PD in the vast majority of cases 
(Sherer et al., 2003a), a genetic mutation or loci is regarded as the sole cause for manifesting 
the disease in a small minority of cases (for a review, see Spacey & Wood, 1999). 
Approximately 15% of diagnosed cases of PD reveal a positive family history of the disease 
(Gasser, 2005). Analysis performed in order to link the health status of members of large 
families and the positional cloning of an increasing number of genes that may be responsible for 
manifesting monogenic forms of PD, have provided substantial new insights into the 
pathogenesis underlying the disease. These studies have linked several genes to autosomal 
recessive forms of PD (Gasser, 2005). Since the discovery of the first PD gene locus in an 
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Italian family (Polymeropoulos et al., 1996), a number of PARK genes (1-8) have been identified 
to be involved in the development of PD symptoms (Foltynie et al., 2002). This finding has led 
to the nosology of various genetic subtypes of parkinsonism, including mutations of the PARK 1 
locus (Singleton et al., 2003), which subsequently led to the identification of aggregations of 
SNCA in PD and the finding that LBs are rich in this protein. SNCA was the first gene to be 
associated with the aetiology of genetic forms of PD, with the protein believed to play an 
essential role in synaptic transmission, synaptic vesicle recycling, DA storage and the 
compartmentalization of neurotransmitters. It also associates with vesicular and membranous 
structures (Abeliovich et al., 2000; Yavich et al., 2004; Yavich et al., 2006), and therefore a 
reduced amount of vesicles have been associated with SNCA mutations. It has been suggested 
that unstored DA due to a mutated form of SNCA might lead to an increase in oxidative stress 
to possibly explain the pathogenesis behind PD (Lotharius & Brundin, 2002). 
Although the precise relationship that familial linked genes have to the more common 
sporadic illness remains uncertain, parkinsonism with nigrostriatal DA-ergic degeneration seem 
to be a common pathogenic mechanism that underlie both disease entities (Hardy et al., 2006). 
In addition, lack of a clear family history of PD in the vast majority of disease-cases seems to 
rule out a primary genetic defect involving a nuclear gene. 
The discovery of a mendelian inheritance pattern that underlies certain forms of PD have 
allowed the development of novel genetic animal models (using knock-out and knock-down 
paradigms), providing the basis for improving understanding of the molecular pathogenesis of 
the disease. It is generally believed that the molecular pathways identified in monogenic cases 
may provide relevance to possible pathogenic mechanisms implicated in the common sporadic 
form of the disease. This improved understanding is expected to contribute to the development 
of novel treatment strategies. More complex genetic models that allow for the interaction of 
several genetic variants or gene-environment interplay may tease apart the relative contribution 
each makes towards disease pathology. 
  An ever-increasing number of novel genes are being discovered, enabling a novel disease 
classification based on aetiology. This suggests for a high degree of etiological heterogeneity, 
as it is becomes increasing clear that mutations in different genes might cause the same 
disease entity at both the clinical and the sub-clinical level. Alternatively, mutations in the same 
gene may associate with different clinical and pathological outcomes. The various genetic forms 
of PD will now be discussed.  
 
4.3.5.1.  Autosomal recessive forms of Parkinson’s disease 
Recessive forms of Parkinsonism find their origin in mutated genes that are increasingly 
recognized as representing an important patho-etiological mechanism in early-onset PD, with 
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the age of onset usually being prior to 40 years of age. The mutated loci or genes identified thus 
far include parkin (PARK2), PINK1 (PARK6) and DJ-1 (PARK7). The clinical phenotype 
associated with early-onset recessive parkinsonism often includes additional symptoms, 
including dystonia at onset, and hyperreflexia, with the disease following a relatively slow 
progression (Gasser, 2005). 
 
 
 
4.3.5.1.1.  PARK2 (PARKIN) mutations as a cause of Parkinson’s disease 
A disease that stems from an autosomal recessive inheritance pattern usually appears in one or 
more siblings only (a single generation), born from unaffected parents. Among the three 
autosomal recessive forms of parkinsonism, the version caused by the parkin gene are by far 
the most common (Gasser, 2005). It has been suggested that the source of recurring mutations 
in parkin may stem from mutational hot spots as well as be due to founder effects (Hedrich et 
al., 2004a).  
Certain heterozygous mutation carriers identified in large families with parkin mutations, 
presented with symptoms of late-onset PD or minor parkinsonian symptoms, while manifesting 
mutation carriers have been identified in most mutational screens (Pramstaller et al., 2002; 
Khan et al., 2005). However, a similar frequency of heterozygous mutations in the parkin gene 
was found when elderly healthy individuals were compared to a cohort with late-onset typical 
PD (Lincoln et al., 2003). Moreover, in a recent report concerning a large family of 12 
heterozygous carriers of a specific parkin mutation (ex3delta40) were asymptomatic (Munhoz et 
al., 2004). In addition, the genotyping of a group of families diagnosed with PD showing 
anticipation due to late-onset disease in the parent generation and early-onset disease in the 
offspring, did not support the notion that the presence of single or compound heterozygous 
parkin mutations contribute to this phenomenon (Poorkaj et al., 2005). Therefore, at the present 
moment, although it is certain that heterozygous mutations have an effect on the DA-ergic 
system, due to heterozygous individuals displaying reduced fluorodopa uptake during positron 
emission tomography studies (Khan et al., 2005), the data remains insufficient to confidently 
judge the degree to which single hesterozygous parkin mutations confer susceptibility to 
parkinsonism or even typical late-onset PD.  
The parkin gene encodes for a 465 amino acid protein that contains an N-terminal ubiquitin-
like domain, a central linker region and a C-terminal RING domain that consists of two RING 
finger motifs separated by an in-between RING domain (Thomas & Beal, 2007). It functions as 
an E3 ubiquitin protein ligase in a similar manner to other RING finger containing proteins by 
targeting misfolded proteins to the UPS for protein degradation purposes. In addition, it offers 
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several neuroprotective functions, particularly for ensuring the survival of DA-ergic neurons 
(Feany & Pallack, 2003). There are studies to suggest that parkin mediates neuroprotection by 
activating IkappaB kinase/nucleur factor-kappaB signaling. This was validated by the finding 
that parkin mutations failed to offer similar protection, by lacking the ability to stimulate the 
pathway (Henn et al., 2007). Furthermore, another study found that the UBL domain of parkin 
interacts with ubiquitin interacting motifs (UIM) of Eps15 (Fallon et al., 2006). This adaptor 
protein is involved in the endocytosis and trafficking of the epidermal growth factor receptor, 
which, upon interaction with parkin it ubiquitinates in a proteasome-independent manner. The 
gene-protein interaction interferes with EPS15 UIM’s ability to bind ubiquitinated EGFR. 
Subsequently, this step delays EGFR internalization and degradation and also promotes 
phosphatidylinositol 3-kinase/Akt signaling for cell survival (Fallon et al., 2006).  
Several in vivo studies have indicated a crucial role for parkin in modulating mitochondrial 
functions. This includes a role played in mitochondrial morphogenesis during spermiogenesis 
(Riparbelli & Callaini, 2007), as well as promoting mitochondrial biogenesis, through the 
transcription and replication of mtDNA (Kuroda et al., 2006). Furthermore, in a fly model of PD, 
parkin seemed to rescue mitochondrial dysfunction, muscle degeneration and DA-ergic cell loss 
(Yang et al., 2006). The mechanism for this was suggested to involve an inactivation of a 
putative mitochondrial serine/threonine kinase (PINK1) that is a further cause of autosomal 
recessive PD (Clark et al., 2006; Park et al., 2006). Due to its loss in E3 ligase activity, the 
mutation manifests as autosomal recessive early-onset PD (Zhang et al., 2000; Shimura et al., 
2000; Kitada et al., 1998). The impairment of E3 ligase activity by parkin’s post-translational 
modification involving oxidative or nitrosative stress can also compromise its usual protective 
function (LaVoie et al., 2005). Oxidative damage may also induce solubility alterations in 
disease-specific mutants of parkin as well as in RING-IBR-RING type ubiquitin ligases that 
show similarness to parkin (Wang et al., 2005).  
Mutations in the parkin gene are a major source of autosomal recessive early onset PD. 
Cyclin-dependent kinase 5 (Cdk5) interacts and phosphorylates parkin at Ser131 of its linker 
region, thereby blocking autoubiquitylation, thus leading to parkin aggregation both in vitro and 
in vivo (Avraham et al., 2007). It has been shown that the activation of the Cdk5 pathway 
presents a particular risk for DA-ergic cell death (Smith et al., 2003).  
There seems to be an interactive relationship between SNCA and parkin that may be 
particularly prominent to induce alterations of SNCA-mediated mitochondrial functions (Stichel 
et al., 2007).  
The claims for a pathological role for mutant parkin in PD-related pathoneurogenesis 
received further validation from evidence gathered from several animal studies. Motor 
impairments had been observed in flies following the expression of mutant human parkin, while 
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the insects displayed normal motor function in the presence of wild-type parkin (Sang et al., 
2007). However, this did not produce similar results in an alternative species, since mouse 
models generated by the targeted deletion of parkin failed to produce nigral DA-ergic 
degeneration. Instead, the study only reported a functional impairment in these mice (Moore et 
al., 2005). This work supports those by others that showed that catecholaminergic neurons from 
parkin knockouts are not more vulnerable towards toxic insults than controls (Thomas et al., 
2007; Perez et al., 2005). Similar findings have been reported for the SNCA-induced human 
disease (Stichel et al., 2007; von Coelln et al., 2006). These in vivo findings suggest that the 
neuroprotective efficiency of parkin seems to be highly selective. Its selective action may 
depend on the particular neuroprotective pathway involved. It is expected that its identification 
will assist in elucidating the role that parkin deficiency plays in PD pathogenesis.  
 
4.3.5.1.2.  PARK6 (PINK1) mutations as a cause of Parkinson’s disease  
PINK1 [phosphatase and tensin (PTEN) homolog-induced putative kinase 1] is a protein 
consisting of 581 amino acids that contains an N-terminal mitochondrial targeting sequences as 
well as a highly conserved protein kinase domain that is similar to the serine/threonine kinases 
belonging to the Ca2+ calmodulin family. Its ubiquitous and punctuated expression pattern 
suggests for the tendency to localize to mitochondria (Gandhi et al., 2006).  
Limited information is available on the normal function of the PINK1 gene. However, its 
mitochondrial localization and the presence of a kinase domain suggest for a role in 
mitochondrial pathology, protein stability and kinase pathways (Leutenegger et al., 2006; Beilina 
et al., 2005). A recent study demonstrated that the human PINK1 locus is regulated by non-
coding naturally occurring antisense RNA, thereby emphasizing its role in mitochondrial 
biogenesis (Scheele et al., 2007). PINK1’s mitochondrial-associated physiological function 
seems essentially to protect. This was demonstrated in several in vitro and in vivo studies. DA-
ergic SH-SY5Y cells show increased vulnerability following exposure to the mitochondrial toxins 
rotenone and MPPP+ after PINK1’s function had been suppressed by siRNA (Deng et al., 
2005). These results are consistent with another study that showed the overexpression of wild-
type PINK1 capable of preventing starosporine-induced cytochrome c release by the 
mitochondria with subsequent neuronal apoptosis due to caspase 3 activation (Petit et al., 
2005).  
 Mutations present in the PINK1 gene have been identified as causing early-onset 
familial PD (Valente et al., 2004), although its mutation frequencies vary, particularly among 
different ethnic groups (Klein et al., 2006).  
  
4.3.5.1.3.  PARK7 (DJ-1) mutations as a cause of Parkinson’s disease  
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The protein DJ-1 is a highly conserved member of the DJ-1/Thi/PfpI protein superfamily that 
consists of 189 amino acids. It has ubiquitous expression, localizing to the mitochondria (Zhang 
et al., 2005b). Although extremely rare, accounting for 1-2% of all early-onset PD cases 
(Hedrich et al., 2004b), mutations relating to functional loss in the DJ-1 locus associate with rare 
forms of autosomal recessive early-onset parkinsonism (Bonifati et al., 2005).  
Although its original proposed role was that of an oncogene functioning in sperm maturation 
and fertilization, it’s newly discovered association with pathogenic mutations in familial PD has 
provided it with a range of newly associated physiological roles. It has been assigned an 
antioxidant role, due to its inherent ability to self-oxidize, thereby functioning as a scavenger 
that eliminates the presence of ROS, such as H2O2 (Canet-Aviles et al., 2004). 
Furthermore, the overexpression of wild-type DJ-1 in both a culture-based as well as an in 
vivo model, showed DA-ergic neurons to receive protection against toxin-induced potential 
oxidative damage (Paterna et al., 2007). Its been assigned chaperone activity, after it was 
observed that DJ-1 displays redox-dependent chaperone function that inhibits SNCA 
aggregation and cell apoptosis (Zhou et al., 2006). Furthemore, the finding that it associates 
with parkin during oxidative stress suggests for a shared role played by both to induce 
neuroprotection (Moore et al., 2005). It has been shown to act as a transcriptional co-activator, 
believed to result in its antioxidant action. DJ-1 stabilizes the antioxidant transcriptional master 
regulator nuclear factor erythroid 2-related factor (Nrf2) through a preventative association with 
Nrf2’s inhibitor, Keap1 as well as by ubiquitinating Nrf2 (Clements et al., 2006).  
PD mouse models that had been induced by knocking-out DJ-1 were observed to 
progressively develop age-dependent motor deficits, hypokinesia and DA-ergic dysfunction. 
However, no nigrostriatal DA-ergic cell loss was observed in either these two studies, raising 
questions on whether DJ-1 gene alterations are sufficient to induce full-scale PD (Goldberg et 
al., 2005). However, when challenged with a neurotoxic response evoked by MPTP, the 
nigrostriatal DA-ergic neurons derived from these DJ-1 deficient mice revealed increased 
vulnerability (Kim et al., 2005). Although the reason for this is unknown, various mechanisms 
have been proposed. The reasons proposed include increased p53 and Bax expression 
(Bretaud et al., 2007), deficits in the phase II detoxification enzyme NQO1 (NADPH quinine 
oxireductase 1) (Clements et al., 2006), impaired Na + /K+ ATPase that induces irreversible 
membrane potential changes (Pisani et al., 2006), defective signaling by phosphatidylinositol 3-
kinase/Akt (Yang et al., 2005), and the inability of the apoptotic protein Daxx to inhibit apoptosis 
signal regulating kinase 1 (ASK1) thereby inducing cell death (Junn et al., 2005). Of particular 
significance to PD also is the finding that DJ-1 enables the transcriptional upregulation of TH 
expression (Zhong et al., 2006).  
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Taken together, all the above-mentioned studies on DJ-1 overwhelmingly suggest for its role 
in maintaining and mediating the survival of DA-ergic neurons.  
 
4.3.5.2.  Autosomal dominant forms of Parkinson’s disease 
Two genes responsible for autosomal dominant forms of PD have been identified, both 
appearing to hold major relevance for the typical late-onset sporadic form of the disease.  
 
4.3.5.2.1.  PARK1 mutations as a cause of Parkinson’s disease  
Researchers have identified three missense mutations in the SNCA gene, an alanine to 
threonine conversion at amino acid 53 (A53T), an alanine to proline (A30P) and and glutamic 
acid to lysine (E46K) (Polymeropoulos et al., 1997; Zarranz et al., 2004) that, in addition to 
genomic triplications of a region of the SNCA gene, associates with autosomal dominant PD. 
Two separate studies have brought the protein SNCA to the centre stage in research 
concerning PD aetiology. A missense A53T mutation was found in the encoding gene on 
chromosome 4 in a large Greek family with members that displayed signs of juvenile-onset PD 
(Polymeropoulos et al., 1997). In addition, antibodies used against SNCA stained strongly for 
LBs and LNs in the PD brain (Spillantini et al., 1997). SNCA has an increased propensity to 
aggregate due to its hydrophobic non-amyloid-β component domain, giving rise to aggregation 
and abnormal processing.  
In a fly (Drosophila melanogaster) model of PD, a non-amyloid-β component domain and 
truncated forms of SNCA mediated neurodegeneration, the formation of large inclusion bodies 
an increased accumulation of SNCA species of high molecular weight (Periquet et al., 2007). β-
amyloid seemingly protects against SNCA-induced toxicity. One suggested way in which this 
may be achieved is by reducing SNCA protein expression (Fan et al., 2006), by blocking pore-
like oligomers from developing (Tsigelny et al., 2007), and by activating Akt signaling, thereby 
promoting cell survival (Hashimoto et al., 2004).  
Another study provided support to the critical role played by C-terminal truncation as a 
regulator of SNCA aggregation and DA-ergic toxicity in vivo (Tofaris et al., 2007). Using mice 
for expressing C-terminally truncated human SNCA, with a rat TH promoter on a mouse SNCA 
null background, the animals developed progressive loss of nigral DA-ergic neurons, 
pathological inclusions and impaired motor function. It was further shown that a pathological 
modification involving phosphorylation of Ser129 in SNCA promotes its aggregation, and that 
SNCA phosphorylated by Ser129 forms a major component of LBs (Anderson et al., 2006; 
Smith et al., 2005).  
 Another mechanism that may possibly underlie SNCA aggregation and promote the 
formation of soluble oligomers is the catalyzation of Ser129 phosphorylation of SNCA by the G-
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protein–coupled receptor kinase 5 (Arawaka et al., 2006). One of the earliest defects following 
SNCA accumulation in vivo is blockage of the ER to a supply by Golgi vesicular trafficking, 
thereby disrupting basic cellular functions through increased ER stress (Cooper et al., 2006). 
Furthermore, SNCA has been assigned a crucial role in modulating mitochondrial function 
during neurodegeneration. Evidence for this derives from transgenic mice expressing the 
human mutant SNCA (A53T) that developed mitochondrial pathology (Martin et al., 2006), 
providing a crucial role to SNCA in modifying mitochondrial function. The role played by SNCA 
in mitochondrial pathology has previously been shown, from a study where SNCA depleted 
mice proved to be resistant to the damaging effects of mitochondrial toxins (Klivenyi et al., 
2006).  
 The overexpression of mutant SNCA (A53T & A30P) have also provided valuable clues 
as to the toxic nature of SNCA. This showed an increase in cytsolic catecholamine 
concentrations thereby disrupting normal function. In addition, this facilitated the toxicity of 
oxidized catechol metabolites that have been implicated before to play a role in the selective 
neuronal degeneration seen in PD (Mosharov et al., 2006; Hasegawa et al., 2006).  
 Furthermore, SNCA aggregation has also been assigned a pathophysiological 
relationship. These include the activation of stress-signaling protein kinase (Klegeris et al., 
2006), impairing microtubule-dependent trafficking (Lee et al., 2006), reducing intercellular 
communications at gap junctions (Sung et al., 2007), and inhibiting histone acetylation in the 
nucleus, thereby promoting toxicity (Kontopoulos et al., 2006).  
 
4.3.5.2.2.  PARK8 (LRRK2) mutations as a cause of Parkinson’s disease  
Point-mutations have been identified in virtually all the known domains of leucine-rich repeat 
kinase 2 (LRRK2). One of them is the G2019S mutation, also known as dardarin (Deng et al., 
2006), an important cause of autosomal dominant PD (Paisan-Ruiz et al., 2004). Increased 
research focus has been placed on its role in the pathogenesis of PD, due to reports that 
LRRK2 mutations may occur beyond mere familial cases. People from certain geographical 
parts seem especially vulnerable. Most notably are North Africans and those of a Middle 
Eastern descent, with a frequency rate of 20-40%, while those of European descent are less 
affected at a prevalence rate of 1-7% (Hardy et al., 2006).  
Although this protein’s precise physiological role is presently unknown, its multiple functional 
domains suggest for its involvement in various functions. In an attempt to shed light on the 
functional role it might play, cell-culture and in vivo studies were conducted intended to identify 
the intracellular and tissue-specific location of LRRK2, to shed light on its functional role. It was 
found that the majority of forebrain structures that includes nigrostriatal DA-ergic neurons 
express LRRK2. Moreover, it was found to be predominantly present in the cytoplasm, 
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particularly in the golgi apparatus, synaptic vesicles, plasma membrane, lysosomes, while it 
was also found to associate with the mitochondria’s outer membrane (Higashi et al., 2007; 
Taymans et al., 2006). 
Several studies have demonstrated LRRK2’s role in synaptic vesicle function. A role for it 
was assigned in the polarized sorting of synaptic vesicle proteins to axons, with evidence for 
this derived at by instigating deletion mutants of LRRK2 homolog in Caenorhabditis elegans 
that depleted synaptic vesicle proteins (Sakaguchi-Nakashima et al., 2007). Additional evidence 
to suggest LRRK2’s involvement in synaptic vesicle recycling, neurite outgrowth and functions 
related to the golgi vesicles, lysosomes and mitochondria have recently been made available. 
Impairment in any of these aspects may compromise neuronal survival (Li & Beal, 2005). The 
studies include those that have shown LRRK2’s ability to associate with lipid rafts, to localize to 
LB’s as well as to regulate neurite length and branching (Hatano et al., 2007; MacLeod et al., 
2006).  
Increased kinase activity in LRRK2 is believed to be caused by disease-causing mutations of 
the G2019S and the nearby I2020T that both form part of the N-terminal portion of the activation 
loop in the kinase domain (West et al., 2005; Goeckner et al., 2006). This is believed to lead to 
dardarin’s toxic effects (Greggio et al., 2006).  
Evidence for the association derives from autophosphorylation and the phosphorylation of 
the generic substance myelin, a basic protein, and comparing this to either the wild-type LRRK2 
or to equivalent mutations in paralogous kinase LRRK1 (Greggio et al., 2007). Multiple studies 
have revealed kinase activity in LRRK2 caused by disease-causing mutations affect cell 
viability. Disease pathogenesis is believed to result from apoptotic-induced activation of kinase 
mechanisms (Greggio et al., 2006). Although this mechanism is believed to influence signaling, 
it remains to be ascertained how kinase activity produces this effect. Abnormal protein 
phosphorylation may be involved, since alterations in the phosphorylation of key proteins have 
been detected that are involved in MAPK signaling in the leukocytes taken from patients with 
G2019S mutations (White et al., 2007).  
 
4.3.5.2.3.  Other genes implicated in Parkinson’s disease 
Several genes not already mentioned have been implicated in the pathogenesis of PD, or have 
been re-examined for a possible role to play in the onset of the disease. A meta-analysis done 
provides support for a role of ubiquitine C-terminal ligase 1 (UCHL1) (Maraganore et al., 2004). 
However, the magnitude of the role assigned to the gene has controversial. For instance, 
controversy surrounds the results of association studies with a polymorphism (S18Y) in the 
gene, and the cohort on which the suggested role is based on has been criticized, since only a 
single family, with relatively few members have been described thus far (LeRoy et al., 1998).  
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To date, neither genetic studies nor post-mortem brain studies have been able to inform on 
the temporal sequence and relationships amongst the various cellular processes. It is hoped in 
vivo animal models can only answer these questions convincingly. However, hitherto, no single 
toxin or gene-based model has succeeded to fully recapitulate all the pathological and clinical 
features that define human PD.  
 
4.3.5.3. Relative contribution made by genetic mutations towards the overall 
incidence of the disease 
The aetiology of PD likely involves both environmental and genetic factors that ultimately 
contribute to the progressive demise of specific neuronal cell populations (Di Monte, 2003). 
Various studies have demonstrated that the majority of PD cases cannot explained be 
explained only by simple genetic models. A study performed in Sweden on twins demonstrated 
a low concordance rate, and the analysis of three clusters of cases found in Canada reported a 
greater compatibility with an environmental cause, than the contribution of known genes and 
mutations to the condition. Moreover, a study that examined a large cohort of first-degree 
relatives of probands (therefore, both population- and referral based) suffering from PD and 
relatives of control probands, found only a modestly overall increased relative risk. Whereas the 
relative risk for probands of a younger onset (66 years or younger) revealed a more significantly 
increased risk, the relatives of probands who manifested symptoms when older had no 
associated increased risk (Rocca et al., 2004). This study confirmed the results of a large 
population-based study conducted earlier (Marder et al., 1996), suggesting that alternative 
studies that reported disproportionately higher relative risk estimates may have been influenced 
by referral and ascertainment bias. Recessive inheritance or reduced penetrance may possibly 
explain the negative family history perceived from studying the profile of previous generations in 
some studies.  
Moreover, a large-scale study designed to asses the relative degree to which genetic versus 
environmental factors contribute to the aetiology of PD reports a high degree of concordance 
within twin pairs for early-onset PD (defined as onset before the age of 50). A far lesser 
concordance was found for disease of late onset (onset >50 years of age) (Tanner et al., 1999). 
The epidemiological findings highlight the genetic causes that might be responsible for the 
majority of early-onset PD cases, whereas onset after a patient’s 50th birth-year may possibly 
increase due to the impact of environmental factors instead.  However, the etiologic role played 
by a shared environment can never be completely excluded.  
 
 
4.3.6.  Drug-induced Parkinson’s disease 
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A number of pharmacological agents for lesioning specific neuronal populations are used for 
mimicking the pathological and functional alterations that characterize a disorder. These models 
are useful for evaluating therapeutic strategies for symptomatic relief and are also used to test 
the neuroprotective capacity of substances. In the current context, the capacity of certain 
substances to disrupt or destroy the catecholaminergic systems has been used extensively to 
induce a selective loss of midbrain DA-ergic neurons and develop PD models in different animal 
species, mainly rodents and non-human primates. However, on the basis of experimental and 
clinical findings, PD was the first neurodegenerative disease to be modelled in animals. 
An association between drinking well water, rural living, and exposure to chemicals 
commonly used for agricultural purposes, with increased risk for PD developing has been 
reported (Liou et al., 1997; Priyadarshi et al., 2001). Further epidemiological evidence to 
support an association between past occupational exposure to pesticides and increased risk of 
developing AD or PD (Baldi et al., 2003), while an inverse, apparently protective relationships 
between cigarette smoking, coffee consumption and PD has also been reported (Hernan et al., 
2002). The ability of certain common environmental agents, such as pesticides, to accurately 
reproduce the key pathological features of the disease has led to the widely-supported 
postulation that exposure neurotoxic agents may increase the risk for developing PD (Gorell et 
al., 1998; Menegon et al., 1998). This will be further discussed in the section to follow.  
Chemical agents that block the DA D2 receptors located in the striatum count amongst the 
most frequent causes of a condition clinically referred to as drug-induced parkinsonism (DIP). 
This includes antipsychotics, anti-emetics, as well as calcium antagonists. DIP occurs regularly, 
with figures of 4-37% of all patients quoted (Gershanik, 1994; Bower et al., 1999).  
DIP was first recognised as a clinical syndrome shortly after the introduction of the first 
antipsychotics in the 1950’s. Subsequent investigation following the clinical observation that 
their use often associate with acute or tardive dyskinesia, it was found that they block striatal 
DA D2 receptors, to inhibit them from performing their usual movement-related function. 
Whereas the ”classic” antipsychotics work by blocking D2 receptors, thereby producing 
catalepsy and terminating amphetamine-induced stereotypical behaviour, more recently 
developed ones, such as clozapine, risperidone and quetiapine are not associated with these 
effects. Moreover, these modern “atypical” antipsychotics cause less than 40-70% of D2 
occupancy, which is probably too low to produce parkinsonism (Hirose, 2006), while it is also 
believed that the binding of these drugs to D2 receptors dissociate effortlessly. Therefore, the D2 
receptors remain accessible to intact DA transmission (Seeman, 2002).  
Anticholinergic compounds are used for treating rigidity and tremor associated with PD, and 
therefore, cholinergic drugs, such as cisapride may also provoke or worsen tremor (Sempere et 
al., 1995). In addition, a range of commonly-prescibed medicines are reported to occasionally 
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induce parkinsonism. Although a clear relationship between the compound and the emergence 
of PD remains to be established, the reports do raise concerns, while an investigation as to the 
validity of these claims should be sought. Possible disease-aggregating compounds include 
amiodarone, a cardiac antiarrhythmic drug that possibly provokes thyrotoxicosis that could 
induce the onset of tremor (Armon, 2007; Dotti & Federico, 1995). In addition, lithium often 
associates with postural tremor (Ghadirian et al., 1996), while a range of selective serotonin 
reuptake inhibitors is known to induce DIP, or to at least increase pre-existing PD in 
approximately 10-15% of patients (Gerber & Lynd, 1998; Richard et al., 1999). Furthermore, in 
patients with an underlying disturbed blood barrier barrier (BBB), the antifungal drug 
amphotericin B may produce leukoencephalopathy to give rise to reversible parkinsonism 
(Walker & Rosenblum, 1992; Balmaceda et al., 1994; Mott et al., 1995).  
A drug commonly used for treating alcoholism, disulfiram, metabolises to carbon disulfide, 
and has neurotoxic properties and can also induce lesions in the pallidum and SN (Richter, 
1945), with co-occurance of parkinsonism (Laplane et al., 1992; de Mari et al., 1993). It is also 
worth the mention that several reports describe an association between the use of the 
chemotherapeutics cyclosporine cytosine arabinoside and cyclophosphamide and DIP. This 
particularly seems to be the case in patients who have undergone bone marrow or organ 
transplantations (Mott et al., 1995; Wasserstein & Honig, 1996). 
 Various in vitro studies have raised the possibility that the DA-agonist L-DOPA may be 
toxic to DA neurons. However, no study has been able to confirm these speculations in a 
physiologically relevant animal model. Although long-term L-DOPA use is associated with the 
onset of debilitating motor complications, these are believed to be a reversible adverse effect, 
rather than the result of a toxic insult on the nerve cells. This matter will be returned to at a later 
stage in the current chapter.  
For approximately 60% of all patients, DIP typically manifests within 1 month of starting the 
offending drug regimen, while they usually appear within 3 months in the remaining cases. The 
general risk for developing DIP is estimated to be between 10-40% (Caligiuri et al., 1999; Kapur 
et al., 2000;). The main risk factors for developing DIP are identified to be the dose and potency 
of the drug take, advanced age, female gender, the presence of pre-existing subclinical 
depletion of DA or parkinsonism (Caligiuri et al., 1999; Llau et al., 1994; Marti Masso et al., 
1996).  
The main diagnostic criterion for DIP is therefore the disappearance of symptoms after a 
delay of up to a year following withdrawal of the drug, to suggest underlying idiopathic PD or 
another related nigrostriatal disease. Therefore, DIP is believed to be reversible. However, full 
recovery may take up to 6 months (Marti Masso & Poza, 1996), while one study suggests that 
DIP may persist for up to 2 years subsequent to the withdrawal of the offending drug (Garcia-
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Ruiz et al., 1992). The time-course necessary for recovery may result from the type of drug 
causing the effect, with antipsychotics generally inducing parkinsonism within a 6 month period 
after first taking the drug, while calcium channel blockers, such as the piperazine derivatives 
flunarizine or cinnirazine, generally take longer (9-12 months) for parkinsonian-like symptoms to 
subside (Llau et al., 1994).  
The initial clue to achieving a differential diagnosis of PD should be to establish whether the 
patient has a history of using drugs known to evoke DIP. Ascertaining a history of toxin 
exposure proves more troublesome, since patients are often not aware of the toxic properties of 
compounds. An additional line of investigation concerns the clinical syndrome the patient 
presents with, with DIP and toxic parkinsonism patients that often present with atypical 
parkinsonism with non-parkinsonian signs and symptoms. Moreover, most of these patients 
show no sign of benefiting from DA-ergic agonist treatment. Since DIP and toxin-evoked PD 
often damage the pathway at a downstream location that is involved in producing movements, 
or block postsynaptic D2 receptors, L-dopa or other DA agonists prove to be of no use, since the 
D2 receptors that they usually act on are blocked by the antipsychotic medication. Therefore, 
imaging techniques such as PET and SPECT may be useful to distinguish sporadic-onset PD 
from DIP or toxin-induced PD, since they often reveal that PD is a disease that affects the 
presynaptic DA receptor, whereas DIP and toxin-induced forms predominantly cause 
postsynaptic degeneration. 
 
4.3.7. Toxin-induced Parkinson’s disease 
Medical discoveries typically start with clinical observation, eventually proceeding towards 
attempts to artificially induce clinical conditions in the laboratory (Peller, 1967). PD is regarded 
as a complex entity that most probably manifest due to a combination of environmental triggers, 
an underlying genetic susceptibility and the natural decline seen during old age.  
 It has been suggested that exposure to environmental toxins, such as pesticides and 
herbicides, either on their own or in synergy with endotoxic and/or genetic predisposing factors, 
may contribute towards damage sustained by DA neurons (Van den Eeden et al., 2003), 
especially when exposure takes place during the developmental period, when neurons are 
particularly vulnerable. The four most popular agents used for recapitulating PD are MPP+, the 
active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), the noradrenergic 
analog 6-hydroxydopamine (6-OHDA), rotenone (RT) and paraquat, a compound that is 
structurally similar to MPP+. All of these are mammalian models capable of evaluating therapies 
transferable to the clinic, and testing in non-human primate models is often the first initial step 
before a clinical trial can commence (STAIR, 1999). All of these cause extensive degeneration 
of nigrostriatal DA neurons and mitochondrial dysfunction, with an unbiased count of surviving 
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DA-ergic neurons in the brains of toxin-exposed animals that remains the ultimate validation of 
toxin-induced neuronal destruction (Emborg, 2004). Since pesticide exposure in animals 
simulates the characteristics associated with the PD phenotype (Menegon et al., 1998; Gorell et 
al., 1998), a leap in understanding was made that by exposing animals to similar agents, 
knowledge concerning possible causes of the disease could be expanded on. 
An accurate in vivo experimental model of PD should simulate the core pathology seen in 
human PD in animals also, such as a progressive, selective nigrostriatal DA-ergic degeneration 
and LB formation, as seen in post-mortem PD brains. In addition, it must be able to effectively 
assess the relevance of the systemic oxidative damage and mitochondrial impairment in the 
pathogenesis of PD, and explain the potential role played by pesticide exposure in the 
development of Parkinsonism. Currently, no existing animal model incorporates all the complex 
chronic neurodegenerative features associated with the disease. However, specific chemical 
compounds are used with the aim of disrupting the nigrostriatal DA-ergic pathway and to mimic 
the striatal DA deficiency seen in PD patients. In addition to this central hallmark, the various 
agents provide additional advantages and disadvantages over each other. 
 
4.3.7.1.  Reserpine-induced parkinsonism 
Although reserpine (RES)-use is far less commonly found in the methods section of current 
animal-related research done on PD nowadays, its use has allowed for a major shift in our 
current understanding of one major patho-mechanism underlying the disease. Carlsson et al. 
(1957) demonstrated in rabbits that the drug evokes catecholamine depletion in the brains of 
experimental animals, observed as akinetic behaviour, subsequently relieved by the systemic 
administration of L-DOPA. Moreover, several other clinically used antiparkinsonian drugs (e.g., 
DA agonists, L-DOPA+benzerazide, amantadine and trihexyphenidyl) were shown to improve 
RES-induced akinesia, proving that the behavioral recovery was DA-dependent (Menzaghi et 
al., 1997). After this radical postulation was also confirmed in a human clinical population 
(Hornykiewicz, 1963), the most common hypothesis concerning PD etiology was established, 
that PD’s motor symptoms result from striatal DA deficiency (Bernheimer et al., 1973). RES-
induced hypokinesia in rodents were revealed to be due to lost storage capacity of the 
intracellular vesicles of monoamines (Hornykiewicz, 1966), through magnesium- and ATP-
dependent mechanisms (Carlsson, 1975). 
RES was commonly in use as a centrally acting hypertensive drug, up until Carlsson’s 
finding that it also acts as a presynaptic DA depleting drug, when it was withdrawn from clinical 
use. As experience with RES’s and knowledge concerning its workings increased, investigators 
expressed their concern as to the suitableness of the model relative to its clinical phenotype.  
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However, despite the concern for RES-induced changes, these were found to be only 
temporary and the direct administration of RES into the striatum of animals failed to produce the 
morphological changes associated with the disease that are expected to be present in the DA-
ergic neurons of the SN (Betarbet et al., 2002). Subsequently, these nonspecific effects by RES 
on all variants of monoaminergic neurotransmission (Gerlach & Riederer, 1996) evoked enough 
concern for the model to be considered inadequate to fit its purpose, especially when compared 
to other animal models (Gerlach & Riederer, 1996). In addition, it was found to stimulate the 
release of neurotransmitters that are not thought to be directly involved with the clinical 
condition. However, some studies suggest that other neurotransmission pathways (e.g., 
serotonin and noradrenaline) may be involved in the association between PD and the onset of 
depressive symptoms (Barbosa et al., 1997).  
 
4.3.7.2.  MPTP-induced parkinsonism 
The systemic administration of the designer drug 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine 
(MPTP) accurately produces a Parkinson-like syndrome in both human and nonhuman primates 
(Langston et al., 1983) and provides the most effective experimental model of PD (Jenner, 
2003). MPTP is metabolized to 1-methyl-4-phenylpyridinium (MPP+) by monoamine oxidase B 
present within glia (Chiva et al., 1984), whereupon it is taken up into DA-ergic neurons by 
means of a dopamine reuptake pump (Jatvich et al., 1985). Meperidine is an analogue of MPTP 
that is well-known to produce a severely debilitating form of PD (Langston et al., 1983). 
However, the symptoms of meperidine-induced PD have been shown to respond favourably to 
treatment (Lieberman & Goldstein, 1985).  
 MPTP-analogues continue to be used for agricultural purposes. This provokes concerns, 
in light of the epidemiologically confirmed relationship between chronic exposure to herbicides 
and PD developing (Liou et al., 1997; Dinis-Oliveira et al., 2006; Brown et al., 2006).  
 
4.3.7.3.  Rotenone-induced parkinsonism 
Chronic systemic exposure to the lipophilic pesticide rotenone reproduces the anatomical, 
neurochemical, behavioral and neuropathological features of PD. These include selective 
nigrostriatal DA-ergic degeneration and generating cytoplasmic inclusions containing SNCA and 
ubiquitin (Betarbet et al., 2002; Sherer et al., 2003). Rotenone has two intracellular molecular 
targets, namely inhibiting complex I of the mitochondrial electron transport chain (Chance et al., 
1963), as well as to evoke a microtubule-depolarizing action (Brinkley et al., 1974; Marshall and 
Himes, 1978). It shares these characteristics with that of MPP+, the active metabolite of the 
experimental PD toxin MPTP, which also inhibits complex I (Dauer & Przedborski, 2003) and 
depolymerizes microtubules (Cappeletti et al., 1999; Cappeletti et al., 2001). It is yet to be 
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determined whether paraquat, a structural analogue to MPP+ (Di Monte, 2003) delivers a similar 
microtubule depolarizing effect for cell-selective toxicity, as other environmental toxins linked to 
PD does. Neither of these effects, however, explains the selective vulnerability of DA-ergic 
neurons to rotenone satisfactorily, since neither are cell-type specific. However, it has been 
shown that catecholaminergic neurons are rendered particularly vulnerable to this 
environmental PD toxin when these known activities are combined, since these neurons 
depend on long-range microtubule-based transport for moving its oxidized cargo. Since 
rotenone disrupts microtubule-based transport of DA vesicles, DA accumulates in the soma, 
resulting in increased oxidative stress due to the oxidation of DA, which has leaked from the 
vesicles (Eisenhofer et al., 2004). Moreover, it has been shown that neurons that synthesize 
neurotransmitters that are not susceptible to oxidative stress, such as glutamatergic or 
GABAergic neurons, are more resistant to rotenone toxicity (Ren et al., 2005). 
In contrast to the rotenone-model (discussed in the section below), intraneuronal inclusions 
reminiscent of early LBs have occasionally been described in the MPTP animal model (Kowall 
et al., 2000), a mitochondrial complex I inhibitor, that was discovered when humans were 
accidentally exposed to its toxic metabolite, MPP+ (Langston et al., 1983). Yet the presence of 
LBs in the cytoplasm is not detected consistently, and the ones reported in MPTP-treated 
baboons differ from those found in human brains (Kowall et al., 2000). Moreover, an absence of 
LBs were found in post-mortem human brains, that had developed parkinsonism due to the 
toxic effects of intravenous MPTP administration (Langston et al., 1999), to suggest that the 
neuropathology may result from factors that are additional to a single toxic exposure. Due to the 
lipophilic nature of the compound, MPTP easily crosses the BBB, thereby allowing for systemic 
(Burns et al., 1985; Langston et al., 1984) or intracarotid infusion (Bankiewicz et al., 1986). 
Combinations of systemic and intracarotid administration have also been performed, in order to 
influence the pathological consequences and speed of syndrome onset (Oiwa et al., 2003). 
Mice and monkeys are better candidates for the MPTP-model, in contrast to rats that display 
increased resistance to the effects of the toxin (Giovanni et al., 1994a; Giovanni et al., 1994b).  
 
4.3.7.4.  6-OHDA-induced parkinsonism 
The catecholaminergic neurotoxin 6-OHDA was the first chemical agent discovered to reveal 
preferential toxic effects on the catecholaminergic pathways (Ungerstedt, 1968) of both the 
peripheral as well as the CNS. Since it is unable to cross the blood brain barrier, the drug is 
injected intracerebrally, by stereotactic lesioning of the nigrostriatal pathway, the SN or the 
striatum. It exhibits a high affinity for various catecholaminregic plasma membrane transporters, 
including for dopamine (DAT) and noradrenaline, to allow it to concentrate in both DA and 
noradrenergic nerve terminals. The 6-OHDA mode of action involves the combined effect of 
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ROS and quinones that stems from its ability to oxidize to superoxide species, such as H2O2, 
and para-quinone (Saner & Thoenen, 1971; Heikkila & Cohen, 1971). Once it accumulates in 
the brain parenchyma, it rapidly degenerates the DA-ergic neurons (within 24 hours), while 
striatal DA diminishes 2 to 3 days later (Zigmond & Keefe, 1997).  The toxin therefore leads to 
large-scale destruction of nigrostriatal DA-ergic neurons. Although this makes the model 
valuable for assessing gross motor impairments, this aspect limits its use for exploring more 
subtle motor deficits.  
Systematic intracerebral injections of 6-OHDA led to the first stereotaxic mapping of the 
monoamine pathways present in the rat brain to be proposed (Ungerstedt, 1971), as well as an 
analysis of rotational behaviour, as a classical behavioral test useful for screening drugs with 
potential therapeutic application in treating a range of neuropathologies.  
The 6-OHDA experimental parkinsonian model has been produced in many species, 
including mice, rats, cats, dogs and non-human primates (Zigmond & Stricker, 1989). Major 
differences in terms of magnitude of the lesion have been detected based on the amount of 6-
OHDA administered, the anatomical site of the injection and inherent differences between 
animal species as to sensitivity shown towards the substance (Betarbet et al., 2002), thereby 
preventing the method from currently being standardized in any way. However, rats remain the 
most commonly used species due to its high degree of replicability and stability, with only minor 
degrees of individual variance (Emborg, 2004). The model has been criticized for inaccurately 
simulating all the clinical and pathological features that characterize PD, such as a failure to 
produce an effect on the locus coerulleus or the lack of typical LB-like inclusions in mammalian-
models. However, despite these limitations, the model provides an efficient route by which to 
ascertain the efficacy of compound that hold promise for use in parkinsonian-related activities, 
such as for determining the value of cell transplants and neurotrophic factors (Dunnett et al., 
1983). A striatal injection of 6-OHDA induces a retrograde degeneration of the mesostriatal 
dopamine pathways (Rodrigues et al., 2004). However, in PD, as opposed to experimental PD, 
neurons may also degenerate in an anti-retrograde manner. 
Due mainly to practical considerations, 6-OHDA has been employed mainly in small animals 
such as rodents, although attempts have been made to administer the toxin to non-human 
primates as well (Crofts et al. 2001).   
 
4.3.7.5.  Metamphetamine-induced parkinsonism 
Metamphetamine is used for the drug’s ability to stimulate DA release (McMillen, 1983), 
resulting in DA depletion at the level of DA-ergic nerve terminals, albeit showing minimal 
reactions within the nigral cell bodies (Fibiger & Mogeer, 1971). Yet, the mechanism with which 
metamphetamine achieves its effects remains debatable. However, the strongest evidence thus 
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far suggests that metamphetamine exerts its neurotoxic effects via the DA receptor and the DA 
transporter (DAT). These studies, that showed how selective antagonists are able to block its 
toxic mechanism of action (Sonsalla et al., 1986; Sonsalla et al., 1989), remains, however, an 
indirect means by which to derive at a conclusion. An alternative explanation suggests that a 
disturbance in the cellular energy metabolism, specifically oxidative stress, due to DA 
autoxidizing and excitotoxicity (Kostrzewa et al., 2002) may be responsible for the adverse 
effects exerted on neurons. The ideal candidates for metamphetamine administration are 
rodents and non-human primates that incur neurotoxic effects when the drug is administered at 
very high doses (Wagner et al., 1980; Wagner et al., 1979). However, major concern with 
regard to the applicability of the disease towards the clinical phenotype, is that histochemical 
profile associated with PD, namely degenerated DA-ergic nerve terminals and intracellular 
inclusions have not been detected. Further criticism is that it is useful as an acute model of 
striatal DA depletion only, and that PD follows fundamentally a chronic, progressive course. Yet, 
despite these limitations, metamphetamine continues to be used extensively in biochemical and 
physiological studies that focuses on the effects of striatal DA depletion.  
 
4.3.7.6.  Paraquat-induced parkinsonism 
Systemic exposure of rodents to the herbicide paraquat, alone or in combination with the 
fungicide, maneb, accurately reproduces certain pathological features of PD. This includes the 
formation of intraneuronal deposits of SNCA and the selective degeneration of DA-ergic 
neurons in the SN (Manning-Boð et al., 2002; McCormack et al., 2002; Thiruchelvam et al., 
2003; Peng et al., 2004). Chronic treatment with paraquat or paraquat/maneb was also shown 
to activate microglia. Although the relevance of paraquat mediated glial activation remains to be 
demonstrated (McCormack et al., 2002; Saint-Pierre et al., 2006), so far epidemiological studies 
have shown a lower risk for PD associated with regular use of non-steroidal anti-inflammatory 
drugs (Chen et al., 2005). In addition, an abundance of reactive microglia, as mediators of 
neuroinflammation were found in post-mortem SN, particularly around nerve cells (Langston et 
al., 1999). As was explained in section 4.3.4. of the current chapter, a so-called “priming” effect 
may possibly be responsible for neuronal cell death that stems from exposure to paraquat.  
Since PD is likely to have a multifactorial etiology, insight as to the mechanisms that underlie 
toxin-mediated cell death, could help to identify conditions that enhance the vulnerability of DA-
ergic cells to degenerative processes. Since this “priming effect” of paraquat may be the toxic 
consequences of NADPH-oxidase-catalyzed reactions such as the ability to redox cycle, which 
a variety of other naturally occurring and synthetic molecules also show the ability for (Frank et 
al., 1987), a range of toxic agents may be particularly relevant to neurodegenerative processes 
that selectively target DA-ergic neurons.   
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4.3.8.   Parkinson’s disease induced by sustaining mechanical trauma 
Mechanical brain damage resulting from traumatic head injury can result in the same core 
symptoms by which PD is recognised. Epidemiological data also suggest for an association 
between the incidental rate of sporadic neurodegenerative diseases and a history of mechanical 
stress, such as head injury. On average, it takes 30 years from when the injury occurred, for the 
first PD symptoms to appear (Taylor et al., 1999; Bower et al., 2003; Semchuk et al., 1993). In 
addition, LB formation (and SNCA aggregation) has been found in the brains of trauma victims 
similar to the brains of PD patients (Uitti & Calne, 1993; Uryu et al., 2003).  
 
 5.    Differentially diagnosing Parkinson’s disease 
Whereas the cause of primary parkinsonism that makes up the majority of PD cases, are 
sporadic and of unknown aetiology, causal agents have been identified for certain forms of the 
disorder. These are also referred to as secondary parkinsonism. While the motor-related 
symptoms were initially considered to be unique to PD, it later became appreciated that other 
neurodegenerative disorders, including multiple system atrophy and progressive supranuclear 
palsy also manifest some or all of these clinical features. Other conditions include certain 
infections (encephalitis lethargica), intoxications (manganese, carbon monoxide poisoning and 
methylphenyltetrahydropyridine), iatrogenic conditions (DA-ergic antagonists) and certain 
disorders of the CNS (i.e. hydrocephalus and infarctions) equally exhibit some of these 
symptoms. In light of the awareness that various clinical conditions can co-occur with some of 
the core symptoms of parkinsonism, it was necessary to develop a system that will allow for 
differentiating idiopathic PD from other related conditions. 
 Idiopathic PD is a generic term used for describing the movement disorders that are 
caused by the degeneration, infection, injury, or intoxification of the DA-ergic neuronal system, 
which compiles the most common cause of parkinsonism (Yahr, 1982). Although PD is 
hallmarked by an imbalance between DA-ergic inhibition and cholinergic excitation via the 
depleted state of endogenous DA levels, numerous other defective mechanisms may underlie 
the eventual manifestation of the disease. Although the term classically means “to have no 
known cause”, this term is not strictly true in light of the plethora of newly discovered genetic 
mutations that were discussed in section 4.3.5. 
Although the diagnosis of PD may conceal a far-ranging pattern of related disorders that 
differ only in terms of its aetiology and course, and therefore challenge clinicians to distinguish 
idiopathic PD from other clinical phenotypes. Classification schemes with limited criteria that 
need to be met have been developed. There are currently no clinical tests available with which 
to confirm a diagnosis of idiopathic PD. However, a positive response to the synthetic 
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administration of dopamine (levodopa/L-DOPA), a DA precursor that provides symptomatic 
relief from symptoms due to the disease’s inherent DA deficiency, separates idiopathic PD from 
disorders that may present a similar clinical profile.  
 Neurological diseases that are characterized by the presence of involuntary 
hypokinesia, hyperkinesias, or the abnormal execution of movements, in the presence of 
definite consciousness, are classified as movement disorders, also sometimes referred to as 
dyskinesias. Dyskinetic disorders refer to functional anomalies that are due to a disruption of 
the DA-modulated, cortico-striato-pallido-thalamocortical neuronal circuitry (the so-called 
extrapiramidal system). This definition, based on the patho-origins of the disease, exclude 
certain forms of movement disorders from the mainstay definition of dyskinetic disorders. 
Examples of these are epileptic fits that occur in the presence of impaired consciousness, as 
well as motor dysfunction induced by upper and/or lower motor neuron diseases that has a 
purely muscular profile. Moreover, arthrogenic disorders are also not defined as dyskinetic 
disorders.  
To achieve a differential diagnosis for PD often proves an exceedingly difficult task. 
However, certain clinical tools may be useful, and could possibly be underutilised in clinical 
practice. Olfactory testing could be a useful adjunct to clinically distinguish between idiopathic 
PD and related conditions, i.e. vascular parkinsonism (Katzenschlager et al., 2004), dementia 
with LBs (Liberini et al., 1999). Although all these pathologies clinically present with disturbed 
olfactory function, the degree and stage of onset during disease progression differs. In addition, 
olfactory function is only mildly impaired in multiple system atrophy (Wenning et al., 1995), while 
appearing normal in progressive supranuclear palsy (Wenning et al., 1995), corticobasal 
degeneration (Wenning et al., 1995) and parkin-positive parkinsonism (Khan et al., 2004).  
 
6. Therapeutic strategies for treating Parkinson’s disease   
6.1. Pharmacological treatment of Parkinson’s disease  
Although a number of decades have elapsed since PD was first recognized as a disease entity 
in the early part of the 19th century, no treatment to either induce a permanent cure or that 
prevents the progressive pathology exists. The reason for this is that the exact mechanisms that 
underlie the neurodegeneration continue to remain elusive.  
Standard therapeutic guidelines for PD entail administration of DA agonists as well as other 
DA-ergic analogues (Hingtgen & Siemers, 1998). The therapeutic aim of these is to correct 
unbalanced striatal DA-levels that form a prominent characteristic of PD.  
In 1967, George Cotzias and colleagues (Kordower & Goetz, 1999) were the first to 
introduce L-DOPA (Levodopa, LARODOPA, DOPAR, L-3,4-dihydroxyphenylalanine), an orally 
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administered DA-ergic precursor (Fig. 4). L-DOPA therapy can have dramatic effects on PD 
symptoms, by near complete improvement of tremor, rigidity, and bradykinesia.   
The introduction of L-DOPA into clinical practice brought about a revolution in treating the 
disease, and it soon became regarded as excellent pharmacotherapy for what was previously 
seen as essentially an untreatable disorder. Its acceptance as the standard therapeutic regime 
for treating the disease dramatically reduced the need for invasive surgical treatment, which 
was the sole treatment option available at that stage. The drug remains the most common 
agent in PD treatment (Hardman & Limbird, 2001).  
After its oral administration, the drug is rapidly taken up from the small bowel through active 
transport mechanisms specific for aromatic amino acids. Plasma levels peak between 0.5 and 2 
hours following oral ingestion, and lasts 1-3 hours. The intake of L-DOPA with food may delay 
its absorption and reduce its peak plasma concentrations, due to dietary amino acids competing 
for absorption sites in the small bowel. The drug crosses the BBB by a carrier of aromatic amino 
acids, and comprises an active process. Competition between dietary protein and the drug may 
again impair L-DOPA’s absorption at this level.  
In the brain, L-DOPA exerts its effects by converting to DA via decarboxylation. This 
alteration primarily takes place within the presynaptic terminals of DA-ergic neurons in the 
striatum. After release, DA is either transported back into DA-ergic neurons by the presynaptic 
uptake mechanism, or metabolised by monoamine oxidase (MAO) or catechol-o-methyl-
transferase (COMT) (Mouradian & Chase, 1994). 
 L-DOPA, along with other DA-like agents, such as Carbidopa, Bromocriptine, Deprenyl and 
Amantadine is often described as the “gold standard” of medicinal therapy currently available to 
PD sufferers (Kordower & Goetz, 1999). L-DOPA’s co-administration with carbidopa, a 
peripherally acting inhibitor of aromatic L-amino acid decarboxylase is common practice. This 
therapy prevents L-DOPA’s decarboxylation by enzymes in the intestinal mucosa and other 
peripheral sites. This combination therapy lets a greater fraction of DA enter the CNS, thereby 
enhancing its central effects.  
 However, the therapy associates with the onset of severe drug-induced complications, which 
restricts its practical use (Jankovic, 2006). Both the therapeutic efficiency as well as the adverse 
effects of L-DOPA are due to the decarboxylation of L-DOPA to DA. These manifest mainly as 
motor fluctuations, particularly as disabling dyskinesias (Calon et al., 2003). Early on during 
disease pathogenesis, a single dose of L-DOPA provides long-lasting symptomatic relief, often 
in excess of 4 hours, despite the drug’s inherently short plasma half-life (Muenter & Tyce, 
1971). However, due to a combination of sustained drug-treatment and the progressive 
pathology of the disease, the period that the patient stands to benefit from treatment following a 
single dose of L-DOPA shortens progressively. This ‘wearing-off’ effect eventually becomes 
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approximately equal to the plasma half-life of the drug (Nutt & Holford, 1996; Nutt, 1987). To 
manage this requires ever-increasing amounts of the drug at greater frequencies in order to 
achieve consistent therapeutic results (Kordower & Goetz, 1999; Lozano et al., 2000). 
Subsequently, increasingly severe motor complications or excessive and abnormal involuntary 
movements (dyskinesia) manifest with ever increasing drug-doses (Schrag & Quinn, 2000).  In 
addition, the results from the highly anticipated Earlier vs. Later Levodopa (ELLDOPA) clinical 
trial, also suggest that motor complications are dose-related (Fahn et al., 1999).  
The fluctuations in L-DOPA’s plasma-levels directly translate to fluctuations in striatal DA 
levels, resulting in pulse-like delivery of L-DOPA, instead of a continuous flow. This could 
activate post-synaptic signal transduction mechanisms, leading to altered neuronal firing 
patterns in the pathway that contains the GPi, STN and the GPe-STN-GPi structures. 
Consequently, treatment regimens that make use of standard formulations that consist of short-
acting L-DOPA result in marked oscillations in both synaptic and striatal DA levels (Abercrombie 
et al., 1990; Miller & Abercrombie, 1999; de la Fuente-Fernandez et al., 2004; Tedroff et al., 
1996). Therefore, the exposure of striatal DA receptors to either extremely high or very low 
levels of DA, instead of a constant concentration, results in intermittent, discontinuous 
stimulation of the DA receptors. This effect, also known as ‘pulsatile stimulation’, destabilizes 
the DA-denervated basal ganglia. 
Furthermore, patho-physiological pulsatile stimulation results in a range of expressional 
changes within the striatal neurons at the gene and protein-level, including preproenkephalin, 
preprodynorphin, ∆fos-B and DA-receptor-related signals (Calon et al., 1998; Cenci et al., 1999; 
Aubert et al., 2005; Papa et al., 1991; Filion et al., 1991; Heimer et al., 2002; Picconi et al., 
2003). As the disease progresses further, the ability of patients to respond to individual doses of 
L-DOPA may completely disappear (‘no-on’) and unpredictable fluctuations between ‘on’ and 
‘off’ periods, often referred to as the ‘on-off’ or the ‘yo-yo’ phenomenon is observed (Marsden & 
Parkes, 1976). Therefore, in relation to time, a marked change in the patient’s pattern of 
response to L-DOPA therapy is observed. These have been attributed to a central 
pharmacodynamic effect, since they don’t associate with any pharmacokinetic L-DOPA 
changes and are evoked by the DA-ergic agonist apomorphine, which is not stored in the 
striatal nerve terminals (Fabbrini et al., 1988). These alterations potentially form the molecular 
basis that underlies L-DOPA induced dyskinesias and attempts are made to correct these by 
implanting novel delivery systems into the brains of PD victims, allowing for continuous L-DOPA 
delivery.  
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Fig.   4.     A schematic diagram illustrating how L-DOPA is converted from Tyrosine hydroxylase 
to dopamine, noradrenalin, and eventually adrenalin. 
 
 The effective treatment of L-DOPA motor and non-motor complications present one of the 
most challenging domains of PD research (Jankovic, 2005). However, the use of L-DOPA is 
limited, due to the onset of debilitating motor complications that is particularly troublesome in 
patients who display symptoms at a young age (Jankovic, 2006). Since these relate to the 
relatively short half-life that is inherent to L-DOPA’s, it has been suggested that DA replacement 
therapies induce discontinuous or pulsatile non-physiological stimulation of DA receptors 
located in the striatum, with the initial “bursting” effect that soon surpasses (Olanow & Obeso, 
2000; Obeso et al., 1994). Continuous stimulation of striatal DA-ergic receptors with DA-ergic 
agonists has been proposed as an alternative therapeutic strategy for the management of these 
(Chase et al., 1989; Nutt et al., 2000; Olanow et al., 2000). The rationale for this therapy is that, 
under normal conditions, DA-ergic neurons in the basal ganglia fire in a random, yet continuous 
manner, thereby maintaining constant DA concentrations. However, these levels are 
substantially depleted in the parkinsonian brain, and therefore intermittent oral doses of L-
DOPA induce discontinuous, pulsatile, wave-like stimulation of striatal DA receptors, with 
concomitant molecular and physiological changes that occur in the basal ganglia. Therefore, it 
is hoped that this novel form of therapy could delay or even altogether prevent the onset of 
debilitating dyskinesias. A number of clinical studies have also demonstrated how continuous 
subcutaneous delivery of a DA agonist (e.g. lisuride or apomorphine), or the intrastriatal infusion 
of L-DOPA can reduce both motor fluctuations and dyskinesia in L-DOPA treated patients 
suffering from PD (Katzenschlager et al., 2005; Manson et al., 2002).  
 Another aspect of L-DOPA treatment that causes concern is that the production of free 
radicals from the metabolism of DA may contribute to nigrostratal cell death. Therefore, the 
addition of L-DOPA may actually accelerate the process (Olanow et al., 2000). In addition, 
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another common side-effect associating with the use of this medication is the induction of 
hallucinations and a confused-state. These are particularly severe in the elderly and those 
suffering from previous cognitive disabilities. Treatment with traditional anti-psychotics, such as 
phenothiazines can worsen parkinsonian symptoms, probably through actions at the D2 
receptor level.  A recent approach is to use atypical antipsychotics (e.g. clozapine and 
quetiapine) instead. These are effective at treating psychosis, but without the adverse motor 
effects associating with the use of typical antipsychotics that may worsen parkinsonism 
(Friedman & Factor, 2000). Other side-effects of L-DOPA include orthostatic hypotension, 
cardiac arrhythmias, while its abrupt withdrawal may precipitate neurologic malignant syndrome 
(Hardman & Limbird, 2001).  
Despite its adverse reactions, L-DOPA remains the most common agent for treating the 
disease. Yet the need for better and more physiologically based types of therapy for treating 
this complex condition has been recognised. Subsequent to this realisation, a number of novel 
therapeutic options have been proposed and are currently being developed as either an 
alternative to L-DOPA therapy or to use in combination with PD’s standard therapeutic regimes. 
However, given the clinical benefits provided to virtually all patients with PD through the use of 
L-DOPA, all new agents are measured against the ‘gold standard’ for PD therapy. One drug 
class that has been earmarked for it’s possible complimentary benefits to the PD therapeutic 
regime, is the orally administered 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase inhibitors, also known as statins (see Fig. 5 for the chemical structure of the statin, 
simvastatin). These agents inhibit the rate-limiting enzyme HMG-CoA reductase that catalyzes 
the reduction of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate during the 
synthesis of cholesterol (Rossi, 2006). 
 
 
Fig.  5.     Chemical structure of the drug simvastatin®. 
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However, despite the promise of additional therapeutic benefits associated with these drugs, 
research into their mechanism of action has been limited. This aspect of the study is elaborated 
on in chapter 7.  
 Another standard therapy for PD is the use of direct striatal DA-ergic receptor agonists. This 
approach offers several potential advantages over L-DOPA therapy. Most prominently these 
drugs do not depend on enzymatic conversion to induce an effect, and therefore do not require 
functional DA-ergic neurons. This characteristic may potentially make them more beneficial for 
treating late-stage PD. Moreover, DA receptor agonists are more selective in their action. Unlike 
L-DOPA that activates all DA-ergic receptor types, this class of drugs displays relative selection 
to receptor subtype activation. Also, their duration of action is prolonged compared to L-DOPA, 
and therefore offer an improved management option of dose-related fluctuations in motor state. 
Finally, if the free radical hypothesis of L-DOPA should prove to be correct, then direct DA 
receptor agonists may offer an advantage over L-DOPA by reducing endogenous DA release, 
as well as to lessen the need for exogenous L-DOPA (Goetz, 1990). However, all four of the 
currently availabe DA receptor agonsts (bromocriptine, pergolide, ropinirole, and pramipexole) 
may produce hallucinations or confusion (similar to L-DOPA), and may also worsen orthostatic 
hypotension. 
   The use of COMT inhibitors (since COMT and MAO are responsible for catabolising DA) is 
another pharmaceutical attempt for treating PD. When L-DOPA is taken orally, nearly 99% of 
the drug is catabolized before it reaches the brain. The drug’s decarboxylation in the periphery 
to DA causes nausea and hypotension. The addition of carbidopa reduces the formation of DA, 
but increases the fraction of L-DOPA that gets methylated by COMT. The principal therapeutic 
action of the COMT inhibitors is therefore to block the peripheral conversion of L-DOPA to 3-O-
methyl DOPA. This increases the plasma half-life of L-DOPA and the amount from each dose 
that reaches the CNS (Goetz, 1998). In double-blind trials, the COMT inhibitors, tolcapone and 
entocapone, reduced the clinical symptoms of “wearing-off” in patients treated with L-
DOPA/carbidopa (Parkinson Study Group, 1997; Kurth et al., 1997). Unfortunately, the adverse 
effects associated with COMT inhibitors are similar to L-DOPA and carbidopa’s separate use, 
and in addition the COMT-inhibitors may also induce hepatotoxicity. Patients receiving this drug 
therefore require careful monitoring.  
MAO has two isoenzymes, MAO-A, and MAO-B, with MAO-B the predominant form in the 
striatum. Here it is responsible for the majority of DA’s oxidative metabolism. Selegiline is a 
selective inhibitor of MAO-B that irreversibly inhibits the actions of this enzyme (Olanow, 1993). 
Since it is a specific inhibitor, it does not inhibit the peripheral catabolism of catecholamines, 
and therefore can be taken safely with L-DOPA. Only a moderate dose of selegiline should be 
taken, since doses higher than 10 mg daily may inhibit MAO-A.  
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Before the discovery of L-DOPA, muscarinic acetylcholine receptor agonists were widely 
used for treating PD. Although the biological basis for the actions induced by these agents are 
not completely understood, the most likely scenario is that they act in the neostriatum where 
they exert their actions on cholinergic striatal interneurons. Five subtypes of acetylcholinergic 
muscarinic (M1-M5) receptors have been identified thus far, with at least four being present in 
the striatum (Hersch et al., 1994). All of the currently-used muscarinic agonists show a modest 
anti-parkinsonian effect. This is useful for treating early PD or as an adjunct to dopamimetic 
therapy. All the side-effects, such as sedation and mental confusion that stem from use of these 
drugs, are attributed to their anticholinergic action. 
Interestingly, it has been shown that amantadine, an anti-viral agent for the prophylactic 
treatment of influenza, has shown anti-parkinsonian effects, although the mechanism by which 
it achieves this effect remains unclear. It may do so by altering DA’s release or reuptake, while 
anticholinergic mechanisms may also be involved. Moreover, the drug’s effect at the level of 
NMDA glutamate receptors, may contribute to its anti-parkinsonian actions (Stoof et al., 1992). 
The anti-parkinsonian effects are often described as modest only, and hence the drug is often 
used as an initial therapy of mild PD only. Although well tolerated, its use has been associated 
with dizziness, lethargy, and sleep disturbances. Fortunately these side-effects are mild and 
usually reversible (Hardman & Limbird, 2001).  
However, to date no drug or surgery-based treatment has succeeded in completely slowing 
down the rate of neural loss following the onset of PD. In addition, in cases where the disease 
has been marginally slowed-down, these have not been without their own clinical reactions, that 
include side-effects due to overmedication, on/off effects as well as idiosyncratic reactions. 
Moreover, it is important to recognise that although laboratory experiments indicate that the use 
of DA direct receptor agonists may offer advantages over that of L-DOPA, clinical studies have 
only been able to provide limited direct evidence for this. Thus it is important to experiment and 
identify new neurobiological targets for preventing and/or treating the disease.  
 
6.2. Neurosurgical intervention therapy for Parkinson’s disease  
The neurosurgical treatment of PD has undergone a dramatic shift in focus over the past few 
years. Between 1950 and 1968, thalamotomy and other neuro-ablative procedures played a 
critical role in the treatment of PD (Jankovic, 2006). During this period, patients who suffered 
from severe forms of PD were left with very little therapeutic hope for improving, often dying 
from poor nutrition, pneumonia and aspiration, and therefore, surgical intervention was 
regarded as a desperate last option. In recent years ablative stereotaxic surgery, particularly 
techniques that target the pallidus, have received rejuvenated status as therapeutic strategies, 
by allowing for improved activities relating to daily living and functional independence (Lozano 
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et al., 1998). Another method makes use of bilateral deep-brain stimulation employing high 
frequency, to reduce the hyperactivity, an essential feature of the parkinsonian state, of the 
STN. This increases excitatory drive in the GPi and SNr, which, in turn, overinhibits the motor 
fibres projecting to the thalamus and brainstem. The GABAergic internal segment of the GPi of 
PD patients are chronically overactive in the PD brain, and therefore the technique aims to slow 
down both the motor thalamus and the cortical motor system to produce the slowness, rigidity 
and poverty of movement that characterizes the parkinsonian state (Lozano & Lang, 1998).  
However, despite the optimism that surgical therapies evoke for treating PD’s motor-
symptoms, certain adverse effects are associated, including potentially life-threatening side-
effects, such as intracranial haemorrhage and infections. In addition, they are expensive and 
not universally available, and they do not seem to provide superior anti-parkinsonian benefits to 
what can be achieved with L-DOPA (Walter & Vitek, 2004; Olanow et al., 2006). Considering 
the above, surgical treatment is regarded as the final therapeutic option after the disease has 
left the patient completely incapacitated and beyond the help of any other forms of medication 
or therapy (Lozano & Lang, 1998; Jankovic, 2006). In addition, surgical intervention is often a 
last resort, when a patient is left completely disabled due to L-DOPA-induced motor 
complications (Olanow et al., 2006).   
Experimental therapeutics of PD also includes implantation of genetically engineered cells 
and stem-cells (Svendsen, 2008). However, clinical trials performed on implanted DA-secreting 
cells taken from the patient's own adrenal gland have yielded little long-lasting beneficial 
impact. Instead, patients that had received this form of surgery developed pneumonia and 
bladder infections related to the adrenal gland’s removal (Porena et al., 1996).  
 
7.  Themes and objectives of the thesis 
  The overall objective of the current study was threefold:  
i) Firstly, to investigate for possible mechanisms that might explain why PD occurs 
more commonly in males than in females. To address this question, a thorough 
search of the literature was conducted in conjunction with a mining-search of the 
World Health Organization’s (WHO) database on adverse drug reactions in order to 
determine a possible relationship between estrogen and progesterone, as the most 
obvious underlying mechanism and symptoms responsible for the PD syndrome 
(Chapter 2). The search highlighted the lack of consensus with regards to the role of 
gonadal hormones to offer protection in the onset and development of PD (Chapter 
3). Subsequent to this, experiments were performed on young rats, to compare the 
effects of a toxic 6-OHDA lesion on the brains and motor-behavior of these animals. 
The exceptional young age of the animals served to limit the extent to which gonadal 
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hormones can affect the final outcome. The difference in neurotrophin levels were 
determined between the genders, in particular nerve growth factor as a possible 
measure of protection against the toxic insult and correlated this with the lesion size 
in the striatum. 
 
ii) Secondly, whether early life stress could predispose DA-ergic neurons to 
subsequent insults was investigated. For this study the conditions injecting 6-OHDA 
needed optimisation, with particular emphasis placed on the delivery of the insult as 
well as on the development of motor-function tests, sensitive to the degree of DA 
loss. The lesion methodology was therefore established (chapter 4 by characterising 
the effects of different modes of toxin-delivery (medial forebrain bundle (MFB) vs. 
striatum) on motor-behavior. Once the experimental conditions, including 
ascertaining a set of co-ordinates were established, the question relating to the 
impact of early life stress on neuron vulnerability could be pursued. In doing so rat 
pups were subjected to maternal separation between postnatal days 2-14, prior to 
receiving a 6-OHDA injection into the MFB on postnatal day 35. Subsequently the 
effects of early-life adverse events on 6-OHDA-induced abnormalities were 
determined (chapter 5). 
 
iii) Statins are used in patients suffering from hyperlipidemic conditions. However, 
recently it has been postulated that statins may also have neuroprotective effects. In 
view of this promising observation, experiments were performed to confirm this 
neuroprotective effect in a rotenone rat model of PD. The focus of the study was on 
the effects it produces on mitochondrial proteins using sensitive proteomic 
techniques, and to relate the biochemical results to the rats’ performance in sensitive 
motor-function tests. This was done in order to generate a better understanding of its 
possible mechanism of action (chapter 7). However, the study is preceded by a 
thorough literature review on current proteomic techniques and its applicability to PD 
(chapter 6). 
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CHAPTER 2 
 
ESTROGEN THERAPY AND SYMPTOMS OF PARKINSONISM:  A REVIEW OF THE 
LITERATURE AND AN EXAMINATION OF THE WHOS’ ADVERSE DRUG REACTION (ADR) 
DATABASE 
 
1. INTRODUCTION 
Several epidemiological studies conducted in the US and Europe report a 1.5 to 2 times higher 
incidence and prevalence of PD in men compared to women (Van den Eeden et al., 2003; De 
Lau et al., 2004; Wooten et al., 2004; Claveria et al., 2002; Benito-Leon et al., 2003; Tanner & 
Ashton, 2000; Baldereschi et al., 2000; Mayeux et al., 1995). However, in contrast, a female 
preponderance for PD has been reported in Japan (Kimura et al., 2002). Reports of a reduced 
anti-parkinsonian threshold dose for Levodopa in women and additional gender differences in 
terms of symptoms and response to Levodopa treatment have also been reported (Blanchet et 
al., 1999). However, there are numerous discrepancies in the literature regarding gender 
differences reported in terms of incidence, symptoms, medication effects and response to 
treatment (Shulman & Bhat, 2006). These include reports by some European-based 
epidemiological studies of a higher prevalence of very late-onset PD found in females (Bower et 
al., 1999) and lifetime fluctuations in the progressive course of PD in female patients (Sato et 
al., 2006).  
 The marked gender difference in the rate of developing the disease, suggest that the brain's 
hormonal environment achieved during adulthood may be an important point of departure in the 
search for explaining the phenomenon. Realization as to the important beneficial effects that 
sex hormones, particularly estrogen, may play in the development and maintenance of not only 
the female reproductive system, but also its recognized neuroprotective effects, has resulted in 
the pharmaceutical development of a vast variety of steroidal and non-steroidal compounds that 
interact with estrogen receptors. An example of this includes the contraceptive pill, which has 
caused a revolution in medical practice over the past 40 years (Cianci & De Leo, 2007). 
Globally, more than 60 million women currently receive oral contraceptive (OC) therapy 
(Tierney & Luine, 1997).  
 The many health benefits associated with the influence of exogenously applied sex 
hormones on endogenous sex hormone levels have led to the development of therapeutic 
strategies not principally aimed at regulating the menstrual cycle, as is the case with OCs, but 
rather to reduce the harmful effects that may follow the cessation of menstruation, that marks 
the onset of menopause.  
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 Due to improvements in medical care over the past few decades, average life expectancy 
has increased, accounting for the population of the Western world aging at a progressive rate 
(Ernst & Hay, 1994). However, the average age at which menopause commences and 
terminates remains constant, so that women in countries that provide a high standard of health 
care can currently expect to live up to one half of their adult lives following the menopausal 
transition phase (Vliet & Davis, 1991). Menopause is a normal milestone experienced annually 
by at least 2 million women in the U.S. alone (Henderson, 2005). Many women are concerned 
about the relationship between menopause and their health due to reports that post-
menopausal hormone deficiency may leave women more exposed to neurotoxic insults. It has 
been suggested that the reproductive female hormones estrogen, progesterone and luteinizing 
hormone, which rapidly decrease post-menopause, may exert protective effects within the 
neuronal environment, specifically against neuronal degeneration and susceptibility to 
environmental toxins.  
 In its traditional sense, HRT entails either a combination product containing both estrogen 
and progestin, or single entity products that contains progestin only. Estrogen was traditionally 
used on its own for providing HRT and not in combination with any other steroid hormone, such 
as progestin, which is a synthetic variety of progesterone. The progestin compound was later 
added to the standard hormone replacement regimen, to diminish the risk for developing 
endometrial and breast cancer, that seems to be associated with using estrogen on its own 
(Sismondi et al., 1999). Non-traditional HRT emphasizes the benefit of combining a variety of 
hormones, for orchestrating their overall effects on energy levels and general well-being. These 
therapies comprise of metabolic precursors of DHEA (dehydroepiandrosterone) and 
pregnenolone, as well as various combinations of growth hormone, melatonin, and the thyroid 
hormones. The addition of an androgen to the therapeutic regime (usually testosterone), has 
proved useful for restoring lowered energy levels, libido and to prevent osteoporosis during 
post-menopause (de Paula et al., 2007; Taelman et al., 1989).  
 Various gynecological benefits are associated with HRT. This includes the ability to reduce 
the incidence of secondary amenorrhea (Romer et al., 2000), prevent benign breast neoplasms 
(Kramer et al., 2006) and anaemia due to an iron-deficiency (Grimes, 1992), reduce the risk of 
endometrial cancer (Chubak et al., 2007; Kelsey et al., 1982; Schlesselman, 1997; Weiderpass 
et al., 1999), prevent ectopic pregnancies (Sivin, 1988; Sivin, 1991; Franks et al., 1990), 
diminish the risk for developing functional ovarian cysts (Peterson et al., 1997), and reduce the 
incidence of pelvic inflammatory disease (Lanes et al., 1992).  
 However, valid concerns have been raised that the substantial hormonal changes 
associated with natural or surgically induced menopause may have adverse reactions and 
contribute towards the initiation and/or development of various diseases. For example, several 
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studies have indicated a significantly higher incidence of strokes, due to thrombo-embolism, 
subarachnoid hemorrhage and cerebral venous thrombosis in users of oral contraceptives, 
particularly in those receiving high estrogen formulations (Vickers et al., 2007). 
 Of the list of active chemical components contained in the most commonly prescribed HRTs, 
estrogen has received the largest blame for adverse effects on systems and organs not directly 
associated with reproduction. At the same time, it has also received the greatest amount of 
praise for its beneficial influence, most notably that of protecting against disease-processes, 
such as against cardiovascular and various neurological disorders, including PD (Gaspard et 
al., 2002).  
 In animal models of PD, an apparent neuroprotective effect was exerted by estrogen when it 
was administered prior to or coinciding with the toxic insult that simulates symptoms of PD. This 
was successfully demonstrated using methamphetamine (Gao & Dluzen, 2001; Gajjar et al., 
2003), while estrogen’s neuroprotective benefit was shown with the use of the neurotoxin MPTP 
in primates (Dluzen et al., 1996; Miller et al., 1998). Beneficial effects were also reported for the 
6-OHDA rat model (Dluzen, 1997). Furthermore, a loss of dopaminergic neurons in the SN of 
non-human primates exceeding 30% due to estrogen deprivation has been reported (Leranth et 
al., 2000), while chronic estrogen replacement restored dopaminergic function in 
ovariectomised rats (Ohtani et al., 2001).  
 Estrogen exerts its effects on the CNS via both genomic mechanisms, modulating the 
synthesis, release and metabolism of neurotransmitters, neuropeptides and neurosteroids, as 
well as through non-genomic mechanisms, by influencing electrical excitability, synaptic 
function and morphological features. These influences may not only exert an influence on the 
male preponderance observed in a disease associated with the nigrostriatal dopaminergic 
system, such as PD (Morale et al., 2006), but may also be pivotal in the pathogenesis of other 
age-related neurodegenerative diseases, such as AD (Benedetti et al., 2001). However, the 
evidence lacks consistency: HRT was found to protect against developing AD when 
administered post-menopause (Morinaga et al., 2007; Hogervorst et al., 2000), while a large, 
randomized, double-blind, placebo-controlled clinical trial of postmenopausal HRT failed to 
replicate these findings (Mulnard et al., 2000). 
 It remains uncertain what estrogen’s mechanism of effect on the CNS involves (Van 
Hartesveldt & Joyce, 1986; Kompoliti, 1999). As far as PD is concerned, studies done using 
animal models of the disease indicate that estrogen affects the synthesis, release and 
metabolism of DA via its effects on DA uptake sites (Becker, 1990). It further showed that 
estrogen may also modulate DA receptor expression and function (Di Paolo et al., 1988), 
thereby influencing the behavior normally regulated by the basal ganglia (Roy et al., 1990). 
Whereas clinical studies have also reported beneficial effects of estrogen in providing 
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symptomatic relief to PD patients (see Schipper, 1988, for a review), some investigators report 
only a slight anti-parkinsonian benefit in response to 17ß-estradiol therapy (Tsang et al., 2000).  
 Lyons et al. (1998) made use of a ‘neuroendocrine challenge’, which is a technique used for 
exploring neurotransmitter tone in humans, providing an indirect means of detecting the effects 
of estrogen on the dopaminergic response. The investigators used an apomorphine-induced 
growth hormone (GH) secretion delivered via post-synaptic D2 receptors, located in the median 
eminence of the hypothalamus (Meltzer, 1979), to investigate central dopaminergic responsivity 
in female patients. The results from this study indicate that post-menopausal women, who 
undergo long-term estrogen therapy, have enhanced GH responses, compared to women who 
are naïve to estrogen therapy, thereby suggesting increased dopaminergic tone, and less 
likelihood for developing PD. Further support for estrogen’s influence on brain function derives 
from experiments showing that ovarian steroids may regulate the expression of the dopamine-
degrading enzyme catechol-o-methyltransferase (COMT) (Di Paolo, 1994; Becker, 1999; Xie et 
al., 1999), while it was also shown that estrogen could also act directly on the striatum (Van 
Hartesveldt & Joyce, 1986). 
 Clinical studies performed on PD patients have also illustrated that estrogen may have 
behavior-mediating effects on DA, due to the influences it exerts on the basal ganglia (Hruska & 
Silbergeld, 1980), with biochemical evidence to suggest that estrogen regulates dopaminergic 
neurotransmission in the basal ganglia (Di Paolo et al., 1988; Becker, 1990). However, 
inconsistent reports are the norm rather than the exception. Studies to investigate whether 
estrogens stimulate or inhibit the human dopaminergic system include reports that the use of 
estrogen on its own (in the absence of progesterone) may increase the risk of developing PD 
among women who have undergone a hysterectomy (Marder et al., 1998), observing a greater 
decline in the D2 dopamine receptor concentration in women (Wong et al., 1988). In addition, 
the complete absence of modifying effects (Currie et al., 2004; Strijks et al., 1999) has also 
been observed.  
 These inconsistencies are difficult to explain, especially in light of evidence suggesting that 
neither dopamine-sensitive cells located in the originating mesencephalic region, nor those in 
the basal ganglia show the ability to concentrate estrogen (Van Hartesveldt & Joyce, 1986). 
These findings add to the confusion and provide inadequate foundations for practice guidelines. 
The uncertainty as to whether PD is provoked or suppressed when the underlying pathology 
comes in contact with the active components of HRT is worrisome, especially since, due to an 
aging population, an increasing number of people can expect to experience age-related 
disorders associated with abnormalities of the dopaminergic system, that includes PD (Tanner 
& Ashton, 2000). In the absence of investigations to establish our insight into the effects that 
estrogen exerts on the dopaminergic system, especially in terms of long-term therapeutic 
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influences, the general regard is that the beneficial results gained from HRT significantly 
outweigh the risks involved, and HRT continues to gain widespread prescriptive support. The 
current article evaluates the apparent paradox of the effects of estrogens on the CNS with 
particular reference to whether the provision of HRT will worsen or reduce the chance of 
developing PD or PD-like symptoms, or alter specific attributes of the PD syndrome. 
 
2. METHODS  
The present chapter reviews currently available data to assess the relative safety 
supplementary hormone therapy offers to women. The rationale for this is that the number of 
women reaching their midlife years and beyond who seek professional advice regarding HRT is 
likely to double. Yet the studies that have investigated the relative safety of estrogen treatment 
in the context of developing PD-related symptoms are limited. At best, and as pointed out, the 
studies are inconclusive with findings to suggest both an associated risk (Morale et al., 2006; 
Currie et al., 2004), as well as no risk associated for developing the disease (Gaspard et al., 
2002). In view of this contradiction, I revisited existing published data, in conjunction with the 
WHO Programme for International Drug Monitoring, based in Uppsala, Sweden, to examine the 
increased risk that HRT may specifically hold for developing PD-related symptoms. The 
programme’s database contains approximately 3.7 million case reports of suspected adverse 
drug reactions that have been filed as reports since 1968. Eighty-one countries in total currently 
participate in the scheme, with these spontaneous reports providing a first-line surveillance 
method for the detection of new adverse drug reactions (ADRs). The database is extremely 
useful because of the sizable population surveyed and the prompt reporting of unexpected 
adverse reactions (Olsson, 1998).  
 A data-mining search (Smith et al., 1996) was performed to search for drug-ADR 
combinations occurring more frequently than expected. A positive drug-reaction association 
implies a significant difference from the entire global report (Bate et al., 1998). The search was 
done using the anatomical therapeutic chemical (ATC) grouping to cover all estrogen-containing 
compounds. Reports with drugs belonging to any of the following ATC groups were included in 
the search: Hormonal contraceptives for systemic use/progestogens and estrogens; 
estrogens/natural and semisynthetic estrogens; synthetic estrogen; estrogen combined with 
other drugs; androgens and estrogens; androgen alone; progestogen and estrogen in 
combination; and progestogens and estrogens in combination. The following WHO-preferred 
terms were used during the search for therapy-associated movement disorders: Bradykinesia, 
Dyskinesia, Hypokinesia, Choreoathetosis, Hypertonia, Tremor, Extrapyramidal disorder and 
Parkinsonism aggravated. Three subterms were included under the preferred term 
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‘extrapyramidal disorder’, namely ‘Parkinson’s syndrome’, ‘Parkinsonism’ and ‘Parkinsonian 
gait’. 
 
3. RESULTS AND DISCUSSION 
Very few reports of PD per sè were revealed during the search, to suggest that PD is either an 
unrecognised adverse effect of estrogen-containing compounds or that only a weak relationship 
exists between the two. However, it is acknowledged that under-reporting and failure to 
recognise adverse reactions with a long latency are two weaknesses inherent to this particular 
reporting system. A disproportionately high amount of chorea-cases was reported, compared to 
all other drugs in the database, though this does not reach significance at the 95% confidence 
level. Differential diagnoses of chorea, in addition to Sydenham’s chorea, include Wilson’s 
disease; encephalitis; Huntington’s chorea; drug intoxication; benign familial chorea; pregnancy; 
systemic lupus erythematosus; Henoch-Schonlein purpura; polycythemia vera; hypocalcemia; 
hyperthyroidism; carbon monoxide poisoning; cerebral infarction and intracranial tumor (Dove, 
1980). It involves rhythmic motor oscillations characterized by brief, irregular muscle 
contractions that are not repetitive or rhythmic in nature, but rather appear to continuously flow 
from one muscle to the next, often co-presenting with athetosis, that adds twisting and writhing 
movements by the hands, feet, trunk, neck and face, to the already existing disorder. Drug-
induced chorea is the most commonly occurring type found in clinical practice (Cardoso et al., 
2006; Wenning et al., 2005). More than 40% of all PD patients, depending on age and the 
dosage used (Fahn, 2000; Schrag & Quinn, 2000), develop chorea after 5-10 years of 
continued Levodopa use, with increasing numbers of patients affected as time progresses 
(Obeso et al., 2000). It is thought that chorea is a side-effect to the drug’s ability to stimulate 
postsynaptic DA receptors in a pulsatile fashion, evoking changed responses amongst the 
neuronal networks that interconnect the basal ganglia with the frontal cortical motor regions, 
with such excessive thalamocortical facilitation overactivating the release of DA (Fahn, 2000). 
However, inconsistencies between the proposed model and clinical evidence have been 
observed, including the absence of increased excitatory thalamocortical drive following 
pallidotomy, which should worsen the chorea according to most hypotheses explaining the 
origin of the phenomenon (Liu et al., 2006). In light of this, current opinion on what constitutes 
hyperkinetic movement disorders, such as chorea, maintain that more complex alterations in 
the temporal and spatial firing pattern of the globus pallidus might be responsible for this clinical 
phenomenon (Liu et al., 2006; Obeso et al., 2002; Moro et al., 2004). For instance, it has been 
postulated that chorea may be due to estrogen’s direct action on DA, or, alternatively, may 
result from its competitive binding to COMT (Schipper, 1988).  
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 Following the first report of an association between chorea and OCs by Fernando in 1966, 
various additional case-reports and epidemiology-based studies have revealed chorea to be a 
rare complication of estrogen-containing oral contraceptive-therapy, such as the use of topical 
vaginal cream containing conjugated estrogen (Caviness & Muenter, 1991). One large-scale 
study reported that 12% of all patients that participated in the study, developed chorea soon 
after starting estrogen-containing oral contraceptive treatment, with 6% developing chorea 
gravidarum and 2% developing the disorder shortly following delivery of a baby (Cervera  et al., 
1997). In contrast to other drugs, that may also lead to the development of chorea as a side-
effect to their use, OCs require the presence of an already existing basal ganglia dysfunction in 
order to induce its adverse effects (Miranda et al., 2004). Such adverse drug reactions are only 
expected to occur as recurring choreic episodes, such as in Sydenham’s chorea, chorea due to 
systemic lupus erythematosis, chorea gravidarum (Karageyim et al., 2002) or when Levodopa-
induced (Fahn, 2000). The time between initiating therapy and the appearance of choreiform 
movements vary between 6 days to 9 months, with 3 months generally regarded as the mean 
norm (Dove, 1980). This supports previous reports that female PD patients present more often 
with tremor than males (Haaxma et al., 2006), with tremor regarded as a mild symptom of 
striatal degeneration.  
 
4. CONCLUDING REMARKS 
There are several ways in which human studies could be performed with different comparisons 
made between genders, age groups, with either the use of HRT or not, as well as by carefully 
differentiating the components of PD. Recent reports of a correlation between estrogen-based 
therapy and chorea were found to lack in recent literature, and large studies on PD with 
sufficient power to examine the differential effects of estrogen on the PD syndrome have not 
been done. However, the current review highlights that there is indeed cause for concern in this 
regard, because of the conflicting results presented, with a definite need for further investigation 
in order to extrapolate for the relationship between female gonadal hormones and the 
nigrostriatal dopaminergic system. The absence of evidence for any signal on the adverse 
effects of estrogen containing compounds on PD in the WHO database could be interpreted as 
a failure to recognize a signal for a causative effect or worsened PD, even though the database 
revealed chorea as a side effect to estrogen-based therapy. However, the result does not 
conflict with the possibility that estrogens may protect from all or some aspects of the PD 
syndrome. Intensified research efforts are called for before agreement can be reached with 
regards to the locus, direction, or the mechanism of OC’s and HRT’s action on basal ganglia 
function. 
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CHAPTER 3 
 
EARLY PUBERTAL FEMALE RATS ARE MORE RESISTANT THAN MALES TO 6-
HYDROXYDOPAMINE NEUROTOXICITY AND BEHAVIOURAL DEFICITS:  
A POSSIBLE ROLE FOR TROPHIC FACTORS 
 
1. INTRODUCTION 
Gender-related differences may play a role in the patho-etiology of PD, since such differences 
have been detected in terms of the prevalence, symptomatology, prognosis, and age of onset of 
the disease. Although the precise biological mechanisms remain to be determined, findings from 
several epidemiological studies indicate that, in general, men are more frequently affected and 
display a younger age of PD onset than women (Baldereschi et al., 2000; Bower et al., 1999; 
Kuopio et al., 1999; Mayeux et al., 1995; Milanov et al., 2001; Schrag et al., 2000). Reports from 
several basic studies provide further support for this phenomenon, and suggest that biochemical 
and functional gender differences inherent to the DA pathway may underlie the male prominence 
seen in PD (Becker, 1990; Becker, 1999; Castner et al., 1993; Murray et al., 2003; Tamas et al., 
2005). A neuroprotective effect of the gonodal steroid hormone estrogen has been demonstrated 
in animal models of PD that involves the administration of DA neurotoxins (Miller et al., 1998; Sa 
& Madeira, 2005). A number of studies support the concept that estrogen may play a role in the 
synthesis (Pasquali et al., 1995), metabolism (Xie et al., 1999) and transport of DA (Disshon et 
al., 1998), suggesting that an intimate interaction exists between estrogen and the DA-system. 
Moreover, the estrogen receptor, ERβ, localizes to mitochondria in a variety of cell types, 
including neurons, cardiomyocytes and a murine hippocampal cell line (Yang et al., 2004). 
Mitochondria generate most of the cell’s ATP by means of oxidative phosphorylation, in addition 
to endogenous oxygen radicals, as its toxic by-product (Brookes et al., 2002), and fulfill a central 
role in regulating apoptosis, calcium homeostasis and a cytoplasmic redox state (Chakraborti et 
al., 1999; Hengartner, 2000). Although the molecular mechanisms that lead to neuronal cell death 
in PD remain elusive, studies done on post-mortem human brain, genetic studies of familial PD, 
and toxin-based animal models of PD, all suggest that a common pathway involving mitochondrial 
dysfunction may be involved in dopaminergic neuron degeneration (Liang et al., 2006; Ramsey et 
al., 2007; Song et al., 2004; Yang et al., 2006).  
  Several studies suggest that estrogen has either direct or indirect effects on mitochondrial 
function (Mattson & Magnus, 2006; Nilsen & Brinton, 2003; Olanow et al., 2003; Wang et al., 
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2001), indicating that mitochondrial ERβ has a mediating role on the effects estrogen has on 
mitochondrial functions. This may have implications concerning DA neurotoxins that target 
mitochondria, as well as for gender-related effects on the manifestation of PD. The male gonadal 
steroid hormone testosterone apparently provides no protection for DA neurons against 
neurotoxic agents (Dluzen et al.,1996; Ekue et al., 2002; Gao & Dluzen, 2001), while certain 
reports even suggest that testosterone may enhance neurodegeneration (Dluzen & McDermott, 
2002; Dluzen & Horstink, 2003; Gillies et al., 2004; Horstink et al., 2003). The search for novel 
forms of therapy against PD has recently undergone a remarkable shift from developing drugs 
that merely relieve the intensity of PD symptoms experienced, to a new generation of remedies 
that can potentially protect DA neurons as well as to modify the course of the disease. In addition 
to the possible neuroprotective effect of estrogen, other neuroprotective agents have displayed 
gender-specific effects also. This includes pituitary adenylate cyclase activating polypeptide 
(PACAP) (Reglodi et al., 2006), which was found to have no effect on DA cell survival in intact 
females, while effectively increasing DA cell survival and decreasing behavioural deficits in 
ovariectomized females.  
  Neurotrophic factors, and their respective receptors, are key regulators during development 
and maintain a homeostatic state within the CNS environment. Neurotrophins, a neurotrophic 
subclass, has been earmarked for potential therapeutic applications in neurodegenerative 
diseases on the basis of results obtained from in vitro experiments and in animal models. Recent 
studies have demonstrated the presence of increased trophic factor levels in the striatum 
following a nigrostriatal lesion (Ling et al., 2000). Although experimental focus has rather been on 
the differential expression of other factors belonging to this trophic class of agents, Nerve Growth 
Factor (NGF), although having received less attention than its trophic counterparts, including Glial 
Derived Neurotrophic Factor (GDNF), Brain Derived Neurotrophic Factor (BDNF) and 
Neurotrophic-3 (NT-3), is a factor highly regarded for its antioxidant (Castner et al., 1993), anti-
apoptotic (Shimoke & Chiba, 2001) and neurorescuing properties. As a universally applicable 
molecule, it controls path finding, spatial patterning, proliferation, as well as to provide protection 
for the cells of the CNS (Stromberg et al., 1990). These properties may be especially relevant to 
PD, since it has been shown that NGF concentrations are decreased in PD patients and in 
experimental parkinsonian rats (Lorigados et al., 2002). This is particularly the case in systemic 
administration of rotenone, an agricultural pesticide used for its capacity to selectively degenerate 
nigral DA neurons and mimic PD-like symptoms in rats (Betarbet et al., 2000). NGF was shown to 
significantly reduce rotenone’s toxic effects on neurons in midbrain neuronal cultures, by staining 
more positively for tyrosine hydroxylase (TH) (Jiang et al., 2006), the rate-limiting enzyme 
involved in catecholamine biosynthesis (Glinka et al., 1997; Kobayashi & Nagatsu, 2005). One of 
the most commonly used experimental models of PD involves the central administration of the 
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neurotoxin 6-OHDA, or 2, 4, 5-trihydroxyphenylethylamine, a structural analogue of both DA and 
noradrenaline (Senoh et al., 1959). It acts by means of a complex mechanism of toxicity, which 
involves a variety of biochemical features, including alkylation, rapid auto-oxidation and the 
impairment of mitochondrial energy production (Brookes et al., 2002; Glinka et al., 1997). It is 
generally used to experimentally induce a relatively selective lesion of neurons in the NSDA 
pathway (Schwarting & Huston, 1996), similar to the damage seen during post-mortem 
investigations of the brains of PD patients. 6-OHDA has been found present in the basal ganglia 
in humans, and urine samples indicate that its concentration increases in response to levodopa 
therapy (Andrew et al., 1993). A useful feature of 6-OHDA is its capacity to create asymmetrical 
DA neurotransmission between the lesioned and the intact hemisphere in animals receiving 
unilateral drug administration. This leads to marked impairment of normal motor function in the 
limbs opposite to the lesion side, resulting in the preferential use of the limbs ispsilateral to the 
lesioned hemisphere. Interestingly, the exogenous application of NGF has been shown to 
increase the degree of antioxidant enzymes, heme oxygenase-1 and prevent apoptosis by 
possibly triggering an anti-apoptotic gene-signaling mechanism following exposure to 6-OHDA 
(Salinas et al., 2003). 
  In the current study, we made use of gonad-intact animals, since limited studies have made 
direct male-female comparisons (Miller et al., 1998; Yu & Liao, 2000; Zhang et al., 1998). We 
specifically opted to work with adolescent rats, since the synthesis-rates of striatal D1 and D2 DA 
receptors reach their apices at this stage with gender differences diverging thereafter (Andersen, 
2002) and since it has been shown that estrogen is only present in the brain after the second 
month of life (Knoll et al., 2000). Emerging evidence also indicates that key gender differences in 
gene expression and biochemistry in SN TH positive neurons do not depend on gonadal sex 
steroids (Dewing et al., 2003; Dewing et al., 2006). Gender differences were found in behavioral 
impairment tests, and these correlated with differences in the degree of TH-staining and NGF 
expression following 6-OHDA administration. 
 
2.   METHODS AND MATERIALS   
 2.1.            Animals   
Sprague-Dawley rats were used throughout the study. Twelve animals were used per group 
(dosage and gender). The animals were kept in clear 40 × 25 × 20 cm Plexiglas cages, in an 
AAALAC accredited facility, in rooms with temperature 22 ± 1◦C and a 12:12 hr. light:dark 
cycle (lights on from 07h00 to 19h00). The rats had ad libitum access to pelleted rat chow and 
tap water. All experimental procedures followed in this study had been approved by the 
Committee for Experimental Animal Research of the University of Stellenbosch (Project 
 128
number: N05/04/004), and were in accordance with the National Institutes of Health Guide for 
care and use of laboratory animals. 
 
2.2. Preoperative and surgical procedures for the infusion of 6-hydroxydopamine 
into the MFB 
Initial experiments were performed to establish a set of medial forebrain bundle (MFB) 
coordinates since information on 6-OHDA injections into the MFB of young animals was very 
limited. For these lesions, Indian ink was injected into the brains of a group of animals at 35 
days of age, in order to ascertain the optimal location of the tip of the injection cannula (30G 
needle). A combination of ketamine hydrochloride (Anaket-V, Bayer Healthcare, South Africa) 
and medetomidine hydrochloride (Domitor, Pfizer, South Africa) (0.1 ml/100g, i.p.) was used 
to anaesthetise the animals. It is acknowledged that ketamine hydrochloride may possibly 
provide a degree of neuroprotection to the animals during surgery. However, most 
experimental studies have failed to show effective long-term protection, despite impressive 
short-term protection offered (Koerner & Brambrink, 2006). Furthermore, although ketamine 
protected the cellular integrity in striatal slices in culture, it did not affect the neurotransmitter 
release of these cells (Becker, 1999) and the anaesthetic agent also failed to alter the results 
of neurobehavioural outcome tests performed on patients at either one or ten weeks post-
intervention (Nagels et al., 2004). Moreover, since all animals were treated with the same 
dosage regime, it can be assumed that all groups were exposed to a potentially similar 
degree of neuroprotection and are thus comparable from this perspective. Following the 
anaesthetic injection, the animals were placed in a stereotaxic frame (David Kopf Instruments, 
Tujunga, CA, USA). To prepare the surgical site, hair was clipped and the site disinfected with 
70% Alcohol (EtOH). The skin was sterilized using an iodophor (Betadine, Purdue 
Pharmaceutical Products). A rubber heating pad (REX C10, RKC, 19.0 ± 99.9◦C heat 
generator, Electronic Services, University of Stellenbosch) maintained the rats’ body heat 
during surgery. Following the Indian ink injection, the rat was decapitated and the brain placed 
in paraformaldehyde for 48 hrs. The tissue was cut with a cryostat at a thickness of 30 μm. 
The sections were mounted onto clear glass slides and examined under a Nikon TE2000-E 
microscope (using a phase 4 resolution) to determine the location of the lesion, while referring 
to a stereotaxic atlas of the rat brain (Paxinos & Watson, 1986). The stereotaxic coordinates 
for the MFB injection established were: 2.5 mm posterior to Bregma, 1.8 mm lateral to the 
midline and 7.8mm below the dura. These coordinates were used throughout the study for 6-
OHDA and sham lesioned rats. For a photographic image of the site of needle placement, see 
Fig. 1. Prior to surgery 35 day-old experimental animals, weighing between 110–142g were 
randomly assigned to either one of the dosage-groups or the control-group. The mean 
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weights of the male rats were comparable to those of the female rats at this young age. In 
accordance with Roberts et al. (1975), rats were injected with 25 mg/kg desipramine (i.p.) 
thirty min before and immediately after the operation to limit concurrent damage to 
noradrenergic pathways by 6-OHDA infusion. A free-base weight of 6-OHDA (Sigma, St. 
Louis, MO) of 1 μg for the low dose and a higher dose of 15 μg was dissolved in 4 μl 0.1% 
ascorbate in 0.9% sterile saline and unilaterally (right MFB) injected. The solution was infused 
over a period of 5 min using a 341-A model syringe pump (Sage Instruments, USA). Following 
the infusion, the needle was left in place for an additional 5 min, before slowly retracting it 
from the brain. The burr-hole drilled through the skull was filled with sterilized oxidized 
cellulose (Ethicon, UK), while the incision was sutured and again coated with iodophor. To 
recover, the rats were placed in individual cages under lamps to provide adequate heating. 
The condition of the sutures, the rats’ food and water intake, and their behaviour were 
monitored daily to ensure full recovery. 
    
 
 
 
 
 
 
 
 
 
 
 
 
Fig.   1.     An image showing the placement of the needle into the MFB, for the injection with 6-
OHDA. The image was obtained with a Nikon TE2000-E microscope, the objective lens being × 4 with 
a Brightfield application attached, while the image was captured with a Sony 3CCD camera that was 
mounted upon the microscope. 
 
 
2.3. General behavioral testing procedures 
Animals were tested for behavioral changes at 14 days post MFB-injection. Testing consisted 
of (1) the adjusting-steps test (Olsson et al., 1995; Schallert et al., 1992), and (2) the 
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vibrissae-evoked forelimb placing test (Anstrom et al., 2007; Woodlee et al., 2005). All testing 
took place between 10h00 and 12h00. 
 
2.3.1. Adjusting-steps test 
The rats were monitored for their ability to make postural adjustments in response to an 
imposed weight-shift by using an isolated forelimb test (initially described by Schallert et al. 
(1979; 1992). The test is useful for monitoring lesion- and transplant-induced changes in 
forelimb motor function, which is a behavioral parameter that may be analogous to limb 
akinesia and gait problems seen in patients with Parkinson’s disease (Olsson et al., 1995). 
Briefly, the experimenter suspended the rat above a tabletop surface, with the hind limbs and 
one forelimb restrained in one hand. This allowed the rat to support most of the weight of its 
body with the unrestrained forelimb only. While the experimenter slowly moved the animal at 
a constant rate (300 cm in 30 sec), the number of adjusting steps taken by each forelimb was 
recorded by the experimenter, who was blind to the treatment of the rat. This procedure was 
performed across two conditions, namely when the animal was moved along the table-surface 
in the lateral forward direction (leftward movement), as well as in the lateral backward 
direction (rightward movement). Two trials for each animal were performed with each trial 
consisting of the rat being moved once in each direction. The mean score of the two trials was 
considered a representative result for each animal. 
 
2.3.2. Vibrissae-evoked forelimb placing test 
In this test, which requires integrated motor and sensory input, the experimenter held the rat 
by the torso, thereby allowing the forepaw being tested to hang freely while the untested 
forelimb was gently restrained. Each forelimb was tested independently by orienting one side 
of the animal towards a tabletop and moving the animal in a slow lateral direction toward the 
edge until the vibrissae of that side made contact with the table’s edge (Barth et al., 1990; 
Schallert & Tillerson, 1999). In an intact animal the stimulated vibrissae will cause the rat to 
instinctively place both forelimbs onto the tabletop, while, with lesioned animals, placing may 
not occur at all (scoring ‘0’), indicating a failed motor response towards a spatio-sensory 
stimulus, or there is a delay between stimulation and placing. Ten trials of each forelimb were 
performed during the testing session. An experimenter, blind to the experimental condition of 
the animals, recorded the number of successful placing reactions by each forelimb. 
 
 
2.4. Animal euthanasia and tissue collection 
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Following the behavioral assessment on PND 49, the rats were decapitated and the left and 
right striatum rapidly dissected on ice. The tissue was immediately frozen in liquid nitrogen 
and stored at −80◦C until NGF levels were determined at a later stage. For assessing the 
degree of TH-staining, a group of anaesthetised animals (n = 12) were transcardially perfused 
with 200 ml of saline followed by 200 ml of 10% paraformaldehyde. Immediately after this, the 
brains were removed and placed into a solution consisting of 30% sucrose dissolved in 
phosphate buffered saline (PBS) for 48 hrs. The selection of animals for either the NGF assay 
or TH-staining was performed randomly, with only the group that had been subjected to the 
higher dose of 6-OHDA being considered for assessing the degree of TH-staining. 
 
2.5. Nerve Growth Factor (NGF) assay 
The Emax ImmunoAssay System, purchased from Promega (Madison, USA) was used to 
determine striatal levels of NGF. The striata on both the left and right (lesioned) side were 
used to determine whether the observed behavioural changes were mirrored by changes in 
neurotrophin expression. Tissue was weighed and then freshly prepared buffer (20 mM Tris-
HCL (pH set at 8), 137mMNaCl, 1% NP40, 10% glycerol, 10 μg/ml aprotinin, 1 μg/ml 
leupeptin, 0.5 mM sodium vanadate (NaVO4) and 1 mM phenylmethylsulfonyl fluoride 
(PMSF), was added. The samples were sonicated for 20s. The lysates were centrifuged for 
20 min at 9.66 × g at 4◦C and the supernatant removed and stored at -20oC overnight. The 
NGF assay was subsequently performed in a 96 well plate as specified by the manufacturer. 
Results were expressed as pg of NGF per mg wet weight (ww) of tissue. 
 
2.6. Tyrosine hydroxylase (TH) immunohistochemistry and  
  quantification of lesion size 
Free-floating coronal sections of a thickness of 30 μm were cut with a cryostat at −20◦C for 
subsequent TH-staining. The sections were quenched by incubating with 0.3% hydrogen 
peroxide for 30 min at room temperature, in a humidifying container followed by a succession 
of washes (5 × 10 min) with PBS (0.15 M, pH 7.4). The sections were placed in Eppendorf 
containers, each containing 10 mM citrate buffer (pH 6.0), and boiled for 5 min in a pot of 
boiling water standing over a heat source. The sections were left to cool down to room 
temperature, before the wash-cycle was repeated. Sections were pre-treated with 150 μl 
horse blocking serum and 0.1% Triton X-100 for 30 min, before primary monoclonal anti-TH 
(BrdU mouse monoclonal, dilution 1:500, DiaSorin, USA) was applied. The sections were 
incubated overnight at 4◦C. The next day, the slices were washed in PBS (5 × 10 min), and 
the secondary biotinylated link antibody (dilution 1:8000) applied for 1 hour at room 
temperature. The wash routine was repeated, before the slices were incubated with 
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peroxidase labeled mouse IgG ABC reagent. Immunostaining was performed with an ABC kit, 
purchased from DakoCytomation (USA), with concentrated diaminobenzidine (DAB) used as 
the chromogen. Tissue sections were incubated at room temperature until staining developed. 
The sections were given a final 15 min rinse with distilled water, before dehydrating them with 
96–100% alcohol (EtOH), cleared with Xylol (Merck, South Africa) and finally mounted onto 
clear glass slides. Sections from six animals from each gender group were analyzed. Digital 
photographic images of all the slices were captured under unchanging, unchanging, 
standardized conditions of lighting and exposure using the 20 × objective on a Zeiss 
microscope fitted with Brightfield optics and a Diagnostic Instruments Spot Insight QE 
camera. For each hemisphere, 3 independent images were taken. Sections representing the 
anterior (plate 14; Paxinos & Watson, 1986), middle (plate 18; Paxinos & Watson, 1986) and 
posterior (plate 22; Paxinos & Watson, 1986) striatum from 6 female and 6 male animals were 
analysed. This was done to ensure that equivalent sections were analyzed. TH-staining 
density of each striatal image was determined with Zeiss’s Axiovision image analysis 
software. Each image of the striatum was outlined with a cursor and the software analysis 
program was used to compute the total surface area that stained positively for TH. The 
combined TH-immunoreactive striatum surface area of all 3 images in the 6-OHDA infused 
hemisphere was divided by that of the striatum in the non-infused hemisphere. The ratio 
between TH-immunoreactivity on the lesioned side to TH-immunoreactivity on the non-
lesioned side that acted as the control condition was then expressed as a percentage. 
Therefore, values closer to 100 indicate that there were areas of TH-immunoreactivity on 
each side that were comparable while values closer to zero indicate severe loss of TH-
positive terminals. The results for each animal were averaged and the result used to obtain a 
mean value for all 6 female and 6 male rats. The percentage loss of TH-staining in the 
lesioned striatum was taken to indicate the degree of neurochemical asymmetry for that 
animal. 
 
 
 
2.7.      Statistical analysis   
The behavioral data was statistically analysed for multiple comparisons against a single 
control group by means of an analysis of variance (ANOVA), with the between-subject factors 
being dosage-group and gender. Simple comparisons between two groups, such as the data 
from the NGF assay and TH-staining were performed using a Student’s unpaired t-test. Post 
hoc comparisons between groups were conducted when appropriate using a Bonferroni test. 
The statistical analysis of all the data was conducted using Statistica software (StatSoft, 
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Tulsa, OK). Differences were considered significant when p < 0.05. Each data point presents 
the mean value ± S.E.M. 
 
3.  RESULTS   
3.1.      Tyrosine hydroxylase (TH) immunocytochemistry   
Fixated brain slices collected from animals treated with the higher dose of 6-OHDA were 
analysed for the area that immunohistochemically stained positively for TH. The level of TH-
staining, expressed as a ratio between lesioned and non-lesioned hemispheres, was found to 
be significantly decreased (p <0.05, t =8.26, df = 10) in the males compared to the females 
(Fig. 2). 
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Fig.   2.     Percentage TH expression in striatal sections of the 6-OHDA infused hemisphere of 
male and female rats. The percentage staining in the toxin-infused hemisphere of the males were 
significantly different from that of the females. Both gender-groups had received the higher dose of 
neurotoxin; *p < 0.05. Data represent the mean ± S.E.M. (n = 6). 
 
3.2.  Nerve Growth Factor (NGF) assay 
A 2 (gender) × 3 (dose) × 2 (hemispheres) factorial design was used to analyze data obtained 
from the NGF assay. A significant main effect was detected for dosage (F = 18.2, df = 2, p < 
0.01) as well as for gender (F = 20.54, df = 1,p < 0.01), but not for hemisphere (F = 1.92, df = 
1, p = 0.17). Post-hoc comparison detected a significant interaction between dosage and 
gender (F = 17.4, df = 2, p < 0.01), but not between dosage and hemisphere (F = 1.3, df = 2, 
p = 0.29), or between gender and hemisphere (F = 3.13, df = 1, p = 0.08). No significant 
overall effect was found between dosage, gender and hemisphere (F = 0.96, df = 2, p = 0.39). 
Post hoc analysis revealed significantly higher levels of NGF (p < 0.01) in the female rats 
treated with the higher dose of 6-OHDA compared to all other groups (Fig. 3). 
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Fig.   3.     A graph showing the average amounts of NGF found in the striatum tissue on the 
hemispheric side that had been injected with 6-OHDA. The graph shows the results of the rats 
subjected to two doses of 6-OHDA in addition to the group injected with the saline vehicle only. The * 
symbol indicates a significant (p < 0.05) difference from the male rats. 
 
3.3.  Behavioral tests     
3.3.1. Adjusting-steps test 
At 14 days post-lesion, male rats were significantly more impaired than females in their 
capacity to make adjusting steps in response to experimenter-imposed lateral shifts of weight 
following the higher, but not the low 6-OHDA dose (Fig. 2). Data were analysed using a cross-
classification ANOVA. This included the between-factors: gender (2 levels: male and female), 
dosage-treatment (3 levels: a saline-control group, 1 μg/4 μl and 15 μg/4 μl of 6-OHDA), 
direction of movement (2 levels: forward and backward), and the side that was allowed to 
make contact with the table-surface during the trial (2 levels: left and right forelimb). No 
significant 4-way interaction was found between the factors dosage, gender, direction and 
forelimb-side (F(2.48) = 1.48, p = 0.23). The interaction plots drawn up between direction and 
gender, indicate that 6-OHDA did not alter use of the right (non-impaired) limb for the various 
dosages of 6-OHDA (F(2,24) = 0.28, p = 0.75). Differences were only detected in terms of the 
number of steps taken by the left (contralateral) forelimb and thus further analyses were 
restricted to use made by the left forelimb only. A significant interaction was detected between 
direction and gender (F(6,90) =8.4, p <0.05). In addition, a significant two-way interaction was 
revealed for gender and treatment (F(6,90) = 21.29, p < 0.05). A post hoc Bonferroni multiple 
comparison of the means show that the greatest difference between males and females 
occurs in the group treated with the higher concentration of 6-OHDA (p < 0.0001) (Fig. 4). 
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Fig.   4.     The mean number of steps taken by the left forelimb in both the forward (A) and 
backward (B) direction for the adjusting-steps test. A significant difference between the two gender 
groups exposed to the higher dose of neurotoxin was observed. The * symbol signifies a significant 
difference (p < 0.0001) from female rats that had also received the higher dose of 6-OHDA. Data are 
expressed as mean ± S.E.M. (n = 6). 
 
 
3.3.2. Vibrissae-evoked forelimb placing response 
Since a comparable difference was not detected between the different dosage- and gender-
groups when stimulating the rats’ ipsilateral (right) vibrissae, these data were excluded from 
the analysis and only the placements made in response to stimulation of the contralateral 
(left) vibrissae were statistically analyzed. Gender, dosage and the side on which the 
vibrissae stimulation occurred were the variables considered for analysis. There was a 
significant interaction between the variables gender and dose (p < 0.05). After applying a 
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Bonferroni correction for multiple comparisons between means and analysing the resultant 
interaction plots and interaction means, no performance difference was found between the 
different genders that had either received the low dose of 6-OHDA or saline. However, for the 
rats that were given higher doses of 6-OHDA, there was significant difference between the 
two gender groups in the mean number of times when no response was given to stimulation 
or the number of times that the rats scored zero (see Appendix B, for a complete description 
of the test) (p < 0.0001) (Fig. 5). Impairment was greater in the male rats at the higher dose of 
6-OHDA. 
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Fig.  5.     Results obtained from the vibrissae-evoked forelimb placing test show the number of 
unsuccessful placing responses made by the forelimb contralateral to the 6-OHDA–infused 
hemisphere. Data was obtained at 14 days post-operation. The difference between the 2 gender 
groups administered the higher treatment dosage was statistically significant. The symbol * indicates 
that the male rats made significantly more unsuccessful responses than female rats (p < 0.05) that 
received the same dose of 6-OHDA. Data represent the mean ± S.E.M. (n = 6).  
 
 
  
4. DISCUSSION   
Gender differences in neural and behavioral indices of brain function in experimental and 
clinical neurology are widely reported (Li et al., 2004; McEwen et al., 1975; Milanov et al., 
2001; Sa & Madeira, 2005). In the current study, we found a significant gender behavioral 
difference in rats after exposure to a dose of the DA neurotoxin 6-OHDA in tests sensitive to 
the degree of DA depletion, namely the adjusting-steps and the vibrissae-evoked forelimb 
placing tests. This finding corresponds to other reports of impaired spontaneous locomotor 
activity in males compared to females, even when the lesion was not severe and therefore 
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(Cass et al., 2005). For the current study, male rats showed a greater behavioral impairment 
at 14 days following the infusion of the toxin 6-OHDA at the higher, but not at the lower dose 
of 6-OHDA, in both the behavioral tests used. In addition, at the higher dose of 6-OHDA, the 
density of staining for TH in the striatum that had previously been injected with the toxin was 
reduced in male rats compared to females. These data suggest that the female brains were 
more significantly protected from DA cell degeneration than the male brains. This finding 
supports other reports of a greater DA depletion in adult male rats after administering the 
neurotoxin MPTP (Dluzen & McDermott, 2002; Heller et al., 2001). In addition, Murray et al. 
(2003) reported significant gender differences in response to a 1 μg dose of 6-OHDA, with the 
DA depletion in adult female rats approximately half of that observed in males. However, this 
difference was lost when higher doses (3 ug and 6 ug) were administered. Other investigators 
(Becker & Ramirez, 1981; Crowley et al., 1978; Fernandez-Ruiz et al., 1992; McDermott et 
al., 1994; Moroz et al., 2003) have also shown a sexually dimorphic response to the toxin, 
with significantly less DA depletion occurring in the female striatum. 
  The potential mechanisms responsible for the phenomenon remain to be identified, but it 
is unlikely that a single gender difference in response to 6-OHDA mediates the neural or 
behavioral effects observed. A surprising finding that emerged from the study was that NGF 
levels were upregulated in the striatum that had been infused with 6-OHDA, but only in female 
rats and only at the higher 6-OHDA dose. Several trophic factors are expressed in both the 
developing and mature SN and striatum (Barroso-Chinea et al., 2005; Hynes et al., 1994), 
such as NGF, BDNF, NT-3 and neurotrophin-4/5 (NT-4/5). A decline in their synthesis levels 
or impaired signal transduction in ageing neurons may contribute to neurodegenerative 
conditions (Mattson & Magnus, 2006). 
  Furthermore, since these compounds exert their effects on selective types of neurons 
they are considered promising therapeutic agents for treating neurodegenerative disorders 
where the underlying pathological event is the selective degeneration of specific neuronal 
groups (Garcia de Yebenes et al., 2000). Evidence to support this includes research 
suggesting that sufficient levels of growth factors may be required for maintaining the viability 
of the remaining DA-producing neurons in pathological conditions, such as PD (Torp et al., 
2006). Although recent research has predominantly focused on the capacity of other 
neurotrophic factors, such as GDNF and BDNF, to correct behavioral deficits and protect 
nigrostriatal neurons against DA neurotoxicity (Cohen et al., 2003; Moroz et al., 2003; Sun et 
al., 2005), the current experiment focused on NGF instead. 
NGF is a neurotrophic agent that is frequently overlooked for its potential therapeutic role in 
PD. NGF is a neurotrophin on which many sensory and sympathetic neurons depend for their 
survival during the developmental phase (Yu & Liao, 2000; Zhou & Rush, 1996). Furthermore, 
 138
its antioxidant (Salinas et al., 2003), anti-apoptotic (Shimoke & Chiba, 2001) and neurorescue 
properties (Stromberg et al., 1990) have been shown to have beneficial effects in neural 
transplantation studies, with exogenously applied levels that prolonged graft survival. 
Decreased concentrations of NGF were also detected in PD patients and in experimental 
parkinsonian rats (Lorigados Pedre et al., 2002). 
  Rats were exposed to the neurotoxin 6-OHDA during the “developmental longevity” 
phase of their life-cycle when it was less likely that the females could benefit from the 
potential neuroprotective effects of sex hormones. According to Knoll et al. (2000), this period 
extends from the discontinuation of suckling by the end of the third week of age, until the end 
of the second postnatal month when sex hormones begin to be detected reliably (Knoll & 
Miklya, 1995). A characteristic of this time-frame is an enhanced level of catecholaminergic 
and serotoninergic activity in discrete brain areas (Knoll et al., 2000). When sex hormone 
regulation commences by the end of the rat’s second month of life, the activity of 
noradrenaline, DA and serotonin in the brain is substantially suppressed, suggesting that the 
“developmental longevity” phase has by then largely ended (Knoll & Miklya, 1995). Several 
studies support the view that the female brain develops in the absence of estrogens while the 
development of the male brain is due to the presence of estrogens (MacLusky & Naftolin, 
1981; Weisz & Ward, 1980). However, this view has been challenged by those who suggest 
that the female brain might depend upon the presence of estrogens (Bakker et al., 2002; 
Döhler et al., 1984; Fitch & Denenburg, 1998; Toran-Allerand, 1984). Technological 
advances, such as the Afp (Afp −/−) mutant mouse model (Gabant, 2002) have provided a 
tool with which to measure brain estrogen levels (Bakker et al., 2006) and to produce findings, 
which corroborate the original hypothesis (McEwen et al., 1975). This classical view of sex-
related brain development proposes that the female brain requires protection from estrogens, 
and its male-typical effects. Therefore, we administered 6-OHDA to rats at postnatal day 35, 
when their sex hormone levels were likely to be low or undetectable, while the activity of 
central monoaminergic neurons was suspected to be high. However, it is acknowledged that 
estrogen may have been decidedly higher at the tissue-collection stage, since the synthesis of 
AFP, a plasma glycoprotein that shows a high affinity for binding to estrogen (McEwen et al., 
1975; Raynaud, 1973; Toran-Allerand, 1984) has been shown to decrease rapidly following 
birth, with only trace amounts detected in adult mice and rats (Andrews et al., 1982). 
However, recent evidence for estrogen-independent sexual dimorphism suggest that, 
independent of the maculating effects of gonadal secretions, gene expression influences the 
patterns by which XY and XX brain cells differentiate and function. Behavioral tests, such as a 
cognitive task of passive avoidance also show striking gender differences, with the female 
rats that outperformed the males in the successful retention of the task that was independent 
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of hormonal or surgical treatment. Similar results have been obtained for the corner test, 
which sensitively detects the degree of damage evoked by experimental stroke (Li et al., 
2004). Moreover, evidence exists that the testes-determining gene Sry is required for normal 
motor function and TH expression in DA neurons of the male SN (Dluzen & McDermott, 2002; 
Dluzen & Horstink, 2003). Progesterone, a neurosteroid that is synthesized by the brain in the 
presence of steroidogenic enzymes, receives far less focus than estrogen in studies 
concerning the biological basis of gender difference. However, it is known to possess 
important properties that can enhance the repair of neurodegenerative and traumatic injuries 
sustained by the CNS. It offers a membrane stabilizing effect that serves to reduce the 
damage caused by lipid peroxidation. In addition, it may also provide neuroprotection by 
suppressing neuronal hyperexcitation (Roof & Hall, 2000). It has shown neurorescueing 
properties in a parkinsonian mouse model, by preventing striatal dopamine depletion caused 
by MPTP (Cass et al., 2005). Nevertheless, not all results have shown such promise. For 
example, in the absence of estrogen, progesterone did not prevent neuronal loss induced by 
kainic acid (Azcoitia et al., 1999). In addition, in ovariectomized female rats, following 
experimentally induced middle cerebral artery occlusion, exogenously applied progesterone 
even exacerbated striatal stroke injury (Murphy et al., 2000). 
  Therefore, it is possible that endogenous progesterone may have provided additional 
neurocapacity to the animals by the time that the striatal tissue was collected for biochemical 
analysis. However, as a sex hormone, it would not have been present in the brain by the 
commencement of the experiment, since this period entailed the “developmental longevity” 
stage of the rat’s life-cycle (Knoll et al., 2000). In summary, very young female rats were 
better able to resist the neural and behavioral effects of 6-OHDA than male rats of similar age. 
The data from the current experiment suggest that estrogen-independent gender differences, 
perhaps together with estrogen-dependent ones, may conceivably contribute to the reduced 
incidence of PD in women. Behavioral outcome measures correlated with the increased 
expression of NGF on the hemispheric side infused with the toxin, and with a higher degree of 
TH expression. However, it can not merely be assumed that a causal relationship exists 
between the NGF data and all other parameters taken. 
  The biological basis underlying gender differences in PD are likely to be multi-factorial, 
and the relative contributions of hormonal, environmental and genetic events throughout the 
lifespan remain to be determined. Future research endeavors should thoroughly explore all 
potential candidate mechanisms that may underlie the gender difference detected in the 6- 
OHDA model of PD. What remains important, however, is that whatever factors are 
responsible for the females showing better functional outcome and higher levels of TH 
expression, the current study has shown that the mechanism is functional even from an early 
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phase of life. This further suggests that gender differences, based on functionally 
compromised nigrostriatal neurons, can possibly commence at any stage throughout the life-
span, and not only during the period that estrogen is available in high concentrations. 
 
5.  CONCLUDING REMARKS  
In summary, young female rats were better able to resist the neural and behavioral effects of 
6-OHDA than male rats of similar age. The data from the current experiment suggest that 
estrogen-independent gender differences, perhaps together with estrogen-dependent ones, 
may conceivably contribute to the reduced incidence of PD in women. Behavioral outcome 
measures correlated with the increased expression of NGF on the hemispheric side infused 
with the toxin, and with a higher degree of TH expression. However, it can not merely be 
assumed that a causal relationship exists between the NGF data and all other parameters 
taken. The biological basis underlying gender differences in PD are likely to be multi-factorial, 
and the relative contributions made by hormonal, environmental and genetic events 
throughout the lifespan remain to be determined. Future research endeavours should 
thoroughly explore all potential candidate mechanisms that may underlie the gender difference 
detected in the 6-OHDA model of PD. What remains important, however, is that whatever 
factors are responsible for the females showing better functional outcome and higher levels of 
TH expression, the current study has shown that the mechanism is functional, even from an 
early phase of life. This further suggests that gender differences, resting on the basis of 
functionally compromised nigrostriatal neurons, can possibly commence at any stage 
throughout the life-span and not only during the period that estrogen is available in high 
concentrations. 
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CHAPTER 4 
 
A COMPARATIVE EVALUATION OF BEHAVIOR, DOPAMINE AND DOPAMINE’S 
METABOLITES AFTER STRIATUM VS. MEDIAL FOREBRAIN BUNDLE SITE OF 6-OHDA 
ADMINISTRATION IN JUVENILE RATS 
 
1. INTRODUCTION 
PD is the second most common neurodegenerative disease (de Lau & Breteler, 2006), affecting 
nearly 2% of the population over the age of 65 (Haugarvoll & Wszolek, 2006). Although certain 
monogenetic mutations may be responsible for the manifestation of the disease, these account for 
only 5-10% of all cases and the majority show idiopathic and sporadic disease onset (Bonifati, 
2005; Dauer & Przedborski, 2003). Akinesia and rigidity comprise the characteristic clinical features 
of the disease (Schuller & Marshall, 2000), caused by extensive degeneration of the nigrostriatal 
pathway. This fiber-bundle connects two nucleic regions, the SN from where the axons originate 
from, and the striatum, to where they project towards and eventually terminates within specific 
dendritic regions of the medium spiny projection neurons located in the dorsal striatum (Moore et 
al., 1971; Fallon et al., 1978). Both neuronal structures fulfill a critical role in voluntary motor control 
(Wooten, 1997; Schober, 2004) through the axonal relay of the neurotransmitter dopamine (DA) via 
the medial forebrain bundle (MFB). The striatum also provides an anatomical substrate at which 
cholinergic, glutamatergic and DA-ergic interactions occur (Bouyer et al., 1984) and acts as the 
primary input nucleus to the subcortical forebrain system, collectively known as the basal ganglia 
(Schuller & Marshall, 2000) that comprise of a group of structures involved in processing highly 
associated cortical information. These functions include a contribution made to the complex process 
of planning and selecting appropriate movements and behavior within a given context (Wise et al., 
1996; Mink, 1996; Redgrave et al., 1999). Therefore, the deregulated movement patterns 
(dyskinesia) associated with PD may be interpreted as the mismatched selection of motor 
responses to contextually derived sensory stimuli (Leblois et al., 2006).  
 No existing animal model completely simulates all the pathological features relating to PD. 
However, the ability of certain neurotoxins, such as 6-OHDA to mimic certain clinical features of the 
human disease in rats has greatly improved our understanding concerning the disease’s 
pathophysiology and has contributed towards developing novel therapies, including L-DOPA that 
remains the “golden standard” for symptomatically managing the disease (Betarbet et al., 2002). 
The toxin induces the selective destruction of catecholamine neurons and damages the 
mitochondrial electron transport system (Olanow, 1993) to lower the supply levels of available 
cellular energy (Sauer & Oertel, 1994), while it has also been shown to augment glutamate release 
(Halliwell, 1992).  
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 A direct, unilateral injection of 6-OHDA into the DA-ergic pathway, targeting the MFB, in which 
case DA originates from the A9 cell group located in the SNpc (Bobillier et al., 1975), is a common 
method for administering a 6-OHDA lesion. The release of a toxic insult near the DA-ergic neuronal 
cell bodies result in a near-immediate and complete loss of DA-ergic neurons (Schwarting & 
Huston, 1996), instead of the gradual neuronal death observed in the clinical entity (Finkelstein et 
al., 2000; Yuan et al., 2004), and is therefore considered representative of the late end-stages of 
the disease. An alternative approach involves injecting the toxin directly into the striatum (Berger et 
al., 1991; Ichitani et al., 1994; Sauer & Oertel, 1994; Przedborski et al., 1995; Lee et al., 1996), 
thereby directly damaging the DA-ergic axonal endpoints, resulting in the slowly evolving death of a 
subpopulation of SN cells by means of a retrograde mechanism (Sauer & Oertel, 1994). The model 
is considered to effectively mimic the slow cellular demise that characterizes disease development 
(Shimohama et al., 2003), although the SN nuclei cells degenerate at a far slower pace in the 
clinical entity (Di Paola & Uitti, 2000). An additional advantage of the striatum-model is that it allows 
for a relatively long window-period for cellular demise to occur, during which the ability of potential 
therapeutic agents to rescue toxically impaired cells can be tested (Fleming et al., 2005). 
 Although both lesion-types evoke a loss of DA that results in reproducible and quantifiable 
contralateral motor deficits (Lee et al., 1996; Cohen et al., 2003), few studies have directly 
compared the effects of the two lesion-types, in terms of the levels of DA and its primary 
metabolites remaining in the striatal tissue, as well as the motor-behavioral profile they evoke. In 
addition, the vast majority of studies have made use of older animal subjects while limited studies 
have focused on the effects left on the developing CNS. For the present study, we used a unilateral 
rat model of neurodegeneration, by injecting the toxin 6-OHDA into the MFB to induce a lesion in 
the nigrostriatal DA-ergic (NSDA) pathway of very young rats (35 days old). The behavioral and 
neurochemical effects were compared to a direct unilateral injection into the striatum, in rats of a 
similar age and gender-type (male). We employed a motor-function (‘cylinder’) test that is sensitive 
to the degree of lesion-induced disability and possible recovery from it. In addition, the extent of the 
lesion produced at both sites was quantified using HPLC coupled to an electrochemical detector 
(HPLC-EC), to determine the amount of striatal DA and DA metabolites (3, 4-dihydroxyphenylacetic 
acid (DOPAC) and homovanillic acid (HVA) remaining in the post-mortem brain. 
 
2.  MATERIALS AND METHODS 
2.1.  Animals 
Sixteen male Sprague-Dawley rats were used for this study. The rats were randomly divided into 
one of two groups: those that had either received a partial lesion (n = 8) by injecting the 6-OHDA 
unilaterally into the striatum, or rats that had sustained a complete lesion (n = 8), by injecting the 
toxin into the MFB. All animals were kept in an AAALAC accredited animal holding facility 
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(University of Stellenbosch) and housed in groups of four, with housing consisting of clear 40 x 25 x 
20 cm Plexiglas cages containing sawdust, with rat pellets and tap water provided ad libitum. A 12 
hr light/dark cycle (lights on from 07h00 to 19h00) was maintained within the animal holding facility. 
All experimental treatments that were used conformed to international ethical standards and the 
protocol has been approved by the local (University of Stellenbosch) Committee for Experiment 
Animal Research (project number: N05/04/004).  
 
2.2. Preoperative & Surgical Procedures for the Infusion of 6-hydroxydopamine 
into the MFB or striatum 
 
For stereotaxic lesioning, the MFB and striatal coördinates were confirmed by lesioning four/lesion-
type 35 day-old (75-85g) rats with India ink. Following the injection the rats were killed by 
decapitation and the brains placed in paraformaldehyde for 48 h, after which the tissue was cut with 
a cryostat at a thickness of 30 μm. The sections were then mounted onto clear glass slides and 
examined under a Nikon TE2000-E microscope (using a phase 4 resolution) to determine the 
location of the tip of the needle, while referring to a stereotaxic atlas of the rat brain (Paxinos & 
Watson, 1986). The original dorso-ventral coordinates were adjusted and the procedure was 
repeated until the correct placement of the needle could be confirmed by two investigators. Bregma 
and Lambda were used to calculate the coordinates used for the MFB and the striatum injection, 
which were calculated from the dura mater, in order to cancel the individual variability observed in 
skull thickness. For the MFB lesion the coordinates were: 2.5 mm anteroposteriorly (AP), 1.8 mm 
mediolaterally (ML) and 7.4 mm dorsoventrally (DV), while for the striatum injection they were 
AP:0.57, ML:2.73 and DV:5.57.  
 Animals were randomly assigned to either the MFB or the striatum-injection. At PND 35, 6-
OHDA was infused unilaterally (right hemisphere) into either the MFB or the striatum. Thirty minutes 
prior to receiving the anaesthetic injection and immediately following surgery, the rats from both 
groups were pretreated with Desipramine HCl (Sigma, South Africa, 20 mg/kg i.p.), dissolved in 
sterile saline (NaCl 0.9%). The drug functions as a noradrenaline-reuptake inhibitor to protect 
noradrenergic neurons by preventing 6-OHDA from entering the cells (Cohen et al., 2003; Espejo & 
Miñano, 2001). The rats were anaesthetized using a combination of ketamine hydrochloride 
(Anaket-V®, Bayer Healthcare, South Africa) and medetomidine hydrochloride (Domitor®, Pfizer, 
South Africa) (0.1 ml/100g, i.p.). The head of the animal was shaved and it was placed in a 
stereotaxic apparatus (David Kopf instruments, CA, USA). The skull was exposed and the cranium 
leveled in the horizontal plane. A burr hole was drilled in the skull using the predetermined striatal or 
MFB coordinates. Infusions of 6-OHDA (Sigma, USA; 12µg) dissolved in 4µl of 0.1% L-ascorbic 
acid which in turn was dissolved in 0.9% sterile saline was administered. The toxin was delivered 
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through the burr hole by using a Hamilton 10 μl syringe with a 22-gauge needle attached, driven by 
a 341-A model syringe pump (Sage Instruments, USA) at a rate of 1µl/min for 4 min. The cannula 
remained in situ for an additional 5 min following the administration to prevent reflux of the toxin 
along the injection tract, before slowly retracting it from the brain tissue and skull. The hole drilled in 
the skull was filled with sterilized oxidized cellulose (Ethicon, U.K.), the wound sutured and covered 
with a layer of iodine. The animal was kept under a heating-lamp until full recovery from the 
anesthesia. Rats were then returned to their cages and their food and water in-take as well as 
general behaviour was monitored daily to ensure their full recovery.  
 
2.3.  General behavioral testing procedures 
Animals were tested for behavioural changes at 28 days post 6-OHDA-injection. Testing consisted 
of the forelimb-use asymmetry (‘cylinder’) test. All testing took place between 10h00 and 12h00, in 
a quiet, dimmed room dedicated to animal testing. 
 
2.3.1.    Forelimb-use asymmetry (‘cylinder’) test 
A lesion sustained on one hemispheric side manifests in spontaneous behavioral alterations with 
these measures serving as litmus tests for confirming lesion size (Schwarting et al., 1991; Sindhu et 
al., 2005). Twenty-eight days following the surgery, drug-free behavioral testing was performed, 
since it reflects a more natural response to the effects of the lesion (Roghani et al., 2002). The 
forelimb-use asymmetry test (‘cylinder’) was used, since asymmetry scores in forelimb usage during 
the vertical-lateral exploration of the inner-walls of a cylindrical chamber has been shown to 
correlate with the extent of nigrostriatal terminal loss resulting from the toxin’s infusion (Schallert & 
Woodlee, 2005; Schallert, 2000). For this test, rats were individually placed in an upright 
transparent Plexiglas cylinder, with the diameters measuring at 19 cm across and 24.4 cm in height. 
The walls were high enough to prevent the animal from reaching the top edge when standing on its 
hind limbs and were wide enough to permit a comfortable 2 cm space between the tip of its snout 
and the base of its tail when all four paws were placed on the ground. The floor of the container 
consisted of a transparent sheet portraying four quarter-of-a-circle sections all equal in size.  
 The parameters used for quantifying the degree of forelimb-use asymmetry were: (1) the 
independent use of a single forelimb (left vs. right) for exploring the inside surface of the cylinder, 
while the other limb remained stationary, but in constant contact with the inner-surface of the 
cylinder wall; and (2) the amount of stereotypic rotations the animal made towards (ipsilateral) and 
away (contralateral) from the lesioned (right) side were recorded. A single rotation was counted if 
the animal made a complete continuous 180° turn in either direction, correlating with the rat moving 
through at least two of the quadrants marked on the cylinder’s floor. For parameter (1) the limb-use 
score was calculated using the number of times that the ispsilateral (left) and contralateral (right) 
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had been placed on the inner-wall surface divided by the total number of forelimb placements 
(ipsilateral + contralateral + both) and expressing this as a percentage by multiplying the value with 
100 (Connor et al., 1999). For parameter (2) a single score was calculated by subtracting the 
amount of contralateral turns made from the ispsilateral ones. Other counts included were the 
amount of steps taken by each of the backlimbs (2), and the amount of times that the animals made 
a full rear against the inner wall of the container, as a measure of gross motor function.  
 The animals were tested during the light phase (between 10h00 and 12h00) with each test 
lasting 5 min in total, following which the rats were immediately returned to their home cage. A 
video recorder with slow-motion and frame-by-frame capabilities mounted on a tripod at an angle 
and underneath the cylinder, allowed full-view of the animal’s activities, even when the rat turned 
away from the camera. The rat’s behavior was analyzed from the video recording by a rater blind to 
the experimental condition of the animals. In cases where it was unclear whether the limb had been 
placed independently or simultaneously with the other, it was neglected from the final score. 
 
2.4.             HPLC-EC analysis for DA, DOPAC and HVA 
Following the last behavioral assessment, all animals were killed by decapitation and the striatum 
tissue was collected for analyzing the DA and DA metabolite content level. The brains were rapidly 
removed from the skull and the total striatum of both hemispheres were dissected out on an ice-
cooled dissection slab by cutting coronal sections at the level of the infundibular stem to form a 
forebrain block containing the striatum. The forebrain was bisected along the midline and cortical 
tissue for each hemisphere was peeled back to expose the striatum, which was dissected along the 
boundary of the corpus callosum. The striata were snapped frozen in liquid nitrogen (-198 ºC) until 
further analysis. DA and DA-metabolites content levels were determined by the same HPLC-EC 
method as was previously described by Harvey et al. (2006). The chromatographic system 
consisted of a GBC LC 1120 HPLC Isocratic pump that contained an inlet filter and a Rheodyne 
7725i injection valve comprising of a 50 μl loop for introducing samples into the system. For the 
separation step, a 5µm C18 Phenomenex Luna reverse phase analytical column (150 × 4.6 mm) 
was connected to a GBC LC 1260 Electrochemical Detector (+0.6 V) as well as a Spectra-Physics 
SP4290 integrator. The mobile phase consisted of 0.1 M sodium formate buffer, 0.5 mM 
ethylenediaminetetraacetic acid (EDTA), 5 mM sodium heptane sulphonic acid, 6% v/v methanol 
and 4% v/v acetonitrile. Milli-Q water was used to make the solution up to 1000 ml. The pH was set 
at three by adding 6 ml of orthophosphoric acid (85%). The composition was degassed twice prior 
to use. The flow rate of the mobile phase running through the system was set at 1.2 ml/min. The 
temperature remained ambient throughout. On the day of analysis the samples were allowed to 
thaw and the weight of each sample recorded. A total volume of 1 ml 0.1 M perchloric acid solution 
was added to each tube, sonicated and then placed on ice for 20 min, after which the tissue was 
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centrifuged (20 min, 4˚C, 24 000 × g, Sorval Discovery 9056 ultracentrifuge). Following the 
withdrawal of 200 μl aliquot of supernatant, 20 μl of the internal standard solution (isoprenaline 
HCL) was added and the solution mixed. A sample of 50 μl was injected into the column for content 
analysis. Standard DA, DOPAC and HVA solutions were prepared in a vehicle of 0.5 mM sodium 
metabisulphite and 0.3 mM Na2EDTA, diluted with perchloric acid (0.1 M). The monoamine 
standards ranged between 10 ng/ml – 200 ng/ml and linear standard curves were found in this 
particular range. DA, DOPAC and HVA were quantified by comparing the area under the curve 
(AUC) of the sample/AUC of the internal standard (isoprenaline) to the monoamine standard, 
utilizing the linear equation obtained from the standard curve. ChemStation Rev A 08.03 software 
was used for data acquisition purposes.  
 
   2.5.  Statistical analysis 
Comparisons for differences in means and variance were statistically assessed by means of a 2-
way Analysis of Variance (ANOVA) using a 2 (site of injection) × 2 (the limb side used by the 
animal) × 2 (behavioral assessment time-points) factorial design. This was followed by a post hoc 
multiple comparison t-test (Bonferroni) when appropriate. For an analysis of the number of rearings 
made by the two groups during the ‘cylinder’ test, a parametric Student’s t-test was used for 
analyzing the data. Differences were regarded as significant when p < 0.05. The statistical analysis 
of the data was performed using the Prism® statistical analysis software program (GraphPad 
Software, version 4.02, USA). All data are expressed as mean ± the standard error of the mean 
(S.E.M.) 
 
3.   RESULTS  
3.1. Independent use of the forelimbs 
An ANOVA analysis of the data obtained from the “cylinder” task revealed no significant 2-way 
interactions (F = 0.03, df = 1, p = 0.86) between the factors site of administration (MVB vs. striatum) 
and independent limb use for exploring the inside of the cylinder (ispsilateral vs. contralateral). Post 
hoc comparisons revealed a significant effect for the preferential use of a single forelimb (F = 40.12, 
df = 1, p < 0.0001), but not for site of administration (F = 0.80, df = 1, p = 0.38). Fig. 1 shows the 
striatal-lesioned group’s performance compared to their MFB counterpart. The figure shows a 
decrease in the percentage contralateral limb use, compared to the ipsilateral limb use in both 
groups.  
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Fig.  1.     Independent placing responses made by the ispsilateral and the contralateral forelimb 
during the ‘cylinder’ task. For both groups, the asterisk (*) indicates a significant (p < 0.05) difference 
compared to the contralateral limb. 
 
3.2.  Spontaneous rotation 
 A 2-way ANOVA was performed to determine for the effect of the factor site of administration (MFB 
vs. striatum) on the dependent variables direction of the turns made (ipsiversive vs. contraversive) 
and the number of 180° rotations in either direction, followed by a Bonferroni multiple comparison 
post hoc analysis. The results revealed no overall significant interaction between the factors (F = 
2.4, df = 1, p = 0.13). A significant overall effect was detected for the direction of turning (F = 10.1, 
df = 1, p = 0.004), but not for the site of administration (F = 0.003, df = 1, p = 0.96). Although both 
groups tended to rotate more in a contraversive than in an ipsiversive direction, only the striatal-
lesioned group showed a statistically significant preference for rotating away from the lesioned 
hemisphere (Fig. 2). 
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Fig.  2.     The number of spontaneously induced continuous 180° rotations towards (ipsiversive) and 
away (contraversive) from the 6-OHDA lesioned hemisphere. The * indicates a significant (p < 0.05) 
difference when comparing the number of contraversive to ipsiversive turns, made by the same animal group.  
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3.3.  Number of steps taken by the hindlimbs 
 No significant overall interaction was detected for this parameter allowing for main effects to be 
interpreted. There were no significant differences between the limb side used (F = 2.47, df = 1, p = 
0.13). However, a significant effect was detected for the site of administration (F = 4.25, df = 1, p = 
0.049).  As shown in Fig. 2, n both groups, use of the contralateral backlimb did not reach 
significance compared to use made of the ispsilateral backlimb (Fig. 3).  
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Fig.   3.     The number of stepping movements by the hindlimbs following a 6-OHDA lesion. No 
significant difference was observed between use made by the ipsilateral and the contralateral backlimb, in 
either group (p > 0.05).  
 
 
 
3.4.  Rearing frequency 
There was a significant difference detected between the amount of full-body rearing movements 
made by the MFB and the striatum group (F = 4.25, df = 7, p = 0.04) (Fig. 4). A similar observation, 
but in older adult rats, had previously been reported by other investigators of a significant increase 
in locomotion and rearing (Castañeda et al., 1990) depending on the size of the lesion. The results 
showed that the size of this parameter may depend on the site at which the toxin was administered 
to juvenile rats, since the MFB-lesioned rats displayed significantly reduced rearing movements 
compared to the striatum-lesioned group (Fig. 4). 
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Fig.   4.     The degree of rearing movements recorded at 28 days following the 6-OHDA lesion. The * 
indicates a significant (p < 0.05) difference when compared to the MFB-lesioned group.  
 
3.5.   HPLC-EC results   
A 2-way factorial ANOVA with a 2 (site of toxin administration) × 2 (hemispheric side from which the 
striatum was dissected) design was used for analyzing the data obtained from the HPLC-EC 
analysis performed on the striatum samples. For the statistical analysis of the DA values, no 
significant interaction was found for the site of administration (F = 0.01, df = 1, p = 0.92) or striatum 
side (F = 2.03, df = 1, p = 0.17), while no significant overall effect was found between DA levels, site 
and hemispheric side (F = 2.18, df = 1, p = 0.1.5). Fig. 5A shows the results of these analyses, in 
which the DA levels in the MFB group had been unaltered by the lesion, while a DA upregulation 
was observed on the lesioned side in the striatum group.  
 For the DOPAC levels, a significant effect was detected for the factor site of administration (F = 
9.01, df = 1, p = 0.006), but not for the factor striatum side (F = 0.03, df = 1, p = 0.85). A significant 
overall effect was found between the factors site of administration and striatum side (F = 15.48, df = 
1, p = 0.0005). Fig. 5B shows an upregulated level of DOPAC on the lesioned side for the striatal-
infused animals, while the opposite holds true for the MFB-infused rats that show a downregulation 
on the lesioned side compared to the unlesioned intact side. 
 The HVA values showed no overall significant interaction (F = 2.76, df = 1, p = 0.12) with the site 
of administration. However, the analysis revealed a significant effect for lesioned vs. unlesioned 
hemispheric side in the striatal lesioned group (F = 11.62, df = 1, p = 0.002). Fig. 5C shows these 
results, with a significant difference indicated between the DOPAC levels of the MFB-infused and 
the striatum-lesioned rats. A difference was detected in both hemispheres.  
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Fig.   5.     Results of the HPLC-EC analysis performed on striatal tissue, showing DA (A), DOPAC (B), 
and HVA (C) concentrations. When comparing the MFB lesioned animals to the striatal lesioned ones, the 
asterisks indicates statistical significance (*p < 0.05, **p < 0.001).  
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An analysis of the DOPAC/DA ratio revealed no significance for striatum side (F = 3.68, df = 1, p = 
0.07), but revealed significance for site of administration (f = 36.97, df = 1, p < 0.001), as well as an 
overall significant interaction effect (f = 16.40, df = 1, p < 0.001). These results are shown in Fig. 6 
with an upregulation of DA metabolism seen on the lesioned side compared the unlesioned side in 
the striatum-infused rats, but the opposite effect seen in the MFB-lesioned group.  
 The HVA/DA ratio was significant for the striatum side (f = 13.32, df = 1, p = 0.001), but not for 
the site of administration (f = 0.002, df = 1, p = 0.96). No significant interaction effect was revealed 
(f = 0.74, df = 1, p = 0.4). In Fig. 6b, the upregulated metabolic effect is seen on the lesioned side 
compared to the unlesioned side in both groups of animals.  
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Fig.   6.     The DA turnover rate representing DA metabolism in the striatum (Altar, 1987b), and 
expressed as DOPAC/DA (A) and HVA/DA (B). The asterisks indicate a significant comparison in relation to 
the MFB lesioned group (*p < 0.05, **p < 0.001).  
 
4.  DISCUSSION 
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Here a parkinsonian animal model was created by centrally administering 6-OHDA, in order to 
provide evidence for anatomically distinct toxin susceptibility directly at the level of the NSDA 
neurons in the developing CNS. Lesions were made at two different neuro-anatomical locations 
within the pathway to determine for behavioral, striatal DA and DA metabolite content differences. 
The results show that the degree of motor deficits, which were demonstrated by using the ‘cylinder’ 
test, a motor-function test that is sensitive to the degree of DA loss, depending on whether the 
destruction of the NSDA pathway took place at the level of the cell body or nerve terminals. The 
significant differences in functional impairment between the groups suggest for a different 
modulation of motor behavior by these different brain regions, possibly due to complex 
neuromodular organization and inter-linkages.  
 Post-mortem brain catecholamine levels provide a good index of the density of DA-ergic 
innervations in rats following recovery from a unilateral 6-OHDA lesion (Ranje & Ungerstedt, 1977; 
Onn et al., 1986; Altar et al., 1987b). In the current experiment, neurochemical analysis using 
HPLC-EC revealed a surprising compensatory DA effect in the lesioned hemispheric side to 
indicate that the nature and/or sensitivity of the processes whereby 6-OHDA transmits its neuron-
damaging effects to the level of the cell body and the striatum may induce different levels of 
degeneration between the mature and the developing CNS. Although the degeneration of 
nigrostriatal DA-ergic fibers compiles the hallmark of idiopathic PD (Kish et al., 1988), it is debatable 
what critical threshold should be reached before symptoms express clinically. The adult nigrostriatal 
system seems to be able to endure substantial DA deficits, the degree of which has not yet been 
fully described. This inherent reserve capacity might explain why parkinsonian features seldom 
manifest before the progressive decline of at least 80% of the DA-ergic neurons located in the 
SNpc, with the slow progression implying that compensatory mechanisms are likely to be in place 
(Finkelstein et al., 2000).  
 In the experimental lesioning of the nigrostriatal DA system of rats, it’s complete (>95%) 
destruction results in severe motor, sensory, and cognitive deficits which animals fail to recover 
from (Stricker & Zigmond, 1976; Marshall, 1985; Robinson et al., 1990). In cases where the loss of 
DA-ergic cells exceed the 95% limit, compensatory mechanisms seem to fail with dialysate DA 
levels decreasing dramatically, even during amphetamine-induced DA release (Robinson & 
Whishaw, 1988; Castañeda et al., 1990). However, certain reports have indicated that even 
following striatal DA depletion in excess of 95%, a return to basal dialysate DA levels may still occur 
(Jonkers et al., 2000; Bergquist et al., 2003).  
On the other hand, considerable sparing of function has frequently been observed following a 
(<80%) depletion of striatal DA (Stricker & Zigmond, 1974). Animals that had sustained partial 
depletions, comprising of an 80-95% striatal DA loss, initially suffer from severe behavioral deficits, 
but eventually regain many of their previously-held abilities (Zigmond & Stricker, 1973; Marshall et 
 161
al., 1974; Marshall, 1979), while dialysate DA levels are seemingly maintained in the striatum. 
However, this only seems to be the case as long as the level of neurodegeneration does not 
exceed 80% (Sarre et al., 2004). Further evidence for a positive correlation between the magnitude 
of behavioral dysfunction and DA levels remaining in striatal tissue was provided by human post-
mortem studies (Lees et al., 1985). In addition, since PD is characterized by the slowly progressive 
demise of DA-ergic neurons in the SNpc, symptoms only appear after most neurons have been lost 
(usually >80%). Such a slow course of degeneration may imply that compensatory mechanisms are 
in place serving to reduce the speed of decline (Finkelstein et al., 2000). Taken together, these 
observations highlight the general consensus that although the NSDA DA system is necessary for 
maintaining normal motor-function, a mere 10-20% of the DA input to the striatum seems to be 
required for functioning relatively intact (Robinson et al., 1994a). However, considerable individual 
variation concerning the magnitude of decline, the ability to maintain extracellular DA levels, and in 
the rate and extent of behavioral recovery contribute towards the lack of consensus on what 
constitutes the “critical depletion zone” (Marshall, 1979; Kozlowski & Marshall, 1981; Stricker & 
Zigmond, 1986).  
 The concept of resistant DA cells gained additional experimental support from reports of similar 
TH-immunoreactive fiber densities and DA neuron loss between animals lesioned either uni- or 
bilaterally with 6-OHDA (Roedter et al., 2001). Furthermore, following the systemic administration of 
the DA agonist d-Amphetamine, Robinson & Whishaw (1988) and Castañeda et al. (1990) reported 
that DA released on demand in the toxin-lesioned striatum compares favorably to the DA levels 
detected in the intact striatum. In the current experiment, HPLC analysis of striatal tissue revealed 
that the MFB lesion had no effect on extracellular DA levels, since the levels compared favorably to 
those detected on the unlesioned side. 
However, in the striatum-lesioned rats the DA in the unlesioned left hemisphere exceeded that of 
the lesioned side. It may be possible that release from DA terminals were increased in the 
remaining neurons via increased mesolimbic pathway afferents and/or by decreasing the number of 
synaptic DA reuptake sites and/or D4 receptors (Ikegami et al., 2006). The DA neurons responsible 
for this DA pool may be located in a few remaining striatal terminals that have either undergone 
partial degeneration or had been spared altogether (Robinson et al., 1994b). However, if the 
terminals had been partially damaged by the toxin, they are likely to be isolated from their cell 
bodies, thereby being prevented from receiving stimulatory action potentials (Mintz et al., 1986).  
Little consensus currently exist regarding the nature of DA-release following a 6-OHDA lesion to 
the nigrostriatal pathway, where a multitude of adaptations presumably interact to maintain and 
“normalize” extracellular striatal DA levels (Castañeda et al., 1990). The precise role played by 
presynaptic vs. postsynaptic contributions towards compensatory neuro-adaptations and the 
animal’s eventual functional recovery remains unclear. Some previous studies suggest for 
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presynaptic adaptations, such as compensatory increases in DA biosynthesis and the rate of 
release by DA neurons surviving the 6-OHDA insult (Marshall, 1984; Robinson & Whishaw, 1988; 
Castañeda et al., 1991). Furthermore, reports of lowered DA metabolism, an increase in DA’s ability 
to diffuse further (Stricker & Zigmond, 1976; Robertson & Robertson, 1989; Zigmond & Stricker, 
1973) and the fractional release of DA in the remaining DA terminals suggest that the lesion may 
provoke “silent” cells to become active in the wake of the toxic onslaught (Hollerman & Grace, 
1988). In addition, some authors have observed vigorous axonal sprouting in the terminal arbors as 
well as increased axonal varicosity size in lesioned animals, suggesting that substantial sprouting of 
new DA-ergic synapses may be the main post-synaptic compensatory attempt (Finkelstein et al., 
2000). 
 The compensatory effect in DA levels observed in the current experiment may be due to the fact 
that the toxic insult was delivered to young CNS system, that may have a superior capacity for 
plasticity over an adult one. The reason for this remains obscure, but it has been suggested that a 
6-OHDA injection in neonatal rats cause norepinephrine depletion in the frontal cortex to trigger a 
compensatory increase in DA, serotonin (5-HT), and met-enkephalins correlated by an increased 
density of tyrosine hydroxylase and 5-HT-positive axons (Germani et al., 1995). The bilateral 
administration of 6-OHDA often causes severely impairs an animal’s ability to feed, drink, and 
move, to often leads to their death. However, for neonatal rats receiving similar treatment, survival 
is common (Brot et al., 2002).  
However, it may be that the normalization of extracellular DA, whether this occurs in the 
developing or the mature CNS, may not be sufficient to account for functional recovery. In the 
‘cylinder’ test, the remaining DA pool appeared not to be adequately mobilized upon functional 
demand, and asymmetric performances were observed in a number of behavioral parameters. 
Although presynaptic compensatory changes maintain normal basal extracellular DA levels in the 
remaining DA terminals (Parsons et al., 1991) and reach their optimal performance within 3 days 
following a unilateral 6-OHDA lesion (Altar et al., 1987a), this fails to explain for the protracted time-
course of behavioral recovery following a 6-OHDA lesion to the NSDA pathway.  
 The MFB group showed significantly less locomotion over that of the striatal-lesioned rats, as 
was measured by the amount of rearing movements displayed during the ‘cylinder’ task. This 
enhanced behavioral response seen in one group compared to the other may be due to normal 
extracellular levels of DA acting on a supersensitive receptor population in the one, but not in the 
other group.  
At 28 days following the lesion, both the groups turned predominantly away from the lesioned 
side, thus in a contraversive direction, although the degree did not reach statistical significance. By 
first observations the tendency to turn contraversively directly opposes the fundamental tenet 
underlying the rotational behavior model, which states that animals tend to rotate away from the 
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more active striatum  (Ungerstedt, 1971a), defined as the hemisphere that releases the greatest 
amount of DA into intersynaptic spaces. In the current experiment, the striatum animals tended to 
turn away from the intact striatum and what was presumably the hemisphere of greatest DA-
release. The explanation for this might be similar to that proposed for a similar behavioral pattern 
seen during ligand-induced rotational assessment (Robinson et al., 1994b). Although DA-release 
may be attenuated on the lesioned side, the DA released by DA-ergic neurons within the lesioned 
hemisphere could interact with supersensitive DA receptors to bring about a greater degree of 
postsynaptic activation on the lesioned side. In contrast, DA acts upon normosensitive neurons 
within the intact side (Ungerstedt, 1971b; Costall et al., 1976; Staunton et al., 1981; Neve et al., 
1982). A report that even a mild increase in extracellular DA, by correcting a functionally defective 
adrenal graft, restored impaired symmetry in striatal DA binding to D2 receptors. Also a tonic 
increase in synaptic DA was able to down-regulate DA receptors (Curran et al., 1993).  
 Taken together, our results argue that a combination of compensatory mechanisms and various 
DA sources resulted in sustaining tissue DA levels in the adult brain following a toxic insult to the 
DA-ergic neurons during the neonatal period. For both groups of rats there were definite signs of 
compensatory mechanisms at work reflected in the HPLC-EC results, while variations were 
observed during the behavioral tests. Overall, the behavioral results indicate that the 
interdependent regulation of the 2 nigrostriatal systems may provide some compensatory support 
for the function and behavioral performance of the lesioned side via the normal unlesioned side. It 
should be noted that steady-state striatal DA content represents a complex balance between 
synthesis, release, reuptake and metabolism. However, this provides limited information on the 
underlying cellular processes responsible for defining the response of the tissue to neurotoxins. It is 
widely accepted that many compensatory mechanisms that still lack a clear definition, are active 
within the NSDA pathway to maintain function, despite extensive neuronal loss that may derive from 
both experimental and clinical situations (Anglade et al., 1995; Finkelstein et al., 2000; Song & 
Haber, 2000; Zigmond & Hastings, 1998). To our knowledge, this is the first report of different 6-
OHDA administration site-specific responses to NSDA toxins in the developing CNS. The current 
data add to emerging insights already gained regarding the compensatory mechanisms active in 
the developing CNS. However, the source of the DA pool that was revealed on the lesioned side 
and whether this source is only of a transient nature remains an interesting topic for future 
investigations. 
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CHAPTER 5  
 
MATERNAL SEPARATION EXAGGERATES THE TOXIC EFFECTS OF 6-
HYDROXYDOPAMINE IN ADULT RATS: IMPLICATIONS FOR NEURODEGENERATIVE 
DISORDERS 
 
1. INTRODUCTION 
In the current study, we hypothesize that exposure to stressful stimuli during the early-life 
phases may predispose an individual to develop neurodegenerative diseases, specifically PD, 
during the later stages of life. During stressful situations various mechanisms, such as the 
hypothalamic-pituitary-adrenal (HPA) axis, are activated with the purpose of restoring the 
internal environment to its baseline activity (homeostasis). However, these mechanisms are 
designed for coping with the demands imposed by short-acting stressors only, and therefore 
chronic exposure to severe stress-provoking demands associate with the suppression of 
reproductive, growth, thyroid and immune functions, and this may lead to various pathological 
states.  
 It is acknowledged that the majority of individuals who experience stressful events, generally 
do not develop severe pathologies as a result of this. It is well documented that genetic factors 
may play a significant role in rendering certain individuals more vulnerable to stress and stress-
related disease than others (Francis et al., 1999). This study intends to show that 
environmental factors such as early life stress may also be a significantly provoking factor in the 
development of neurodegenerative disorders  
 
2. THE PHYSIOLOGICAL RESPONSE TO STRESS    
An organism is incapable of surviving in the absence of the ability to adapt to its immediate 
environment. Homeostasis is constantly under threat due to exposure to a multitude of 
stressors. Therefore, the stress response is also referred to as “allostasis”, meaning to 
“maintain stability through change” (Sterling & Eyer, 1988). Virtually all physiological systems, 
including the cardiovascular, immune, respiratory, digestive, sensory, metabolic and nervous 
system are modified in order to meet the perceived danger during the body’s response to 
stress.  
 The initial response to stress involves an activation of the various bodily systems that play a 
part in the general alarm response raised to restore homeostasis. A critical component of this 
includes activating the HPA axis. Upon activation, energy is released from stored nutrients (i.e. 
triglycerides, glycogen) by transferring them into energy sources (free fatty acids, glycerol, 
glucose, amino acids) available for immediate use by the body. In addition, cardiovascular and 
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pulmonary tone is increased to facilitate delivery of oxygen and glucose to the tissue, while 
anabolic processes are slowed. Moreover, processes that are not vital for survival during the 
stress-crises, including digestion, growth, reproduction, inflammatory and immune responses 
are suppressed until the acute emergency has been survived. In prehistoric times, the physical 
changes in response to stressful stimuli were often an essential adaptation for avoiding the cost 
of natural threats, such as loss of life or sustaining severe injuries. In modern times, the stress 
response can be of benefit for raising performance levels during critical events, such as sports 
events, an important meeting, and/or when meeting situations of actual danger or crisis. In 
addition, cognitive processes are altered, tending towards lowered sensory thresholds and a 
logical adaptation for coping with an emergency situation.  
 Stress also triggers the release of certain neurotransmitters, such as adrenaline and 
noradrenaline. The released catecholamines activate the amygdala-region of the brain, which 
appears to trigger an emotional response, such as fear, to the stressful event. 
Neurotransmitters also signal the hippocampus, located in close proximity, to store the 
emotionally-rich experience in long-term memory, serving a survival-related role, to allow the 
organism to recognise the early signs relating to the particular danger during a future encounter, 
in order to avoid the danger and the adverse effects associated with this altogether.  
 The HPA constitutes the major neuroendocrine stress response system (Malarkey et al., 
1995, Heim & Nemeroff, 2001), while the sympathetic-adrenal-medullary (SAM) system 
comprises the other important component in mediating the response. Both systems have a non-
specific response pattern, although their activation threshold and time-course differs. (Pecoraro 
et al., 2006). Interestingly, while the short-term activation of the HPA axis allows adaptive 
responses to the challenge, in the long-run this can hold devastating consequences for the 
organism. 
 The neurons of the paraventricular nucleus (PVN) of the hypothalamus produce 
corticotropin-releasing factor (CRF). Projecting from the CRF cells to the median eminence the 
axons transport their contents to the primary portal vasculature where passive transport 
mechanisms diffuse these into the primary portal vasculature comprising of leaky capillaries. 
Vascular transport to the secondary plexus in the anterior pituitary occurs, whereupon CRF 
stimulates glandular corticotrope cells to synthesize pro-opiomelanocortin (POMC). This large 
molecule is processed by convertases in the cell to adrenocorticotropic hormone (ACTH) which 
is then stored in secretory vesicles. An additional immediate effect to CRF release is that stored 
ACTH is released directly into the systemic circulation system. The augmented plasma ACTH 
concentration then stimulates cells in the zona fasiculata of the adrenal cortex to secrete 
glucocorticoids into the peripheral blood circulation. Glucocorticoids act upon peripherally 
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located cells as well as CNS neurones that contain glucocorticoid receptors, which they reach 
after crossing the blood brain barrier (BBB) (Power & Schulkin, 2006).   
3. EARLY LIFE AS A WINDOW OF DEVELOPMENTAL VULNERABILITY FOR 
DEVELOPING STRESS-INDUCED PATHOLOGY DURING LATER LIFE 
Development represents a critical moment for shaping adult behavior and may set the stage to 
disease vulnerability later in life. The perinatal period shows enhanced plasticity, especially by 
the stress system, and is therefore particularly vulnerable to stressors. Exposure of the 
developing brain to severe and/or prolonged stress may result in hyper-activity of the stress 
system, defective glucocorticoid-negative feedback, altered cognition, novelty seeking, 
increased vulnerability to addictive behaviour and mood-related disorders (Charmandaru et al., 
2003). Therefore, stress-related events that occur during the perinatal period can permanently 
change brain functions and the behaviour of the developing individual. For example, prenatal 
restraint stress (PRS) in rats is a well-documented model of early stress known to induce long-
lasting neurobiological and behavioral alterations, including impaired feedback mechanisms of 
the HPA axis, disruption of circadian rhythms and altered neuroplasticity (Maccari & Morley-
Fletcher, 2007). Specifically, PRS rats associated with hippocampal dysfunctions and several 
behavioral and endocrine disorders relating to this brain area. In view of estimates that between 
5-16% of pregnant women could be exposed to physical or sexual abuse while they are 
pregnant (Cokkinides et al., 1999; Goodwin et al., 2000; Hedin & Janson, 2000; McFarlane et 
al., 1996), it is likely that a large proportion of children are exposed to prenatal stress.  
A number of studies have shown strong associations between child maltreatment – either of 
a physical, emotional and/or a sexual nature – and various forms of mental disorder manifesting 
during childhood, adolescence and adulthood as major depression, posttraumatic stress 
disorder (PTSD), attention-deficit/hyperactivity disorder (for a review, see Famularo & Pelcovitz, 
1992). In addition, a community-based study containing a database of over 2000 women 
reported that those with a history of childhood sexual or physical abuse, in the absence of a 
similar traumatic event occurring during adulthood, exhibited a higher frequency of depression 
and anxiety, with a higher rate of attempted suicides than women without such a history 
(McCauley et al., 1997).  
Genetically sensitive ‘natural experiments’ had been important in showing that environmental 
mediation was a highly likely factor in the behavioral outcome seen. Discordant twin designs 
showed that the mental disorders in adult life were much more likely to arise in the twin who 
suffered sexual abuse than the twin who did not. Moreover, the strength of association was very 
comparable to that found in the population as a whole (Kendler & Prescott, 2006). Multivariate 
twin analysis (Jaffee et al., 2004) also proved crucial for showing a marked difference between 
corporal punishment (with no evidence of environmental mediation detected) and maltreatment.  
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However, these studies usually implicate adverse exposure during adulthood, while only 
limited reports propose a neurodevelopmental basis for neurodegeneration. Environmental 
exposures during early life pose an enhanced risk due to the CNS receiving exposure to 
neurological insults during critical periods of vulnerability. These include the possible effects 
that certain teratogens may have on the nigrostriatal dopaminergic system, including exposure 
to agrichemicals (Barlow et al., 2004), an iron-enriched diet (Jones et al., 2002) during the 
perinatal period, or exposure to maneb (Cory-Slechta et al., 2005), cocaine (Glatt et al., 2004) 
or bacterial endotoxin lipopolysaccharide (LPS) (Ling et al., 2006) during the prenatal period. In 
addition, a highly concentrated prenatal endocrine environment, characterized by high levels of 
glucocorticoids, seems to have detrimental effects on the long-term survival rate of cerebellar 
granule cells, leaving these cells more susceptible to the effects of oxidative stress (Ahlbom et 
al., 2000). 
  
3.1.  Physical and sexual abuse of children as a source of stress 
Children subjected to physical or sexual abuse are at greater risk to develop psychiatric 
problems later in life (Bifulco et al., 1991). The definition of abuse is multifold and includes 
persistent emotional neglect, without necessarily including physical abuse as well, to act as a 
risk-factor for developing depression during adult-life (Canetti et al., 1997). Such vulnerability 
might reflect rearing conditions exposed to during early postnatal life (Brake et al., 2004). 
During normal rat mother pup-interactions, the dam leaves the litter routinely for only 20-25 min. 
at a time. Thus, by extending this period of separating the dam from her pups, a model 
deprivation of maternal care is created and applied to the human species. However, separating 
the mother from the pups should not be regarded as an extreme form of deprivation, since it is 
not unusual behaviour to observe the dam leaving the litter for up to 3 hrs to forage for food 
when in the wild (Calhoun, 1962). However, the difference between separation as a natural 
phenomenon and when experimentally induced, is that, in the case of maternal separation as 
an animal model, dams are forced away from their litters and are unable to hear vocalizations 
from the pups.  
Experiments performed on rats show that disrupted normal care during this period can have 
chronic effects on the normal neuroendocrine response to environmental stress.  More 
specifically, repeated exposure of animals to periods of MS during the first 2 weeks post-birth 
resulted in an increased stress reactivity that can last across the animal’s entire lifespan 
(Plotsky & Meaney, 1993; Liu et al., 2000). During adulthood, rats subjected to maternal 
separation during the postnatal period display increased fearfulness, greater HPA axis and 
behavioral responses to stressors, as well as increased locomotor activity in a novel setting 
(Piazza & Le Moal, 1997).  
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3.2. Early-life exposures to stressful events as a trigger for adult 
neuropathogenesis 
Stress can be defined both as an internal or external stimulus (as described above), or as a 
non-specific adaptive response by the body to any demand, leading to rapid changes affecting 
the entire body (Harshpinder & Aujila, 2006). These adaptations serve to restore a state of 
homeostasis when this is threatened, or perceived to be threatened (Selye, 1949) that can 
prove life-saving in a critical life-or-death situation. However, with extended periods of time, 
exposure to repeated stressful situations place excessive strain on the body that may contribute 
substantially towards developing medical problems of both a physical and psychological kind. 
Clinical conditions associated with exposure to severe or chronic forms of stress (e.g. post-
traumatic stress disorder and depression) have been found to demonstrate signs of neuronal 
degeneration, including evidence of atrophy in the hippocampus (Sapolsky et al., 1996; 
Bremner et al., 1997). Similarly, the subjection of rodents and non-human primates to chronic 
levels of restraint stress (Watanabe et al., 1992), chronic multiple stressors (Magarinos & 
McEwen, 1995), or psychosocial stress (Uno et al., 1989; McKittrick et al., 2000; Czeh et al., 
2001), resulted in degenerative changes within hippocampus CA3 pyramidal neurons. 
The aetiology of neurodegenerative disorders, including PD, continues to receive intense 
investigation, with the aim of developing improved treatments. However, although the precise 
mechanism by which PD is induced remains unknown, both genetic susceptibility and exposure 
to adverse environmental conditions are regarded as major risk factors for developing the 
disease (for a recent review, see Yamashita & Matsumoto, 2007). The idea that PD is 
environmentally influenced seems feasible due to evidence that an inflammatory reaction by the 
CNS’s resident immune cells, the microglia and astrocytes, when exposed to noxious elements 
during early life may be a possible cause or contribute to developing PD in later life (Liu et al., 
2003).  
 Although many individuals experiencing stressful events do not develop pathologies, chronic 
stress seems to be a triggering factor in those individuals that are particularly vulnerable. There 
is evidence to suggest that the neuroendocrine response to stressful stimuli may act as a 
causative factor to neurodegenerative diseases, with evidence for a possible genetic link 
between the intensity of the stress response, the rate of age-dependent neurodegeneration and 
the individual’s life expectancy (Glad & Gilad, 1994). For instance epigenetic factors may 
permanently increase HPA axis activation (Tsankova et al., 2007).  
  
4.  RESEARCH HYPOTHESIS 
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To expand current knowledge of environmental impact on the state of DA neurons, the present 
study investigated whether exposure to stress early in life could predispose individuals to the 
development of a neurodegenerative process such as PD. To test this hypothesis, rats were 
maternally deprived for 3 hrs a day between postnatal days (PND) 2-14, and injected with a 
single unilateral injection of 6-OHDA into the striatum when at 35 days of age. We specifically 
opted to lesion the rats when they reached an adolescent stage (at 35 days of age), since the 
synthesis-rates of striatal D1 and D2 DA receptors reach their apices at this stage (Andersen, 
2002). The motor performance of the animals was assessed at 28 days following surgery using 
a series of behavioral measures, and the results compared to a group of rats that had not 
previously been exposed to MS prior to toxin exposure. Following the behavioral assessment, 
the rats were decapitated and the brain tissue collected for immunohistochemical analysis. 
 
5.  MATERIALS AND METHODS  
5.1.  Animals 
Sprague-Dawley rats were used to generate the pups for this study. These animals were 
obtained from the Central Animal Research Facility of the University of Cape Town. The 
animals were housed in 40 × 25 × 20 cm acrylic cages (4 rats per cage) with pine wood 
shavings that covered the cage floor. Rat chow and tap water were available ad libitum. 
Temperature was maintained at 22˚C and lights were on each day from 06:00 to 18:00. The 
experimental procedures were approved by the Committee for Experimental Animal Research 
of the University of Cape Town (project number: 006/008) and were also in accordance with the 
National Institutes of Health Guide for Care and Use of Laboratory Animals. 
 
5.2.  Maternal separation paradigm  
Maternal Separation (MS) has been described as a potent naturalistic stressor (Stanton et al., 
1988) and has been used extensively as a model of early life stress in our laboratory (Daniels 
et al., 2004; Faure et al., 2006), as well as by many others (Ladd et al., 1996; Lubach et al., 
1995; van Oers et al., 1998; Lyons et al., 1999; Sánchez et al., 2001). Adult male-female pairs 
were housed under normal conditions to allow for mating. Immediately after the rat pups were 
born, the adult males were removed, while the mothers remained with the pups. Litters were 
sexed and culled to 8 pups per dam. If there were fewer than 8 males, then females were 
included to complete the group to ensure equal nurturing. The various dams with their pups 
were randomly assigned to either a control (non-separated) or to an MS group. MS involved 
physically removing the dam from the home cage that contained the pups for 3 hrs per day from 
09:00 to 12:00 beginning on PND 2, and leaving the pups undisturbed in their home cage. 
During the separation period, the pups were housed in a room away from the mother to prevent 
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communication via ultrasound vocalizations from taking place (Hofer, 1994). The temperature 
of the room to which the rat pups were transferred was maintained between 31˚C and 33˚C, 
thereby minimizing the possible influence of hypothermia. After PND 14, the pups returned to 
normal housing conditions. Control animals were handled identically to experimental ones, 
except that the pups were not separated from the dam during the first 14 days after they were 
born. On PND 21 both groups were weaned by permanently removing them from the dam. 
 
5.3.  Preoperative and surgical procedures 
Surgery occurred at PND 35. To prepare the surgical site, the scalp hair was clipped and the 
site disinfected with 70% ethanol. Body heat was conserved during surgery by placing the rat 
on a heating pad (Rex C10, Centre for Electronic Services, University of Stellenbosch). The 
rats (n = 16) were anaesthetized using a combination of ketamine hydrochloride (Anaket-V®, 
Bayer Healthcare, South Africa) and medetomidine hydrochloride (Domitor®, Pfizer, South 
Africa) (0.1 ml/100g, i.p.) and placed in a stereotaxic frame (David Kopf Instruments, Tujunga, 
USA). Bregma and Lambda were used to level the horizontal plane of the skull. From bregma, 
the following coordinates were used: anterior, 0.30 mm; lateral, 2.7 mm; ventral, 5.6 mm below 
the dura mater. A small burr hole was drilled at the determined coordinates and a 22-gauge 
surgical-steel cannula was slowly inserted into the brain. A 6-OHDA solution was freshly 
prepared, kept on ice, and protected from exposure to light. The solution consisted of 12 µg 
(free-base) 6-OHDA (Sigma, St. Louis, USA), dissolved in 4 µl 0.1% L-ascorbic acid in 0.9% 
sterile saline, and was administered unilaterally into the left striatum, using a 341-A model 
syringe pump (Sage Instruments, USA), running at an injection rate of 0.5 µl/min. The cannula 
was left in place for an additional 5 min following the infusion to facilitate the optimal diffusion of 
the solution. Subsequently, the needle was slowly retracted from the brain. The hole drilled in 
the skull was filled with sterilized oxidized cellulose (Ethicon, UK), the incision sutured, and 
lastly coated with an iodine solution (Purdue Frederick, USA). The rats were placed in individual 
cages under heating-lamps until full recovery was achieved, after which they were returned to 
their home cages.  
 The unihemispheric administration of the neurotoxin 6-OHDA to rodents is used 
frequently for studying various aspects relating to PD, including disease aetiology (Schwarting 
& Huston, 1996; Ungerstedt, 1971), the potential therapeutic benefits of brain grafts (Curran et 
al., 1993; Dunnett et al., 1983), as well as the implications of other agents, including 
neurotrophic factors (Winkler et al., 1996; Zigmond & Keefe, 1997). The toxic effects of 6-
OHDA are considered species-dependent, with severe parkinsonism induced by administering 
the toxin to rats, but seemingly resolving spontaneously after 4-6 weeks when infused in rats 
(Rothblat et al., 2001). In addition, the effects of the lesion may also be strain dependent, since 
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Lewis rats require a two-fold higher dose of 6-OHDA to evoke the same behavioral change as 
seen in Fischer and Sprague-Dawley rats (Collier & Sortwell, 1999; Flores et al., 1998).  
 Furthermore, using a particular mouse strain, Hefner et al. (2007) were unable to 
produce robust behavioral changes following exposure to periods of MS, to indicate that the 
effects pertaining to MS might also be species-constrained. Hence, my decision to use 
Sprague-Dawley rats in this particular study was influenced by the above findings.  
 
5.4.  General behavioral testing procedures  
A number of behavioral tests were done to ascertain the degree of asymmetry following the 6-
OHDA injection. These tests were performed between 09:00 and 13:00, 28 days after the intra-
striatal injection. 
 
5.4.1.  Vibrissae-evoked forelimb placing test 
Rats were subjected to the vibrissae-evoked forelimb placing test as previously described by 
Schallert et al. (2000). See chapter 3 (5.2) for a complete description of the methodology 
followed in performing this test. Independent testing of each forelimb was induced by carefully 
brushing its vibrissae against the edge of a tabletop. Each vibrissae brush constituted a trial, 
with 10 trials from each side being performed. If the rat placed its forelimb swiftly upon the 
table’s surface immediately following vibrissae stimulation, a score of 1 was allocated, while a 
failure to place the paw on the table provided a score of zero. 
 
5.4.2.  Single-limb akinesia (Bracing) test  
This test evaluates the animal’s capacity to adjust its stepping to regain postural stability, when 
weight-shifts are imposed by the experimenter (Schallert et al., 1979; Lindner et al., 1995; 
Schallert et al., 1992; Olsson et al., 1995). The animal was held by its torso with its 
hindquarters and one forelimb lifted above the surface of a table to allow the weight of its body 
to be supported by one forelimb alone. The animal was then slowly moved in the forward 
direction. The number of adjusting steps was recorded as the animal was moved in 30 sec trial 
periods. The test was performed once for each forelimb. 
 
5.4.3.  Small open field test 
The rat was placed in an upright transparent acrylic cylinder (20 cm in diameter and 25 cm in 
height). The cylinder height was such that the animal was unable to reach the top edge when 
rearing and wide enough to permit a 2 cm space between the tip of its snout and the base of its 
tail when all four paws were placed on the floor. Care was taken for the rats not to habituate to 
the cylinder lest they should become inactive. This was done by restricting the period of testing 
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to 5 min (Schallert et al., 2000) and by placing the rats back in their home cage between the 
behavioral tests.  
A defecation and urination index was also determined based on the number of defecation boli 
and urination spots observed. The number of rearing (standing on hind limbs without touching 
the wall of the cylinder) was also recorded. These parameters served as robust measures of 
the emotional status of the animals (Gray & Cooney, 1982; Pijlman et al., 2002). 
 
5.5.  Animal euthanasia and tissue collection 
Following the behavioral assessment on PND 63, the rats were decapitated and the left and 
right striatum rapidly dissected on ice. The animals were anaesthetized with HalothaneTM 
(Safeline Pharmaceuticals, South Africa), after which 60 ml of phosphate buffered saline (PBS) 
was used to exsanguinate the animals via transcardial perfusion. This was followed by 180 ml of 
4% paraformaldehyde-PBS (Merck, South Africa) to fix the brain tissue. The brains were rapidly 
removed from the skull and the tissue placed in 30% sucrose solution. Following this, the brain 
tissue was blocked and frozen over liquid nitrogen vapor until sectioning. 
 
5.6.  Tyrosine hydroxylase (TH) immunohistochemistry  
The effect of the injections on tyrosine hydroxylase immunoreactivity (TH-ir) was evaluated in 3 
rats belonging to each group. To stain for TH, free-floating coronal sections 60 µm thick were 
cut with a cryostat at -20 °C. The sections were quenched by incubating with 0.3% hydrogen 
peroxide for 30 min at room temperature in a humidifying container. This was followed by a 
succession of washes (5 ×10 min) with PBS (0.15 M, pH 7.4). The sections were placed in a 10 
mM citrate buffer (pH 6.0) and boiled in a microwave oven for 15 min. The sections were left to 
cool, before the wash-cycle was repeated. The sections were then pretreated with 150 µl horse 
blocking serum and 0.1% Triton X-100 for 30 min before application of the primary monoclonal 
anti-TH antibody (dilution 1:500, DiaSorin, USA) and overnight incubation at 4ºC. The next day 
the slices were washed in PBS (5 ×10 min), before applying the secondary biotinylated 
antibody (dilution 1:400) for 1 hour at room temperature. The wash routine was repeated before 
incubating the slices with peroxidase labeled Mouse IgG ABC reagent (ABC kit, 
DakoCytomation, USA) with concentrated diaminobenzidine (DAB) as the chromogen. Tissue 
sections were incubated at room temperature until staining developed. The sections were given 
a final 15 min rinse with distilled water, before dehydrating them with 96-100% ethanol, clearing 
with Xylol (Merck, South Africa) and mounting the sections onto clear glass slides.  
 
5.7.  Quantification of relative TH immunoreactivity 
We adopted the method of Anstrom et al. (2007) to assess the extent of the damage caused by 
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the unilateral 6-OHDA injection. Sections representing the anterior, middle, and posterior 
striatum from 3 control and 3 maternally separated animals were analyzed. Digital photographic 
images of all the slices were captured under constant, standardized lighting conditions and 
exposure using the 10x objective on a Zeiss microscope fitted with Brightfield optics and a 
Diagnostic Instruments Spot Insight QE camera. For each hemisphere, 3 independent 
digitalized photographic images were produced (Fig. 7). This was done in a consistent manner 
anchored by objective landmarks (anterior commissure dorsally, optic chiasm ventrally, and the 
third ventricle medially). The degree of neurochemical asymmetry of each image was 
determined with Zeiss’s Axiovision image analysis software. The TH-ir surface area of the 
image in the 6-OHDA-infused hemisphere was divided by that of its corresponding image in the 
non-infused hemisphere. The ratio of TH-ir on the lesioned side to TH-ir on the non-lesioned 
side was expressed as a percentage. Values closer to 100 indicate minimal loss of TH staining, 
while values closer to zero indicate severe neurochemical asymmetry. The percentage values 
of the 3 images were averaged to give an indication of damage per section, and averaging the 
percentages of the 3 sections for a given rat provided the degree of neurochemical asymmetry 
for a specific animal. The final value was calculated by averaging the scores of the 3 individual 
rats per group. See figure 1 for an example of such an analysis.  
 
Fig.  1.     Sequence of maternal separation, lesioning and behavioral testing. The time-points are 
given in days.  
 
 
 
5.8.  Statistical analysis 
The statistical analysis of all the data was performed using Graphpad Prism V.4 (USA). For 
analyzing the behavioral data, comparisons between groups were performed using the Kruskal-
Wallis test, followed by Dunn’s Multiple Comparison’s test, while the Mann-Whitney test was 
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applied when only two groups were compared. To analyse the results of the TH-stain analysis, 
a student’s t-test was used. Data is expressed as the mean ± S.E.M. and results are 
considered to differ significantly if p < 0.05. For the statistical analysis of the HPLC results, data 
were subjected to a parametric unpaired student’s t-test. All the results of analysis were 
considered to differ significantly if p < 0.05, and data were expressed as the mean ± S.E.M. 
 
6.  RESULTS  
6.1.  Behavioral results 
6.1.1.  Vibrissae-evoked forelimb placing test 
A number of behavioral tests was employed at 28 days after lesioning to evaluate the effect of 
6-OHDA on the locomotor abilities of rats. This was achieved by comparing ipsilateral limb 
movements to those of the contralateral limb. For the vibrissae-elicited forelimb placing test, a 
failed response was defined as the inability of the rat to place its paw on the tabletop following 
stimulation of the vibrissae. 6-OHDA produced a 65% increase in the number of errors made by 
the contralateral paw as compared to the ipsilateral paw (p < 0.01). Moreover, the number of 
failed responses with the contralateral paw was 100% greater in the MS group than in the non-
MS group (p < 0.05; Fig. 2). 
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Fig.  2.     
Failed responses in non-MS and MS rats during the vibrissae-evoked forelimb placing test, 
performed at 28 days after receiving a unilateral 6-OHDA injection into the left striatum. *p < 0.01 
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indicates a significant difference from the number of failed responses made by the ipsilateral limb, while 
**p < 0.05 indicates a significant difference between the number of failed responses of the contralateral 
limb of the non-MS and MS groups (Kruskal-Wallis test, followed by Dunn’s Multiple Comparison test). 
Data represent the mean ± S.E.M (n = 15).  
 
6.1.2.  Single-limb akinesia (Bracing) test 
The bracing test showed that in non-MS animals the number of steps made within a 30 sec 
time interval along a straight line by the contralateral limb was significantly decreased by 6-
OHDA, when compared to its ipsilateral limb (p < 0.01). The MS rats revealed a significantly 
greater deficit in use made by the contralateral limb when the results were compared to the 
non-MS rats (62% versus 39%, respectively, p < 0.05; Fig. 3). 
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Fig.  3.     The number of steps taken by the contralateral limb compared to the respective 
ipsilateral limb during the bracing test, performed at 28 days after a unilateral 6-OHDA injection 
into the left striatum. Fewer steps where taken by the limb contralateral to the 6-OHDA-induced lesion, 
and this reduction was exaggerated in the MS group compared to the non-MS group (*p < 0.01; **p < 
0.05; Kruskal-Wallis, followed by Dunn’s Multiple Comparison’s test). Data represent the mean ± S.E.M 
(n = 15). 
 
6.1.3.  Small open field test 
6.1.3.1. Defecation-urination index 
The small open field test revealed that rats subjected to MS had a significantly (p < 0.0001) 
greater defecation-urination index (2.88 ± 0.63) than non-MS animals (1.27 ± 0.43) (Fig. 4).  
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Fig.  4.     The defecation-urination (DU) index obtained in the small open field test. As shown 
above, the index of the MS animals are significantly higher compared to the non-MS animals (*p < 
0.0001, Mann-Whitney test). The data represent the mean ± S.E.M (n = 15).  
 
 
 
6.1.3.2. Frequency of rearing 
In addition, MS animals display a significantly (p < 0.0001) higher frequency of rearing (2.68 ± 
0.27) than the non-MS controls (1.0 ± 0.21) (Fig. 5).  
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Fig.  5.     The increase in rearing frequency displayed by MS rats compared to non-MS ones 
during the cylinder test. Data represent the mean ± S.E.M (n = 15). *p < 0.0001, Mann-Whitney-U test. 
 
6.2.  Analysis of Tyrosine hydroxylase (TH) density staining    
The extent of the intrastriatal lesions were qualitatively assessed by investigating the loss of 
TH-ir fibers in coronal sections of the forebrain using light microscopy. The 6-OHDA injections 
produced a consistent and distinct lesion, as reflected by a substantial decrease in immuno-
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staining in the lesioned striatum compared to the contralateral side. There is a significantly 
greater loss of TH-ir in the striatum of the MS rats compared to controls that reached statistical 
significance (p < 0.05; Fig. 6). 
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Fig.  6.     TH staining detected in striatal sections of MS and non-MS rats. TH staining percentages 
were calculated by expressing total degree of TH staining of the lesioned hemisphere in relation to the 
stained area of the non-lesioned control side. The percentage TH staining was significantly less in MS 
animals compared to the non-MS group (*p < 0.05; Mann-Whitney-U test). Data represent the mean ± 
S.E.M. (n = 3). 
 
 
 
 
Fig.  7.     A photomicrograph showing decreased TH staining in the lesioned (left) striatum 
following a unilateral 6-OHDA injection. The broken lines depict the 3 sample areas per hemisphere 
that were used to quantify TH stain density using Zeiss K3100 (v.4) analyzing software.  
Lesioned hemisphere Unlesioned hemisphere
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7. GENERAL DISCUSSION  
The experimental strategy for the current study was to subject rat pups to MS as the stressful 
early life event, and then to investigate its effects on 6-OHDA-induced alterations in locomotor 
activity and DA neuron loss. The results shows that animals subjected to MS and having 
undergone 6-OHDA lesions experience exaggerated locomotor deficits compared to normally 
reared controls. Furthermore, stressed animals displayed poorer performance in sensorimotor 
tests, such as the vibrissae and bracing tests, a higher defecation-urination index and rearing 
frequency, and an apparently greater 6-OHDA-induced loss of DA terminals in the striatum as 
reflected in augmented loss of TH-ir. These findings may relate to clinical reports that stressful 
experiences can worsen the degree of motor-related impairment in PD patients, such as 
increased tremor when patients express anger or anxiety (Schwab & Zieper, 1965), and that 
experiencing severe bouts of stress may even exacerbate the underlying neuropathology 
(Smith et al., 2002).  
Mesencephalic dopaminergic neurons function as the most important source of DA in the 
mammalian CNS, and their loss lead to both the motor-associated symptoms commonly 
associated with PD. Although they are few in number, they play a critical role in regulating 
various brain functions, including voluntary movement and a broad array of other processes, 
such as mood, reward, addiction and stress (Lim, 2005). The motor symptoms that were 
observed during this study may be the result of the pulsatile stimulation of the dopamine 
receptors, to provide just enough in order to observe a behavioral deficit, or it may be possible 
that either no recovery occurred or that degeneration continued at a rate sufficient to mask 
ongoing plasticity. Consistent with the findings of others (Glavan & Zivin, 2005), a near total 
loss of TH-positive fibres was observed on the hemisphere side that had been treated with 6-
OHDA, due to the substantial decrease in TH-positive neuron numbers. This provides a 
platform on which to argue that particular subpopulations of the affected neurons are better 
adapted to survive under such toxic insults, by providing a buffering capacity towards 
fluctuating dopamine levels. Our results therefore imply that synaptic plasticity, in response to 
the administration of 6-OHDA, is exacerbated and involve a complex pattern of changes in the 
surviving dopaminergic population, to result in an increase in firing potential and the heightened 
release of DA to near-normal levels. This phenomenon may result from increased expression of 
the neurotrophic factors, especially of the neurotrophins that provide for increased expression 
of trophic agents in such young animals. In particular, BDNF has been implicated to play a 
fundamental role in regulating neuronal survival, differentiation and synaptic plasticity (Baquet 
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et al., 2005). Further relevance for this statement is provided in that reduced levels of BDNF 
expression has been detected within the substantia nigra in patients suffering from PD. 
In studies of 6-OHDA-treated rats, compensatory adaptations in the remaining DA neurons 
have been observed, with rats often completely recovering from the gross motor deficits 
ordinarily expected from a larger dose or even not manifesting any gross motor symptoms at all 
(Abercrombie et al., 1990; Robinson et al., 1994a; b; Fornaquera & Schwarting, 1999). 
However, studies have also shown that the presentation of added stressors to these seemingly 
recovered animals often results in sustained neurological impairments (Stricker & Zigmond, 
1974; Snyder et al., 1985). These findings are consistent with clinical reports that stressful 
experiences can worsen the degree of motor-related impairment in PD patients, such as 
increased tremor when patients express anger or anxiety (Schwab & Zieper, 1965), and that 
experiencing severe bouts of stress may even exacerbate the underlying neuropathology 
(Smith et al., 2002). Sapolsky (1992) coined the term “neuro-endangerment”, to describe the 
phenomenon that exposure to stressful events can increase the vulnerability of neurons to a 
subsequent insult.  
The current finding that MS rats display greater impairments than controls after 6-OHDA 
lesioning could reflect a direct effect that early life stress has on neuronal function. Zhang et al. 
(2002) found, for example, that maternal deprivation enhances cell death in the cerebral cortex 
and hippocampus.  
  Thus, MS may have increased the vulnerability of DA neurons to the oxidative stress 
associated with 6-OHDA. Consistent with this is our finding that staining for striatal TH was 
significantly lower in the lesioned hemisphere of MS rats than in control animals, suggesting 
greater DA cell loss in the 6-OHDA-treated animals. Rearing conditions have been shown to 
induce long-lasting alterations in the central monoaminergic systems of the brain (Daniels et al., 
2004), particularly DA levels (Arborelius & Ecklund, 2007; Miura et al., 2002), DA receptor 
density (Ploj et al., 2003), and decreased DA turnover (Matthews et al., 2001). Although these 
changes have been reported for brain areas other than the SN or the striatum, it raises the 
possibility that similar alterations could also occur within the nigrostriatal system.  
 Since it has been shown that the cell-mediated immune status of animals are affected by 
exposure to early social deprivation, with evidence of a decreased ratio of helper to suppressor 
T cells (Lewis et al., 2000), compromised immune function may also have played a role in the 
augmented neurological impairments seen in the MS rats. One mechanism may involve 
biochemical pathways affected by glucocorticoids, since it is well accepted that stress can 
trigger increased glucocorticoid release into the peripheral circulation. Daniels et al. (2004) and 
others (Plotsky & Meaney, 1993; Ladd et al., 2000; Slotten et al., 2006) have previously shown 
that early life stress results in a deregulated HPA axis, reflected by a blunted response to 
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subsequent stress and high circulating corticosterone levels. Although this biochemical 
alteration may initially serve to improve focus, information processing, and the response to the 
stressful event, an excessive amplitude and duration of such changes may lead to neuronal cell 
death (Sapolsky, 2000). In accordance with this possibility, administration of corticosterone to 
adrenalectomised rats has been shown to increase the size of neuronal lesions induced by the 
injection of quinolinic acid into the striatum (Ngai & Herbert, 2005), and to decrease GC 
receptor density (Morale et al., 2006). Moreover, the key role played by GCs in stress-induced 
neuropathology has been shown, particularly for the hippocampus, to reduce the ability of some 
cells to survive toxic threats. Mechanisms by which this may occur include reduced energy 
metabolism, initiated through an inhibition of glucose uptake (Horner et al., 1990), by increasing 
extracellular Ca2+ signaling (Han et al., 2005), decreased expression of neurotrophic factors, 
such as brain-derived neurotrophic factor (Cosi et al., 1993; Schaaf et al., 1998; Lippmann et 
al., 2007), or by overstimulating apoptosis, through reduced expression of anti-apoptotic 
proteins and increased expression of pro-apoptotic proteins (Almeida et al., 2000; Cárdenas et 
al., 2002; Sapolsky, 2000). 
 A significant difference between maternally separated and normally reared rats was 
detected in terms of the defecation-urination index, with the maternally deprived rats obtaining a 
higher score. Spontaneous micturition following bladder distension does not occur within the 
first 10 PNDs of a rat pup’s life. During this period, urination is usually dependent on perigenital 
stimulation by the mother (Maggi et al., 1986). It is therefore reasonable to predict that 
subjection of rat pups to MS may result in a disruption in the development of the micturition 
reflex (Wu & de Groat, 2006). Our data are contrary to this expectation, perhaps because 
following the 3-hour separation period the mothers immediately attended to the pups upon 
reunion (personal observation). This additional attention could have enhanced the development 
of the micturition reflex in our animals. However, the enhanced defecation of the MS animals 
correlates with the findings of others who also report enhanced colonic motor function 
(Coutinho et al., 1999; Daniels et al., 2004). The increased defecation suggests that the MS 
animals were more anxious than their normally reared counterparts.  
The physiological basis for this effect may well relate to the increased vulnerability of the MS 
animals to 6-OHDA-induced degeneration and behavioral dysfunction. When a relatively 
smaller amount of 6-OHDA is administered, compensatory adaptations in the remaining DA 
neurons are observed, with rats often completely recovering from the motor deficits ordinarily 
expected from a larger dose or even not manifesting any gross motor symptoms at all 
(Robinson et al., 1994a; Fornaquera & Schwarting, 1999). However, studies have shown that 
when challenging stressors are presented to these seemingly recovered animals, they often 
manifest with neurological impairments (Stricker & Zigmond, 1974; Snyder et al., 1985). 
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Hind-limb rearing is important for the survival of the animal as it allows the rat to orient itself 
(Colorado et al., 2006) and examine its environment, to seek new sources of food, shelter or 
mating partners (Mällo et al., 2007). The significant increase in rearing in MS rats could 
therefore be interpreted as positive exploratory behaviour. Alternatively, the animal may 
experience rearing as a response to perceived personal threat, especially when escape routes 
are sought from a perceived hostile surrounding. In addition, exposure to predatory onslaughts 
may increase during this activity, thereby rendering the animal more fearful. Under these 
circumstances elevations in rearing frequency may reflect a state of hyperarousal and hence 
anxious behaviour (Uys et al., 2006). It is acknowledged that other measures, such as the 
standard open field and the elevated-plus maze are more commonly used to determine the 
degree of anxious-like behaviour in rats, than the small open field. Yet, whilst these two 
parameters used in the small open field may not be sufficient to clearly define the emotional 
status of MS animals, these suggest behavioral differences between the two groups. As in the 
case of the increased defecation-urination index, the basis for the increased rearing may relate 
to the mechanism underlying increased 6-OHDA toxicity. 
 
8. CONCLUDING REMARKS 
In summary, exposure to early life stress exacerbated the toxic effects of 6-OHDA on locomotor 
activity and decreased the degree of TH expression determined on the lesioned hemispheric 
side. Whether the effects observed are directly due to the effects that separation stress has on 
the central dopaminergic system, or whether it is induced indirectly via other centrally acting 
factors are uncertain. Further investigation will be required to elucidate the mechanism of the 
effects observed. Such investigations are well advised, as they will provide important insights 
into the means by which early adversity can increase the risk of developing a 
neurodegenerative condition such as PD. Furthermore, since it is widely reported that the 
immediate effects that exposure to unavoidable physical stress or even merely participating as 
a witness to these traumatic events has on animal physiology includes elevated corticosterone 
plasma levels (Weinstock, 2008), hyperthermia (Kikusui et al., 2001), and the suppressed 
activity of killer T- and B-cells (Kimura et al., 2005) future work should assess the degree of 
change in these analytical measures. Lastly, the possible influence of additional factors such as 
the concentration of neurotrophins and/or adrenocorticotropin (ACTH) and corticosterone were 
demonstrated in chronically stressed rats compared to normal-reared animals through a 
decreased expression of BDNF observed in the hippocampus and striatum, as well as 
augmented plasma ACTH and corticosterone concentrations (Lippmann et al., 2007). Although 
the current work did not include measures of neuro-endocrine function, it highlights the impact 
that adverse experiences during development may have in rendering neurons more susceptible 
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to subsequent insults. The possible contributions that decreased levels of neurotropins such as 
BDNF and GDNF, as well as increased may have made to the currently reported findings was 
further investigated in follow-up work, since molecular adaptations may induce alterations in 
neural circuitry that may affect the risk of developing a neurodegenerative condition, such as 
PD. In addition,  we conclude that the toxin 6-OHDA acts as a robust inducer of neurogenesis 
and in striatal cellular plasticity in the rat lesioned during a young age, to protect the surviving 
neural microenvironment from damage, thus acting as an effective compensatory mechanism. 
However, in the case of those that have experimentally been subjected to MS stress, this 
physiological and behavioral mechanism has proved to be less effective. 
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CHAPTER 6  
 
NEUROPROTEOMICS AS A NOVEL TOOL IN PARKINSON’S DISEASE RESEARCH 
 
1.   INTRODUCTION 
This chapter discusses the potential offered by the technological advances made in proteomics 
in providing a clearer understanding of the pathogenesis as well as revealing possible new 
targets for therapeutic intervention. It has already given insight into the role played by the 
aggregation and deposition of proteins in human PD and in chemically induced models of the 
disease (Schulenborg, 2006). In addition, it can reveal the patterns of PD-specific cellular 
markers to provide for earlier diagnosis and more effective tracking of treatment responses. 
Therefore proteomics is seen to allow the therapeutic regime to start earlier, when it is likely to 
have a more beneficial effect.  
 At present, the tools to diagnose PD preclinically are not yet available to clinicians 
(Montgomery et al., 2000a; Montgomery et al., 2000b). It is foreseen by many that the emerging 
field of neuroproteomics will allow for detecting new biomarkers with which to diagnose PD 
more accurately and earlier, thereby offering the possibility for early intervention (Zetterberg et 
al., 2008). This could allow the technological barriers imposed on previous studies to be 
overcome. By studying the unique expression pattern and level of PD-associated proteins, it is 
hoped that PD can be differentially diagnosed and insight gained into the mechanisms 
underlying this disorder. In addition, it may provide much-needed surrogate end-points with 
which to validate the clinical efficacy of novel treatment options (Michell et al., 2004).  
 
 2.  A BRIEF OVERVIEW OF PROTEOMIC TECHNIQUES 
The technology that is broadly described under the umbrella-term ‘proteomics’, derives from the 
term “proteome”, that refers to “the proteins expressed by a particular genome” (Wilkins, 1996), 
which is the large-scale analysis of many proteins simultaneously (David et al., 2005b; Hoerndli 
et al., 2005). While this could potentially include all the proteins encoded by the genome at any 
given time (i.e. the proteome), it more commonly refers to specific subsets of proteins found in 
specific regions or cell-type, under specific conditions (Pandey & Mann, 2000; Righetti et al., 
2004). Sensitive proteomics techniques have been developed to determine the structure, 
localization, biochemical activity, interactions (i.e. protein-protein, protein-lipid) and the cellular 
roles played by a multitude of proteins, with the results translated either to a natural 
physiological or to a pathological state of events (Onn & Mann, 2005).  
Substantial technological advances have been made in novel instrumentation, experimental 
strategies, and bioinformatics tools for analyzing the proteome (De Hoog & Mann, 2004). 
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However, despite the bewildering range of available techniques and analysis tools, some form 
of protein separation procedure, followed by techniques for peptide detection and identification 
are routinely required, with mass spectrometry (MassSpect) remaining its key technology (Fig. 
1). The speed of advancements in peptide-sequencing technology may allow quantifying most 
cellular proteins by high resolution MassSpect (Lipton et al., 2002). To quantify proteins 
according to their degree of expression, MassSpect technology is frequently applied in 
conjunction with two-dimensional polyacrylamide gel electrophoresis (2-D PAGE). This 
combined experimental approach allows for inter-sample comparisons relating to the disease 
state as well as between experimental subjects and normal controls (De Iuliis et al., 2005).  
There is an inherent risk of preferentially detecting proteins that are present in abnormally 
high concentration, thereby repressing the weaker signals by less abundant proteins 
(Fountoulakis, 2001; Fountoulakis, 2004; Vercauteren et al., 2004; Wiederkehr, 1991). To 
reduce the complexity of the protein sample, and thereby increase sample resolution, strategies 
have been developed to reduce levels of highly abundant (and generally less interesting) 
proteins, which may obscure detection of the less abundant ones. In blood-based proteomics, 
this can be achieved by affinity separation of abundant proteins (such as albumin, fibrinogen 
and transferrin) from either human or mouse plasma, using affinity-purified antibodies covalently 
conjugated to microbeads. Another practical and economically feasible approach is to first apply 
proteomic techniques to detect for markers of the disease in organs where protein 
concentrations are expectedly high, before searching for them in fluids where they are less 
abundant (Meyer & Stuhler, 2007). The application of this approach to neurodegeneration is not 
trivial, as human brain tissue can be of bad quality and show high variability, e.g. with regards to 
gender, age and medication of patients. Nonetheless, one may be able to choose tissue from 
brain areas that are affected only relatively late in disease and thus spared from massive 
degeneration. For Alzheimer’s disease (AD), this could be the brain stem as a brain area that is 
relatively preserved in late stage AD, but still displays the typical hallmark lesions of the 
disease. Alternatively, animal models of AD or PD may be employed to apply proteomics first to 
dissected brain areas and eventually body fluids such as plasma or CSF, which are likely to 
reflect, at least in parts, the deregulation of proteins in the brain (Götz et al., 2007). Subcellular 
proteomics provides another means for combining the direct analysis of the proteome of 
isolated organelles such as mitochondria. Methods for fractionating subcellular organelles 
include traditional techniques, such as centrifugation (e.g. high-speed sedimentation/density 
gradient) (Pasquali et al., 1997; Fialka et al., 1997; Tribl et al., 2006a; Tribl et al., 2006b), but 
also highly sensitive commercial fractionation kits for extracting nuclear, cytosolic, mitochondrial 
or membrane fractions (Huber et al., 2003; Heimlick & Cidlowski, 2006; Chen et al., 2005b; Vila-
Carriles et al., 2007). The limitations of the subfractionation approach are in its experimental 
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variability and the fact that the fractions are rarely pure as, e.g. in synaptosomal preparations, 
mitochondria are easily co-purified. The subcellular fractionation and purification techniques can 
be effectively combined with gel-dependent methods, such as 2-D PAGE, or gel-independent 
ones.  
In 2-D PAGE, proteins are first separated in the first dimension according to their charge (z) 
and molecular weight using isoelectric focusing (IEF) (Klose, 1975; O'Farrell, 1975; Görg et al., 
1985) (Fig. 1). The proteins migrate through a thin gel-strip embedded with immobilized pH 
gradients (IPG). Migration terminates when the protein reaches the point where the net charge 
is neutral (i.e. the isoelectric point, or pI). Different IPG strips can be used: wide pH ranges (IPG 
3-10) that cover many pH units, those that cover narrower ranges (IPG 4-7), or very narrow 
ones that only provide a single pH unit-width (IPG 5-6, or IPG 5.5-6.7) (Simpson, 2003). Narrow 
pH ranges allow zooming in and give a better resolution of the protein spot pattern within a 
smaller window (Hoving et al., 2002). Proteins are then separated in the second dimension 
(orthogonal direction) using electrophoresis that takes place in acrylamide gels containing 
sodium dodecyl sulphate (SDS), where SDS imparts a net negative charge, allowing proteins to 
separate according to mass (m). Separation in these two dimensions allows for the resolution of 
multiple isoforms and variants of the same protein. A variety of chemical stains and fluorescent 
markers are available to visualize and detect the differences in protein staining intensities 
between samples (David et al., 2005a). Approximately 1000-3000 proteins can be visualized 
per stained gel, with the capacity to resolve up to 10,000 proteins in a single gel (Klose, 1975; 
O'Farrell, 1975). A comparison of different 2-D PAGE methods and their application to mouse 
brain has been done by several groups including Stühler and colleagues (2006). 
 Despite 2-D PAGE being a relatively old-fashioned biotechnological technique, from a 
proteomics perspective it remains popular since it allows for the use of high through-put 
screening in an easily executable and cost-effective manner. However, its main drawbacks are 
the limited dynamic range and often a failure of detecting membraneous or low abundant 
proteins (Aebersold et al., 2000). In addition, it is often difficult to accurately compare two 
samples when the comparison is based on the degree of protein-expression alone, since 
protein spots often overlap or appear small and/or blurry, thereby increasing the risk of over- or 
undercounting them.  
 The technique known as ‘Differential In-Gel Electrophoresis’ (DIGE) by which the samples 
are labeled with different fluorescent dyes (such as Cy3 and Cy5) and then separated on the 
same gel, has proved very useful in increasing the dynamic range and reducing technical 
variability (Wu, 2006).  
Liquid chromatography (LC) coupled to MS has proved to be an important alternative to 2-D 
gels (Fig. 1). Various LC techniques (such as affinity, size exclusion, reverse phase or charge 
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chromatography) provide different means for separating complex samples (Wolters et al., 
2001). The separated protein mixture is then fed directly into an electrospray ionisation (ESI) 
MS, using tubes of microcapillary diameter, which greatly reduces the amount of sample 
needed for analysis (Graves & Haystead, 2002; Link et al., 1999; Opiteck et al., 1997; 
Washburn & Yates, 2000). The LC-MS technique is particularly useful for membrane-associated 
proteins, phosphopeptides, enzymes such as kinases and phosphatases, and transcription 
factors that are difficult to detect through 2-D PAGE because of their low levels of abundance 
(Washburn et al., 2002). Of the various ionization methods developed for coupling, LC to MS-
ESI is the most widely used technique that allows for the gentle ionization of large biomolecules 
(Jorge et al., 2007). An alternative technique is MALDI (Matrix-assisted laser 
desorption/ionization), a “soft” ionization technique used for analyzing biomolecules and large 
organic molecules that tend to be too tender to be fragmented and ionized by other, more 
conventional means. Compared to MALDI, ESI takes longer to perform but has the advantage 
of easy coupling to separation techniques such as LC or HPLC. This allows for high-throughput 
and on-line analysis of peptide and protein mixtures.  
 An ionization method known as SELDI (surface-enhanced laser desorption/ionisation) 
makes use of the protein-chip array technology (Hutchens & Yip, 1993). The “chip” consists of a 
thin strip of aluminium containing eight sample-loading areas. Depending on the nature of the 
chip surface, only specific types of proteins bind. In other words, the chip forms the target 
surface to which proteins and matrices are applied. Depending on the composition of the matrix, 
particular types of proteins (acidic, basic, antigens, etc.) are captured. For example, an IMAC30 
ProteinChip Array that is activated by coating the surface with transition metals such as gallium 
allows for the detection of posttranslational modifications such as phosphorylation (Escher et 
al., 2007). This method is typically used in combination with time-of-flight MS (TOF-MS) and is 
similar to MALDI. The speed and ease of SELDI-TOF in principal allows for use in a clinical 
environment (Paweletz et al., 2001), but compared to other MS methods, SELDI does not allow 
for the identification of peptides or proteins but only detects signals.  
Whereas some techniques have been developed with the aim of providing qualitative 
information on protein expression, a number of methods have been developed to specifically 
obtain quantitative information. One such method is the ICAT (isotope coded affinity tag) 
technique, where cysteine residues are differentially tagged with stable isotopes (Olsen et al., 
2004). Proteins from two different samples (e.g. control and experiment) are labeled with either 
deuterium d0 (light) and d8 (heavy) tagging reagents, which have a mass difference of only 
eight mass units. This allows for mixing two samples prior to separating them on the same gel, 
thereby eliminating in-between-gel variation. A comparison of the peak intensities of these tags 
provides information on the differential expression of the proteins of interest under two different 
 207
conditions. ICAT is particularly well suited for targeting membrane proteins, as it is compatible 
with strong detergents (Gygi et al., 1999; Moseley, 2001). However, drawbacks of the ICAT 
method are that it requires the presence of a cysteine in the protein sequence and that it usually 
requires large initial sample sizes, in the order of 100 μg. Other labeling methods were recently 
developed to accommodate smaller sample sizes, such as labelling with 12C and 13C, or 16O and 
18O (Zang et al., 2004). 
 iTRAQ (Isobaric Tagging for Relative and Absolute protein Quantification) is another 
quantitative protein identification approach (Fig. 1). It was the first reagent developed for LC-
based differential proteome analysis. The isobaric tagging reagents consist of a reporter group, 
a balance group (to make up for the mass difference of the reporter group), and a peptide 
reactive group. The latter covalently links an iTRAQ tag with each lysine side chain and amino-
terminal group of a peptide, allowing for labeling multiple peptides in a sample digest. The 
complex mixtures are then fractioned by chromatographic means and analyzed with LC/MS/MS 
(Olsen et al., 2004, Abdi et al., 2006). Together with ICPL (isotope coded protein label) 
(Schmidt et al., 2005), iTRAQ has now more or less substituted ICAT. In biomarker research, 
however, label-free MS is increasingly applied, owing to the high costs of ICAT or iTRAQ 
labeling, since large numbers of samples need to be analyzed (Horvatovich et al., 2007). 
 MECT (metal element chelated tags) uses eight uncommon earth metals that couples to 
peptides. It is cheaper than isotope-based methods, with the bicyclic anhydride 
diethylenetriamine-N,N,N',N' ',N' '-pentacetic acid (DTPA) coupling covalently to primary amines 
of peptides, and the ligand then chelating to the rare earth metals Y and Tb. The tagged 
peptides are mixed, analyzed by LC-ESI-MS/MS, and peptides quantified by measuring the 
relative signal intensities for the Y and Tb tag pairs (Liu et al., 2006).  
Strategies are constantly improved to functionally categorize the stream of proteins that are 
newly discovered through proteomics. One technique that was recently shown to be effective 
for establishing cofactor preferences for proteins is fingerprinting with saturation transfer 
difference (STD) NMR for detecting closely related cofactors. This approach was validated with 
both dehydrogenases and cyclic nucleotide-binding proteins (Yao & Sem, 2005).  
The increased use of proteomics in the field of neurodegeneration research is greatly 
assisted by the development of integrated technologies that apply high-resolution separation 
strategies to complex protein samples, combined with sophisticated computer-based 
identification methods. Ingenious novel hardware and software developments continuously 
lower detection limits, while widening the dynamic range, making profiling of highly complex 
protein mixtures for identification of PD biomarkers possible. Although the different search 
engines and databases (i.e. SwissProt, MASCOT) vary in their sensitivity and accuracy for 
detecting protein sequences, eventually this should have little influence on experimental 
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outcomes, due to the standardization in data collection and interpretation that is enforced by the 
proteomics community.  
 
3.  PROTEIN MARKERS FOR MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE 
STRESS IN PD 
Mitochondrial dysfunction and oxidative stress have been implicated in PD (Schapira, 1998; 
Betarbet et al., 2000; Hardy et al., 2003; Kaur et al., 2003; Lopes & Melov, 2002; Beal, 2003). 
Proteomics has proved to be a useful tool to examine the oxidative-stress induced changes in 
proteins (Butterfield & Castegna, 2003). A deficit of complex I of the respiratory chain has been 
shown by reduced activity of the enzyme NADH-ubiquinone reductase in neuronal tissue, such 
as the SN (Schapira et al., 1989; Dexter et al., 1994) and frontal cortex of PD patients (Parker 
et al., 2008), as well as in non-neuronal tissue such as blood platelets (Parker et al., 1989; 
Benecke et al., 1993; Haas et al., 1995; Swerdlow et al., 1996; Gu et al., 1998) and skeletal 
muscle (Bindoff et al., 1991, Shoffner et al., 1991). A proteomic analysis of PD and control SN 
revealed that neurofilament chains were less abundant in PD specimens, whereas 
peroxiredoxin II, mitochondrial complex III, and the ATP synthase D chain, among others, were 
significantly increased in PD samples compared to controls, indicating a compensatory 
upregulation in surviving SN neurons (Basso et al., 2004). A role for mitochondrial dysfunction 
in PD is further supported in animal models as administration of environmental toxins known to 
inhibit mitochondrial function caused dopaminergic cell loss (Betarbet et al., 2000; Di Monte et 
al., 2000) and increased production of ROS, another correlate of the clinical phenotype (Beal, 
2004).  
 Ubiquitin carboxy-terminal hydroxylase L-1 (UCHL1), also known as PGP9.5, is one of the 
most abundant neuronal proteins present in brain (Wilkinson et al., 1989). Studies have shown 
that it is extensively downregulated and structurally modified in the presence of oxidative stress 
(Castegna et al., 2002; Choi et al., 2004). In addition, mutating isoleucine 93 to methionine of 
UCHL1 causes autosomal dominant PD (Leroy et al., 1998). Furthermore, increased amounts 
of oxidatively modified UCH-L1 were found in sporadic PD cases compared to normal brain 
(Castegna et al., 2002; Choi et al., 2004; Butterfield et al., 2006). This deregulation has been 
implicated in the pathogenesis of PD since oxidative modification and the subsequent decrease 
in UCH-L1 enzymatic activity may affect normal neuronal function and plasticity (Setsuie & 
Wada, 2007). Interestingly, increased expression of UCH-L1 has been found also in AD using 
MALDI MS (Sultana et al., 2007). Hence, the application of redox proteomics may be an 
invaluable tool to help ascertain the role played by oxidised UCH-L1 and other proteins in the 
pathogenesis of PD and possibly, AD.  
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MPTP is a potent mitochondrial toxin that causes dopaminergic degeneration and LB 
formation in nigral neurons. When mice were chronically treated with MPTP, compared to 
control animals, more than 300 mitochondrial-related proteins were identified, of which more 
than 100 displayed a differential expression pattern (Jin et al., 2005). A category analysis 
revealed their involvement in signal transduction, the ubiquitin-protease system, oxidative stress 
and mitochondrial function, all of which has been implicated in the pathogenesis of PD (Dauer & 
Przedborski, 2003; Fiskum et al., 2003; Rego & Oliveira, 2003). Of the more than 300 proteins 
detected, DJ-1 was validated by Western blotting.  
As discussed before, genetic mutations have been identified in a small subset of cases, 
mainly in families with early-onset familial PD. DJ-1 is one of the genes implicated in disease 
pathogenesis (Bonifati et al., 2003). DJ-1 has also been identified as a possible marker in 
plasma for the progression of sporadic PD (Waragai et al., 2007). Gene-based animal models 
indicate that DJ-1-associated disease onset and progression may operate through the ubiquitin-
proteasomal pathway, which is a molecular pathway common to all genetic variants of PD 
(Dauer & Przedborski, 2003; von Bohlen und Halbach et al., 2004).  
In its mutant form, DJ-1 confers a reduced protective function against endoplasmic reticulum 
stress. Two recent reports (Taira et al., 2004; Yokota et al., 2003) show that DJ-1 has a 
repressive effect on cellular toxicity induced by overexpression of Pael-R, a newly identified 
substrate for parkin that is localized within the core of LBs (Yokota et al., 2003). Pael-R has also 
been assigned a distinct role in LB formation (Murakami et al., 2004).  
DJ-1 seems to antagonize many of the deleterious effects of SNCA, including its 
aggregation (Shendelman et al., 2004; Zhou & Freed, 2005; Zhou et al., 2006). Therefore, 
although the exact physiological function of DJ-1 remains elusive, increasing evidence suggests 
that it may confer protection, for instance as an anti-oxidative protein. In this regard, DJ-1 has 
been identified as a hydroperoxide-responsive protein that increases its acidity following 
exposure to oxidative stress (Mitsumoto & Nakagawa, 2001; Mitsumoto et al., 2001), thereby 
revealing the presence of oxidative stress (Kinumi et al., 2004; Taira et al., 2004).  
In addition to this role, many lines of evidence argue that DJ-1 modulates the function of 
SNCA and vice versa (Zhou et al., 2004; Jin et al., 2005). Robust proteomics, consisting of 
stable isotope labelling by amino acids in cell culture (SILAC) was used on dopaminergic 
neurons exposed to the mitochondrial toxin rotenone (Jin et al., 2007). Compared to controls, 
324 proteins were associated with SNCA and 306 with DJ-1. Although no direct interaction has 
been observed between DJ-1 and SNCA, 144 proteins mutually associated with DJ-1 and 
SNCA, displaying significant changes in terms of relative abundance. Further validation was 
performed on a subset of these, revealing that the docking proteins mortalin (mthsp70/GRP75), 
nucleolin, grp94, calnexin and clathrin associate with both SNCA and DJ-1. The study 
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confirmed the absence of a direct interaction between SNCA and DJ-1 and reported the 
identification of five novel proteins that associate with both SNCA and DJ-1. It is anticipated that 
future work will shed light on the functional interaction between these two critical proteins and 
the mechanism by which they participate in cellular functions and PD pathogenesis.  
Mitochondria-enriched fractions obtained from the SN of mice chronically treated with MPTP 
have been subjected to ICAT and compared with controls (Jin et al., 2005). The animals 
received a 5-week treatment regime together with an adjuvant, probenecid (prob) that caused 
selective nigrostriatal neurodegeneration and the formation of LB-like cytoplasmic inclusions in 
surviving nigral neurons. After identifying more than 300 proteins, of which >100 displayed 
changes in relative abundance between the MPTP/prob-treated mice and controls, the high 
throughput proteomic analysis was validated by Western blotting. This demonstrated that one of 
the identified proteins, DJ-1, co-localized with SNCA in dopaminergic neurons as well as in 
cytoplasmic inclusions in the mice that had been treated with MPTP/prob. By using this 
particular proteomics approach, the study successfully overcame a limitation usually imposed 
when using pooled samples that prevents the results from telling whether the DJ-1 increase 
results from a single mouse or from multiple mice. By conducting Western blot analyses in 
separate animals a DJ-1 increase was demonstrated in the majority of subjects. 
Jin et al. (2007) created a quantitative profile of mitochondrial proteins harvested from PD 
patients compared to normal age-matched controls. In addition, they used a cellular model of 
PD, consisting of rotenone-treated dopaminergic cells. In this study, a ‘shotgun proteomic’ 
approach was used called multidimensional protein identification technology (MudPIT), that 
entails the direct analysis of complex samples for rapidly producing a global profile of the 
protein complement (Link et al., 1999; Wu & MacCoss, 2002). To quantify the proteins, ICAT 
was combined with SILAC (Jin et al., 2007). Among the differentially expressed proteins was 
mortalin, a mitochondrial stress protein that was substantially decreased in both PD brain and 
the cellular PD model. The study further showed that several mortalin-binding proteins might 
participate in rotenone-mediated toxicity and that by overexpressing and/or silencing mortalin 
expression, PD-related pathology was significantly affected. Together, the studies suggest that 
mortalin modulates PD development via pathways involving mitochondrial and proteasomal 
functions as well as oxidative stress (Jin et al., 2007).  
By integrating proteomics technologies (2-D gel electrophoresis and MALDI-TOF), Lee et al. 
(2003) gathered evidence that expression levels of calreticulin, a high-capacity calcium 
buffering protein located in MN9D dopaminergic cells may correlate with the degree of cell 
death following 6-OHDA treatment. This implies that calreticulin may either directly mediate 6-
OHDA-induced cell death or, alternatively, it may participate in inducing a general cellular 
response prior to apoptosis.  
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Calreticulin further functions as a chaperone by binding to oligosaccharide moieties on 
proteins in addition to retaining proteins in the ER (Spiro et al., 1996). Its other assigned roles 
have been controversial, such as promoting cell death when over-expressed (Arnaudeau et al., 
2002; Nakamura et al., 2000), as other studies suggest that it might be involved in preventing 
oxidative stress-induced cell death (Liu et al., 2001; Nunez et al., 2001). Although the direct 
mechanisms through which calreticulin might induce dopaminergic neuronal death remain to be 
established, proteomics suggests that this protein may be a marker of oxidative stress (Lee et 
al., 2003).  
Parkin is another marker for oxidative stress and mitochondrial dysfunction in PD. Periquet 
et al. (2005) generated parkin knock-out mice and searched for possible changes in the brain 
proteome using 2-D-DIGE. The study indicated compensatory mechanisms that protect 
dopaminergic neurons from ROS-induced death. This phenomenon was ascribed to 87 proteins 
that differed in relative abundance compared to wild-type brains. A high proportion of the altered 
proteins related to energy metabolism, detoxification, stress-related chaperones and 
components of the ubiquitin-proteasome pathway. In a related study, parkin knock-out mice 
were analyzed by 2D-PAGE followed by MS (Palacino et al., 2004). This revealed a decreased 
abundance of a number of proteins involved in mitochondrial function or oxidative stress that 
could be confirmed functionally. The mice also showed decreased serum antioxidant capacity 
and increased protein and lipid peroxidation. Together, this identifies an essential role for parkin 
in the regulation of mitochondrial function. Interestingly, in the mice mitochondrial dysfunction 
and oxidative damage was found in the absence of nigral degeneration (Palacino et al., 2004). 
This is supported by studies in parkin-deficient flies (Greene et al., 2003) and reminiscent of 
P301L tau mutant mice that model aspects of AD and also show mitochondrial dysfunction and 
oxidative damage, in the absence of overt cell loss (David et al., 2005a; David et al., 2006; Götz 
et al., 2008). 
Another protein found in an oxidatively modified state in PD brain tissue is superoxide 
dismutase 1 (SOD1) that was identified by MALDI-TOF MS in a cell-culture system in a screen 
for changes in mitochondrial protein expression (Wood-Allum et al., 2006). In PD, not only is 
residue Cys-146 of SOD oxidized to cysteic acid, but SOD1 is also carbonylated (Choi et al., 
2005). The nature of these modifications are still unclear, and it is hoped that proteomics will 
provide an explanation for the accumulation and posttranslational modifications of SOD1 in the 
PD brain (Bandopadhyay et al., 2004). 
 
4.  ALPHA-SYNUCLEIN AND ITS ROLE IN PD 
Alpha-synuclein (SNCA) is a presynaptic protein associated with PD pathogenesis. It appears in 
both a soluble and membrane-bound form (Zhu et al., 2006a), and comprises the central 
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filamentous component of LBs. Under physiological conditions, it forms a protein complex in the 
cytosol. As interacting proteins in this complex, 250 candidate proteins have been identified by 
Zhou and coworkers (2004). However, DJ-1 was not among them. It is important to note, that a 
‘negative’ proteomic result does not necessarily entail that the protein of interest is completely 
absent within the protein complex (Corthals et al., 2000), especially when 
immunohistochemistry has been applied. For example, Neumann et al. (2004) and Jin et al. 
(2007) convincingly demonstrated that DJ-1 is present within the halo part of LBs that is known 
to contain insoluble SNCA. 
 In an effort to identify proteins that are associated with SNCA and may contribute towards 
its aggregation, Zhou et al. (2004) exposed MES rat cells to rotenone. Duplicate 2-D gels were 
run with one gel probed with an anti-SNCA antibody, while the other was stained with 
Coomassie Blue. The stained gel sections that corresponded to SNCA-immunoreactive bands 
were cut, trypsin-digested and analyzed with LC-MS/MS spectrometry. The study identified 
more than 250 proteins associated with SNCA. Under conditions where rotenone was cytotoxic 
and induced the formation of SNCA-immunoreactive cytoplasmic inclusions, >51 proteins 
displayed significant differences in terms of relative abundance. This list included heat shock 
proteins (HSP) 70 and 90 which, when overexpressed in MES cells not only protected cells 
from rotenone-mediated cytotoxicity, but also decreased SNCA aggregation. From this, it can 
be concluded that the protection afforded by hsp70 transfection may relate to suppression by 
rotenone-induced oxidative stress (Zhou et al., 2004). This putative protective role of hsp70 was 
further supported in subsequent in vivo studies carried out by Klucken et al. (2004). Other 
neuronal proteins that may couple to SNCA in a similar fashion include parkin (Paciello et al., 
2006) and the microtubule-associated protein tau (Jensen et al., 1999), the principal component 
of the neurofibrillary tangles in AD (Chen et al., 2004). 
 A ‘shotgun proteomic’ experimental approach was applied to A30P SNCA transgenic 
Drosophila and age-matched controls (Xun et al., 2007). By conducting the analysis at seven 
different time-points across the organism’s adult lifespan, disease-associated differences 
appeared to change substantially as the flies aged. Interestingly, the majority of the perturbed 
protein levels only existed over a narrow distribution of ages indicating the necessity to take 
multiple time-points for analysis.  
 
5.  ROLE OF THE CYTOSKELETON AND SMALL PEPTIDES IN PD  
Axonal transport and in particular the integrity of microtubules is essential for neuronal function. 
Not surprisingly, impaired axonal transport has been implicated in a range of neurodegenerative 
disorders (Götz et al., 2004). Among the proteins with a causal role in AD is tau, a microtubule-
associated protein, that similar to SNCA, is found in an unfolded state when in solution. Tau is 
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mainly a neuronal protein. However, it has been found also, although at low levels, in astrocytes 
and oligodendrocytes (Chen et al., 2004; Götz, 2001; Davidsson & Sjögren, 2005). Tau’s 
cardinal functions in neurons are to regulate the assembly and stabilization of microtubules that 
determine cellular morphology and serve as tracks for vesicles, axonal proteins and 
mitochondria (Shahani & Brandt, 2002). Under physiological conditions, tau is transported along 
axons at a rate compatible with a slow transportation mechanism (Mercken et al., 1995; Utton et 
al., 2002; Zhang et al., 2004). Under pathologic conditions such as AD and frontotemporal 
dementia (FTD), tau aggregates and form filaments, which fill up the entire soma of a 
degenerating neuron. Here, a failure of axonal transport has been implicated as a possible 
mechanism underlying tau accumulation (Praprotnik et al., 1996; Flament-Durand & Couck, 
1979; Richard et al., 1989; Bendiske et al., 2002; Dai et al., 2002; Götz et al., 2006).  
 There is increasing evidence for an overlap between PD and AD, not only in clinical terms 
(Kurosinski et al., 2002), but also biochemically and histopathologically (Hoerndli et al., 2005). 
For example, LBs are not only present in PD brain, but also abundant in Dementia with Lewy 
bodies (DLB) and in the LB variant of AD (Hansen et al., 1990). Specifically, LBs have been 
detected in the amygdala of more than half of all familial AD cases, and some LBs colocalized 
with tau-positive neurofibrillary tangles (NFTs) (Lippa et al., 1998). Biochemically, many of the 
functional categories, which are deregulated in PD are also deregulated in AD (Hoerndli et al., 
2005).  
 Another cytoskeletal protein with a role in neurodegeneration is β–actin, found abundantly 
within neurons, astrocytes, and blood vessels in the CNS, and concentrated particularly along 
the periphery of the neuronal perikaryon (De Iuliis et al., 2005). This preferred location places it 
in an ideal position to integrate incoming signals and produce the mechanical tension necessary 
for shaping the perikaryal surface (Pannese et al., 1996). A recent study found that specific 
protein carbonyl levels in β–actin are significantly higher in postmortem human AD brain 
samples than in controls (Aksenov et al., 2001). Also, when a ‘hemiparkinson’ rat model of PD 
was obtained by unilaterally injecting the neurotoxin 6-OHDA, De Iuliis et al. (2005) found 
increased levels of β–actin in the ipsilateral striatum, compared to the contralateral side (Lee et 
al., 2003). Previous studies described β-actin to be in an oxidized state in AD again suggesting 
common patho-mechanisms for the two diseases.  
Much of the signaling in brain is mediated by small peptides. The study of endogenous 
peptides, termed peptidomics, however is complicated by the presence of protein fragments 
produced post-mortem during conventional sample handling. This can be partially prevented by 
rapidly heat-denaturing brain tissue before analysis (Svensson et al., 2007). This approach has 
been applied to the MPTP model for PD, by which a polypeptide termed PEP-19 (Peptide 19) 
was found to be significantly decreased in the striatum of treated animals compared to controls 
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(Svensson et al., 2007). PEP 19 is a 7.6-kDa polypeptide that binds calmodulin and prevents 
calcium-calmodulin-dependent signaling (Ichikawa & Sugimoto, 2005). As a neuron-specific 
calmodulin-binding polypeptide, it is believed to play a pivotal role within the second messenger 
system that allows for the transduction of signals within cells. Elevated levels have been found 
in selective neuronal populations, such as the granule cells of the hippocampus and the 
Purkinje cells of the cerebellum, implying resistance towards degeneration (Johanson et al., 
2000). In contrast, Skold et al. (2006) recently demonstrated by in situ hybridization analysis, 
that PEP-19 mRNA levels are significantly decreased in the striatum, following MPTP 
administration in mice. Disease-specific differences have been found in an earlier study (Utal et 
al., 1998) that reported that although PEP-19 immunoreactivity appeared to be significantly 
reduced in AD and Huntington’s disease brain, no apparent alterations were detected in PD 
brain. Thus, the exact nature of PEP-19 in PD remains controversial. 
 
6.  FROM POST MORTEM TISSUE TO BODY FLUIDS AS SOURCES OF PROTEINS  
Proteome searches are frequently conducted within post-mortem brain tissue of a diseased 
state. This approach entails its own set of difficulties, including the potential confounds caused 
by additional age-related diseases that the usually aged patient may have suffered from, the 
time between death and autopsy that could have resulted in protein changes unrelated to the 
disease, how rapidly death ensued, the time of death and the duration of the coma that 
preceded death. In addition, the pharmacological treatment, i.e. the medication, may result in 
deranged protein levels, that may be mistaken for being disease-related. It is essential to 
consider the homogeneity of all these parameters in both the control and the patient group 
(Riederer & Wuketich, 1976). However, in spite of these difficulties several groups have 
proteomically probed brain tissue for parameters that may assist in predicting or diagnosing the 
disease, monitor its progression, or be used to follow-up therapy outcomes (Hoerndli et al., 
2005).  
 In addition to post-mortem tissue, body fluids such as cerebrospinal fluid (CSF), serum, 
blood or urine are increasingly collected from either animal models or humans and subjected to 
proteomics analysis. Obviously, animal models do not reproduce all aspects of disease, 
especially as far as the clinical features and the spatiotemporal distribution of brain lesions is 
concerned, but at a single cell level and biochemically, they have proved to be a very powerful 
tool (Götz et al., 2004).  
Although there is currently no blood test available with which to confirm the diagnosis or 
monitor PD, the accessibility of serum, as a component of blood, that is more readily available 
than any other body-fluid, offers potential exploitation using proteomics technology. 
Sophisticated techniques, including MS are used to identify rare proteins in blood serum and 
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CSF to identify biomarkers that represent unique proteomes. At present, thirty-four blood serum 
protein biomarkers are used for diagnosing neurodegenerative diseases (Sheta et al., 2006).  
In particular, CSF has been used as a medium from which to launch a proteome-based 
search strategy for detecting disease biomarkers, since the CSF reflects the state of proteins 
present in the brain under healthy and diseased conditions (Hühmer et al., 2006). As a complex 
mixture, consisting of proteins, peptides, proteolytic fragments and antibodies, CSF provides an 
excellent repository of pathologic information concerning the CNS (Romeo et al., 2005).  
In one study, quantitative proteomics has been applied successfully to CSF samples from 
patients with PD at different stages as well as with AD and compared to normal controls (Pan et 
al., 2008). The frequently encountered problem was addressed that while biomarkers are 
generally validated by enzyme-linked immunosorbent assays (ELISAs), often there are no 
specific antibodies available to set up these assays. Hence Pan and coworkers (2008) used a 
quantitative LC-MALDI TOF/TOF approach by spiking CSF samples with isotope-labeled 
peptides derived from a total of 14 proteins that had been previously identified as being 
deregulated in disease. Importantly, they were able to identify and quantify the peptides in CSF 
without prior depletion of abundant proteins (Pan et al., 2008). It should be mentioned that for 
quantitative proteomics of body fluids, label-free profiling has been successfully used by 
applying a microfluidics-based chip-LC-MS system, a method that has gained increased 
attraction for reasons of cost (Horvatovich et al., 2007). Sophisticated softwares have been 
developed to assist in the quantification of label-free profiling, including the open software tool, 
SuperHirn (Mueller et al., 2007). 
Several strategies exist for characterizing lipid-metabolizing proteins in human CSF. These 
proteins are potentially therapeutic targets due to their ability to transport lipids required for 
neural growth or to convert these into molecules that control brain physiology (Fonteh et al., 
2006). By combining lipid analysis with proteomics, the existing knowledge of disease pathology 
may be enhanced and the likelihood increased for discovering distinct markers and biochemical 
mechanisms of disease. In an effort to profile tau in CSF as a reflection of the degree of 
neuronal degeneration and damage sustained, Blennow et al. (1995) combined a pre-
fractionation step consisting of liquid phase isoelectric focusing (LP-IEF) with immunoblotting. 
This revealed that both phosphorylated and unphosphorylated forms of tau are present in CSF 
and that tau appeared both in truncated and full-length versions. For a comprehensive review of 
the posttranslational modifications of tau, the reader is referred to Chen et al. (2004).   
Quantitative 2-D gel electrophoresis has been used to analyze serum proteins derived from 
422 patients suffering from different neurodegenerative diseases and compared with normal 
controls, in an effort to identify potential biomarkers (Goldknopf et al., 2006). Differential protein 
spots were found for a total of 34 serum proteins between amyotrophic lateral sclerosis (ALS), 
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PD and related disorders, with nine relating to the complement system. Components of 
complement C3, including C3c and C3dg as well as complement factor H showed a marked 
increase in both disease-types compared to controls. In addition, the results indicated elevated 
levels for full-length factor B for PD, but not the control group. This reported elevation of factors 
H and B contradicts recent work proclaiming that they are significantly reduced in PD CSF 
(Finehout et al., 2005). In this study, it is possible that elevations of fragment Bb arose from 
elevated levels of factor H, which has been found to induce dissociation of C3 convertase 
(C3bBb(Mg2+))(Hourcade et al., 2002), thereby liberating factor Bb and interrupting the 
alternative pathway of the complement cascade (Goldknopf et al., 2006). The study generated a 
list of potentially useful biomarkers for further exploitation in future studies. In addition, the 
identified proteins provide evidence for an involvement of neuro-inflammatory processes in the 
pathogenesis of ALS and PD. The study indicates further that a comparison of the expression 
level of individual protein isoforms in conjunction with a measurement of the total protein 
expression level may be useful for investigating a protein as a possible biomarker. 
 The results on the complement cascade add strength to existing evidence suggesting that 
inflammatory processes involving complement activation may play a definitive role in the onset 
of PD. It also complements work that provides evidence for neuronal injury resulting from 
activated microglial release of free radicals in PD (He et al., 2002). This finding provides a 
potential avenue for developing treatment targets and for monitoring their clinical application. It 
further shows that two different neurodegenerative diseases can differentially express members 
of the complement system. In another study performed by Sjögren et al. (2001) it was found 
that the CSF concentrations of tau and phosphotau are increased in around two-thirds of 
probable AD cases while revealing normal levels in PD and in controls. The insight gained from 
such studies may potentially provide valuable information regarding their respective 
pathological mechanisms and identify markers that are shared between diseases and others 
which are disease-specific. In these endeavours, it is worth mentioning that the analysis of post-
translational modifications remains a technological challenge, but various generic strategies 
have recently emerged to aid this strategy (Reinders et al., 2004; Fountoulakis & Kossida, 
2006). 
 
7.  FUTURE DIRECTIONS 
It is evident that our present knowledge of PD pathogenesis and potential treatment strategies 
is inadequate. A growing body of evidence indicates that the accumulation of altered proteins 
and impaired protein clearance may be a common pathomechanism in both familial and 
sporadic PD. To fully understand the role played by abnormal protein aggregates in PD, it is 
imperative that additional proteins with a role in disease are identified and that their disease-
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related roles are defined. Recent advances in proteomics indicate that this technology may 
equip us with methodologies with which to study PD in a systematic manner that has not been 
possible to this extent in the past, by offering the opportunity to explore the proteome at all 
levels, ranging from fundamental neuroscience to clinical trials. However, to utilise 
neuroproteomics to its full potential, it is imperative that standard operating protocols are 
developed that allow these techniques to be applied reproducibly in a clinical setting.  
 The systems-based approach offered by proteomics not only allows for identifying multiple 
key proteins and signaling cascades, but also shows how these proteins interact with each 
other. It is anticipated that such data may eventually improve our understanding of the disease 
at a biochemical level and help identify novel biomarkers to assist in making an early, 
presymptomatic diagnosis of PD. In addition, it is hoped that the application of this technology 
will lead to the identification of new targets for more effective therapeutic intervention. The 
clinico-pathological profiles of AD and PD seem to overlap, or at least synergise to a certain 
extent (Kurosinski et al., 2002). Information is increasingly emerging to support such a 
postulation and therefore, the possibility is increasingly upheld that drugs that target the 
blocking of SNCA or tau may therapeutically benefit a much broader spectrum of 
neurodegenerative disorders.  
Since PD likely has a multifactorial etiology, proteomics provides the possibility for 
characterizing inter-patient variance. The lessons learned from this may eventually assist in 
developing personalized therapies, resting on the basis of individual patterns of protein 
expression (Jain, 2004). With this in mind, the future development of protein markers with which 
to identify not only the motor-related, but also the non-motor manifestations of PD, including 
cognitive dysfunction, autonomic dysfunction and speech disturbance, will contribute greatly 
towards a more global perspective of the disease. 
The greatest challenge facing the optimal utilization of this technology lies in detecting and 
quantifying low-abundant and hydrophobic proteins. In addition, the accurate detection of post-
translational modifications, their origin and the role they play in PD should also be made a 
priority. However, it is anticipated that protein chips and miniature separation systems will play a 
significant role in overcoming these limitations.  
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CHAPTER 7 
 
A PROTEOMICS AND MOTOR-FUNCTION ANALYSIS OF THE EFFECTS OF  
SIMVASTATIN ON MITOCHONDRIAL PROTEINS IN A ROTENONE RAT MODEL OF 
PARKINSON’S DISEASE 
 
1.  INTRODUCTION 
Accumulating evidence suggests that the etiology of the neuronal loss seen in the non-familial 
forms of PD may involve several molecular and cellular events, including oxidative stress, the 
accumulation of altered proteins, excitotoxicity, proapoptotic mechanisms and dysregulated 
mitochondrial functions (Dauer & Przedborski, 2003; Hirsch et al., 2005). This was further 
substantiated by reports that the effects of various chemically-induced parkinsonian models, 
including MPTP, rotenone, paraquat and most recently, epoxomycin are primarily due to 
mitochondrial and proteosomal dysfunction (Langston et al., 1983; Betarbet et al., 2002; 
McNaught et al., 2004). Initial models failed to fully reproduce all the features associated with 
PD, for example LBs, a pathological hallmark of the disease. However, subsequent attempts, 
consisting of the chronic infusion of rotenone in rodents (Betarbet et al., 2000) and of MPTP in 
mice (Fornai et al., 2005) have recapitulated this pathological feature of PD in addition to 
producing SNCA aggregates. These findings support the notion that sporadic PD results from 
environmental toxins that act by inhibiting the mitochondrial respiratory chain to induce selective 
dopaminergic cell loss.  
Complex I of the mitochondrial electron transport chain (METC) consists of 26 subunits and 
acts as the opening gateway to the METC (Mizuno et al., 1989; Parker et al., 1989; Bindoff et 
al., 1991; Mann et al., 1992; Beal et al., 1993). It has been shown that a complex I defect can 
result from a depleted state of endogenous mitochondrial DNA (mtDNA), due to either a single 
or multiple mutations in the genes encoding for this protein complex (Swerdlow et al., 1996). 
Henceforth, the expression of mtDNA-derived defects in neuronal host cells, such as a SH-
SY5Y neuroblastoma cell line, inhibits recovery from intracellular calcium transients (Sheehan 
et al., 1997), increases the production of harmful reactive oxygen species (ROS) (Swerdlow et 
al., 1996) and alters the activities of several antioxidant enzymes (Cassarino et al., 1997), 
including superoxide dismutase (SOD) (Kurtz, 2004), catalase (CAT) (Doctrow et al., 2003), 
glutathione peroxidase (GSHPx), glutathione reductase (GR) and thioredoxin/thioredoxin 
reductase (Arnér & Holmgren, 2000), peroxiredoxin (Ree, 2006), and glucose-6-phosphate 
dehydrogenase (G-6-PDH) (Tome et al., 2006). Although scavenging systems are in place to 
reduce the cellular build-up of toxic by-products (Hockenbery et al., 1993; Kluck et al., 1997), 
ROS exposure leaves cells more susceptible for undergoing apoptosis (Swerdlow et al., 1996). 
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The use of the pesticide rotenone is a common approach to model PD in rats (Betarbet et 
al., 2000). It crosses cellular membranes freely, independent of a DA transporter to gain access 
to the cytoplasm of dopaminergic neurons (Betarbet et al., 2000; Greenamyre et al., 1999). 
Following this, the toxin accumulates in mitochondria where it inhibits electron transportation at 
complex I (NADH CoQ1 reductase) of the METC (Earley et al., 1987), impairing oxidative 
phosphorylation (Schuler & Casida, 2001), and stimulating superoxide production and 
mitochondrial matrix dehydrogenases at proximal redox sites, leading to DA neuron apoptosis 
(Fiskum et al., 2003).  
Mitochondria in differing cell types vary widely in terms of size, shape and number present. 
Mammalian cells typically contain between 800 to 2500 mitochondria. The numbers of 
mitochondria in cells differ according to the energy needs of the cell. For example, the purpose 
of human erythrocytes is merely the transportation of oxygen to tissue, and therefore do not 
contain any mitochondria whatsoever (Garrett & Grisham, 1995).  
Each mitochondrion is surrounded by an outer membrane that allows for the free diffusion of 
large molecules into and out of the organelle, in addition to a far more complex inner membrane 
that is relatively impermeable and contains the electron transport enzyme complexes. Situated 
between the two membranes is the intermembrane space. The inner compartment of the 
mitochondrion is enclosed by the inner membrane to form the matrix in which the Krebs cycle 
takes place. During the Krebs cycle 2 electron carriers are generated, namely the reduced 
coenzyme (NADH) and reduced flavoproteins (FADH2), which are oxidized in the inner 
membrane and contain a chain consisting of electron carriers. These 2 molecules function as 
electron donors to the series of transport enzymes that are located either inside or on the inner 
mitochondrial membrane (see Figure 1). Concomitantly, the ejection of protons across the inner 
mitochondrial membrane results in an electrochemical proton gradient, which stores potential 
energy.  
 The electron transport chain consists of five enzymatic complexes (Wallace, 1992) and is 
located within the inner mitochondrial membrane. The first electron carrier involved in the 
oxidation of most metabolites is nicotinamide adenine dinucleotide (NAD+). The dinucleotide is 
formed by linking the two phosphate groups of two nucleotides. Another electron (hydrogen) 
carries FAD or flavin adenine dinucleotide, and derives from vitamin B2 or riboflavin. An 
important feature of this molecule is that, in combination with the appropriate proteins, accept 
two H atoms to become FADH2.  FAD forms a prosphetic group, as a permanent attachment to 
its apoenzyme. This is in contrast to NAD+, which moves from one dehydrogenase to another.   
 Four enzymes (complexes I-IV) transport electrons, ranging from NADH, succinate and 
oxygen.  The complexes pump protons into the mitochondrial intermembrane space, thereby 
forming an electrochemical gradient. Complex I [NADH dehydrogenase (ubiquinone)], forms the 
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main entry port to the electron transport chain and is composed of 26 subunits, of which seven 
are encoded by mitochondrial DNA. Complex II [succinate dehydrogenase (ubiquinone)] forms 
another entrance to the electron transport chain, and consists of 5 subunits that are encoded by 
nuclear DNA. Complex III (ubiquinol-cytochrome-c reductase) consist of 11 subunits, with one 
of these encoded for by the mitochondrial DNA, and complex V (ATP synthase) which is 
composed of 12 subunits, with 2 subunits encoded for by the mitochondrial genome. ATP 
synthase uses the generated electrochemical gradient to synthesize ATP from ADP (Lee & 
Martens, 1986). 
 Although the exact relevance that rotenone holds in relation to the etiology of PD remains 
unknown (Perier et al., 2003), PD postmortem studies strongly implicate for the involvement of 
oxidative damage and mitochondrial impairment in the pathogenesis of the human disease 
(Dexter et al., 1989). Reports of reduced activity of complex I (NADH 
dehydrogenase/ubiquinone) of the METC in post-mortem PD brains (Schapira et al., 1990; 
Reichmann et al., 1990) support these postulations. Furthermore, some investigators have 
detected complex I defects in muscle-cells (Bindoff et al., 1991; Shoffner et al., 1991) and blood 
platelets (Parker et al., 1989; Benecke et al., 1993; Haas et al., 1995; Swerdlow et al., 1996; Gu 
et al., 1998) of PD patients. However, this issue remains controversial, with some studies failing 
to support previous claims of a complex I deficiency in peripheral PD cells (Mann et al., 1992; 
Reichmann et al., 1994; Hanagasi et al., 2005).  
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Fig.   1.     A cartoon illustrating the structure and function of the mitochondrial electron 
transport chain. Taken from www.dialogica.com, accessed on 29/05/2008. 
 
Microtubules seem to be an additional intracellular molecular target of rotenone (Brinkley et al., 
1974; Marshall & Himes, 1978). Microtubular depolarization disrupts the microtubule-based 
transport of DA vesicles, leading to the selective degeneration of nigral DA neurons, thereby 
simulating PD-like symptoms in rats (Jiang et al., 2006; Ren et al., 2005). Experimental 
evidence for this alternative non-mitochondrial mechanism of rotenone derives from the finding 
that the microtubule–depolymerizing drug colchicine effectively mimics rotenone’s action, while 
the microtubule stabilizing drug taxol, attenuates the toxin’s effects (Ren et al., 2005).   
 Statins are cholesterol-lowering drugs administered to hypercholesterolemic individuals to 
normalize their elevated plasma low-density lipoprotein levels (LDL) (Stüve et al., 2003), reduce 
triglyceride levels and augment high-density lipoprotein (HDL) levels (Doncheva et al., 2006; 
Davidson et al., 2003). They currently rank among the most widely prescribed agents for 
preventing cardiovascular disease, decreasing cardiovascular events and for improving survival 
rates following both secondary and primary heart disease (Martin et al., 2001; Stüve et al., 
2003). The drug acts by competitively inhibiting 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase, a key regulatory and rate-limiting enzyme present in the biosynthetic pathway 
of cholesterol, thereby preventing the biological activities of L-mevalonate by catalyzing 
mevalonate (Ginsberg, 1998; Michal, 1999). Since L-mevalonate is an intermediate step for 
isoprenoid and cholesterol production, statin-therapy prevents the formation of both (Mason, 
2003). Although the described events occur predominantly in the liver, resulting in, for example, 
an upregulation of hepatic high affinity receptor levels for LDL (Goldstein & Brown, 1984), other 
tissues may also partake in the process (Brown & Goldstein, 1980; Goldstein & Brown, 1990). 
 The brain is the most cholesterol-rich body organ, containing approximately 25% of total 
body levels. In order to maintain homeostasis, cholesterol synthesis, removal, storage, and 
transport is strictly regulated. The majority of the brain’s cholesterol is synthesized locally in the 
CNS, since transportation via peripheral circulation prevents entering of the brain’s immediate 
environment by an intact blood-brain barrier (BBB), except for the oxidized cholesterol products 
27-hydroxycholesterol and 24S- hydroxycholesterol (Papassotiropoulos et al., 2000). 
Cholesterol is an essential component of cell membranes as well as being necessary to 
maintain synaptic plasticity and it is believed that astrocytes supplement the adult brain, since 
endogenous cholesterol synthesis is reduced in mature neurons (Poirier et al., 1993; Pfrieger, 
2003). However, molecular and mechanistic evidence, as well as longitudinal, population-based 
studies suggest for a direct role played by hypercholesterolemia in the pathogenesis of 
numerous neurological disorders. This includes the findings that amyloid beta (Aβ) peptide 
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aggregates, a pathological hallmark of the AD brain, preferentially bind cholesterol (Avdulov et 
al., 1997) and increase brain cholesterol levels during the early stages of AD progression 
(Kivipelto et al., 2001). Moreover, statins also decreased intracellular and extracellular amyloid 
load in cultured hippocampal and mixed cortical neurons, while an in vivo study demonstrated 
the reduced effects of simvastatin treatment on cerebral Aβ isoform levels in cerebrospinal fluid 
and brain homogenates (Fassbender et al., 2001). Mounting evidence suggests that in addition 
to their potent effects on plasma lipid concentrations, statins exert additional pleiotropic effects 
that may be independent to their primary lipid-lowering actions (Liao, 2002). These include 
endothelial protection via actions on the nitric oxide synthase system (Bellosta et al., 1998), 
antioxidant (Molcányiová et al., 2006), anti-inflammatory (Selley, 2005), and anti-platelet actions 
(Ferroni et al., 2006).  
 Six statins are currently available for clinical use. Simvastatin is a fungal-derived lipophilic 
statin capable of crossing the BBB (Lu et al., 2007). Due to its lipophylic nature, and being only 
4.19 kDa in size, it readily crosses the BBB, after which it exerts effects on the CNS. Approval 
has been granted for its application in the treatment of patients diagnosed with diabetes mellitus 
and/or peripheral vascular disease (Schmeer et al., 2006). In addition, several studies suggest 
that statins may have potential therapeutic uses in strokes (Law et al., 2003), AD (Vega et al., 
2003), multiple sclerosis, primary brain tumors, traumatic brain injury (Lu et al., 2004), as well 
as being responsible for an upregulation in D1 and D2 receptors, thereby offering potential 
therapeutic benefit for treating PD (Wang et al., 2005a; Rajanikant et al., 2007).  
 However, the inhibition of an enzyme that plays a key part in regulating cholesterol 
synthesis, and indirectly membrane integrity, does raise some concern. For instance synaptic 
function may become disturbed when cholesterol levels decrease unrestrictedly (Mauch et al., 
2001). Adverse events associated with statin treatment have been reported, including statin-
induced hepatotoxicity, dose-independent myotoxicity, as well as a number of fatal cases 
resulting from statin-induced rhabdomyolysis and cerebral hemorrhage (Johnson et al., 2005; 
Talbert, 2006; no authors listed, 1998; Black et al., 1998; Davidson, 2001; Iso et al., 1989). 
 A recent study demonstrated that short-term therapy with simvastatin induce changes in the 
dynamics and survival of oligodendoglial processes in cultures of rat newborn and human fetal 
oligodendrocyte progenitor cells as well as human adult oligodendrocytes (Miron et al., 2007). 
The human-derived cells were more sensitive relative to the rodent cells, and susceptible to 
increased cell death. This highlights the importance of considering the short- and long-term 
effects of statins, particularly the potential for inducing an immunomodulatory effect on neural 
cells known to be affected in multiple sclerosis. Mitochondrial impairment, as evidenced by a 
disturbed membrane potential, mitochondrial swelling and functional analysis of the enzymatic 
complexes of the METC, may proclaim a prominent place in the etiology of these serious side 
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effects (Amacher, 2005; Chan et al., 2005, Dykens et al., 2007). Evidence for this includes an 
inhibition of coenzyme Q10 (CoQ) synthesis, that plays a critical role in regulating normal 
mitochondrial function, when cholesterol biosynthesis was inhibited (Rundek et al., 2004). The 
supplementation of coenzyme Q10 seemingly reversed these effects (Nawarskas, 2005).  
 The purpose of the present study was to determine whether or not the active chemical 
component of simvastatin provide protection against mitochondrial damage. Male SD rats were 
treated with simvastatin 14 days, after which they received a single unihemispheric injection of 
rotenone in the substantia nigra or an equal volume of vehicle. Performance assessment in 
apomorphine-induced rotational asymmetry and the vibrissae-evoked forelimb placement test 
was performed, after which the animals were sacrificed; mitochondrial-enriched fractions 
isolated from the SN and the samples processed for proteomics analysis with the results 
compared to placebo-fed controls.  
 
 
2.  METHODS AND MATERIALS  
2.1.  Animals 
Adult male SD rats, weighing between 300 and 320g at the beginning of the experiment, raised 
within the Animal Research Facility of the University of Stellenbosch were used for the purpose 
of this study. The animals were housed under standard laboratory conditions of 12 h light/dark 
cycles, with the temperature set at 22 ± 1 °C and humidity maintained at 60 ± 5%. All testing 
and training of the animals were performed during the light phase of the cycle at a 
correspondingly similar time of day (09:00-13:00). Food and water were provided ad libitum. All 
experimental procedures were performed in accordance with the guidelines of the Committee 
for Ethical Animal Research of the University of Stellenbosch. 
 
2.2. Experimental design 
The following study was designed and implemented: 48 male Sprague-Dawley rats were 
randomly divided into one of four groups: placebo + vehicle (P + V) (n = 12), placebo + 
rotenone (P + R) (n = 12), simvastatin + rotenone (S + R) (n = 12), or simvastatin + vehicle (S + 
V) (n = 12). Rats were treated for 14 days with simvastatin after which they received stereotaxic 
injections of vehicle or rotenone. Rats were tested for apomorphine-rotational asymmetry and 
non-drug induced motor behaviour at three separate time-points: before the placebo/drug 
treatment commenced in order to obtain a baseline-score, by the end of the drug treatment 
regime, and 5 days after stereotaxic lesioning with rotenone. A day after the final test, the 
animals were sacrificed, the SN dissected, and the samples snap-frozen in liquid nitrogen, for 
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subsequent proteomics analysis. Figure 1 provides a time-sequence of the experimental 
protocol. 
 
 
Fig.   2.     A time-line by which the experimental protocol was executed. The protocol consisted of 
drug treatment, behavioral assessment, followed by animal sacrifice and brain tissue collection. 
 
2.3.           Drugs and chemicals used 
Rotenone, apomorphine were procured from Sigma Chemicals (St. Louis, MO, USA), while the 
active chemical compound of simvastatin was kindly donated to us by Ranbaxy Laboratories 
(Dewas, India). 
 
2.4.  Drug treatment 
For 2 weeks prior to the unilateral infusion of rotenone into the SNc (see below), simvastatin 
was administered orally on a daily basis. Two weeks of training was spent on training the rats to 
eat a gelatin-cube consisting of flavoured sugar. A drug-treatment regime was then followed 
consisting of dissolving 6 mg of the active chemical component of simvastatin in 50 µl of 
absolute Ethanol (EtOH) in an Eppendorf microtube, which was mixed with the gelatin-solution. 
For preparing a single gelatin-cube, a drop of the gelatin solution in an ice-tray using a Pasteur 
pipette, while 50 µl of the EtOH-dissolved statin-solution was re-suspended in the sugar solution 
with a sterilized pipette. After the solution had set completely, the gelatin-cube was removed 
from its plastic holder. A single cube was given to each rat every day for 14 days, between 
13:00 and 13:30, until the day preceding surgery. During feeding, the experimenter remained 
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present in the room, to ensure that the rats ingested the sweet in its entirety. Control rats were 
treated with placebo, i.e a gelatin-cube with EtOH but without any simvastatin.  
 
2.5.  Surgical procedure 
The stereotaxic coordinates for the SN were determined a priori by injecting Indian ink. The 
injection was verified histologically in an animal of the same strain, sex and weight range, to 
ascertain the optimal location of the tip of the injection cannula (30G needle). Reference was 
made to a stereotaxic atlas of the rat brain (Paxinos & Watson, 1986), and the final stereotaxic 
coordinates for the SNpc injection established: 5.3 mm posterior to Bregma, 2 mm lateral to the 
midline and 7.5 mm from the dura. These coordinates were used throughout the study for all 
experimental groups. For the rotenone/vehicle injections, adult male experimental animals, 
weighing between 375-390 g were randomly assigned to their various experimental groups 
before surgery. Rats were anesthetized with a combination (0.1 ml/100g, i.p.) of ketamine 
hydrochloride (Anaket-V®, Bayer Healthcare, South Africa) and medetomidine hydrochloride 
(Domitor®, Pfizer, South Africa). The surgical site was prepared by clipping the animal’s head-
hair and disinfecting the site with 70% EtOH. The rat was immobilized in a stereotaxic frame 
(David Kopf Instruments, USA) in a flat-skull position. A rubber heating-pad (REX C10, RKC, 
19.0~99.9°C heat generator, Electronic Services, University of Stellenbosch) maintained the 
rat’s body heat during surgery. A 2 cm mid-saggital skin incision was made through the scalp to 
expose the skull. A burr-hole was drilled at the predetermined coordinates and an infusion 
cannula consisting of a sterilized length of 30 gauge stainless steel hypodermic tubing was 
stereotaxically advanced to a depth where the internalized tip was located within the SNc cell 
bodies. A stock solution of the rotenone solution was freshly prepared by dissolving rotenone in 
the vehicle (dimethyl sulphoxide (DMSO):Polyethylene glycol (PEG), at a 1:1 ratio). Each rat 
received 3 µg of rotenone/4 µl of vehicle. The solution was infused through a tube attached to a 
Hamilton syringe over a period of 5 min using a 341-A model syringe pump (Sage Instruments, 
USA). Following the infusion, the needle was left in situ for an additional 5 min, before slowly 
retracting it from the brain. The drilled burr-hole through the skull was filled with sterilized 
oxidized cellulose (Ethicon, U.K.), the incision was sutured and the skin coated with an iodophor 
(Betadine®, Purdue Pharmaceutical Products, South Africa). To recover, the rats were placed 
in individual cages under heating lamps and a post-operative pain reliever (Temgesic, 0.01 
mg/kg, i.p.) was administered. The condition of the sutures, the rat’s food and water in-take and 
behaviour were monitored daily to ensure full recovery. 
 
2.6.  Motor-function assessment 
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Upper extremity sensorimotor function was assessed by means of tests that are sensitive to the 
degree of degeneration of the nigrostriatal dopaminergic projection neurons. The tests included 
the vibrissae-evoked forelimb placing test, which measures spontaneously induced motor 
asymmetries, and the apomorphine-induced rotometer test. 
 
2.6.1.  Vibrissae-evoked forelimb placing test 
At 14 days post-lesion, the degree of forelimb placing asymmetry was quantified using a 
vibrissae-elicited forelimb placing test, which is sensitive to the sensorimotor or proprioceptive 
capacity (reviewed by Schallert et al., 2000). Briefly, the experimenter held the animals aloft by 
the torso in such a way that the forelimbs were allowed to dangle freely. Before commencing 
with each trial assessment, the experimenter moved the animal gently up and down in space, 
with intermittent landing of all four limbs onto the tabletop surface, thereby facilitating muscle 
relaxation and preventing the animal from struggling against the experimenter’s mild grip. On 
the scoring trials, the vibrissae on each side were brushed against the edge of a tabletop, to 
test vibrissae-evoked forelimb placing independently on each side of the body. The forelimb not 
being tested was gently restrained by the experimenter by placing a finger in front of the 
forelimb. The sensory input to the vibrissae signals the presence of a stable surface, and the 
intact animal will immediately place a forelimb onto the table (Schallert et al., 2000; Schallert et 
al., 2002). In contrast, rats with severe striatal or nigrostriatal injury show an impaired ability to 
place the forelimb contralateral to the damaged hemisphere (Schallert et al., 1989), while still 
placing the unimpaired limb reliably (Schallert et al., 2000; see movies at www.schallertlab.org). 
A 4-point scale, adapted from Anstrom et al. (2007) was used for rating each successful, partial 
and non-placing response given, assessed by an assessor blind to the treatment of the animal. 
A score of 3 was allocated if vibrissae stimulation generated a vigorous forward and upward 
movement of the limb, enabling the paw to make solid contact with the table top. A score of 2 
was given each time the rat placed one forelimb on the edge of the tabletop rather than the 
upper surface. A score of 2 was given if there was a delay in placing that exceeded 2 seconds 
or if there was a movement of the forelimb that did not reach the table at all. A score of 0 was 
given if the rat made no response with the forelimb upon vibrissae stimulation, the trial scored 
zero. To determine the degree of successful placing by the contralateral forelimb, these scores 
were totalled over the 20 trials and averaged for each animal. In addition, as a second index 
that is more widely used in PD models, the percentage of completely successful contralateral 
forelimb placing responses to vibrissae stimulation was calculated for each side by multiplying 
the ratio number of successful responses/total number of trials (n = 20) and multiplying by 100. 
Trials that received a score of 3 were considered “successful placements”, while trials scoring 2, 
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1 and zero were considered unsuccessful attempts. Asymmetry was calculated by dividing the 
percentage of successful contralateral forelimb placing trials by the percentage successful 
ipsilateral forelimb trials and multiplying this number by ten (Anstrom et al., 2007). Trials during 
which there was any non-limb movement, detectable muscle tension, struggling, or premature 
forelimb movement were not scored. Each time-point assessment for this particular test 
consisted of 2 sessions × 10 trials from each side, with the mean score of the two test sessions 
considered representative. The data were analyzed using analysis of variance (ANOVA), with 
the critical P value set at 0.05. 
 
2.6.2.  Apomorphine-induced rotation test 
Animals with severe unilateral DA depletion exhibit asymmetrical rotational behavior in a 
contraversive direction in response to the DA agonist apomorphine (Borlongan et al., 1995; 
Ungerstedt & Arbuthnott, 1970). The infusion of rotenone to specifically damage the 
dopaminergic nigrostriatal pathway, results in progressive stereotypic rotations following the 
administration of amphetamine or apomorphine (Alam et al., 2004; Heikkila et al., 1984).  Here 
apomorphine-induced rotational behavior was assessed, as had been described in earlier 
reports (Sindhu et al., 2005). The degree of apomorphine-induced stereotypic asymmetry was 
assessed for all four groups by challenging with 0.75 mg/kg apomorphine hydrochloride 
(Sigma), dissolved in 0.2% ascorbate in 0.9% saline, injected subcutaneously (in the scruff of 
the neck). Thirty min after the injection the animal was placed in a spherical rotometer (with a 
diameter of 25 cm) for 60 min. The animals were video-recorded from a ventral perspective and 
the amount of ipsiversive (towards the lesioned hemisphere) and contraversive (away from the 
lesioned hemisphere) was analysed with using Noldus Ethovision software (Noldus Information 
Technology, The Netherlands). For each assessment, the total number of half (180°) turns in 
left and right directions was counted for the 60 min time interval. Analysis of data was based on 
net ipsilateral (right-left) turns and on net contralateral (left-right) turns. The amount of clockwise 
half-circle (180°) rotations (ispsilateral to the lesion) was scored as positive turns, and 
counterclockwise turns were counted as negative turns. The net rotational asymmetry score 
was calculated by subtracting the number of ispsilateral turns from clockwise turns made over 
the 60 min duration of the trial, with recording starting half an hour following the injection of 
apomorphine (Sun et al., 2005). 
 
2.7.  Animal sacrifice and brain tissue collection 
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At the end of the experiment, the rats were decapitated and the brain removed from the skull 
using the flat end of a spatula. The left and right SN were micropunched (see Fig. 3) and 
immediately frozen and stored under liquid nitrogen.  
 
 
Fig.   3.     A photograph to illustrate the micropunched-out SN taken from a coronal section. The 
SN sections for each group was pooled prior to subjecting them to mitochondrial isolation.  
 
2.8.  Isolating the mitochondria prior to proteomics 
Since abundant proteins are sometimes exclusively analyzed by mass spectrometry (Aebersold 
& Goodlett, 2001; Haynes & Yates, 2000) sample fractionation and enrichment of lower 
abundance proteins are necessary to achieve a better characterization of the proteome of 
interest. The tissue samples, were removed from the -80°C fridge and placed on ice. 
Mitochondrial fractions were isolated from dissected brain tissue using a commercially available 
kit (MITO-ISO1, Sigma-Aldrich, USA). The tissue was weighed and then cut into smaller pieces 
with a scalpel-blade on a glass plate cooled with liquid nitrogen vapours. The samples were 
pooled and homogenized with a glass homogenizer in 10 volumes of extraction buffer. The 
buffer contained 10mM HEPES, 200mM Mannitol, 70mM Sucrose, 1mM EGTA and Bovine 
Serum Albumin to remove excess lipids, with the pH set at 7.5. The homogenate was 
transferred to a 2 ml Eppendorf tube and kept on ice. In order to obtain a mitochondrial fraction 
of ultra-high concentration, and to minimise the presence of contaminants, such as lysosomes 
or peroxisomes, the homogenate was centrifuged at a differential gradient. Centrifugation first 
occurred at a low rate of 1000 × g for 5 min, after which the supernatant liquid was transferred 
to a new tube and then centrifuged again at a higher rate of 3500 × g lasting for 10 min. The 
supernatant was removed and the pellet resuspended in 10 volumes of extraction buffer. The 
centrifugation steps were repeated, and the pellet resuspended in storage buffer, containing 
10mM HEPES, 250 mM sucrose, 1 mM ATP, 0.08 mM ADP, 5 mM sodium succinate, 2 mM 
K2HPO4, and 1 mM DTT, pH 7.4.  
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2.9.  Proteomics analysis of the isolated mitochondria 
Conventional approaches for studying the effects of pharmacological agents on the 
parkinsonian brain are limited by its focus on select molecules only, thereby excluding others as 
well as pathways that may be relevant also. Proteomics techniques defined as the 
characterization of all proteins encoded by the genome, were applied to determine the 
mechanism by which the behavioral changes may have been accomplished (Liu et al., 2007). 
Proteomics is particularly useful as a direct measure of gene products, rather than gene 
transcripts that may or may not translate into proteins. 
 
2.9.1.  Protein extraction and purification  
The supernatant containing mitochondria (section 2.8) was purified using a ReadyPrep Cleanup 
Kit (Bio-Rad Laboratories, USA), and the protein concentration of the sample quantified with a 
Model 550 Microplate reader and RC DC Protein Assay Kit (Bio-Rad Laboratories) using BSA 
as the standard. Aliquots of the final protein solution were stored at -80˚C until further use. Two-
dimensional gel electrophoresis (2-D) is a protein separation technique that allows for the 
separation of proteins according to charge (Isoelectric focusing, IEF) in the first dimension and 
by molecular mass (SDS-PAGE) in the second (Mary, 1999). 2-D was subsequently performed 
on mitochondrial proteins derived from the SN in order to assess differential protein expression 
between the placebo + vehicle-infused and the statin-treated + vehicle-infused groups of 
animals.  
 
2.9.2.  Electrophoretic protein separation  
The extracted mitochondrial proteins were separated by IEF followed by 2-D SDS-PAGE. 
Separation in the first dimension was performed by mixing the appropriate amount of protein 
sample with a rehydration buffer, containing 8 M urea, 4% (w/v) CHAPS, 65 mM DTT, 0.2% 
(v/v) Bio-Lytes and a trace of bromophenol blue. The sample was loaded in the IEF tray, 
followed by the IPG gel strip gently being placed gel side down onto the rehydration solution 
and overlaying the IPG strip with 3 ml of mineral oil to prevent evaporation taking place during 
the rehydration process. The focusing tray was placed on a PROTEAN IEF Cell (Bio-Rad 
Laboratories, USA) and the software program was then run. Following IEF, the strip was 
equilibrated for 15 min in the equilibration buffer containing DTT, followed by an additional 15 
min in equilibration buffer II containing iodo-acetamide.  
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2.9.3.  Gel staining, image acquisition and analysis 
For separation in the second dimension, the gel strip (11 cm in length with an ampholyte range 
of 5-8, Bio-Rad Laboratories, USA) was placed on the upper edge of the 4-12% separation gel 
with its backside pasted tightly along the surface of the glass plate. A marker of low molecular 
weight protein (5 µl) was added at one end of the IPG strip. Low-Melt Agarose was used for 
fixing the gel strip and to remove air bubbles. The gel was run at 200V, until the bromophenol 
blue ran clear of the gel strip and condensed in a single line. As soon as the bromophenol blue 
front had traversed the gel, electrophoresis was stopped. Completed polyacrylimide 2-D gels 
were stained with G-Colloidal concentrated Coomassie Brilliant Blue-R (Sigma-Aldrich, USA) for 
visualizing the separated proteins. Gels were scanned using a GS-800 calibrated scanner (Bio-
Rad, USA) and the Quantity One-4:5.2 (Basic) software program (Bio-Rad, USA) employed to 
create gel images. These gel images were subsequently analysed using the PDQuest (version 
8) software program (Bio-Rad, USA) to identify the differentially expressed (p < 0.05, student’s 
t-test) spots between control and statin-treated animals. 
 
2.9.4.  Destaining, in-gel digestion and peptide extraction 
For identifying the protein profile, the spots of interest were subjected to Mass Spectrometric 
(MassSpect) analysis. Briefly, the gel pieces containing the proteins of interest were manually 
excised from the 2-D gels followed by subjection to in-gel enzymatic digestion using trypsin 
(Shevshenko et al., 1996). Using the manufacturer’s protocol, the gel plugs were processed by 
a MassPrep Robotic Protein Handling System (MS Technologies, UK). The samples were 
placed in a 96-well polypropylene microtiter plate and destained twice, using 50 % acetonitrile in 
50 mM ammonium bicarbonate, followed by a rinse with acetonitrile and allowed to air dry for 10 
min. They were then reduced with 10 mM dithiothreitol for 30 min, followed by subjecting them 
to alkylation with 55 mM iodoacetamide. These steps were followed by rinsing the samples 
three times with acetonitrile, followed by 100 mM ammonium bicarbonate, and finally by 
acetonitrile. Digestion was performed by adding to each sample a 25 μl aliquot containing 6 
ng/µl  trypsin. The samples were then allowed to incubate for 4.5 h at 37 °C. The initial 
extraction of the peptides was done using 30 µl of an aqueous solution containing 2% 
acetonitrile and 1% formic acid. A second extraction using 15 µl  of an aqueous solution 
containing 51% acetonitrile and 0.5% formic acid was then performed and combined with the 
first extraction in a cooled second 96-well plate and stored at –80oC prior to analysis by mass 
spectrometry. 
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2.9.5.  Peptide separation by means of in-line Liquid Chromatography and Electrospray 
Ionisation Mass Spectrometry (EI-MassSpect) 
The partially digested peptide mixture was contained in a 96-well microtitre plate, which was 
transferred to a modular CapLC and autosampler system (MS Technologies, UK). Using the 
method described by Wilm et al. (1996) and Chen et al. (2006), the eluted peptides were then 
analysed further using quadripole time of flight (ESI-QUAD-TOF) mass spectrometry (MS 
Technologies, UK) fitted with a nano-electrosprayer having an applied capillary voltage of 3.5 
kV. Prior to analysis, the instrument was calibrated against a collisionally induced 
decomposition (CID) spectrum of the doubly charged precursor ion of [glu1]-fibrinopeptide B 
(GFP). Calibration was accepted when the error obtained on all subsequent acquisitions was < 
20 ppm, while the sensitivity of the machine was assessed by detecting a 500 fmol injection of 
GFP, with a base peak signal:noise ratio of > 50:1 on the doubly charged ion. Throughout 
analysis, the sensitivity and calibration of the MassSpect instrument as the chromatographic 
resolution of the GFP peak were checked at regular intervals. For recording spectra, the 
MassSpect instrument was operated in data dependent acquisition (DDA) mode over the 
mass/charge (m/z) range of 50-2000. During the DDA analysis, both MassSpect and tandem 
mass spectrometry were performed on the most intense peptides as they eluted from the 
column.  
 
2.9.6.  Homology protein searches 
Following data acquisition, all the individual uninterpreted MS/MS spectra that had been 
acquired for each of the precursors within a single LC run, were combined, smoothed, the 
background subtracted, centred, deisotoped and centroided automatically using the ProteinLynx 
Global Server search engine (MS Technologies, UK). The MASCOTTM peptide identification 
search algorithm (Perkins et al., 1999) was used for querying the nonredundant database at the 
National Center for Biotechnology Information (NCBInr) with the ProteinLynx Global Server 
output that was generated as a single Mascot-searchable peak list file. The search parameters 
were defined to include up to two missed cleavage sites, a 100 ppm tolerance against the 
database-generated theoretical peptide and product ion masses, and a minimum of a single 
matched peptide. A list of the twenty highest scoring entries was produced and each suggested 
protein identification was either confirmed or rejected by comparing the theoretical sequence 
with the observed MS/MS data. The generated dataset was searched against Matrix software 
(http://www.matrixscience.com/cgi/), by using a rat reference database, the IPI rat version 3.34 
(http://www.ebi.ac.uk/IPI/IPIrat.html, released 02/10/2007). 
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 Furthermore, fragments were sequence-identified by performing a database search against 
several publicly available databases, i.e. SwissProt, www.ebi.ac.uk/swissprot; NCBI nr, 
www.ncbi.nlm.nih.gov; and ENSEMBL (http://www.ensembl.org/index.html). BLAST searches 
(www.ncbi.nlm.nih.gov/BLAST; http://www.arabidopsis.org/Blast/) were performed on the peptide 
fragments obtained earlier, to further analyze non-annotated expressed sequence tag (EST) 
hits (Altschul et al., 1990). 
 
3.  RESULTS 
3.1.  Motor-function assessment 
3.1.1.  Vibrissae-evoked forelimb placing test 
In accordance with others (Woodlee et al., 2005; Anstrom et al., 2007), vibrissae stimulation 
evoked placement of the contralateral limb. When the non-lesioned side was tested, no deficit 
was detected in terms of placing the unaffected paw (ipsilateral to the lesion) and therefore this 
data was excluded from further analysis. Only performance by the affected, contralateral limb 
was considered. Analysis using a 2-way ANOVA indicated a significant interaction between the 
two dependent variables, i.e. drug treatment and infusion (F(1, 44)=16.26, p < 0.01). Post hoc 
analysis using a Bonferroni test detected a significant difference (p < 0.01) between P + V 
(mean 59.58 ± 0.26) and P + R (P + R, mean 8.25 ± 1.6) rats, as well as between the P + V  
and S + R (mean 15.83 ± 0.8) groups (p < 0.01). While no statistically significant difference was 
detected between the P + V and S + V (mean 59.83 ± 0.11) groups (p = 1), a difference was 
found between the S + R and P + R rats (p < 0.001). Sixty denoted the perfect placing score. 
Statin-use improved performance in the rotenone groups, while no improvement was detected 
in the vehicle group (Fig. 4).  
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Fig.   4.     Results obtained from the vibrissae-evoked forelimb placing test. The graph depicts the 
placing scores of the contralesional forelimb of the various groups. Rats received placebo/statin 
treatment for 14 days, followed by a single unihemispheric stereotaxic injection with rotenone/vehicle into 
the substantia nigra. Behaviour was assessed at 5 days following the intra-cerebral injeciton. Data are 
expressed as the mean ± S.E.M. *p < 0.001 indicates significantly different from the P + V group, while ** 
indicates a significant difference when comparing the P + R to the S + R group. 
 
3.1.2.  Apomorphine-induced rotation test 
Rats with unilateral DA depletion show motor asymmetries characterized by a spontaneous 
ipsiversive bias, and the induction of a contraversive bias when treated with the DA agonist 
apomorphine that acts on postsynaptic D1 and D2 receptors, and are upregulated on the 
lesioned striatal side (Ungerstedt, 1971). Apomorhine’s effect was obtained by analysing the 
summed difference between ipsilateral and contralateral half-turns (180°), providing a single 
independent variable, or “net rotation asymmetry score”. The four groups of animals were 
classified according to the 2 dependent variables: statin vs. placebo, and rotenone vs. vehicle-
infusion. Drug-treatment (statin vs. placebo), and infusion (vehicle vs. rotenone) were regarded 
as the main effects and drug-treatment*infusion as the interaction effect. The data were 
analyzed by means of a two-way ANOVA. This revealed significance for drug-treatment 
(placebo vs. statin) (F(1, 44)= 4.5103, p = 0.04) and unihemispheric infusion (vehicle vs. rotenone) 
(F(1, 4)= 206.04, p < 0.01). Subsequent post hoc analysis employing a Neuman-Keuls test 
revealed a significant difference (p = 0.04) between the rats that had received placebo only 
(22.67±1.96) and those treated with statins (16.79±1.96). A statistical significant interaction 
effect (F(1, 44)= 4.13, p = 0.048) was detected, but a non-significant difference was obtained 
between statin vs. placebo-treated rats (p = 0.99), with all animals receiving a vehicle injection. 
For the rotenone-infused rats, significant interaction was found between statin vs. placebo-
treatment (p = 0.03), implying that the significant main effect for drug-treatment resulted from 
the rotenone infusion, and not from the vehicle-infusion. No rotation bias was detected in the P 
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+ V, or in the S + V group. Fig. 5 portrays the total net number of rotations recorded for the 
entire 60 min duration of the trial. 
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Fig.   5.     Apomorphine-induced rotation response bias in rats infused with rotenone (3 μg in 4 μl 
DMSO:PEG or vehicle (DMSO), targeting the SNpc unilaterally.  Fourteen days following surgery, the 
rats were subcutaneously injected with 0.75mg/kg apomorphine. All animals that received rotenone 
predominantly displayed ipsilateral rotations. Controls (placebo treated followed by a unilateral vehicle 
infusion) displayed no bias in rotation. The ‘net rotation asymmetry score’ was calculated by subtracting 
the number of half-turns (180°) made towards the contralateral (unlesioned) side from the number of half-
turns towards the ipsilateral (unlesioned) side. The net ipsilateral rotations are represented as mean ± 
S.E.M. (n = 12). **p ≤ 0.05 significantly different to control (P + V) animals. *p ≤ 0.05 significantly different 
from statin-treated, lesioned (S + R) group. 
  
3.2.  Proteomics results 
3.2.1.  2-D image analysis of SN mitochondrial proteins 
Figure 6 shows the 2-D images of proteins in SN tissues of normal control and statin-treated 
rats, together with the molecular weights of the respective protein spots. Altogether, image 
analysis detected 23 protein spots, with the same parameters applying for each image.  
 
3.2.2. ESI-QUAD-TOF Mass Spectometry identification of mitochondrial proteins 
As the SN from a single animal does not yield adequate amounts of protein for reliable 
quantitative proteomic analysis, SN tissue from 12 rats treated with statins and 12 rats treated 
with placebo was pooled together. Table 1 shows the proteins that displayed significant 
changes in relative abundance between controls and rats treated with statins. Twenty-four 
proteins were found to be differentially expressed 15 of which were upregulated and 9 
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downregulated. In addition, Fig. 6 shows the difference in terms of spots between the P+V (Fig. 
6A) and the S+V (Fig. 6B) groups. Subsequently to identification, all the proteins that showed 
statistical significant differences in terms of relative abundance, were classified in one of 6 
broad categories describing mitochondrial-protein function (Fig 8).  
 
 
 
 
 
 
 
 
Fig.   6.     2-DE images of SN mitochondrial proteins in control (A) animals, treated with placebo 
for 14 days, and statin-treated rats (B), and stereotaxically infused with a vehicle. Proteomics 
were performed on mitochondria collected from the SN of the right lesioned hemisphere. The proteins 
were extracted and separated on an immobilized pH 4-10 gradient strip, followed by separation on a 
12% polyacrylamide gel with SDS-PAGE and Coomassie Brilliant Blue staining. Spots found to be 
differently expressed to a statistically significant degree (p < 0.05) have been annotated. These sports 
were excised for the purpose of identification using Mass Spectometry.  
 
Table 1.     Relative changes in mitochondria-enriched proteins identified by Mass Spectrometry. 
The data represents the differentially expressed proteins when comparing placebo-controls with statin-
treated animals. Only those proteins whose concentration changed to a significant extent (p < 0.05, 
student’s unpaired Student’s t-test), as determined by PDQuest and MASCOT are reported here. An SSP 
number was automatically assigned to each sample by the PDQuest software.   
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Spot  
no. SSP 
Mr  
(Da) Protein name 
Swiss-Prot  
accession  
number 
 
Amount  
of  
peptides 
Seq.  
coverage 
(%) 
Fold  
change 
     1 0701  61335 Neurofilament light subunit (NF-L) IPI00231302        4    6.6  2.91 
     2 2401  47141 Gamma-enolase IPI00326412.4        5    12.7  1.12 ↓ 
     3 2102  27378 NADH dehydrogenase (ubiquinone)  flavoprotein 2 IPI00367152.1        3    12.9  1.08 
     4 3101  20801 Phosphatidylethanolamine-binding  protein 1 (PEBP1) IPI00230937.5        3    25.1  1.82 ↓ 
     5 2103  24822 Ubiquitin carboxylase IPI00204375.2        4    19.7  1.16 ↓ 
     6 3502  60955 HSP-60 IPI00339148.2       11    21.1  1.42 
     7 3602  56257| Alpha-internexin IPI00211936.2       10    21.9  1.18 
     8 3402  52849 Cytochrome b-c1 complex subunit 1 IPI00471577.1        6    8.5  1.37 ↓ 
     9 4202  38982 Pyruvate dehydrogenase E1 component subunit beta IPI00194324.2        6    16.4  1.15 
    10 4203  37 Guanine nucleotide-binding protein  G(I)/G(S)/G(T) subunit beta-2 IPI00212658.4        5 17.3 1.36 
    11 6101  18763 ATP synthase D chain IPI00230838.5        2    15.5  1.18 
    12 3801  79412 NADH-ubiquinone oxireductase 75 kDa subunit IPI00358033.1        4    7.0  3.07 
    13 4401  49490 Isoform 2 of Glial Fibrillary Acidic protein IPI00210211.3        8    20.6  1.82 ↓ 
    14 5201  39614 Isocitrate dehydrogenase (NAD(+)) IPI00198720.1        6   16.4  1.38 
    15 5202  39614 Isocitrate dehydrogenase [NAD] subunit alpha IPI00198720.1        6   16.4  1.69 ↓ 
    16 6403  47116 Alpha Enolase-1 IPI00768951.1        4   9.7  1.38 
    17 6601  73161 Dihydropyrimidinase-related protein 2 IPI00192034.2        4   6.1  1.26 
    18 6201  36483 Dehydrogenase antiporter  IPI00198717.8        3   9.3  1.22 ↓ 
    19 8201  35783 Glyceraldehyde-3-phosphate  dehydrogenase (GAPDH) IPI00554039.1        7   21.0  2 ↓ 
    20 8301  43026 NAD-dependent deacetylase sirtuin-2 IPI00562798.1        3   9.0  1.47 ↓ 
    21 8503  61416 Glutamate dehydrogenase 1 IPI00324633.2        4   7.0  4.93 
    22 5601  108802 PTPRF interacting protein IPI00366315.3        1   2.4  1.3 
    23 9801  85433 Aconitate hydratase IPI00421539.3        8   12.1  3.29 
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Fig.   7.     Bar graphs representing the total number of proteins detected by Mass Spectrometry 
analysis. Those that underwent a statistically significant changeare given in white, whie the proteins that 
increased are represented by the grey bar, while those that decreased are shown in black. 
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Fig.   8.     The pie chart provides a functional classification of the proteins detected and 
represents them in proportion to each other. The identified proteins were assigned to one of six 
different categories, according to major functional entities of mitochondrial proteins.  The figure shows 
that the majority (>50%) of the functionally annotated proteins are associated with energy production. 
Where it was possible to functionally assign a protein to more than one class, it was annotated according 
to its best-known function. 
 
 
4.  DISCUSSION 
The results from both behavioral tests that were employed, the vibrissae-evoked forelimb 
placing test and the apomorphine-induced rotation test, show that at least a partially protective 
effect is exerted by the statins against the damaging effects manifesting as impaired motor 
function. In order to investigate what possible molecular mechanisms may underly this 
phenomenon, measured at the whole-animal physiology level, sensitive biochemical screens 
were used to assess for protein-regulated changes occurring at the subcellular level, the 
mitochondria. A high-concentration subcellulr fractionation consisting of mitochondria was 
therefore prepared, since rotenone exerts its toxic effects by targeting the mitochondrial 
electron transport chain, and since statins have reportedly shown selective effects on 
mitochondria.  
 For the current study, powerful proteomics techniques were applied to investigate the effects 
of a lipophilic statin on brain mitochondria. In addition, a behavioral profile was gathered of the 
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effects these drugs have in the context of the rotenone model of PD. Whereas proteomics 
revealed the presence of specific protein targets of statin-induced alterations in the brain, the 
behavioral results indicate that the drug may protect against the mitochondrial protein oxidation 
associate with rotenone. The proteomics results will be discussed in the context of the rat’s 
performance in the series of behavioral tests.  
 A total of 23 proteins were identified by Mass Spectrometry analysis, the majority of which 
were expected to be mitochondria-related. Mitochondria play a fundamental role in regulating 
cellular physiology. In respiring mammalian cells, they are responsible for 90% of all ATP 
production, and contain the fundamental steps necessary for heme biosynthesis, ketone body 
production, and hormone synthesis (Stryer, 1988). Moreover, the oxidative phosphorylation 
machinery as well as the enzymes necessary for free fatty acid metabolism and those involved 
in the Kreb's cycle are located within the mitochondria (Mootha et al., 2003). Given the above, it 
is not surprising that when they experience mechanistic failures this may contribute significantly 
to a range of complex pathological conditions in humans, including diabetes, obesity, cancer, 
aging, neurodegeneration, and cardiomyopathy (Wallace, 1999).  
 
4.1.  Functional categorization of identified proteins 
The mitochondrial genome (mtDNA) encodes for 13 polypeptides, two ribosomal RNAs (rRNAs) 
and 22 transfer RNAs (tRNAs) (Fernéndez-Silva et al., 2003). Although the exact number of 
mammalian mitochondrial proteins remain unknown, proteomic and genetic approaches 
propose the inventory of mammalian mitochondrial proteins to be at approximately 1200 
(Andersson et al., 1998; Kumar et al., 2002; Lopez et al. 2000; Rabilloud et al. 1998). Of these, 
the functional role of 600–700 have been defined (Da Cruz et al., 2003; Lopez et al., 2000; 
Ozawa et al., 2003; Taylor et al., 2003; Westermann & Neupert, 2003), while the remaining 
ones are of unknown function. 
 In the present study, 23 proteins were identified that had undergone a modification in their 
expression levels. Most of the proteins identified through MassSpect listed in Table 1 are 
mitochondria related in localization and function, with a well-balanced representation of both 
soluble (matrix and intermembrane) and membrane-bound mitochondrial proteins. See Fig. 7 
for a bar-chart display of the total number of proteins detected that had undergone significant 
changes, as well as the amount of these that were upregulated and those that showed 
significant downregulation. Moreover, Fig. 8 provides a pie chart of the functional breakdown of 
the 23 proteins identified. The listed proteins include components of the tricarboxylic acid cycle; 
proteins of the METC (complexes I–IV) and subunits of ATP synthase (complex V); components 
of the mitochondrial transcription and translation machinery, mitochondrial carrier proteins; 
chaperones (HSP-60), enzymes involved in lipid, amino acid and coenzyme metabolism, as 
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well as iron–sulfur cluster formation. The identified proteins will be discussed now in terms of 
their location in key mitochondrial pathways and the functional role each fulfill.  
 
4.1.4.           Protein folding, binding and degradation 
The study found that protein disulphide isomerase was significantly (p < 0.05) downregulated 
(a 1.315 fold increase) compared to the placebo-treated rats. This microsomal enzyme is 
involved in folding newly synthesized proteins that belong to the thioredoxin family (Freedman 
et al., 1994; Gilbert, 1997) that is reduced by both thioredoxin reductase and thioredoxin. 
Protein disulphide isomerase was recently isolated from rat liver mitochondria (Rigobello et al., 
2000), and its distribution in the submitochondrial compartments was localized to the outer 
membrane (Rigobello et al., 2001). The enzyme may play a critical role in the regulating 
mitochondrial redox functions and potentially co-operate with thioredoxin reductase in 
maintaining thiol homeostasis. Whereas thioredoxin reductase essentially exerts a reducing 
action, mitochondrial protein disulphide isomerase is thought to deliver the oxidizing counterpart 
of the equation. Although the major site of PDI localization is in the ER lumen, it has also been 
shown to localize to locate to the plasma membrane surface of a range of cell types. 
Observations of the presence of PDI have been made in platelets (Essex et al., 1995), B 
lymphocytes (Kroning et al., 1994), pancreatic cells (Akagi et al., 1988), hepatocytes (Terada et 
al., 1995) and thyroid cells (Couët et al., 1996). Although the presence of all of these are 
believed to be involved in transport regulation, as well as being up-regulated in response to ER 
stress, such as is induced by hypoxic or hypoglycemic conditions (Nomura, 2004), was 
suggested to contribute to the assemblage and functioning of enzyme systems endowed with a 
range of functions. These include pore-forming proteins, receptors devoted to protein import 
and to play a part in the systems that regulate mitochondrial-dependent apoptosis (Rigobello et 
al., 2001).  
 It has previously been suggested that the neuroprotective effects seen in diseases such as 
AD, multiple sclerosis, and certain variants of retinal and other eye diseases, may involve 
mechanisms that express heat shock proteins (HSPs) (Schmeer et al., 2006). The increased 
expression of these molecular chaperones encompass what is often referred to as the heat 
shock response. Recent findings suggest that unfolded or misfolded proteins participate in the 
neuropathology that underlie PD (Kitamura & Nomura, 2003). Of these, the expression and 
transcription of HSPs in the CNS are greatly modified by disease or injury (Chopp, 1993). 
Chaperone-like HSPs promote cell survival and suppresses apoptotic cellular events due to 
noxious stimuli, including heat, DNA damage and death receptor ligation (Klettner, 2004). The 
mechanism proposed to account for these relate to suppressing both the ‘intrinsic’ pathway, that 
is mitochondria-dependent, as well as to the ‘extrinsic’ apoptotic death-receptor mediated one 
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(Schmeer et al., 2006). Various neuroprotective agents show the ability to induce the heat 
shock response, particularly the expression of Hsp70 and Hsp72. When this mechanism is 
evoked in the brain, a decrease in the infarcted area due to ischemia, as well as a protection of 
neuronal and non-neuronal cells have been observed (Klettner & Herdegen, 2003; Klettner, 
2004). This observation has spurred the hope that the induction of HSPs may provide a 
possible treatment strategy against various neurological disorders. For example, pretreatment 
with heat shock induces Hsp72 to overexpress in the striatum and offers protection against 
heatstroke-induced striatal injury due to the ability to reduce oxidative stress and prevent 
energy depletion (Wang et al., 2005b). Mass spectrometry analysis revealed a 1.31 increase in 
the degree of expression of HSP-60, located in the mitochondrial matrix, when compared to the 
placebo treated controls. This nucleus-encoded mitochondrial-resident protein (Ostermann et 
al., 1989) is a homologue of the bacterial chaperone GroEL (Cheng et al., 1989) and plays a 
critical role in mitochondrial protein assembly and folding (Okubo et al., 2000). Since the 
protective effects of HSP overexpression against several kinds of insults have been confirmed 
under various stress conditions (Okubo et al., 2000; Lau et al., 1997), the current findings 
suggest a statin-induced protection that may involve the heat shock protein chaperons.  
 Ubiquitin carboxylase expression levels were significantly upregulated (p < 0.05, 1.162) 
following statin treatment. This protein is believed to play a key role in degrading abnormal 
intracellular proteins present in eukaryotic cells (Manetto et al., 1988; Rechsteiner et al., 1987; 
Hershko & Ciechanover, 1986; Ciechanover et al., 1985). It forms part of the ubiquitin-
proteasome system that is responsible for degrading abnormal, mutant or damaged proteins 
(Sherman & Goldberg, 2001). Empirical evidence is accumulating to suggest that when the 
UPS fails to degrade oxidated, nitrated or mutant proteins, LB aggregation may be provoked, 
with subsequent degeneration of DA neurons in the SNc (McNaught et al., 2001). Suppressed 
proteasomal activity in dopaminergic and cortical neurons results in cell death and generates 
proteinacous inclusion bodies that stain positive for α-synuclein and ubiquitin (Rideout et al., 
2001; 2003; 2004; McNaught et al., 2002a). These preliminary findings were substantiated by 
PD post-mortem studies indicating reduced proteasomal activity (McNaught et al., 2002b) and 
the selective loss of the 20S proteasome α-subunit within the SNc (McNaught et al., 2001).The 
contribution of this enzyme in relation to statin-treatment should be pursued in further studies. 
 
4.1.5.           Transport 
Mass spectrometry analysis identified a significant downregulation (p < 0.05, 1.219) of 
dehydrogenase antiporter, annotated as a mitochondrial carrier protein. Members of the 
mitochondrial transport family facilitate the continuous exchange of solutes by performing key 
steps during energy-generating pathways that exist across the inner mitochondrial membrane. 
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The diversity of these carrier proteins may reflect the metabolic capacity and diversity of 
mitochondria (Kunji, 2004). They are not only involved in the citric acid cycle and fatty acid β-
oxidation (Fiermonte et al., 1999; Iacobazzi et al., 1996; Iacobazzi et al., 1992), but also in the 
synthesis and degradation of amino acids (urea cycle) and for synthesising iron–sulphur 
clusters and haem. Moreover, they generate heat when protons re-enter the matrix and abolish 
the electrochemical proton gradient (Nicholls & Locke, 1984). They also play a role in 
mitochondrial DNA replication, as well as in transcribing and translating mitochondrial mRNA 
(Cho et al., 1998). The proteomics results showed that mitochondrial dicarboxylate 
underexpressed compared to the control samples. This carrier protein is involved in exchanging 
malate, an intermediate of the citric acid cycle with the cytosol (Iacobazzi et al., 1992). It is also 
indirectly involved in transporting glutamate into the mitochondrial matrix, since both the 
aspartate/glutamate exchanger and the oxoglutarate/malate carrier form part of the malate–
aspartate shuttle to remove reducing amounts of glutamate from the cytosol through a series of 
conversions and transport steps (Palmieri et al., 2001; Iacobazzi et al., 1992). 
 
 
 
4.1.3.           Morphology 
Phosphatidylethanolamine-binding protein 1 is a basic protein that that is well  represented 
in mitochondria. This protein displays a preferential affinity for phosphatidylethanolamine, a 
component of the cell membrane in vitro (Frayne et al., 2004). It widely expresses in both 
neuronal as well as non-neuronal tissue, including a particularly high expression found in liver 
and testis (Perry et al., 1994).. Although primarily classified as a cytosolic protein, its N- and C-
terminal ends allow it to bind to cellular and model membranes, while a cavity localised to the 
protein surface attaches phosphatidylethanolamine with high affinity (Vallee et al., 2001). 
Additionally, this cavity site can also bind other phospholipids of a lower affinity range or opioids 
(Jones & Hall, 1991).  When expressed in the brain, a specific N-terminal fragment of 
phosphatidylethanolamine-binding protein 1 known as the “hippocampal cholinergic stimulating 
peptide” is likely to fulfil a role in neuroendocrinology and as a transmitter (Goumon et al., 
2004). Decreased expression levels of phosphatidylethanolamine-binding protein 1 have also 
been found in animal models that mimic other human neurological conditions, including AD 
(George et al., 2006) and trisomy 21 (Kazuki et al., 2004).  
 With regards to normal mitochondrial function, phosphatidylethanolamine is a specific 
requirement for reconstituting ubiquinone-cytochrome c oxidoreductase (complex III) of the 
mitochondrial electron transport chain (Nelson & Fleischer, 1981). The presence of this 
unsaturated lipid is critical in protecting the structure and function of cytochrome c.  The 
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reduced levels observed in our statin treated group may indicate that this protective mechanism 
may have been compromised by statin therapy. Furthermore, a role has been assigned to 
phosphatidylethanolamine in α-synucleinopathies, involving the presence of missense 
mutations (A53T and A30P) in SNCA detected in several families diagnosed with early onset 
familial PD (Polymeropoulos et al., 1997; Kruger et al., 1998). Previous studies suggest that 
SNCA fulfils a key role in regulating brain lipid metabolism, particularly in lipid binding and their 
extracellular transport (Epand, 1993; Cole et al., 2002). A strong binding interaction between 
phosphatidylethanolamine and α-synuclein had been reported (Jo et al., 2000). If the binding of 
SNCA to phospholipids should be compromised, possibly due to a decreased expression of 
phosphatidylethanolamine, this could result in increased cytosolic concentration of SNCA, 
leading to fibril formation, which has been shown to have toxic effects on neurons (El Agnaf et 
al., 1998). Interestingly, the presence of one of the PD-linked point mutations (A30P) eliminated 
the ability of SNCA to bind to the lipid vesicles (Jensen et al., 1998), suggesting that SNCA’s 
function to bind to lipids is only intact in the absence of a deranged neurological state, and may 
be adversely affected during PD. Although the precise functional involvement of SNCA in PD 
largely speculative, the overall consensus is that it fulfills a protective role (George et al., 1995).  
 Neurofilament, light polypeptide (NF-L) was found to express 2.91 times greater in the 
statin-treated rats compared to the placebo-treated controls. This 68kDa semi-flexible polymer 
forms the main structural component of axons with its principle role being to maintain axonal 
integrity neuronal size and shape (Lasek, 1988; Fabrizi et al., 2007). Recent evidence suggests 
that it may also serve an important function in regulating certain intracellular depositions 
and to protect against oxidative stress in the peripheral nervous system (Shea et al., 2004). It 
has furthermore been deemed to be an important marker for neuronal degeneration (Karlson et 
al., 1991). The protein is transported to the axons from the cell body where it has been 
synthesized, and is expressed specifically in large myelinated axons (Stankovic & Li, 2006). 
Numerous human diseases are characterized by defects in intermediate filament structure. A 
notable example includes recent work reporting a set of mutations in the gene that encodes for 
the light subunit of the neurofilament polypeptide in patients diagnosed with either the axonal 
(CMT1) or the demyelinating form (CMT2) of Charcot-Marie-Tooth disease, a neurological 
disorder characterised by a reduction in nerve conduction velocity. Animal studies support these 
claims, with mice null for NFL revealing viability, but displaying a 15–20% reduction in the 
number of myelinated axons, decreased axonal diameters and impaired nerve regeneration 
(Zhu et al., 1997). The general consensus is that underlying these conditions, a single amino 
acid component of the neurofilament light subunit is replaced by a mutated building block. 
Alternatively, sections of the N-FL gene may also be deleted or undergo duplication, thereby 
altering the genetic code for neurofilament light subunit synthesis. Either way, mutations of this 
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sort may alter the size, shape or assembly of NF-L subunits, ultimately affecting their transport 
towards the axonal endings. Neurofilament alterations have also been identified in PD 
(Trojanowski & Lee, 1998), as was suggested by recent data that neurofilament proteins, in 
addition to the 140-amino acid SNCA, form major constituents of Lewy bodies 
(Goldman et al., 1983). Studies that have used transgenic mice that lack the intermediate 
filament (IF) desmin (Milner et al., 2000) implicate that it plays an important role in positioning 
mitochondria at particular locations within the cell, within regions where the local energy 
requirements are relatively higher. Electron microscopic ultrastructural studies have further 
confirmed a mitochondria-NF interconnection revealing cross-bridges between mitochondria 
and NFs (Hirokawa, 1982). It was shown that the aggregation of LFs on the mitochondrial 
surface is mediated by the NF-H and the NF-M side-chains (Wagner et al., 2003). In addition, 
axonal mitochondria spend considerable time being immobile, undergoing elastic recoil. 
However, when traveling in a retrograde direction, they maintain consistent interconnections 
with neurofilaments (Martz et al., 1984; Forman et al., 1987; Morris & Hollenbeck, 1996; Ligon & 
Steward, 2000). Furthermore, it was shown that mitochondria localize and immobilize not only 
due to the metabolic status of mitochondria, as revealed by their ATP/ADP ratio (Overly et al., 
1996), but Wagner et al. (2003) showed that mitochondrial spatial position is also directly 
regulated by the phosphorylation level of NFs. 
 Alpha-internexin (NF66) is a 66 kDa neuronal intermediate filament protein that belongs to 
the class IV intermediate filament proteins. It expresses primarily in the CNS axons, with 
embryonic neurons containing a higher proportion of α-internexin than what is found in the 
mature nervous system (Kaplan et al., 1990). Other members of this class include the 
neurofilament triplet proteins, namely NF-L, NF-M, and NF-H (Ching & Liem, 1991). In this 
study, the protein expressed significantly more than in the control brains. While it was originally 
named α-internexin for its ability to bind intermediate filaments (Pachter & Liem, 1985), it also 
expresses heavily in neurons undergoing differentiation and maturation, suggestive of a critical 
role played in regulating neurite outgrowth (Chiu et al., 1989; Kaplan et al., 1990; Fliegner et al., 
1994). Moreover, it was shown to regulate the expression of other neurofilaments during 
neuronal development (Chien et al., 2005), yet α-internexin-null mice exhibited normal 
development (Levavasseur et al., 1999). Whereas it had been shown that deregulation of 
intermediate filament protein synthesis, defective axonal transport mechanisms, abnormal 
phosphorylation and proteolysis can lead to intermediate filament protein aggregation (Julien, 
1999). Apoptosis-like cell death was observed following the overexpression of α-internexin in a 
rat adrenal pheochrompcytoma cell line with morphological changes occurring in the 
mitochondria, suggesting that an overaccumulation of the α-internexin gene product may play a 
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part in indirectly impairing mitochondrial function and subsequently inducing cell death (Chien et 
al., 2005). However, these cells belong to the peripheral NS and the relevance of these findings 
to the current study therefore remains to be determined.  
 Protein-tyrosine, receptor type, f, polypeptide interacting proteins is a member of the LAR 
protein-tyrosine phosphatase-transmembrane protein (liprin) superfamily that plays a critical 
role in a number of cellular processes. Liprins interact with members of the LAR family of 
transmembrane proteins, the tyrosine phosphatases that are important for axonal guidance 
(Burden-Gulley et al., 2002; Ensslen & Brady-Kalnay, 2004; Ensslen-Craig et al., 2005) ad is 
suspected of regulating the signals required to allow neurites to extend on an N-cadherin 
substrate (Burden-Gulley & Brady-Kalnay, 1999), and may also form complex structures and 
act as scaffolds for recruiting and anchoring the LAR family of tyrosine phosphatases (Schoch 
et al., 2002). In the present, study, a 1.3. fold-increase in the expression of this protein was 
observed.  
 The dihydropyrimidinase related protein 2 (DRP-2), also known as collapsin response 
mediator protein 2 (CRMP-2) is a 64 kD protein (TOAD-64) intracellular protein involved in 
neuronal differentiation, axonal outgrowth and guidance (Quinn et al., 1999). The level of this 
protein was significantly increased level when statin treated animals were compared to the 
controls, suggesting an improved natural neuroprotective mechanism of neuronal networks as a 
result of statin treatment. This member of the CRMP/TOAD/Ulip/DRP family (CRMP-1-5) of 
cytosolic phosphoproteins, abundantly expresses in both the developing and adult brain 
(Veyrac et al., 2005). Apart from its assigned role in neurogenesis, it may also be involved in 
promoting microtubule formation by binding to tubulin heterodimers (Fukata et al., 2002). Since 
DRP-2 was shown to be decreased in a number of brain pathologies, including traumatic brain 
injury (Kobeissy et al., 2006), Down's syndrome (Weitzdoerfer et al., 2001; Lubec et al., 1999) 
and AD patients (Castegna et al., 2002), it has been suggested that DRP-2 loss translates into 
an inability of neurons to correct impaired synaptogenesis and differentiation. However, since a 
significantly increased expression level for DRP-2 has also been reported to be consequential 
to normal ageing (Poon et al., 2006a), the possibility that neuronal sprouting is a regulated 
compensatory response to aged-induced neuronal dysfunction, should not be eliminated. The 
extent of involvement of this protein in neurogenic and plastic mechanisms, as was indicated by 
the current results, should be explored in future studies.  
 Glial fibrillary acidic protein (GFAP), a 50 kDa protein that forms the major constituent of 
glial filaments makes up the cytoskeleton of mature astrocytes (Eng et al., 2000). The protein is 
thought to be important in modulating astrocyte motility and shape by providing structural 
stability to astrocytic processes. Mice lacking GFAP are hypersensitive to cervical spinal cord 
injury caused by sudden head acceleration. This finding has provided direct evidence for 
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GFAP’s structural role (Nawashiro et al., 1998). An increase in GFAP synthesis has been 
associated with astrogliosis, with immunohistochemical studies revealing a rapid over-synthesis 
of GFAP content in astroglia in the brains of AD patients (Mancardi et al., 1983). In addition, it 
has been proposed as a sensitive and early biomarker of neurotoxicity, since increased GFAP 
mRNA levels were detected in the substantia nigra of 6-hydroxydopamine lesioned rats 
(Rodrigues et al., 2004). GFAP mutations associate with Alexander disease, a rare 
neurodegenerative disorder characterized by white-matter degeneration, and the formation of 
cytoplasmic inclusions called Rosenthal fibers detected in the astrocytes (Alexander, 1949). 
Mitochondrial abnormalities have been implicated as a contributing cause for the disease 
(Gingold et al., 1999; Schuelke et al., 1999; Nobuhara et al., 2004). In the current study, GFAP 
was downregulated 1.818-fold compared to the control animals, possibly indicating an activation 
of protective mechanisms due to statin-treatment.  
 
4.1.4.  Energy metabolism 
Gamma-enolase, with its γγ isoform known as neuronal-specific enolase (NSE), is a neuron-
specific subunit of the glycolytic enzyme enolase. Significant difference in its relative abundance 
was shown being down-regulated as a result of statin-treatment. It has previously been 
suggested that an up-regulation in the expression of NSE marks a mobilization of cellular 
defence mechanisms in the damaged striatum (Valastro et al., 2007), with increased NSE levels 
detected in the CSF of patients suffering from Kreitzfeld-Jakob disease and victims of 
cerebrovascular accidents and cerebral trauma (Dauberschmidt et al., 1983; Hay et al., 1984; 
Wakayama et al., 1987; Jimi et al., 1992). In line with the neuroprotective and neurorestorative 
functions, as well as its ability to promote neuronal survival assigned to NSE (Hattori et al., 
1995), an increased expression was found in the striata of L-Dopa-induced dyskinetic rats 
compared to non-functionally impaired ones (Valastro et al., 2007).  
 The variation in ATP synthase D chain between control and PD-like animals reported here 
(this protein was significantly upregulated at 3.07-fold compared to the control rats) is consistent 
with others who reported similar results derived from human PD patients (Basso et al., 2004). 
The expression levels of 9 proteins were reduced, including α-enolase (ENO1), a glycolytic 
enzymatic protein, that has an evident N-terminal extension and exhibits characteristics of a 
typical mitochondrial targeting peptide. α-enolase is proposedly affected in age-related 
neurodegenerative diseases, including in PD and Alzheimer disease cases (Poon et al., 2006b).  
Glutamate dehydrogenase (GDH) is an important branch-point enzyme localised to the 
mitochondria that plays an important role in carbon and nitrogen metabolism (Stillman et al., 
1993). The current study found this protein significantly upregulated (4.93 fold), compared to the 
controls. 
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 Aconitate hydratase (aconitase) was found to be significantly upregulated (p < 0.05, 3.29 
fold) as a result of statin therapy. The enzyme is located in two subcellular compartments, 
cytosolic aconitase and aconitase that is mitochondrial-matrix bound, and has been implicated 
in the Krebs cycle (Pickworth Glusker, 1971). The majority of eukaryotic cells contain two types 
of aconitase. This enzyme participates in the citric acid, and is responsible for reversibly 
hydrating the labile, enzyme-bound intermediate cis-aconitate yielding citrate and isocitrate. In 
the current study, isocitrate dehydrogenase (NAD(+))was also found to be significantly 
upregulated in response to statin-treatment.  
 In this study, a 3.07 fold increase in the expression of NADH:ubiquinone oxireductase was 
found, a 75 kDA subunit of the inner mitochondrial membrane (Galante & Hatefi, 1979). This 
protein complex plays a critical role in regulating energy metabolism, by catalyzing the transport 
of electrons from NADH to ubiquinone for ATP synthesis, in addition to proton translocation from 
the mitochondrial matrix to the intermembrane space (Smeitink et al., 1998; Hatefi, 1985). 
Several reports suggest that mitochondrial enzyme deficiencies can contribute to the 
progressive pathology of several neurodegenerative diseases, including PD where a significant 
and selective reduction of complex I activity has been identified in key brain regions associated 
with PD (Schapira et al., 1990; Mizuno et al., 1989). Other studies also report a strong 
correlation between decreased complex I activity and reduced levels of mitochondrial 
ubiquinone (CoQ10) in the PD brain (Shults et al., 1997; Gotz et al., 2000).  
 The current study revealed glyceraldehyde-3-phosphate dehydrogenase, an essential 
glycolytic enzyme for catalyzing reversible oxidative phosphorylation of glyceraldehyde-3-
phosphate, to be upregulated (2 fold) in response to statin treatment. This important energy-
yielding step in carbohydrate metabolism, depends on the presence of inorganic phosphate and 
nicotinamide adenine dinucleotide (NAD). Recent evidence suggests that it may be 
multifunctional, independent of its role in carbohydrate metabolism. Possible activities include 
phosphorylating transverse-tubule proteins (Kawamoto et al., 1986), stimulating RNA 
transcription (Morgenegg et al., 1986), interacting with microtubules (Huitorel & Pantaloni, 
1985), influencing RNA catalysis by binding to hammerhead ribozyme (Sioud & Jesperson, 
1996) and acting as a diadenosine tetraphosphate binding protein to influence DNA replication 
and DNA repair (Baxi & Vishwanatha, 1995). This protein also acts as a ‘markers protein’ that is 
particularly vulnerable to damage caused by excessive ROS production (Cabiscol et al., 2000). 
A similarly vulnerable one is pyruvate dehydrogenase, which the current study also found to 
be significantly upregulated at the protein level, suggesting decreased ROS production.  
 A slightly significant expression is reported here for Sirt2, an nicotinamide adenine 
dinucleotide (NAD)-dependent deacetylase belonging to the sirtuin family that deacetylates the 
'Lys-40' of alpha-tubulin as well as histones in vitro (North et al., 2003). It shows involvement in 
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controlling mitotic exit during the cell cycle, probably due to its role in cytoskeleton regulation 
(Inoue et al., 2007). Sirtuins have been implicated in a broad range of biological processes, 
including stress resistance and glucose homeostasis, while sirtuin deacetylase activity also 
associates with pathways that oppose age-associated diseases, such as type II diabetes, 
obesity, and neurodegenerative disorders (Haigis & Guarente, 2006;). In addition, Sir2 mediates 
lifespan extension through a caloric restriction pathway, thereby extending lifespan in species 
ranging from yeast to flies (Lin et al., 2000; Rogina & Helfand, 2004) while its overexpression 
was also shown to lower cellular ROS levels (Wang et al., 2007).  
 The mitochondrial precursor cytochrome b-c1 complex subunit 1 expressed 1.369 times 
less than in the control rats. This enzyme, of the cytochrome (cyt) bc1 mitochondrial complex 
family form a component of complex I of the METC, catalyzing the transfer of electrons from a 
quinol in the lipid phase (ubihydroquinone in the classical bc1 complexes) to a higher-potential 
acceptor protein in the aqueous phase. The complex plays a central part in cellular energy 
metabolism and has been implicated in a diverse range of mitochondrial myopathies located to 
mutations in genes encoding for the proteins of the bc1 complex (Fisher & Meunier, 2001; 2002; 
Rose, 1998; Vogel, 2001). Although a decreased expression was found for this complex in the 
statin-treated rats, no compromise in motor-function was observed, and therefore any adverse 
effect that the drug might have had at this level did not impinge on physiological function. 
Although the results caution that statins might be implicated in complex I related pathology, this 
matter deserves further attention before a risk for this can be confirmed.  
 MassSpect identified the mitochondrial, tetrameric enzyme isocitrate dehydrogenase as 
expressing 1.69-fold less in the statin-treated than in the control animals. In particular, where 
this enzyme consists of three subunit types (Ramachandran & Colman, 1980), the alpha 
subunit was identified in the current experiment. As a group of enzymes, they are responsible 
for catalyzing the conversion of threo-D-isocitrate to -ketoglutarate in the presence of the 
mitochondrial enzyme NAD (Haselback & McAlister-Henn, 1993). This enzyme catalyzes the 
oxidative decarboxylation reaction that consists of converting isocitrate to -ketoglutarate and 
CO2, by reducing NAD to NADH. In turn, NADH forms the energy storage compound ATP 
(Bzymek & Colman, 2007). The downturn in its expression could possibly be explained by the 
fact that the enzyme is under strict cellular control, being activated by ADP and inhibited by the 
ultimate products of the reaction, namely NADH and ATP. Therefore, when the cell does not 
require additional energy, the enzyme is inhibited by ATP thereby decreasing the rate of 
oxidation of isocitrate. On the other hand, when the cell requires energy, the conversion of 
isocitrate to -ketoglutarate is promoted through the activation of ADP. 
 
4.1.5.  Cofactors and prosphetic groups 
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As the largest of the respiratory complexes, NADH dehydrogenase, also known as ubiquinone 
acts as the input site to the mitochondrial ETC. NADH dehydrogenase uses flavin adenine 
dinucleotide (FAD) as the redox prosthetic group, from where electrons are passed from various 
dehydrogenation reactions to ubiquinone, that constitute part of the “classical” respiratory chain 
complexes. Thus, functionally speaking, it is extremely similar to complex I of the respiratory 
chain. The transferal takes place via two flavoproteins, the electron transfer flavoprotein (ETF) 
and ETF:ubiquinone oxidoreductase (ETF:QO). Ubiquinone oxidoreductase (ETF:QO) is a 
monomer located in the inner mitochondrial membrane after being imported from the cytosol, 
containing a 4Fe4S cluster as well as FAD (Simkovic et al., 2002). Flavin binding only occurs 
once the enzyme is inside the mitochondrial space, forming an NADH dehydrogenase 
(ubiquinone) flavoprotein (Nagao & Tanaka, 1992; Saijo & Tanaka, 1995; Brizio et al., 2002). 
This constitutes an essential step for catalysing flavoprotein activity, regulating their folding, 
assemblage and/or stability (Nagao &  Tanaka, 1992; Saijo & Tanaka, 1995; Sato et al., 1997; 
Muralidhara et al., 2006) and to link the oxidation of fatty acids and certain amino acids to the 
mitochondrial ETC (Zhang et al., 2006). MassSpect analysis revealed that the expression of this 
enzyme was significantly upregulated (1.08) compared to the control samples. An EFT 
dehydrogenase deficiency has been linked to the human genetic disease multiple acyl-CoA 
dehydrogenase deficiency (Vianey-Liaud et al., 1987), while multiple acyl-CoA dehydrogenation 
deficiency (MADD), a disorder thought to be due to inborn errors of metabolism of fatty acids, 
amino acids and choline may result from defects present in 2 flavoproteins. Mutations have 
been detected in the ETFDH gene of patients, coding for ETF:QO (Olsen et al., 2003), as well 
as in the electron transfer flavoprotein (ETF). The disease is marked by impaired multiple 
dehydrogenation reactions due to defective electron transfer from several primary flavoprotein 
dehydrogenase to mitochondrial respiratory chain. MADD patients were found to be responsive 
to riboflavin dietary supplement. Although the molecular defect in this particular form remains 
unknown (Gregersen et al., 1982), a recent study suggests that riboflavin-responsive MADD 
may associate with defects in the ETFDH gene also (Olsen et al., 2007). 
 
4.1.6.  Signal transduction 
The guanine nucleotide-binding proteins (G proteins) serve as modulators or transducers in 
a variety of transmembrane signaling systems, by transferring stimulatory or inhibitory signals to 
intracellular protein targets in response to activation by specific cell-surface receptors. The G 
protein family is present in all eukaryotic cells, where they control a wide range of metabolic, 
humoral, neural and developmental functions, by coupling hormones and neurotransmitters to 
their cellular response targets (Stryer & Bourne, 1986; Bourne, 1986; Gilman, 1984). G protein-
linked receptors (GPLR) is activated by a diverse groups of effector units. These range from the 
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visual G protein-linked receptor rhodopsin that detects a small numbers of photons, and are 
therefore involved in regulating retinal cyclic GMP phosphodiesterase (Ando et al., 1991; 
Chabre et al., 1993), to those found in the olfactory system for transducing olfaction-related 
signals from odorant receptors (Buck & Axel, 1991; Chess et al., 1992), as well as the operation 
of gustatory signals via GPLRs (Margolskee, 1993). Receptor-G protein forms a complex with 
the integral membrane glycoprotein adenylyl cyclase (AC), to play a fundamental role in 
regulating numerous physiological processes including hormone effects, metabolism, learning, 
and memory. In addition, a multitude of human diseases may stem from inherited or sporadic 
mutations of the genes encoding this component’s various signaling components (Raymond, 
1994). Moreover, several G protein–linked neurotransmitters inhibit N and P/Q type channels, 
which are voltage-gated Ca2+-selective channels (Hille, 1994), thereby initiating a signal 
transduction cascade where the channels open less readily upon depolarization (Bean, 1989). 
G-proteins are generally composed of 3 units, alpha, beta and gamma, with the beta and 
gamma chains that are required for GTPase activity, for replacement of GDP by GTP, and for G 
protein-effector interaction. Specific transient interactions between these components generate 
the pathways that modulate cellular responses to complex chemical signals. For example, G ß γ 
subunits activate phospholipase A2 (PLA2) (Jelsema & Axelrod, 1987), while both G ß γ (Camps 
et al., 1992; Boyer et al., 1999) and Gα (reviewed by Sternweiss, 1994) are potential activators 
of the PLCβ isozymes in vitro and in vivo. The MassSpect results identified a significant 
upregulation (1.36 fold) of a ß subunit of G proteins that is encoded for by Guanine nucleotide 
binding factor 2 (GNB2). Protein detection methods specifically identified the 35,000 Mrs 
individual variant, the other being of 36,000 Mrs (Sternweis et al., 1981; Sternweis & Robishaw, 
1984; Neer et al., 1984; Evans et al., 1987). Although the Gßγ subunit is made up of two 
polypeptides, namely Gß and Gγ, Gß is functionally regarded as a monomer since the two 
subunits cannot dissociate except by means of denaturants (Clapham & Neer, 1997). The G 
beta gamma subunit was only recently recognized as a signal transduction molecule in its own 
right, with the first evidence that G ß γ could regulate effectors itself when it was shown that the 
G ßγ subunit activates a K+-selective ion channel (IKACh) in cardiac atrial cells (Logothetis et al., 
1987). It is therefore implied that statins induced an upregulation of intra- and intercellular 
communication systems, possibly operating via G-protein coupled receptors.  
 
5. CONCLUSION 
A robust quantitative proteomic approach was used that identified >300 proteins from 
mitochondria-enriched fractions isolated from rat SN. Of these proteins, 24 showed statistical 
significant differences (p < 0.05) in terms of relative abundance expression between rats treated 
with statins and those on placebo only. 
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 The data is consistent with the hypothesis that mitochondrial dysfunction (as was 
experimentally modeled by the central infusion of rotenone) plays a key role in the pathogenesis 
of PD and that treatments targeted at mitochondria might decrease the functional decline seen 
in PD. Although rotenone’s relevance to the etiology of PD is unknown, the published data raise 
several important implications pertaining to its significance and reliability as a tool for inducing 
models of PD. Increasing evidence also suggest for the involvement of mitochondrial 
abnormalities in the etiology of neurodegenerative diseases other than PD, such as a complex I 
deficiency in the METC in the cerebral cortex and in the platelets of AD patients (Jimenez-
Jimenez et al., 1998).  
 No significant adverse effects on the CNS have been reported following long-term use of 
statins in humans (Pedersen et al., 1996), while caloric restriction has been shown to increase 
life span and heighten resistance to various age-related disorder in rodents (review in Koubova 
& Guarente, 2003). Taken together, the findings from the current study provide clues for future 
studies to further investigate the molecular basis of the protective effects of statin-treatment on 
an underlying PD pathology. A better understanding of these may assist in developing 
therapeutic strategies for effectively treating this human neurological disease. However, it is 
acknowledged that the differential expression of mitochondrial proteins demonstrated in the 
current study, may be due to another factor, unrelated to statin treatment, remaining to be 
identified. The results further emphasize the power and importance that direct MassSpect-
based analysis of mitochondria hold towards revealing drug-induced changes that occur at the 
proteome level. 
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CHAPTER 8 
 
CONCLUDING REMARKS AND RECOMMENDATIONS FOR FUTURE RESEARCH  
 
The overall purpose of my project was to develop and ascertain 2 animal models known for 
mimicking the core pathology seen in clinical PD. It is becoming increasingly clear that complex 
diseases stem from gene-environment interactions. A new field in health research, the 
developmental basis of health and disease, emphasizes the important role that the timing of 
exposure to adverse pathogens could play in developing diseases later in life. The fundamental 
tenet for this assumption stems from a multitude of animal studies that have demonstrated that 
the in utero/developmental period is a particularly sensitive window for environmental 
exposures, nutritional or chemical.  
 As an example of an environmental influence that could worsen the pathogenesis of the 
disease, the study described in chapter 5 demonstrated how exposure to a particular adverse 
factor, maternal separation (MS) that acts as a model of early adverse experiences can induce 
greater neuropathological harm and motor-related deterioration in an animal model of PD, 
compared to non-separated control animals. What remains to be established in future studies is 
whether these toxic-induced pathogenic responses result from altered gene expression or 
altered protein regulation associated with altered cell differentiation that are involved in the 
interactions between cell types and the establishment of cell lineages. In addition, a thorough 
investigation of the type and extent of the altered morphological and/or functional character of 
the tissues, organs and systems should be pursued in subsequent work. These states of altered 
potential or compromised function that result from changes in gene expression, may be due, at 
least in part, to altered imprinting, and the underlining methylation-related protein-DNA inter-
relationship associated with chromatin remodeling. These effects may occur in a time-specific 
(i.e. vulnerable window) and/or tissue-specific manner and such alterations may be irreversible. 
Therefore, a detailed analysis of the steps that led to establishing the end-result of the current 
work, namely an animal sensitized to the extent that it is more susceptible to diseases later in 
life, should be pursued. Moreover, future research should also attempt to tease apart the 
relative contribution that several factors, including genetic predisposition, stressor intensity, 
cognitive appraisal mechanisms and coping processes may offer towards influencing the 
likelihood of an individual developing a neuropathological disease. This is important since it will 
not only shed light on why the vast majority of individuals exposed to stressful life events do not 
develop a neurodegenerative disease, but also promises to elucidate on how interactive patho-
mechanisms work to play a role in inducing the onset and development of neurodegenerative 
disease, where exposure to stressful events played a conceivable part.  
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 The thesis also investigated claims that a commonly prescribed hypolipodemic drugs, 
marketed under the tradename simvastatin, may result in mitochondrial-related damage. Since 
this patho-mechanism is also implicated as an underlying cause of PD, significant clinical 
implications could be induced in patients vulnerable to mitochondrial-related disease, as PD 
patients are assumed to be. On the other hand, a group of pharmacological agents known as 
statins have been hailed for their possible therapeutic benefit to alleviate the symptomatic 
burden of patients suffering from a range of neurodegenerative conditions other than PD. In the 
case of PD, the use of statins by PD patients have been reported to increase DA output by the 
dopaminergic cells, providing additional motivation to investigate the role of the drug in the 
context of PD. Although Levodopa has been successfully applied as a valuable therapy with 
which to treat the disease, its application is limited as a form of long-lasting therapy by the onset 
of debilitating complications following long-term use. In addition, it fails to address the root of 
the disease, and contributes much towards an oversimplified and misleading conception of PD 
as a malady of the substantia nigra only, since synthetic dopamine (Levodopa) aims to replace 
the lost dopamine. Traditional animal paradigms that focuses essentially on the demise of nigral 
dopaminergic neurons, seem to fail regarding the provision of a simplistic, single mechanism 
view of the pathogenesis of PD, while it is commonly acknowledged that it has a multi-factorial 
origin, that includes mitochondrial activity dysfunction. My results show that statins provide a 
degree of protection against rotenone-induced neuronal insults. Since the neuropathological 
features evoked by this neurotoxin at a molecular and behavioral level are similar to that of the 
human disease, it is conceivable that statin-use may be of benefit to PD patients also. These 
claims deserve further investigation, particularly with regards to elucidating the functional role 
played by the proteins that display expressional changes, and whether their function relates to 
neuroprotective properties.  
 In both the studies reported in chapter 5 and 7, the variable factor (whether environmental or 
drug-induced) preceded exposure to the known parkinsonian-agent. The choice if neurotoxic 
agent was carefully chosen in the context of the disease mechanism that was to be 
investigated. In this regard, 6-OHDA was infused following subjection to an MS paradigm, for its 
ability to create consistent dopaminergic cell death. On the other hand, rotenone was the agent 
of choice to deliver to rats that had previously been treated with statins, since it is well 
established that it works to induce cyto-functional impairments by inhibiting complex I and III of 
the mitochondrial ETC.  
Nerve growth factor (NGF) was seen to be upregulated in female rats compared to the 
males in a 6-OHDA model of PD. This finding deserves further investigation using 
complimentary techniques, particularly a genetic approach to ascertain whether the effect can 
be repeated using an NGF knock-down or knock-out paradigm. In addition, future work should 
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investigate whether the upregulation of NGF was modified in any way, by even the trace 
amounts of female gonodal steroids. Using a surgical or chemical approach to remove the 
gonads, or by knocking down estrogen receptors, an undisputed position on this should be 
attained. Should the mechanism underlying NGF’s upregulation that was responsible in this 
model become known, whether the growth factor functions independently or in synchrony with 
any of the female steroidal factors, the validity and reliability of the protein to produce similar 
effects should be assessed in other (i.e. primate) models of PD, for possible future clinical 
application.  
Every effort had been made to overcome the limitations that may have been imposed by 
resource restrictions, or other reasons. For chapter 4, the use of a lower number of rats, may 
have prevented certain measures from showing a greater (and statistically significant) effect. 
This particularly pertains to the results obtained from subjecting the tissue to HPLC-EC 
analysis. Furthermore, for chapter 7, It is acknowledged that the pathways induced by 
simvastatin in the rat model, to affect the SN’s mitochondrial proteome in the way 
demonstrated, may differ significanty from those of humans. Future work should aim to 
establish the extent to which the rat and human data overlap in this regard. Moreover, the 
mitochondrial fractions generated from the SN of the statin and placebo-treated rats for 
proteomic analysis had to be pooled, in order to generate enough proteins for detection. This 
prevented the analysis of the changes in mitochondrial protein-levels brought on by simvastatin-
use in individual rats. In addition, confirmation of the presence of these proteins detected 
through proteomics, were hampered by the limited availability of monoclonal antibodies 
generated against these proteins.  
 
 
 
 
 
 
 
 
 
 
APPENDIX A 
 
GENERAL METHODOLOGY AND MATERIALS USED 
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1.  Animal maintenance   
Sprague-Dawley rats were used for each experiment described in this Thesis. Animals were 
subjected to a 12-hour light/dark cycle (lights came on at 6am till 6pm). The animals were kept 
in clear 40 x 25 x 20cm Plexiglas cages, in an AAALAC accredited facility, in rooms with 
temperature 22±1°C and a 12:12 hr. light:dark cycle (lights on from 07h00 to 19h00). The rats 
had ad libitum access to pelleted rat chow and tap water. All experimental procedures followed 
in this study had been approved by the Committee for Experimental Animal Research of the 
University of Stellenbosch (Project number: N05/04/004), and were in accordance with the 
National Institutes of Health Guide for care and use of laboratory animals. 
 
2.  Maternal separation paradigm   
MS has been described as a potent naturalistic stressor (Stanton et al., 1988) and has been 
used extensively as a model of early life stress by various investigators, i.e. Daniels et al. 
(2004), Faure et al., (2006), Ladd et al., (1996), Lubach et al., (1995), van Oers et al., (1998), 
Lyons et al. (1999), and  Sánchez et al. (2001). Adult male-female pairs were housed under 
normal conditions to allow for mating. Immediately after the rat pups were born, the adult males 
were removed while the mothers remained with the pups. On postnatal day (PND) 1 (day zero 
was regarded as date of birth), rats were sexed and culled to 8 pups per dam. If there were 
fewer than 8 males, then females were included to make up the 8 so as to ensure equal 
nurturing. Litters were randomly assigned to either a control (non-separated) or MS group (n = 
8/group). Beginning on PND 2, MS involved physically removing the dam from the home cage 
that contained the pups, for 3 hrs per day from 10:00 to 13:00, leaving the pups undisturbed in 
their home cage. During the separation period that occurred daily for 13 days, the pups were 
housed in a room away from the mother to prevent communication via ultrasound vocalizations 
from taking place (Hofer, 1994). The temperature of the room to which the rat pups were 
transferred was maintained between 31˚C and 33˚C with two heaters on either side of cages, 
recording thermometer at same location as cages, thereby minimizing the possible influence of 
hypothermia. After PND 14, the pups returned to normal housing conditions. Control animals 
were handled identically to experimental ones, except that the pups were not separated from 
the dam during the first 14 days after they were born. On PND 21 both groups were weaned by 
permanently removing them from the dam. 
 
3.   Drug treatment 
For 2 weeks prior to unilateral infusion of rotenone into the SNc (see below), simvastatin was 
delivered daily. After 2 weeks of training the animals to eat a jellie-cube given to each rat 
individually, a drug-treatment regime was prepared and executed for each animal in the 
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following manner: 6 mg of the active chemical component of simvastatin was administered 
orally on a daily basis for 14 days, between 13:00 and 13:30, until the day preceding surgery. 6 
mg of the drug was dissolved in 50 µl of absolute Ethanol (EtOH) in an Eppendorf microtube. A 
sugar solution, consisting of commercially-available jelly and gelatine, was dissolved in boiling 
water. For each animal a droplet of the solution was placed with a Pasteur pipette in a single 
container of an ice-maker, and 50 µl of the dissolved statin-solution was re-suspended in the 
sugar solution with a sterilized pipette. When the solution had completely stalled, the jelly-block 
was removed from its container, and given to each rat. Control rats treated with placebos, 
received a jelly-block only, without statin added as an ingredient.  
 
4.  Preoperative and stereotaxic surgical procedures 
4.1.  General surgical procedures 
If the toxin was delivered to the MFB/SNc rats were injected with 25 mg/kg desipramine (i.p.) 
thirty minutes before and immediately after the operation to limit concurrent damage to 
noradrenergic pathways by 6-OHDA infusion (Roberts et al., 1975). To prepare the surgical site, 
the scalp hair was clipped and the site disinfected with 70% ethanol. Body heat was conserved 
during surgery by placing the rat on a heating pad (Rex C10, Centre for Electronic Services, 
University of Stellenbosch). The rats were anaesthetized using a combination of ketamine 
hydrochloride (Anaket-V®, Bayer Healthcare, South Africa) and medetomidine hydrochloride 
(Domitor®, Pfizer, South Africa) (0.1 ml/100g, i.p.) and placed in a stereotaxic frame (David 
Kopf Instruments, Tujunga, USA). A small burr hole was drilled at the determined coordinates 
and a 22-gauge surgical-steel cannula was slowly inserted into the brain through which the 
toxin was infused using a 341-A model syringe pump (Sage Instruments, USA), running at an 
injection rate of 0.5 µl/min at the predetermined coordinates.  
 
4.2.     Establishing the coordinates for toxin injection into the medial forebrain 
bundle (MFB) of very young rats 
The injection of the toxin (6-OHDA) entailed a scientific protocol to administer toxin to very 
young animals (weighing between 110–142g, see chapters 4). It was particularly important to 
perform initial experiments to establish a set of medial forebrain bundle (MFB) coordinates for 
the very young group of rats, since information on toxin injections into the MFB of young 
animals is very limited.  
 The stereotaxic coordinates were determined a pirori and verified in an animal of the same 
strain, sex and weight range, to ascertain the optimal location of the tip of the injection cannula 
(30G needle) in the MFB. A combination of ketamine hydrochloride (Anaket-V®, Bayer 
Healthcare, South Africa) and medetomidine hydrochloride (Domitor®, Pfizer, South Africa) 
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(0.1 ml/100g, i.p.) was used to anaesthetise the animals before placing them in a stereotaxic 
frame (David Kopf Instruments, Tujunga, CA, USA). Following the Indian ink injection, the rat 
was decapitated and the brain placed in paraformaldehyde for 48h. The tissue was cut with a 
cryostat at a thickness of 30 μm. The sections were mounted onto clear glass slides and 
examined under a Nikon TE2000-E microscope (using a phase 4 resolution) to determine the 
location of the lesion, while referring to a stereotaxic atlas of the rat brain (Paxinos & Watson, 
1986). The stereotaxic coordinates for the MFB injection delivered to the young animals were:  
2.5mm posterior to Bregma, 1.8 mm lateral to the midline and 7.8 mm from the dura mater. 
These coordinates were used throughout the study for both toxin-induced and sham lesioned 
rats.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  The image shows the placement of the needle into the MFB, for the injection with 6-OHDA. The 
image was obtained with a Nikon TE2000-E microscope, the objective lens being × 4 with a Brightfield 
application attached, while the image was captured with a Sony 3CCD camera that was mounted upon 
the microscope. 
 
4.3. Establishing the coordinates for the injection of the toxin  
   into the striatum of very young rats 
The brain stereotaxic atlas by Paxinos and Watson (1986) was referred to with no initial 
experiments performed to determine the coordinates for injecting the toxin into the striatum, 
since a large body of literature on this exists and the striatum is a relatively large structure. 
Bregma and Lambda were used to level the horizontal plane of the skull. From bregma, the 
following coordinates were used: anterior, 0.30 mm; lateral, 2.7 mm; ventral, 5.6 mm below the 
dura mater.  
3rd ventricle 
Supraoptic decussation 
Mammillothalamic tract Ansa lenticularis
Needle tip 
Optic tract 
Medial 
forebrain 
bundle 
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4.4. Establishing coordinates for toxin injection into the substantia nigra (SNc) 
of adult rats  
For the surgical protocol employed in the study (as is described in chapter 5) the coordinates for 
inject through stereotaxic means were determined a pirori and verified in an animal of the same 
strain (Sprague Dawley, sex (male) and weight range (mature animals weighing between 300 
and 320g at the beginning of the experiment). This was done in order to ascertain the optimal 
location of the tip of the injection cannula (30G needle) in the Substantia nigra compacta (SNc). 
The stereotaxic coordinates established for the SNpc injection were: 5.3 mm posterior to 
Bregma, 2 mm lateral to the midline and 7.5 mm from the dura. These coordinates were used 
throughout this particular study for all the experimental groups used. 
 
4.5.  The stereotaxic infusion of the neurotoxin and surgical post-care 
Following the infusion of toxin, the needle was left in place for an additional 5 min, before slowly 
retracting it from the brain. The burr-hole drilled through the skull was filled up with sterilized 
oxidized cellulose (Ethicon, U.K.), the incision sutured and the wound coated with an iodine 
solution (Purdue Frederick, USA). The rats were placed in individual cages under heating-lamps 
until full recovery was achieved, after which they were returned to their home cages. The 
condition of the sutures, the rat’s food and water intake and behaviour was monitored daily to 
ensure full recovery. 
 
4.5.1.  The infusion of 6-hydroxydopamine (6-OHDA)   
6-OHDA solution (Sigma, St. Louis, MO) was kept on ice, and protected from exposure to light. 
The solution (the particular free-base weight of 6-OHDA, dissolved in 4 µl 0.1% L-ascorbic acid 
in 0.9% sterile saline) was infused over a period of 5 min using a 341-A model syringe pump 
(Sage Instruments, U.S.A.).  
 
4.5.2. The infusion of hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-
b]furo(2,3-h) chromen-6-one (Rotenone)   
Rotenone is a major active ingredient and principal component of cubé resin that derives from 
Lonchocarpus utilis commonly used as a botanical insecticide and piscicide (Caboni et al., 
2004). It is classified as a potent complex I (NADH:ubiquinone oxidoreductase) inhibitor that 
shows the ability to induce a PD-like syndrome in rats through the degeneration of the 
nigrostriatal dopaminergic pathway (Betarbet et al., 2000). Rotenone was freshly prepared, and 
protected from exposure to light. A stock solution of the rotenone solution was prepared by 
dissolving rotenone in the vehicle, that consisted of Dimethyl sulphoxide (DMSO):Polyethylene 
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glycol (PEG), with the vehicle that was prepared at a 1:1 ratio. Each rat received 3 µg of 
rotenone / 4 µl of vehicle. Rotenone is extremely hydrophobic, managing to cross biological 
membranes easily, and does not depend on a dopamine transporter for access to the cytoplasm 
of dopaminergic neurons (Betarbet et al., 2000; Greenamyre et al., 2001). It is also a well-
characterized specific inhibitor of mitochondrial NADH dehydrogenase (Complex I), one of the 
five enzyme complexes of the inner mitochondrial membrane involved in oxidative 
phosphorylation (Betarbet et al., 2000; Thiffault et al., 2000). 
 A combination of ketamine hydrochloride (Anaket-V®, Bayer Healthcare, South Africa) and 
medetomidine hydrochloride (Domitor®, Pfizer, South Africa) (0.1 ml/100g, i.p.) was used to 
anaesthetise the animals before placing them in a stereotaxtic frame (David Kopf Instruments, 
Tujunga, CA, USA). The surgical site was prepared by clipping the hair on the animal’s head 
and disinfecting the site with 70% Alcohol (EtOH). The skin was sterilized using an iodophor 
(Betadine®, Purdue Pharmaceutical Products). A rubber heating-pad (REX C10, RKC, 
19.0~99.9°C heat generator, Electronic Services, University of Stellenbosch) maintained the 
rat’s body heat during surgery. Following the Indian ink injection, the rat was decapitated and 
the brain placed in paraformaldehyde for 48h. Forty-eight hours later the tissue was cut with a 
cryostat at a thickness of 30 μm. The sections were mounted onto clear glass slides and 
examined under a Nikon TE2000-E microscope (using a phase 4 resolution) to determine the 
location of the lesion, while referring to a stereotaxic atlas of the rat brain (Paxinos and Watson, 
1986). The stereotaxic coordinates for the SNc injection established were: 5.3 mm posterior to 
Bregma, 2 mm lateral to the midline and 7.5 mm from the dura. These coordinates were used 
throughout the study for all experimental groups. Adult male experimental animals, weighing 
between 375-390 g were randomly assigned to their various experimental groups before 
surgery. A rat anesthetized with a combination of Ketamine and Domitor® was immobilized in a 
stereotaxic frame in a flat-skull position. A 2 cm midsagital skin incision was made through the 
scalp to expose the skull. An infusion cannula consisting of a sterilized length of 30 gauge 
stainless steel hypodermic tubing was stereotaxically placed via a hole in the skull and 
advanced so that the internalized tip was located within the SNc cell bodies. A stock solution of 
the rotenone solution was prepared by dissolving rotenone in the vehicle, consisting of Dimethyl 
sulphoxide (DMSO):Polyethylene glycol (PEG), with the vehicle that was prepared at a 1:1 
ratio. Each rat received 3 µg of rotenone / 4 µl of vehicle. Rotenone is extremely hydrophobic, 
managing to cross biological membranes easily, and does not depend on a dopamine 
transporter for access to the cytoplasm of dopaminergic neurons (Betarbet et al., 2000; 
Greenamyre et al., 2001). It is also a well-characterized specific inhibitor of mitochondrial 
NADH dehydrogenase (complex I), one of the five enzyme complexes of the inner 
mitochondrial membrane involved in oxidative phosphorylation (Betarbet et al., 2000; Thiffault 
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et al., 2000). The solution was infused through a tube attached to a Hamilton syringe over a 
period of 5 min using a 341-A model syringe pump (Sage Instruments, USA). Following the 
infusion, the needle was left in situ for an additional 5 min, before slowly retracting it from the 
brain. The drilled burr-hole through the skull was filled with sterilized oxidized cellulose 
(Ethicon, U.K.), while the incision was sutured and again coated with iodophor. To recover, the 
rats were placed in individual cages under heating lamps and a post-operative pain reliever 
(Temgesic 0.01 mg/kg, i.p.) was administered. The condition of the sutures, the rat’s food and 
water in-take and behaviour were monitored daily to ensure full recovery. 
 
5.  Specific tests used for assessing rodent behavior   
The following tests were used to elicit certain behaviors that have proved to be a reliable and 
valid indication of the degree of DA loss sustained from the lesion. A significant proportion of 
behavioral testing was carried out drug-free, since it reflects a more natural response following 
the lesion (Roghani et al., 2002). 
 
5.1.  Forelimb use asymmetry (‘cylinder’) test   
Limb use asymmetry during vertical-lateral exploration of the walls of a cylindrical chamber 
correlates to the extent of nigrostriatal terminal loss (Schallert & Woodlee, 2005; Schallert, 
2000). Rats were placed individually in an upright transparent Plexiglas cylinder that had been 
placed on a tabletop. The diameters of the container measured at 19 cm across and 24.4 cm in 
height. The walls were high enough to prevent the animal from reaching the top edge when 
rearing by standing on its hind limbs and were wide enough to permit a comfortable 2 cm space 
between the tip of its snout and the base of its tail when all four paws were placed on the 
ground. The floor of the container consisted of a transparent sheet portraying four equal quarter-
circular sections. The animals were tested during the light cycle (between 10h00 and 12h00) 
with each testing session lasting 5 min in total. This also served to prevent the rats from 
habituating to the cylinder environment, lest they should become passive (Schallert et al., 2000).  
Following the assessment, each rat was immediately returned to its home cage. A video 
recorder with slow motion and frame-by-frame capabilities was used to analyze and rate the 
rat’s behavior in the cylinder at a later stage. The camera was mounted on a tripod at an angle 
and underneath the cylinder, to allow a full-view of all the animal’s activities, even when turning 
away from the camera as well as its movements on the floor of the cylinder. This test was also 
referred to as ‘the small open field maze’ (chapter 6).  
A number of parameters were included for quantifying the degree of forelimb-use asymmetry 
shown. Each of these will now briefly be discussed. 
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5.2.1.  The independent use of the forelimbs   
The independent use made of the forelimb is defined as the active use made of a single 
forelimb, while the other remains stationary but in constant contact with the surface of the 
cylinder wall. The rater was blind as to the condition of the animals and scored limb use as 
number of times that the left (ipsilesional), right (contralesional), or “both” limbs were placed on 
the wall surface or moved laterally during vertical exploration. The score of each was expressed 
relative to the total amount of times that the forelimbs (ipsilesional + contralesional + both) was 
placed and by multiplying this with 100 to present the values as percentages (Connor et al., 
1999). In cases where it was unclear whether the limb had been placed independently or 
simultaneously, it was neglected for evaluative purposes. 
 
5.1.2.  Independent forelimb exploration (‘wall stepping’) 
Forelimb use during explorative activity was analyzed by videotaping rats in a transparent 
container of a cylindrical shape, of diameter19 cm across and 24.4 cm in height. The container 
neither had a top nor a bottom. ‘Wall stepping’ was defined as the rat making independent use 
of either the right or the left forelimb for making initial contact with the wall, followed by 
subsequent ‘stepping’ movements in a lateral direction, when the animal moved in a vertical 
posture by shifting its weight side-ways by using its hind limbs. The number of wall stepping 
movements performed with the rat’s contralateral (to the lesioned hemisphere) forelimb was 
compared to the number of times this was performed by the ispsilateral (to the lesioned 
hemisphere) forelimb.  
 
5.1.3.  The amount of steps taken by the hindlimbs   
The amount of steps taken by each of the hindlimbs (ispsilateral vs. contralateral), in either a 
forward or a backward direction were counted.  
 
5.1.4.  The defecation-urinary (DU) index   
A defecation and urination index was determined based on the total sum of defecation boli and 
urination spots observed.  
 
5.1.5.  The frequency of vertical rearing   
The number of rearing (standing on hind limbs without touching the wall of the cylinder (19 cm in 
diameter) was also recorded. The height of the cylinder was such that it prevented the animal 
from reaching the top edge when rearing on its hind legs. The amount of rearing displayed by 
each animal was scored. This was counted each time the rat reached a full-rearing posture, with 
neither of the front-paws making contact with the inside of the wall. Together with the DU index, 
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vertical rearing serves as robust measures of the emotional status of the animals (Gray & 
Cooney, 1982; Pijlman et al., 2002). 
 
5.1.6.  The number of non-drug induced (spontaneous) half-turn rotations 
The floor of the cylinder was divided into 4 equal-sized quarters. The amount of times that the 
rat rotated towards the side of the lesion (ispsilateral) as well as away from the lesion 
(contralateral) were counted, with a rotation consisting of a continuous 180° turn.  
 
5.2.  The vibrissae-evoked forelimb placing test   
There are various experimental advantages that the vibrissae sensory system offers for analysis 
of motor control. Whisker motor-neurons are located in the lateral facial nucleus with numerous 
structures providing input to the lateral facial nucleus, the most mysterious and important one 
being the putative central pattern generator (CPG). Although recent studies identified candidate 
structures for the CPG, the precise identity and the functional organization of this structure 
remains uncertain. The vibrissae cortex (VMC) is the largest motor representation in the rodent 
brain, and recent work has clarified its localization, subdivisions, cytoarchitectonics and 
connectivity.  
This test evaluates the degree of sensorimotor integration that occurs across the two 
hemispheres. Intact rats instinctively attempt to place their forelimb(s) upon any nearby surface 
when their whiskers are stimulated (Woodlee et al., 2005). Consistent with parkinsonian 
akinesia, unilaterally 6-OHDA-lesioned rats fail to evoke a placement response from the limbs 
regardless of the sensory trigger, while the contralateral vibrissae maintain the ability to reliably 
trigger limb placement. 
 In this test, the experimenter held the rat by the torso, thereby allowing the forepaw being 
tested to hang freely while the untested forelimb was gently restrained. Each forelimb was 
tested independently by orienting one side of the animal towards a tabletop and moving the 
animal in a slow lateral direction toward the edge until the vibrissae of that side made contact 
with the table’s edge (Schallert & Tillerson, 1999; Barth et al., 1990). In an intact animal the 
stimulated vibrissae will cause the rat to instinctively place the corresponding forelimb onto the 
tabletop, while, with lesioned animals, placing may not occur at all (scoring ‘0’), indicating a 
failed motor response towards a spatio-sensory stimulus, or there is a delay between 
stimulation and placing. Ten trials of each forelimb were performed during the testing session. 
An experimenter, blind to the experimental condition of the animals, recorded the number of 
successful placing reactions by each forelimb.  
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5.3.  The bracing (‘adjusting steps’) test  
The rats were monitored for their ability to make postural adjustments in response to an 
imposed weight-shift by using an isolated forelimb test (initially described by Schallert et al., 
1979; 1992). The test is useful for monitoring lesion- and transplant-induced changes in forelimb 
motor function, which is a behavioral parameter that may be analogous to limb akinesia and gait 
problems seen in patients with Parkinson's disease (Olsson et al., 1995). Briefly, the 
experimenter suspended the rat above a tabletop surface, with the hind limbs and one forelimb 
restrained in one hand. By doing so, the rat supported most of the weight of its body with the 
unrestrained forelimb. While the experimenter slowly moved the animal at a constant rate (300 
cm in 30 sec), the number of adjusting steps taken by each forelimb was recorded by the 
experimenter, who was blind to the treatment of the rat. This procedure was performed across 
two conditions, namely when the animal was moved along the table-surface in the lateral 
forward direction (leftward movement), as well as in the lateral backward direction (rightward 
movement). Two trials for each animal were performed, with each trial consisting of the rat 
being moved once in each direction. The mean score of the two trials was considered a 
representative result for each animal. 
 
5.4.   The isolated forelimb (‘catch-up’) stepping test 
The test provides a useful means for evaluating an animal’s ability to make postural 
adjustments in response to weight shifts imposed by the experimenter handling the rat. The test 
was initially described by Schallert et al., 1979; 1992; Olsson et al., 1995 as a way with which to 
monitor lesion- and transplant-induced changes in forelimb motor function, and is seen as a 
behavioral parameter that may be analogous to postural instability or akinesia seen in patients 
with PD (Olsson et al., 1995). The experimenter held one forelimb and both hind-limbs off the 
surface of a tabletop, while permitting one forelimb to hold the animal’s full weight. The animal 
was then moved laterally (held in the position described) first in one direction (leftward), and 
then in the opposing (rightward) direction. The number of catch-up (adjusting) steps taken by 
each of the forelimbs when slowly moved at a constant rate (300 cm in 30 seconds) was 
counted. A trial consisted of moving the rat twice in both directions.  
 
5.5.  The standard open field maze   
Although the Open Field maze classically functions as a paradigm used for measuring levels of 
anxiety in animals, its can also be used for measuring the degree of locomotor activity displayed 
by animals (Prut & Belzung, 2003). The behaviour of each rat was recorded for 5 minutes. As 
 302
was previously described by Ramos et al. (2002), each rat was individually tested and to signal 
the start of the test, the rat was placed on the outer-left corner of the arena with the snout 
pointing towards the inner zone. The activities of the rat were video-recorded and subsequently 
analyzed with Noldus EthoVision software (Noldus Information Technology, V 3.0). The 
frequency of rearing that the animals exhibited, the total distance traveled (cm), the mean 
velocity (cm/s) of their movement and the total duration (in seconds) that the rat spent moving, 
were regarded as constituting an index of locomotor activity. 
 
5.6. The apomorphine-induced rotation test 
The degree of apomorphine-induced stereotypic rotations were assessed. All rats received 
three tests of apomorphine-induced rotation: on the day prior to starting statin/placebo therapy 
(lasting for 14 days), the day before surgery, and on the 5th day post-infusion. Animals with 
severe unilateral dopamine depletion exhibit asymmetrical rotational behavior in a contraversive 
direction in response to the dopamine agonist apomorphine (Borlongan et al., 1995; Ungerstedt 
and Arbuthnott, 1970). Rats were tested for rotation-asymmetry by challenging with 0.75 mg/kg 
apomorphine hydrochloride (Sigma), dissolved in 0.2% ascorbate in 0.9% saline, injected 
subcutaneously (in the neck). Thirty min after injection the animal was placed in a spherical 
rotometer (diameter 25 cm) for 60 min. The animals were video-recorded from a ventral 
perspective, and their behavior analysed with a macro designed in the Noldus Ethovision 
software (Noldus Information Technology, The Netherlands). For each assessment, the total 
number of 180° turns in left and right directions was counted during the 60 min interval that the 
trial lasted. Analysis of data was based on net ipsilateral (right-left) turns and on net 
contralateral (left-right) turns. The amount of clockwise half-circle (180°) rotations (ispsilateral to 
the lesion) was scored as positive turns, and counterclockwise turns were counted as negative 
turns. The net rotational asymmetry score was calculated as the difference between clockwise 
and counterclockwise turns over the 60-min duration of the trial following the injection of 
apomorphine (Sun et al., 2005). 
 
 6.  Animal sacrifice  
At the pre-determined terminal endpoint of each experiment, the rats were killed by a method 
deemed appropriate for the particular neurochemical analysis that was due to be performed on 
the collected brain tissue. All treatments given confirmed to international ethical standards and 
the protocol has been approved by the local committee for Experiment Animal Research of the 
University of Stellenbosch and are were accordance to the National Institutes of Health Guide 
for Care and Use of Laboratory Animals.  
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6.1.  Decapitation  
Upon reaching the experiment’s terminal end-point, certain animals were decapitated and the 
brain tissue removed, since this particular method for terminating the life of the animal was the 
most rapid and efficient, and also represented the most appropriate for the particular 
biochemical analyses to be performed on the collected brain tissue.  
 An hour preceding decapitation the animals were moved from their home cage to another 
cage and transferred to a room isolated from all the other rodents. No anaesthesia was given 
prior to this method of killing since it would modify the biochemical activity of the brain tissue. 
Any anaesthetic agents will contaminate the samples and obscure the effects of the 
experimental manipulations that had been given (Carney & Walker, 1973; Barna et al., 1993; 
Carlberg et al., 1995; Illera et al., 2000). 
 The guillotine was placed upon a clean and stable benchtop. Each rat was brought into the 
dissection room individually so the rest of the colony could not detect the blood odor. The rat 
was gently restrained, but with every effort made to adjust the transport of the rodent until it  
appeared calm. The rodent was held securely, and placed on the stage at the entrance to the 
guillotine. The animal was gently, but assertively pushed forward until its head was securely in 
the guillotine apparatus. As soon as the head was in position, it was verified that the the head is 
completely through the opening of the guillotine. The guillotine lever was smoothly and quickly 
depressed, thereby decapitating the rodent. The rest of the carcass was disposed of in 
accordance with the regulations of the local animal ethics committee (University of 
Stellenbosch).   
 
6.2.  Transcardial perfusion 
The effect of the injections on dopaminergic neuron survival was evaluated in rats belonging to 
each group (experimental versus control) using transcardial perfusion, a method commonly 
used for fixating tissue in immunohistochemical localization protocols. The method takes 
advantage of the subject’s circulatory system to deliver the fixative solution evenly throughout 
the body tissues, with optimal penetration of the brain. The method is particularly suited for 
evaluating tyrosine hydroxylase immunoreactivity (TH-ir, and discussed below) since the fixation 
preserves neuronal ultrastructure, and stabilizes protein and peptide conformation so that 
antibodies can bind to antigen sites.   
 
6.2.1.      Perfusion solutions 
6.2.1.1.  Pre-fixation solution: Phosphate buffer stock solution (PBS) 
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The ×10 stock solution was made by dissolving 80 grams NaCl, 2 grams KCl, 14.4 grams of 
Na2HPO4 and 2.4 grams in 800ml of distilled water. The pH was adjusted to 7.4 with 5M NaOH. 
Distilled water was added to make up the solution to 1 litre. A 0.15M PBS working solution was 
prepared by mixing the stock solution with distilled water to a ration of 1:10.  
 
6.2.1.2.    Fixation solution: 4% paraformaldehyde solution in 0.15M PBS 
40 grams of paraformaldehyde were mixed in 800 ml of 0.15M PBS, which had been made from 
the stock solution. The mixture was covered and mixed on a stirring magnetic plate with the 
heat set at 40°C and the mixture continuously stirred until the solution was completely clear. 
The solution was prepared under a fume hood.   
 
6.2.1.3.    Post-fixative solution: 20% sucrose in 0.15M PBS 
200 grams of sucrose was dissolved in 800 ml of 0.15M PBS working solution made from the 
stock solution described earlier. The solution was made up to 1 litre. 
 
6.2.2.  Perfusion procedure 
The perfusion pump was set up and the perfusion needle (catheter) was attached with the valve 
kept closed. A 100 ml of distilled water was run through the system (consisting of the bottle and 
tubing) with the aim to remove any residue that may have remained from previous use. The 
pump bottle was filled with 200 ml of pre-fixation solution (PBS) of room temperature (21-23°C). 
The valve of the tubing was briefly opened, allowing the solution to drip slowly and steadily (20 
ml/min), and the valve closed then again. The surgery site was set up, complete with tools, 
guillotine, specimen bottle (which contained the 30% sucrose solution). A rack (the top cage of a 
standard rat holding box) was placed over the sink and the tap opened to allow water to drip at 
a steady pace.  
 Rats were deeply anaesthetized by administering 30% urethane anesthetic (1 cc/100 g, IP), 
and the pinch-response method was used to determine the depth of anesthesia. Great care was 
taken to ensure that the animal was completely unresponsive before proceeding with the 
procedure. The animal was placed on the rack, and an incision was made with sharp surgical 
scissors through abdomen comprising the length of the diaphragm. Using the same pair of 
scissors, a cut was made through the connective tissue at the bottom of diaphragm to allow 
access to rib cage. With the blunt side of the scissors facing down, the ribs were cut through just 
left of the rib cage midline. A single center cut was made through the rib cage to open up the 
thoracic cavity. The rib cage was secured with mosquito clamps to expose the heart and provide 
drainage for blood and fluids.  
 With the heart still contracting and diluting, the heart was held steady and a catheter needle 
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inserted directly into the protrusion of the left ventricle and extend straight up ≈ 5 mm. The 
needle position was secured by clamping it in place. The catheter valve was allowed to slowly 
release the fluid, delivering the pre-fixative solution (PBS) at a steady flow rate of ≈ 20 ml/min. A 
cut was made through the atrium with sharp scissors, and care taken to make sure the solution 
was flowing freely. 
As soon as exsanguinations had been achieved (when it was seen that blood had been 
cleared from the animal’s body), infusion with 10% paraformaldehyde (200 ml) commenced. 
Spontaneous movement (the so-called ‘formalin dance’) and the lightened color of the liver were 
taken as good indicators of clearing of blood from the body, and replacement with formalin.  
 
 6.3.  Brain tissue collection 
The animal was then removed from the rack and decapitated as close as possible to the back of 
the ears. A cut was made with sharp scissors from the base of the head up to the level of the 
eyes. The skin was pulled away from the skull and the skull plates removed with tweezers to 
expose brain. Any remaining dura was cut away with small sharp scissors. The flat end of a 
spatula was carefully slid underneath the brain, and the optic, olfactory, and cranial nerves 
severed. The brains were rapidly removed from the skull with the spatula and placed in a 
specimen bottle containing the 30% sucrose solution that offered cryoprotection. The brains 
were stored at 4ºC in the 30% sucrose solution for ≈ 48 hrs until they had descended to the 
bottom of the container, indicating complete tissue penetration with the solution, they were 
removed, the brain tissue blocked, placed in plastic covers, frozen over liquid nitrogen vapor 
and kept at -80°C until sectioning. 
 
7.  Brain dissections 
The brains were rapidly removed from the skull by means of the flat end of a spatula and lifted 
out of the brain case. The respective areas were dissected out as follows: 
 
7.1.  The striatum 
The total left and right striatum was dissected out on an ice-cooled dissection slab (cooled by 
liquid N2 fumes) by cutting coronally at the level of the infundibular stem, thereby forming a 
forebrain block containing the striatum. The forebrain was bisected along the midline and 
cortical tissue for each hemisphere peeled back to expose the striatum, which was dissected 
along the boundary of the corpus callosum. 
 
7.2.  Substantia Nigra pars compacta (SNpc) 
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The dopaminergic neurons located in the SNpc act as important regulators of corticostriatal 
neurotransmission. In the neuropathology seen in PD, progressive loss of these neurons leads 
to debilitating motor dysfunction (Chichung Lie et al., 2002). The SN was dissected using a 
dissection microscope, taking care to avoid contamination by ependymal and subependymal 
cells by complete removing the tissue adjacent to the 3rd ventricle. The two half sections 
(collected from both cephalic hemispheric halves) were used as a matched pair of slices: one 
half having had received the injection with the toxin/vehicle, and the other half that was used as 
an internal control. 
 
8.  Investigations to determine the neurochemical content 
8.1.  High Performance Liquid Chromatographic (HPLC) analysis for analysing 
Dopamine (DA) and DA Metabolites (DOPAC & HVA) 
After the respective lesions were complete, at two weeks following a lesion made to the MFB, 
and four weeks following lesioning of the striatum, all animals were killed by decapitation. The 
brains were rapidly removed from the skull and the total striatum was dissected out on an ice-
cooled dissection slab. This was done by cutting coronally at the level of the infundibular stem, 
thus forming a forebrain block containing the striatum. The forebrain was bisected along the 
midline and cortical tissue for each hemisphere peeled back to expose the striatum, which was 
dissected along the boundary of the corpus callosum. The striata were snapped frozen in liquid 
nitrogen (-198 ºC) until analysis for DA and its metabolites by using HPLC-EC.    
 Dopamine (DA),and  DA-metabolites (3, 4-dihydroxyphenylacetic acid (DOPAC), 
homovanillic acid (HVA), contents of the left and right striatum were determined by the same 
HPLC-EC method that has previously been described by Harvey et al. (2006). The 
chromatographic system consisted of a GBC LC 1120 HPLC Isocratic pump that contained an 
inlet filter and a Rheodyne 7725i injection valve comprising of a 50 μl loop for introducing 
samples to the system. For separation a 5 µm C18 Phenomenex Luna reverse phase analytical 
column (150 × 4.6 mm) was connected to a GBC LC 1260 Electrochemical Detector (+0.6 V) as 
well as a Spectra-Physics SP4290 integrator. The mobile phase consisted of 0.1 M sodium 
formate buffer, 0.5 mM ethylenediaminetetraacetic acid (EDTA), 5 mM sodium heptane 
sulphonic acid, 6% v/v methanol and 4% v/v acetonitrile. Milli-Q water was used to make the 
solution up to 1000 ml and the pH set at 3 by adding 6 ml of orthophosphoric acid (85%). The 
composition was degassed twice prior to use. The flow rate of the mobile phase running through 
the system was set at 1.2 ml/min. The temperature remained ambient throughout. On the day 
that analysis took place the samples were allowed to thaw and the weight of each sample was 
recorded. A total volume of 1 ml 0.1 M perchloric acid solution was added to each tube, 
sonicated and then placed on ice for 20 min, whereafter the tissue was centrifuged (20 min, 4˚C, 
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24 000 × g, Sorval Discovery 9056 ultracentrifuge). Following the withdrawal of 200 μl aliquot of 
supernatant, 20 μl of the internal standard solution (isoprenaline HCL) was added and the 
solution was mixed. A sample of 50 μl was injected into the column for direct content analysis. 
Standard dopamine and metabolites (DOPAC and Homovanillic Acid or HVA) solutions were 
prepared in a vehicle of 0.5 mM sodium metabisulphite and 0.3 mM Na2EDTA diluted with 
perchloric acid (0.1 M). Monoamine standards ranged from 10 ng/ml – 200 ng/ml and linear 
standard curves were found in this particular range. The monoamines and metabolites were 
quantified by comparing the area under the curve (AUC) of the sample/ AUC of the internal 
standard (isoprenaline) to the monoamine standard, utilizing the linear equation obtained from 
the standard curve. Chemstation Rev A 08.03 software was used for data acquisition and 
analysis purposes. The monoamine concentrations were expressed as ng/g wet weight (ww) of 
tissue (mean ± S.E.M.).  
 
8.2.  Tyrosine hydroxylase immunohistochemistry (TH-ir) 
To stain for tyrosine hydroxylase, free-floating coronal sections of 60µm thicknesses were cut 
with a cryostat at −20 °C. The sections were quenched by incubating with 0.3% hydrogen 
peroxide for 30 min at room temperature, in a humidifying container. This was followed by a 
succession of washes (5 ×10 min) with PBS (0.15 M, pH 7.4). The sections were placed in a 10 
mM citrate buffer (pH 6.0) and placed in a microwave oven for 15 min, at full-power. The 
sections were then left to cool, before the wash-cycle was repeated. The sections were then 
pretreated with 150 µl horse blocking serum, and 0.1% Triton X-100 for 30 min, before 
application of the primary monoclonal anti-TH (BrdU mouse monoclonal (dilution 1:500, 
DiaSorin, USA) and overnight incubation at 4ºC. The next day the slices were washed in PBS (5 
×10 min), before applying the secondary biotinylated antibody (dilution 1:400) for 1 hour at room 
temperature. The wash routine was repeated, before incubating the slices with peroxidase 
labeled Mouse IgG ABC reagent (ABC kit, DakoCytomation, USA, with concentrated 
diaminobenzidine (DAB) as the chromogen). Tissue sections were incubated at room 
temperature until staining developed. The sections were given a final 15 min rinse with distilled 
water, before dehydrating them with 96-100% alcohol (EtOH), clearing with Xylol (Merck, South 
Africa) and mounting the sections onto clear glass slides. 
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Fig.   2.1.     The figures portray examples of photographs obtained with a Nikon TE2000-E microscope, 
the objective lens being × 4 with a Brightfield application attached. The photographic image was captured 
with a Sony 3CCD camera that was mounted on top of the microscope. Figure A shows the typical image 
of an intact hemisphere, with dense populations of DA-ergic neurons remaining, following either no 
infusion or having merely been infused with vehicle (i.e. saline or DMSO:PEG). Figure B shows the 
consequences of exposure of DA-ergic neurons to neurotoxins (i.e. 6-OHDA or rotenone). As can be 
seen, when comparing this image to that of figure A, the DA-ergic neurons that had survived the toxin 
infusion make up for a very sparse population.  
 
9.   Proteome contents analysis  
9.1.  Proteomics subfractionation: Isolation of the mitochondria 
The tissue samples, stored in Eppendorf containers, were removed from the -80°C fridge and 
placed on ice. Mitochondrial fractions were isolated from dissected brain tissue using a 
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commercially available kit (Sigma-Aldrich, USA). The tissue was weighed and then cut into 
smaller pieces with a scalpel-blade on a glass plate cooled with liquid Nitrogen vapours. The 
samples were pooled and homogenized with a glass homogenizer in 10 volumes of extraction 
buffer. The buffer contained 10mM HEPES, 200mM Mannitol, 70mM Sucrose, 1mM EGTA and 
Bovine Serum Albumin for removing excess lipids, with the pH set at 7.5. The homogenate was 
transferred to a 2ml Eppendorf tube and kept on ice. In order to obtain a mitochondrial fraction 
of ultra-high concentration, and to minimise the presence of contaminants, such as lysosomes 
or peroxisomes, the homogenate was centrifuged at a differential gradient. Centrifugation first 
occurred at a low rate of 1000 × g for 5 min, after which the supernatant liquid was transferred 
to a new tube and then centrifuged again at a higher rate of 3500 × g lasting for 10 min. The 
supernatant was removed and the pellet resuspended in 10 volumes of extraction buffer. The 
centrifugation steps were repeated, and the pellet resuspended in storage buffer, containing 
10mM HEPES, 250 mM sucrose, 1mM ATP, 0.08 mM ADP, 5mM sodium succinate, 2mM 
K2HPO4, and 1 mM DTT, pH 7.4.  
 
9.2.  Protein extraction and purification  
The supernatant was purified using a ReadyPrep Cleanup Kit (Bio-Rad Laboratories, USA), 
and the protein concentration of the sample quantified with a Model 550 Microplate reader and 
RC DC Protein Assay Kit (Bio-Rad Laboratories) using BSA as the standard. Aliquots of the 
final protein solution were stored at -80˚C until further use. Two-dimensional gel electrophoresis 
(2-DE) is a protein separation technique that allows for the separation of proteins according to 
charge (Isoelectric focusing, IEF) in the first dimension and by molecular mass (SDS-PAGE) in 
the second (Mary, 1999). 2-DE was performed on mitochondrial proteins derived from the SN in 
order to assess differential protein expression between the placebo + vehicle-infused and the 
statin-treated + vehicle-infused groups of animals.  
 
9.3.  Electrophoretic protein separation  
The extracted mitochondrial proteins were separated by IEF followed by 2-D SDS-PAGE. The 
first dimension separation was performed by mixing the appropriate amount of protein sample 
with a rehydration buffer, containing 8 M urea, 4% (w/v) CHAPS, 65 mM DTT, 0.2% (v/v) Bio-
Lytes and a trace of bromophenol blue. The sample was loaded in the IEF focusing tray, 
followed by the IPG gel strip gently being placed gel side down onto the rehydration solution 
and overlaying the IPG strip with 3 ml of mineral oil to prevent evaporation taking place during 
the rehydration process. The focusing tray was placed on a PROTEAN IEF Cel (Bio-Rad 
Laboratories, USA) and the software program was then run. Following IEF, the strip was 
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equilibrated for 15 min in the equilibration buffer containing DTT also, followed by an additional 
15 min in equilibration buffer II containing iodo-acetamide.  
 
 
9.4.  Gel staining for protein expression  
For the second dimension separation, the gel strip was placed on the upper edge of the 4-12% 
separation gel with its backside pasted tightly along the surface of the glass plate. 5 µl of low 
molecular weight protein marker was added at one end of the IPG strip. Low-Melt Agarose was 
used for fixing the gel strip and to remove air bubbles. The gel was run at 200V, until the 
bromophenol blue ran clear of the gel strip and condensed in a single line. As soon as the 
bromophenol blue front had traversed the gel, electrophoresis was stopped.  
 
9.5.  Image acquisition and data analysis 
The strip size was 11 cm and had an ampholyte range of 5-8 (Bio-Rad Laboratories, USA). 
Completed polyacrylimide 2-D gels were stained with G-Colloidal concentrated Coomassie 
Brilliant Blue-R (Sigma-Aldrich, USA) to visualize the separated proteins. Gels were scanned 
using the GS-800 Calibrated scanner (Bio-Rad, USA)  and the Quantity One - 4:5.2 (Basic) 
software program (Bio-Rad, USA) employed to create gel images.  These gel images were 
subsequently analysed using the PDQuest (version 8) software program (Bio-Rad, USA) to 
identify the differentially expressed (p< 0.05, student’s t-test) spots between control and statin-
treated animals. 
 
9.6.  Destaining, in-gel digestion and peptide extraction 
For identifying the protein profile, the spots of interest were subjected to Mass Spectrometric 
(MS) analysis. Briefly, the gel pieces containing the proteins of interest were manually excised 
from the 2-D gels followed by subjection to in-gel enzymatic digestion using trypsin 
(Shevshenko et al., 1996). Using the manufacturer’s protocol, the gel plugs were processed by 
a MassPrep Robotic Protein Handling System (MS Technologies, UK). The samples were 
placed in a 96-well polypropylene microtiter plate and destained twice, using 50 % acetonitrile 
in 50 mM ammonium bicarbonate, followed by a rinse with acetonitrile and allowed to air dry for 
10 min. They were then reduced with 10 mM dithiothreitol for 30 min, followed by subjecting 
them to alkylation with 55 mM iodoacetamide. These steps were followed by rinsing the 
samples three times with acetonitrile, followed by 100 mM ammonium bicarbonate, and finally 
by acetonitrile. Digestion was performed by adding to each sample a 25 μl aliquot containing 6 
ngµL-1 trypsin. The samples were then allowed to incubate for 4.5 h at 37 °C. The initial 
extraction of the peptides were done using 30 µL of an aqueous solution containing 2% 
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acetonitrile and 1% formic acid. A second extraction using 15 µL of an aqueous solution 
containing 51% acetonitrile and 0.5% formic acid was then performed and combined with the 
first extraction in a cooled second 96-well plate and stored at –80oC prior to analysis by mass 
spectrometry. 
 
9.7. Peptide separation by means of in-line Liquid Chromatography and 
Electrospray Ionisation Mass Spectrometry (EI-MassSpect) 
The partially digested peptide mixture was contained in a 96-well microtitre plate, which was 
transferred to a modular CapLC and autosampler system (MS Technologies, UK). Using the 
method described by Wilm et al. (1996) and Chen et al. (2006), the eluted peptides were then 
analysed further using quadripole time of flight (ESI-QUAD-TOF) mass spectrometry (MS 
Technologies, UK) fitted with nano-electrosprayer having an applied capillary voltage of 3.5 kV. 
Prior to analysis, the instrument was calibrated against a collisionally induced decomposition 
(CID) spectrum of the doubly charged precursor ion of [glu1]-fibrinopeptide B (GFP). Calibration 
was accepted when the error obtained on all subsequent acquisitions was < 20 ppm, while the 
sensitivity of the machine was assessed by detecting a 500 fmol injection of GFP, with a base 
peak signal:noise ratio of > 50:1 on the doubly charged ion. Throughout analysis, the sensitivity 
and calibration of the MS instrument as the chromatographic resolution of the GFP peak were 
checked at regular intervals. For recording spectra, the MS instrument was operated in data 
dependent acquisition (DDA) mode over the mass/charge (m/z) range of 50-2000. During the 
DDA analysis, both MS and tandem mass spectrometry (CID) was performed on the most 
intense peptides as they eluted from the column.  
9.8.  Homology protein searches using bio-informatics tools 
        Following data acquisition, all the individual uninterpreted MS/MS spectra that had been 
acquired for each of the precursors within a single LC run were combined, smoothed, the 
background subtracted, centred, deisotoped and centroided automatically using the ProteinLynx 
Global Server search engine (MS Technologies, UK). The MASCOTTM peptide identification 
search algorithm (Perkins et al., 1999) was used for querying the nonredundant database at the 
National Center for Biotechnology Information (NCBInr) with the ProteinLynx Global Server 
output that was generated as a single Mascot-searchable peak list file. The search parameters 
were defined to include up to two missed cleavage sites, a 100 ppm tolerance against the 
database-generated theoretical peptide and product ion masses, and a minimum of a single 
matched peptide.  A list of the twenty highest scoring entries was produced and each suggested 
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protein identification was either confirmed or rejected by comparing the theoretical sequence 
with the observed MS/MS data. The generated dataset was searched against Matrix software 
(http://www.matrixscience.com/cgi/), by using a rat reference database, the IPI rat version 3.34 
(http://www.ebi.ac.uk/IPI/IPIrat.html, released 02/10/2007). Furthermore, fragments were 
sequence-identified by performing a database search against several publicly available 
databases, i.e. SwissProt, www.ebi.ac.uk/swissprot; NCBI nr, www.ncbi.nlm.nih.gov; and 
ENSEMBL (http://www.ensembl.org/index.html). BLAST searches 
(www.ncbi.nlm.nih.gov/BLAST; http://www.arabidopsis.org/Blast/) were performed on the 
peptide fragments obtained earlier, to further analyze non-annotated expressed sequence tag 
(EST) hits (Altschul et al., 1990). 
10.  Drug treatment regime 
For the experiment described in chapter 7, a drug treatment protocol was followed prior to the 
unilateral infusion of rotenone into the SNc. The drug was administered orally on a daily level 
for 2 week, with the drug administered at a fixed time every day (between 13:00 and 13:30). 
Prior to starting the drug regime, two weeks was allowed for training the rats to eat a jellie-cube 
that consisted of flavoured sugar-water dissolved in hot water and gelatine (the gelatine was 
used for setting the solution rapidly). A drug-treatment regime was then followed that consisted 
of dissolving 6 mg of the active chemical component of simvastatin in 50 µl of absolute Ethanol 
(EtOH) in an Eppendorf microtube, which was mixed with the jelly-solution. For preparing a 
single jellie-cube, a droplet of the solution was placed with a Pasteur pipette in an ice-maker 
holder, while 50 µl of the EtOH-dissolved statin-solution was re-suspended in the sugar solution 
with a sterilized pipette. After the solution had set completely, the jelly-cube was removed from 
its plastic holder, and a single cube was given to each rat. Control rats were treated with 
placebos, consisting only of a jelly-block, however with an equal amount of ethanol as the 
statin-treated rats had received.  
 
